15882284
D001241_D007676 CID <e1>aspirin</e1> use <e2>disease</e2>
D001241_D007676 CID <e1>aspirin</e1> use disease <e2>esrd</e2>
D001241_D007676 CID <e1>aspirin</e1> associated <e2>esrd</e2>
D001241_D007676 CID <e1>aspirin</e1> use increase risk <e2>esrd</e2>
D001241_D007674 NONE <e1>aspirin</e1> associated esrd risk related high subset patients <e2>nephropathy</e2>
17159032
D006886_D014786 CID <e1>hydroxychloroquine</e1> taking patients <e2>loss</e2>
D006886_D014786 CID <e1>hydroxychloroquine</e1> treatment attributed <e2>abnormalities</e2>
7018927
D006220_D006966 CID <e1>haloperidol-induced</e1> <e2>hyperprolactinemia</e2>
D006220_D006966 CID <e1>haloperidol</e1> infusions course found <e2>hyperprolactinemia</e2>
6305660
2553470
D016291_D013226 NONE <e1>mk-801</e1> actions model <e2>epilepticus</e2>
D016291_D013226 NONE <e1>mk-801</e1> administration i.e. <e2>epilepticus</e2>
D008094_D013226 CID <e1>lithium-pilocarpine</e1> model <e2>epilepticus</e2>
D008094_D013226 CID <e1>lithium</e1> induced seizures block easy difficult terminate <e2>epilepticus</e2>
D008094_D013226 CID <e1>lithium-pilocarpine</e1> model <e2>epilepticus</e2>
D010862_D013226 CID <e1>lithium-pilocarpine</e1> model <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine</e1> lithium induced seizures block easy difficult terminate <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine</e1> prior block easy difficult terminate <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine</e1> min administration i.e. <e2>epilepticus</e2>
D010862_D013226 CID <e1>lithium-pilocarpine</e1> model <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine</e1> nmda doses synergistic resulting <e2>epilepticus</e2>
D016291_D012640 NONE <e1>mk-801</e1> tested using models <e2>seizure</e2>
D016291_D012640 NONE <e1>mk-801</e1> pretreatment produced suggesting control <e2>seizures</e2>
D016291_D012640 NONE <e1>mk-801</e1> effect occurred periods activity <e2>seizure</e2>
D016291_D012640 NONE <e1>mk-801</e1> administration reduced activity <e2>seizure</e2>
D016202_D012640 NONE <e1>n-methyl-d-aspartate</e1> antagonist mk-801 tested using models <e2>seizure</e2>
D016202_D012640 NONE <e1>nmda</e1> antagonist mk-801 tested using models <e2>seizure</e2>
D008094_D012640 NONE <e1>lithium</e1> coadministration models <e2>seizure</e2>
D008094_D012640 NONE <e1>lithium-pilocarpine</e1> model action produced suggesting control <e2>seizures</e2>
D008094_D012640 NONE <e1>lithium-pilocarpine</e1> model effect occurred periods activity <e2>seizure</e2>
D008094_D012640 NONE <e1>lithium</e1> induced <e2>seizures</e2>
D008094_D012640 NONE <e1>lithium</e1> induced seizures block easy difficult terminate block lethality <e2>seizures</e2>
D010862_D012640 NONE <e1>pilocarpine</e1> lithium coadministration models <e2>seizure</e2>
D010862_D012640 NONE <e1>pilocarpine</e1> dose administration coadministration models <e2>seizure</e2>
D010862_D012640 NONE <e1>lithium-pilocarpine</e1> model action produced suggesting control <e2>seizures</e2>
D010862_D012640 NONE <e1>pilocarpine</e1> treated rats model action produced suggesting control <e2>seizures</e2>
D010862_D012640 NONE <e1>lithium-pilocarpine</e1> model effect occurred periods activity <e2>seizure</e2>
D010862_D012640 NONE <e1>pilocarpine</e1> lithium induced <e2>seizures</e2>
D010862_D012640 NONE <e1>pilocarpine</e1> lithium induced seizures block easy difficult terminate block lethality <e2>seizures</e2>
D010862_D012640 NONE <e1>pilocarpine</e1> prior block <e2>seizures</e2>
D010862_D012640 NONE <e1>pilocarpine</e1> prior block easy difficult terminate block lethality <e2>seizures</e2>
D010862_D012640 NONE <e1>pilocarpine</e1> min administration reduced activity <e2>seizure</e2>
D016202_D013226 NONE <e1>nmda</e1> receptors activation plays <e2>epilepticus</e2>
D016202_D013226 NONE <e1>nmda</e1> doses synergistic resulting <e2>epilepticus</e2>
D016202_D001930 NONE <e1>nmda</e1> receptors activation plays epilepticus <e2>damage</e2>
D008094_D001930 NONE <e1>lithium-pilocarpine</e1> model epilepticus <e2>damage</e2>
D010862_D001930 NONE <e1>lithium-pilocarpine</e1> model epilepticus <e2>damage</e2>
9132810
D008727_D056784 CID <e1>methotrexate</e1> treated leukemia developed enhancement <e2>leukoencephalopathy</e2>
D008727_D054198 NONE <e1>methotrexate</e1> treated <e2>leukemia</e2>
10219427
12828076
D000082_D017114 CID <e1>paracetamol</e1> overdose fas patients <e2>failure</e2>
D000082_D017114 CID <e1>paracetamol</e1> overdose greater patients <e2>failure</e2>
D000082_D062787 NONE <e1>paracetamol</e1> <e2>overdose</e2>
D000082_D062787 NONE <e1>paracetamol</e1> <e2>overdose</e2>
D000082_D056486 NONE <e1>paracetamol</e1> overdose greater those non-a <e2>hepatitis</e2>
11229942
D003042_D066126 NONE <e1>cocaine</e1> <e2>cardiotoxity</e2>
D003042_D066126 NONE <e1>cocaine</e1> metabolite cocaethylene <e2>toxicity</e2>
D003042_D066126 NONE <e1>cocaine</e1> <e2>cardiotoxicity</e2>
D003042_D019970 NONE <e1>cocaine</e1> model <e2>abuse</e2>
D003042_D000437 NONE <e1>cocaine</e1> model <e2>abuse</e2>
D000431_D066126 NONE <e1>ethanol</e1> cocaine <e2>cardiotoxity</e2>
D000431_D066126 NONE <e1>ethanol</e1> presence formed metabolite cocaethylene <e2>toxicity</e2>
D000431_D066126 NONE <e1>ethanol</e1> cocaine <e2>cardiotoxicity</e2>
D000431_D019970 NONE <e1>ethanol</e1> cocaine model <e2>abuse</e2>
D000431_D000437 NONE <e1>ethanol</e1> cocaine model <e2>abuse</e2>
C066444_D066126 NONE <e1>cocaethylene</e1> <e2>cardiotoxity</e2>
C066444_D066126 NONE <e1>cocaethylene</e1> <e2>toxicity</e2>
C066444_D066126 NONE <e1>ce</e1> cocaethylene <e2>toxicity</e2>
C066444_D066126 NONE <e1>ce</e1> role <e2>cardiotoxicity</e2>
C066444_D019970 NONE <e1>cocaethylene</e1> cardiotoxity cocaine model <e2>abuse</e2>
C066444_D000437 NONE <e1>cocaethylene</e1> cardiotoxity cocaine model <e2>abuse</e2>
C066444_D002303 CID <e1>ce</e1> levels associated % decrease <e2>output</e2>
C066444_D009202 NONE <e1>cocaethylene</e1> concentrations associated <e2>depression</e2>
12487093
D004837_D006973 CID <e1>adrenaline-induced</e1> <e2>hypertension</e2>
D004837_D006973 CID <e1>adrenaline</e1> giving evaluated bbb destroy used <e2>hypertension</e2>
C009591_D006973 NONE <e1>triphenyltetrazolium</e1> staining using evaluated bbb destroy used <e2>hypertension</e2>
C009591_D006973 NONE <e1>ttc</e1> staining using evaluated bbb destroy used <e2>hypertension</e2>
C009591_D006973 NONE <e1>ttc</e1> staining exhibited used <e2>hypertension</e2>
256433
D014031_D007239 NONE <e1>tobramycin</e1> infusion combined <e2>infections</e2>
D014031_D009369 NONE <e1>tobramycin</e1> infusion combined infections patients <e2>cancer</e2>
D002228_D007239 NONE <e1>carbenicillin</e1> combined <e2>infections</e2>
D002228_D009369 NONE <e1>carbenicillin</e1> combined infections patients <e2>cancer</e2>
D014031_D009503 NONE <e1>tobramycin</e1> given overcome effects <e2>neutropenia</e2>
D002228_D009503 NONE <e1>carbenicillin</e1> combined given overcome effects <e2>neutropenia</e2>
D003404_D053099 NONE <e1>creatinine</e1> <e2>azotemia</e2>
D014031_D053099 CID <e1>tobramycin</e1> concentration therapy duration related <e2>azotemia</e2>
612112
D005045_D009207 CID <e1>etomidate</e1> prove incidence <e2>myoclonia</e2>
12752472
D010862_D004827 CID <e1>pilocarpine-induced</e1> <e2>epilepsy</e2>
D010862_D006985 NONE <e1>pilocarpine-treated</e1> rats ventilation decrease caused maneuver <e2>hyperventilation</e2>
15096374
D016559_D003872 NONE <e1>tacrolimus</e1> ointment treatment induction <e2>dermatitis</e2>
D016559_D003872 NONE <e1>tacrolimus</e1> ointment complication report <e2>dermatitis</e2>
D016559_D003872 NONE <e1>tacrolimus</e1> ointment complication spectrum <e2>dermatitis</e2>
D016559_D005148 NONE <e1>tacrolimus</e1> ointment treatment <e2>dermatoses</e2>
D016559_D005148 NONE <e1>tacrolimus</e1> ointment treated patients <e2>dermatoses</e2>
D016559_D012393 CID <e1>tacrolimus</e1> ointment used indicate effective <e2>rosacea</e2>
D016559_D019557 NONE <e1>tacrolimus</e1> ointment used indicate effective rosacea <e2>dermatitis</e2>
D013256_D012393 NONE <e1>steroid-aggravated</e1> <e2>rosacea</e2>
D013256_D019557 NONE <e1>steroid-aggravated</e1> rosacea <e2>dermatitis</e2>
20495512
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> thrombocytopenia <e2>hit</e2>
D006493_D013921 CID <e1>heparin</e1> exposure occurs suspected acknowledged <e2>hit</e2>
D006493_D013921 CID <e1>heparin</e1> exposure cessation mandates treatment <e2>hit</e2>
D006493_D013921 CID <e1>heparin</e1> alternatives patients history <e2>hit</e2>
D006493_D013921 CID <e1>heparin</e1> remains potential <e2>hit</e2>
D006493_D013921 CID <e1>heparin</e1> exposure <e2>hit</e2>
D006493_D013921 CID <e1>heparin</e1> initiated practiced remains potential <e2>hit</e2>
D006493_D013927 CID <e1>heparin</e1> exposure occurs suspected acknowledged predilection <e2>thrombosis</e2>
D006493_D013927 CID <e1>heparin</e1> exposure occurs <e2>thrombosis</e2>
D000991_D013921 NONE <e1>inhibitor</e1> using mandates treatment <e2>hit</e2>
D000991_D013921 NONE <e1>inhibitors</e1> appropriate alternatives patients history <e2>hit</e2>
8825380
D011692_D007674 CID <e1>aminonucleoside</e1> <e2>nephropathy</e2>
D011692_D007674 CID <e1>aminonucleoside</e1> injury exacerbates <e2>nephropathy</e2>
D011692_D007674 CID <e1>aminonucleoside</e1> injury exacerbates model <e2>disease</e2>
D011692_D007674 CID <e1>pan</e1> aminonucleoside injury exacerbates <e2>nephropathy</e2>
D011692_D007674 CID <e1>pan</e1> aminonucleoside injury exacerbates model <e2>disease</e2>
D011692_D007674 CID <e1>pan</e1> <e2>nephropathy</e2>
D011692_D007674 CID <e1>pan</e1> injections induced <e2>glomerulopathy</e2>
D011692_D007674 CID <e1>pan</e1> <e2>nephropathy</e2>
D011692_D007674 CID <e1>pan</e1> animals <e2>nephropathy</e2>
D011692_D007674 CID <e1>pan</e1> <e2>nephropathy</e2>
D011692_D007674 CID <e1>pan</e1> <e2>nephropathy</e2>
D011692_D006130 NONE <e1>pan</e1> nephropathy rats <e2>failure</e2>
D008315_D007674 NONE <e1>malondialdehyde</e1> content glomerulosclerosis <e2>hypertrophy</e2>
D008315_D007674 NONE <e1>malondialdehyde</e1> content gain <e2>damage</e2>
D008315_D005921 NONE <e1>malondialdehyde</e1> content <e2>glomerulosclerosis</e2>
D008315_-1 NONE <e1>malondialdehyde</e1> content glomerulosclerosis <e2>injury</e2>
D008315_D011507 NONE <e1>malondialdehyde</e1> content gain pressure <e2>proteinuria</e2>
20192893
D003287_D007674 CID <e1>medium</e1> <e2>nephrotoxicity</e2>
D003287_D007674 CID <e1>medium</e1> administration induced <e2>dysfunction</e2>
D003287_D007674 CID <e1>cm</e1> administration induced <e2>dysfunction</e2>
D003287_D007674 CID <e1>cm</e1> effect <e2>nephrotoxic</e2>
D003287_D007674 CID <e1>cm</e1> administration induced <e2>damage</e2>
D003287_D064420 NONE <e1>cm</e1> <e2>toxicity</e2>
7739955
D002220_D009205 CID <e1>carbamazepine-induced</e1> myocarditis had had <e2>myocarditis</e2>
D002220_D009205 CID <e1>carbamazepine-induced</e1> <e2>myocarditis</e2>
D002220_D004802 CID <e1>carbamazepine-induced</e1> <e2>myocarditis</e2>
D002220_D012770 NONE <e1>carbamazepine-induced</e1> myocarditis had had hemosiderosis resulting <e2>shock</e2>
24653743
C042288_D016757 CID <e1>pilsicainide-induced</e1> torsades pointes case <e2>death</e2>
C042288_D016757 CID <e1>pilsicainide</e1> received developed <e2>death</e2>
C042288_D016171 CID <e1>pilsicainide-induced</e1> torsades <e2>pointes</e2>
C042288_D016171 CID <e1>pilsicainide</e1> dose low impaired high produce torsades <e2>pointes</e2>
C042288_D016171 CID <e1>pilsicainide</e1> concentration high produce torsades <e2>pointes</e2>
C042288_D001281 NONE <e1>pilsicainide</e1> received convert <e2>fibrillation</e2>
C042288_D001281 NONE <e1>pilsicainide</e1> drugs administration effective terminate <e2>fibrillation</e2>
D012964_D001281 NONE <e1>sodium</e1> channel blocker pilsicainide received convert <e2>fibrillation</e2>
D012964_D016757 NONE <e1>sodium</e1> channel blocker pilsicainide received developed <e2>death</e2>
9071336
D017239_D001943 NONE <e1>paclitaxel</e1> acid <e2>cancer</e2>
D017239_D001943 NONE <e1>paclitaxel</e1> acid 5-fluorouracil therapies patients <e2>cancer</e2>
D017239_D001943 NONE <e1>taxol</e1> company 5-fluorouracil therapies patients <e2>cancer</e2>
D017239_D001943 NONE <e1>paclitaxel</e1> trial performed women <e2>cancer</e2>
D005472_D001943 NONE <e1>5-fluorouracil</e1> paclitaxel acid <e2>cancer</e2>
D005472_D001943 NONE <e1>5-fluorouracil</e1> therapies patients <e2>cancer</e2>
D005472_D001943 NONE <e1>5-fluorouracil</e1> followed performed women <e2>cancer</e2>
D002955_D001943 NONE <e1>acid</e1> <e2>cancer</e2>
D002955_D001943 NONE <e1>acid</e1> 5-fluorouracil therapies patients <e2>cancer</e2>
D002955_D001943 NONE <e1>acid</e1> followed performed women <e2>cancer</e2>
D017239_D064420 NONE <e1>paclitaxel</e1> have <e2>cytotoxicity</e2>
D005472_D064420 NONE <e1>5-fluorouracil</e1> paclitaxel have <e2>cytotoxicity</e2>
D016179_D009503 NONE <e1>factor</e1> required reported associated <e2>neutropenia</e2>
D016179_D009503 NONE <e1>factor</e1> required <e2>neutropenia</e2>
19967075
D012964_D007674 NONE <e1>na/k-atpase</e1> expression <e2>nephropathy</e2>
D012964_D007674 NONE <e1>na(+)/k(+)-atpase</e1> expression related <e2>nephropathy</e2>
D011188_D007674 NONE <e1>na/k-atpase</e1> expression <e2>nephropathy</e2>
D011188_D007674 NONE <e1>na(+)/k(+)-atpase</e1> expression related <e2>nephropathy</e2>
D005839_D007674 CID <e1>gentamicin-induced</e1> <e2>nephropathy</e2>
D005839_D007674 CID <e1>gentamicin-induced</e1> <e2>nephropathy</e2>
D005839_D007674 CID <e1>gentamicin-induced</e1> <e2>nephropathy</e2>
17879100
D001241_D005334 NONE <e1>aspirin</e1> put took ibuprofen <e2>fever</e2>
D007052_D005334 NONE <e1>ibuprofen</e1> <e2>fever</e2>
24999722
D005446_C537630 NONE <e1>acetonide</e1> safety intravitreal <e2>retinochoroidopathy</e2>
D005446_C537630 NONE <e1>acetonide</e1> outcomes report intravitreal patients <e2>retinochoroidopathy</e2>
D005446_C537630 NONE <e1>acetonide</e1> implant helps control cases <e2>retinochoroidopathy</e2>
D005446_D007249 NONE <e1>acetonide</e1> implant helps control <e2>inflammation</e2>
9323412
D017294_D003866 NONE <e1>ondansetron</e1> <e2>depression</e2>
D017294_D020250 NONE <e1>ondansetron</e1> prophylaxis used anaesthetic presented history nausea <e2>vomiting</e2>
D012701_D003865 NONE <e1>serotonin</e1> antagonist use related developed <e2>disorder</e2>
D015742_D009325 NONE <e1>propofol</e1> infusion anaesthesia provided course <e2>nausea-free</e2>
D015742_D003866 NONE <e1>propofol</e1> infusion anaesthesia provided exacerbation <e2>disorder</e2>
D012701_D009325 NONE <e1>serotonin</e1> antagonists infusion anaesthesia provided course <e2>nausea-free</e2>
D012701_D003866 NONE <e1>serotonin</e1> antagonists infusion anaesthesia provided exacerbation <e2>disorder</e2>
2131034
D013852_D011115 CID <e1>thiotepa</e1> chemotherapy loss <e2>polyneuropathy</e2>
D013852_D020258 CID <e1>thiotepa</e1> chemotherapy administration related <e2>toxicity</e2>
D013852_D020258 CID <e1>tspa</e1> thiotepa chemotherapy administration related <e2>toxicity</e2>
D013852_D020258 CID <e1>it-tspa</e1> it-methotrexate described <e2>toxicities</e2>
D013852_D020258 CID <e1>tspa</e1> agent fact spite cause <e2>neurotoxicity</e2>
D008727_D020258 CID <e1>it-methotrexate</e1> described <e2>toxicities</e2>
D008727_D020258 CID <e1>mtx</e1> combination cause <e2>neurotoxicity</e2>
D003561_D020258 CID <e1>arabinoside</e1> it-methotrexate described <e2>toxicities</e2>
D003561_D020258 CID <e1>ara-c</e1> mtx combination cause <e2>neurotoxicity</e2>
10672628
D009569_D002375 NONE <e1>nitric-oxide</e1> synthesis modifies <e2>catalepsy</e2>
D009569_D002375 NONE <e1>nitric-oxide</e1> synthase inhibitor ng-nitro-l-arginine rationale induces <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> drugs cause <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D009249_D002375 NONE <e1>nadph-diaphorase</e1> neurons number <e2>catalepsy</e2>
D019335_D002375 NONE <e1>ng-nitro-l-arginine</e1> rationale induces <e2>catalepsy</e2>
D019335_D002375 NONE <e1>l-noarg</e1> ng-nitro-l-arginine rationale induces <e2>catalepsy</e2>
D019335_D002375 NONE <e1>l-noarg</e1> treatment <e2>catalepsy</e2>
D019335_D002375 NONE <e1>l-noarg</e1> administration produced tolerance l-noarg <e2>catalepsy</e2>
D019335_D002375 NONE <e1>l-noarg</e1> <e2>catalepsy</e2>
D004298_D002375 NONE <e1>dopamine</e1> receptors block drugs cause <e2>catalepsy</e2>
3711722
D003035_D009202 CID <e1>cobalt</e1> <e2>cardiomyopathy</e2>
D004317_D006333 CID <e1>doxorubicin-induced</e1> <e2>failure</e2>
19020118
11988250
D007052_D006976 CID <e1>ibuprofen</e1> prophylaxis <e2>hypertension</e2>
D007052_D000860 CID <e1>ibuprofen</e1> administration cases <e2>hypoxaemia</e2>
D007052_D000860 CID <e1>ibuprofen</e1> arteriosus treatment trial report cases <e2>hypoxaemia</e2>
D007052_D000860 CID <e1>ibuprofen</e1> administration occurs <e2>hypoxaemia</e2>
D007052_D004374 NONE <e1>ibuprofen</e1> administration cases report trial treatment <e2>arteriosus</e2>
D007052_D004374 NONE <e1>ibuprofen</e1> <e2>arteriosus</e2>
D009569_D000860 NONE <e1>oxide</e1> therapy resolved <e2>hypoxaemia</e2>
17351238
D005996_D007022 CID <e1>gtn</e1> administration drop <e2>pressure</e2>
D005996_D007022 CID <e1>gtn</e1> minutes experienced drop <e2>pressure</e2>
D001285_D007022 NONE <e1>sulphate</e1> rectified experienced drop <e2>pressure</e2>
17223814
D015251_D054537 CID <e1>epirubicin</e1> chemotherapy result <e2>block</e2>
D017239_D054537 CID <e1>paclitaxel</e1> epirubicin chemotherapy result <e2>block</e2>
7457821
25031906
D017311_D004408 CID <e1>amlodipine</e1> side-effect rare going <e2>dysguesia</e2>
D017311_D004408 CID <e1>amlodipine</e1> side-effect <e2>dysguesia</e2>
D017311_D004408 CID <e1>amlodipine</e1> cause <e2>dysguesia</e2>
D017311_D004408 CID <e1>amlodipine</e1> <e2>dysguesia</e2>
D017311_D006973 NONE <e1>amlodipine</e1> treatment <e2>hypertension</e2>
D017311_D012678 NONE <e1>amlodipine</e1> treatment hypertension female case report developed loss <e2>sensation</e2>
4082192
C026729_D007674 NONE <e1>p-aminophenol</e1> role <e2>nephrotoxicity</e2>
C026729_D007674 NONE <e1>p-aminophenol</e1> role effect acetaminophen <e2>nephrotoxicity</e2>
C026729_D007674 NONE <e1>p-aminophenol</e1> acetaminophen effect role <e2>nephrotoxicity</e2>
C026729_D007674 NONE <e1>p-aminophenol</e1> acetaminophen <e2>nephrotoxicity</e2>
C026729_D007674 NONE <e1>pap</e1> formation step <e2>nephrotoxicity</e2>
C026729_D007674 NONE <e1>pap</e1> apap <e2>nephrotoxicity</e2>
C026729_D007674 NONE <e1>pap</e1> apap administration prior pretreatment resulted reduction <e2>nephrotoxicity</e2>
C026729_D007674 NONE <e1>pap</e1> apap administration prior pretreatment resulted reduction nephrotoxicity <e2>nephrotoxicity</e2>
C026729_D007674 NONE <e1>pap</e1> nephrotoxicity <e2>nephrotoxicity</e2>
C026729_D007674 NONE <e1>pap</e1> <e2>nephrotoxicity</e2>
D000082_D007674 NONE <e1>acetaminophen-induced</e1> <e2>nephrotoxicity</e2>
D000082_D007674 NONE <e1>acetaminophen-induced</e1> nephrotoxicity role effect acetaminophen <e2>nephrotoxicity</e2>
D000082_D007674 NONE <e1>acetaminophen</e1> effect role <e2>nephrotoxicity</e2>
D000082_D007674 NONE <e1>acetaminophen</e1> <e2>nephrotoxicity</e2>
D000082_D007674 NONE <e1>apap-induced</e1> <e2>nephrotoxicity</e2>
D000082_D007674 NONE <e1>apap</e1> <e2>nephrotoxicity</e2>
D000082_D007674 NONE <e1>apap</e1> administration prior pretreatment resulted reduction <e2>nephrotoxicity</e2>
D000082_D007674 NONE <e1>apap</e1> administration prior pretreatment resulted reduction nephrotoxicity <e2>nephrotoxicity</e2>
D000082_D007674 NONE <e1>apap</e1> reduction <e2>nephrotoxicity</e2>
D000082_D007674 NONE <e1>apap</e1> reduction nephrotoxicity <e2>nephrotoxicity</e2>
D000082_D007674 NONE <e1>apap-induced</e1> <e2>nephrotoxicity</e2>
D000082_D007674 NONE <e1>apap</e1> deacetylation inhibition appears reduction <e2>nephrotoxicity</e2>
C002887_D007674 NONE <e1>phosphate</e1> effect role <e2>nephrotoxicity</e2>
C002887_D007674 NONE <e1>phosphate</e1> effect acetaminophen <e2>nephrotoxicity</e2>
C002887_D007674 NONE <e1>phosphate</e1> effect <e2>nephrotoxicity</e2>
C002887_D007674 NONE <e1>bnpp</e1> phosphate effect <e2>nephrotoxicity</e2>
C002887_D007674 NONE <e1>bnpp</e1> animals pretreatment resulted reduction <e2>nephrotoxicity</e2>
C002887_D007674 NONE <e1>bnpp</e1> animals pretreatment resulted reduction nephrotoxicity <e2>nephrotoxicity</e2>
C002887_D007674 NONE <e1>bnpp-induced</e1> reduction <e2>nephrotoxicity</e2>
D000082_D007683 CID <e1>acetaminophen</e1> produces <e2>necrosis</e2>
D000082_D007683 CID <e1>apap</e1> acetaminophen produces <e2>necrosis</e2>
D000082_D007683 CID <e1>apap-induced</e1> <e2>necrosis</e2>
C026729_D007683 CID <e1>pap</e1> formation accounts <e2>necrosis</e2>
6299641
D001262_D013610 NONE <e1>atenolol</e1> doses effects compared placebo <e2>tachycardia</e2>
D011433_D013610 NONE <e1>propranolol</e1> atenolol doses effects compared placebo <e2>tachycardia</e2>
D007545_D013610 CID <e1>isoproterenol-induced</e1> exercise- <e2>tachycardia</e2>
D007545_D013610 CID <e1>isoproterenol</e1> <e2>tachycardia</e2>
D007545_D013610 CID <e1>isoproterenol</e1> activates consistent hypothesis results <e2>tachycardia</e2>
D001285_D013610 NONE <e1>atropine</e1> determined effects <e2>tachycardia</e2>
24132704
C029036_D006949 NONE <e1>crocin</e1> reduced inhibition activation <e2>hyperlipemia</e2>
C029036_D006949 NONE <e1>crocin</e1> considered agent <e2>hyperlipemia</e2>
D003976_D006949 CID <e1>diazinon-induced</e1> <e2>hyperlipemia</e2>
D003976_D006949 CID <e1>diazinon-induced</e1> <e2>hyperlipemia</e2>
6321816
D014667_D006973 NONE <e1>vasopressin</e1> contributor <e2>hypertension</e2>
D014667_D006973 NONE <e1>vasopressin</e1> role agent process <e2>hypertensive</e2>
D014667_D006973 NONE <e1>vasopressin</e1> plays pathogenesis <e2>hypertension</e2>
D014667_D006973 NONE <e1>vasopressin</e1> action appears important development model <e2>hypertension</e2>
D014667_D006973 NONE <e1>vasopressin</e1> action appears observed stage <e2>hypertension</e2>
D014667_D006973 NONE <e1>vasopressin</e1> secretion promotes factor <e2>hypertension</e2>
D014667_D006973 NONE <e1>vasopressin</e1> role remains determined <e2>hypertension</e2>
D014667_D003919 NONE <e1>vasopressin</e1> plays substantial rats <e2>insipidus</e2>
D003900_D006973 CID <e1>doca-salt</e1> <e2>hypertension</e2>
D003900_D006973 CID <e1>doca-salt</e1> treatment substantial plays pathogenesis <e2>hypertension</e2>
D003900_D003919 NONE <e1>doca-salt</e1> hypertension pathogenesis plays substantial rats <e2>insipidus</e2>
D003900_D003919 NONE <e1>doca-salt</e1> treatment substantial rats <e2>insipidus</e2>
D008094_D006973 NONE <e1>lithium-treated</e1> insipidus rats substantial plays pathogenesis <e2>hypertension</e2>
D008094_D003919 CID <e1>lithium-treated</e1> <e2>insipidus</e2>
6884395
D003276_D000784 CID <e1>contraceptives</e1> hypertension association case <e2>aneurysm</e2>
D003276_D006973 NONE <e1>contraceptives</e1> <e2>hypertension</e2>
D003276_D011782 NONE <e1>contraceptives</e1> hypertension association case reported patient <e2>syndrome</e2>
24739405
D003687_D012559 NONE <e1>dehydroepiandrosterone</e1> effects models <e2>schizophrenia</e2>
D003687_D012559 NONE <e1>dehydroepiandrosterone</e1> effects models <e2>schizophrenia</e2>
D003687_D012559 NONE <e1>dhea</e1> dehydroepiandrosterone effects models <e2>schizophrenia</e2>
D003687_D012559 NONE <e1>dhea</e1> displays used treatment <e2>schizophrenia</e2>
D000661_D012559 CID <e1>amphetamine-induced</e1> models <e2>schizophrenia</e2>
D000661_D012559 CID <e1>amphetamine</e1> locomotion used models <e2>schizophrenia</e2>
D000661_D006948 NONE <e1>amphetamine</e1> locomotion <e2>hyper</e2>
D000661_D002375 NONE <e1>amphetamine</e1> locomotion climbing tests <e2>catalepsy</e2>
D001058_D006948 NONE <e1>apomorphine</e1> locomotion <e2>hyper</e2>
D001058_D002375 NONE <e1>apomorphine</e1> locomotion climbing tests <e2>catalepsy</e2>
D001058_D012559 CID <e1>apomorphine</e1> locomotion used models <e2>schizophrenia</e2>
D006220_D006948 NONE <e1>haloperidol</e1> climbing locomotion <e2>hyper</e2>
D006220_D002375 CID <e1>haloperidol</e1> climbing tests <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> test <e2>catalepsy</e2>
D006220_D012559 CID <e1>haloperidol</e1> climbing locomotion used models <e2>schizophrenia</e2>
D003687_D002375 NONE <e1>dhea</e1> reduced increased <e2>catalepsy</e2>
23871786
C006780_D001008 CID <e1>a</e1> exposure increases behavior <e2>anxiety-like</e2>
C006780_D001008 CID <e1>bpa</e1> exposed mice increased behavior <e2>anxiety-like</e2>
C006780_D001008 CID <e1>bpa</e1> exposure increased behavior <e2>anxiety-like</e2>
12699527
D002712_D009224 NONE <e1>chloride</e1> channel function defect caused <e2>congenita</e2>
D002712_D009224 NONE <e1>chloride</e1> channel function defect caused congenita <e2>mc</e2>
D002712_-1 NONE <e1>chloride</e1> channel function defect cause <e2>depolarisation</e2>
D013390_D013035 CID <e1>suxamethonium</e1> injection developed <e2>spasm</e2>
7315949
D009638_D013035 CID <e1>l-norepinephrine</e1> induced <e2>spasm</e2>
D009638_D006547 NONE <e1>l-norepinephrine</e1> induced vasoconstriction produced <e2>hernias</e2>
3439580
D007099_D006973 CID <e1>imipramine</e1> induced neuroblastoma <e2>hypertension</e2>
D007099_D006973 CID <e1>imipramine</e1> given girl occurrence <e2>hypertension</e2>
D007099_D006973 CID <e1>imipramine</e1> discontinuation had believe caused <e2>hypertension</e2>
D007099_D009447 NONE <e1>imipramine</e1> induced <e2>neuroblastoma</e2>
D007099_D009447 NONE <e1>imipramine</e1> given girl <e2>neuroblastoma</e2>
D007099_D002653 NONE <e1>imipramine</e1> given control <e2>disorder</e2>
17151160
C076029_D012559 NONE <e1>olanzapine</e1> comparison treatment <e2>schizophrenia</e2>
C076029_D012559 NONE <e1>olanzapine</e1> patients disorders <e2>schizophrenia</e2>
C076029_D012559 NONE <e1>olanzapine</e1> treatment assigned method subjects <e2>schizophrenia</e2>
D018967_D012559 NONE <e1>risperidone</e1> olanzapine comparison treatment <e2>schizophrenia</e2>
D018967_D012559 NONE <e1>risperidone</e1> olanzapine patients disorders <e2>schizophrenia</e2>
D018967_D012559 NONE <e1>risperidone</e1> assigned method subjects <e2>schizophrenia</e2>
C076029_D011618 NONE <e1>olanzapine</e1> treatment assigned method subjects schizophrenia <e2>disorder</e2>
C076029_D011618 NONE <e1>olanzapine</e1> treatment assigned method subjects schizophrenia <e2>disorder</e2>
D018967_D011618 NONE <e1>risperidone</e1> assigned method subjects schizophrenia <e2>disorder</e2>
D018967_D011618 NONE <e1>risperidone</e1> assigned method subjects schizophrenia <e2>disorder</e2>
D018967_D010302 NONE <e1>risperidone</e1> differ outcomes measures <e2>parkinsonism</e2>
D018967_D017109 NONE <e1>risperidone</e1> differ outcomes measures parkinsonism <e2>akathisia</e2>
D018967_D001480 CID <e1>risperidone</e1> differ scores severity <e2>symptom</e2>
C076029_D010302 NONE <e1>olanzapine</e1> differ outcomes measures <e2>parkinsonism</e2>
C076029_D017109 NONE <e1>olanzapine</e1> differ outcomes measures parkinsonism <e2>akathisia</e2>
C076029_D001480 CID <e1>olanzapine</e1> differ scores severity <e2>symptom</e2>
C076029_D015430 CID <e1>olanzapine</e1> occurred <e2>gain</e2>
C076029_D015430 CID <e1>olanzapine</e1> occurred <e2>gain</e2>
C076029_D015430 CID <e1>olanzapine</e1> greater caused <e2>gain</e2>
C076029_D015430 CID <e1>olanzapine</e1> greater <e2>gain</e2>
D018967_D015430 CID <e1>risperidone</e1> occurred <e2>gain</e2>
D018967_D015430 CID <e1>risperidone</e1> occurred <e2>gain</e2>
439781
D007213_D007022 CID <e1>indomethacin</e1> induced <e2>hypotension</e2>
D012964_D007022 NONE <e1>sodium</e1> induced <e2>hypotension</e2>
19419794
D016627_D004409 NONE <e1>6-hydroxydopamine</e1> lesion vulnerability reduced development <e2>dyskinesias</e2>
C005177_D004409 NONE <e1>l-dopa+benserazide</e1> treatment resulted <e2>dyskinesias</e2>
D004298_D004409 NONE <e1>da</e1> lesion impairment severity increased reduced <e2>dyskinesias</e2>
D007980_D004409 CID <e1>l-dopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 CID <e1>l-dopa-induced</e1> <e2>dyskinesias</e2>
23864035
C400082_D009101 NONE <e1>bortezomib</e1> therapy patients <e2>myeloma</e2>
C400082_D009101 NONE <e1>bortezomib</e1> (bort)-dexamethasone therapy <e2>myeloma</e2>
C400082_D009101 NONE <e1>bortezomib</e1> (bort)-dexamethasone therapy myeloma <e2>mm</e2>
C400082_D009101 NONE <e1>(bort)-dexamethasone</e1> therapy <e2>myeloma</e2>
C400082_D009101 NONE <e1>(bort)-dexamethasone</e1> therapy myeloma <e2>mm</e2>
C400082_D009101 NONE <e1>bort</e1> day mg dex treatment patients <e2>mm</e2>
C400082_D009101 NONE <e1>bort-dex</e1> treatment patients <e2>mm</e2>
D003907_D009101 NONE <e1>dexamethasone</e1> bortezomib therapy patients <e2>myeloma</e2>
D003907_D009101 NONE <e1>(bort)-dexamethasone</e1> therapy <e2>myeloma</e2>
D003907_D009101 NONE <e1>(bort)-dexamethasone</e1> therapy myeloma <e2>mm</e2>
D003907_D009101 NONE <e1>dex</e1> (bort)-dexamethasone therapy <e2>myeloma</e2>
D003907_D009101 NONE <e1>dex</e1> (bort)-dexamethasone therapy myeloma <e2>mm</e2>
D003907_D009101 NONE <e1>dex</e1> treatment patients <e2>mm</e2>
D003907_D009101 NONE <e1>bort-dex</e1> treatment patients <e2>mm</e2>
7931490
D017829_D009325 NONE <e1>granisetron</e1> efficacy prevention <e2>nausea</e2>
D017829_D009325 NONE <e1>granisetron</e1> doses effects assess administered dose prophylaxis <e2>nausea</e2>
D017829_D009325 NONE <e1>kytril</e1> assess administered dose prophylaxis <e2>nausea</e2>
D017829_D014839 NONE <e1>granisetron</e1> efficacy prevention nausea <e2>vomiting</e2>
D017829_D014839 NONE <e1>granisetron</e1> doses effects assess administered dose prophylaxis nausea <e2>vomiting</e2>
D017829_D014839 NONE <e1>kytril</e1> assess administered dose prophylaxis nausea <e2>vomiting</e2>
D017829_D014839 NONE <e1>granisetron</e1> doses micrograms/kg response < <e2>vomiting</e2>
D017829_D014839 NONE <e1>granisetron</e1> doses recorded results % response <e2>vomiting</e2>
D017829_D014839 NONE <e1>granisetron</e1> dose 10- effective controlling <e2>vomiting</e2>
D017829_D014839 NONE <e1>granisetron</e1> dose 10- effective controlling % patients received prevented <e2>vomiting</e2>
D012701_D009325 NONE <e1>5-hydroxytryptamine-3</e1> antagonist granisetron efficacy prevention <e2>nausea</e2>
D012701_D014839 NONE <e1>5-hydroxytryptamine-3</e1> antagonist granisetron efficacy prevention nausea <e2>vomiting</e2>
D002945_D009325 CID <e1>cisplatin</e1> induced <e2>nausea</e2>
D002945_D009325 CID <e1>cisplatin-induced</e1> <e2>nausea</e2>
D002945_D014839 CID <e1>cisplatin</e1> induced nausea <e2>vomiting</e2>
D002945_D014839 CID <e1>cisplatin-induced</e1> nausea <e2>vomiting</e2>
D002945_D014839 CID <e1>cisplatin</e1> received patients % controlling <e2>vomiting</e2>
D002945_D014839 CID <e1>cisplatin</e1> received prevented <e2>vomiting</e2>
931801
D005937_D007674 NONE <e1>d-glucarates</e1> effect <e2>damage</e2>
D005937_D007674 NONE <e1>d-glucarates</e1> effective <e2>damage</e2>
D005937_D007674 NONE <e1>d-glucarate</e1> obtained <e2>damages</e2>
D005937_D007674 NONE <e1>d-glucarates</e1> had ability prevent <e2>damage</e2>
D005937_D007674 NONE <e1>d-glucarates</e1> effect <e2>nephrotoxicity</e2>
D000617_D003681 NONE <e1>aminoglycoside</e1> antibiotics injection failure develop rats <e2>dehydrated</e2>
D000617_D058186 CID <e1>aminoglycoside</e1> antibiotics injection <e2>failure</e2>
C038936_D051437 NONE <e1>6,3-dilactone</e1> rats <e2>failure</e2>
D007612_D051437 NONE <e1>kanamycin-dextran</e1> induced <e2>failure</e2>
D000617_D007674 NONE <e1>aminoglycoside</e1> antibitocis antibiotics induced <e2>damage</e2>
D009005_D007674 NONE <e1>monosaccharides</e1> spared <e2>lesions</e2>
7967231
C059447_D020195 NONE <e1>s-312</e1> showed effects <e2>convulsions</e2>
C059447_D020195 NONE <e1>s-312-d</e1> s-312 showed effects <e2>convulsions</e2>
C059447_D020195 NONE <e1>s-312-d</e1> effects observed showed effects <e2>convulsions</e2>
C059447_D012640 NONE <e1>s-312</e1> showed observed <e2>convulsions</e2>
C059447_D012640 NONE <e1>s-312</e1> showed observed <e2>convulsions</e2>
C059447_D012640 NONE <e1>s-312-d</e1> s-312 showed observed <e2>convulsions</e2>
C059447_D012640 NONE <e1>s-312-d</e1> s-312 showed observed <e2>convulsions</e2>
C059447_D012640 NONE <e1>s-312-d</e1> effects observed <e2>convulsions</e2>
C059447_D012640 NONE <e1>s-312-d</e1> effects observed showed observed <e2>convulsions</e2>
-1_D020195 NONE <e1>s-312-l</e1> s-312 showed effects <e2>convulsions</e2>
-1_D012640 NONE <e1>s-312-l</e1> s-312 showed observed <e2>convulsions</e2>
-1_D012640 NONE <e1>s-312-l</e1> s-312 showed observed <e2>convulsions</e2>
D002118_D020195 NONE <e1>calcium</e1> channel antagonists s-312 showed effects <e2>convulsions</e2>
D002118_D012640 NONE <e1>calcium</e1> channel antagonists s-312 showed observed <e2>convulsions</e2>
D002118_D012640 NONE <e1>calcium</e1> channel antagonists s-312 showed observed <e2>convulsions</e2>
D005444_D020195 NONE <e1>flunarizine</e1> that 34.0 showed effects <e2>convulsions</e2>
D005444_D012640 NONE <e1>flunarizine</e1> that 34.0 showed observed <e2>convulsions</e2>
D005444_D012640 NONE <e1>flunarizine</e1> that 34.0 showed observed <e2>convulsions</e2>
D010433_D020195 NONE <e1>pentylenetetrazole</e1> induced convulsions observed showed effects <e2>convulsions</e2>
D010433_D012640 CID <e1>pentylenetetrazole</e1> induced <e2>convulsions</e2>
D010433_D012640 CID <e1>pentylenetetrazole</e1> induced convulsions observed showed observed <e2>convulsions</e2>
D001534_D020195 NONE <e1>bemegride</e1> convulsions observed showed effects <e2>convulsions</e2>
D001534_D012640 CID <e1>bemegride</e1> <e2>convulsions</e2>
D001534_D012640 CID <e1>bemegride</e1> convulsions observed showed observed <e2>convulsions</e2>
D016202_D020195 NONE <e1>n-methyl-d-aspartate</e1> induced convulsions observed showed effects <e2>convulsions</e2>
D016202_D012640 NONE <e1>n-methyl-d-aspartate</e1> induced convulsions observed showed observed <e2>convulsions</e2>
D016202_D012640 NONE <e1>n-methyl-d-aspartate</e1> induced <e2>convulsions</e2>
D010852_D020195 NONE <e1>picrotoxin</e1> n-methyl-d-aspartate induced convulsions observed showed effects <e2>convulsions</e2>
D010852_D012640 CID <e1>picrotoxin</e1> n-methyl-d-aspartate induced convulsions observed showed observed <e2>convulsions</e2>
D010852_D012640 CID <e1>picrotoxin</e1> n-methyl-d-aspartate induced <e2>convulsions</e2>
C059447_D004827 NONE <e1>s-312-d</e1> useful therapy types <e2>epilepsy</e2>
17828434
C002647_D012640 NONE <e1>mip</e1> inhibition replicate augment effects model <e2>seizures</e2>
D008094_D012640 NONE <e1>lithium</e1> effects model <e2>seizures</e2>
D007294_D012640 NONE <e1>inositol</e1> model <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> model <e2>seizures</e2>
20859899
D000809_D013575 NONE <e1>angiotensin-converting</e1> inhibitor therapy use caused <e2>syncope</e2>
D000809_D006947 NONE <e1>angiotensin-converting</e1> inhibitor therapy use caused <e2>hyperkalemia</e2>
D013148_D013575 NONE <e1>spironolactone</e1> inhibitor therapy use caused <e2>syncope</e2>
D013148_D006947 CID <e1>spironolactone</e1> inhibitor therapy use caused <e2>hyperkalemia</e2>
D013148_D006947 CID <e1>spiranolactone</e1> doses considered cause <e2>hyperkalemia</e2>
D000450_D006947 NONE <e1>aldosterone</e1> antagonist spiranolactone doses considered cause <e2>hyperkalemia</e2>
D017257_D006947 CID <e1>ramipril</e1> intake addition considered cause <e2>hyperkalemia</e2>
D011188_D006947 NONE <e1>potassium</e1> agents combination using patients alert possibility <e2>hyperkalemia</e2>
D011188_D007674 NONE <e1>potassium</e1> agents combination using patients have <e2>disturbance</e2>
26115410
D001152_D009369 CID <e1>ias</e1> exposure relate mechanisms identifying relationship <e2>cancer</e2>
D001152_D009369 CID <e1>ias</e1> exposure associated development <e2>cancer</e2>
D001152_D009369 CID <e1>ias</e1> exposure elicits mechanisms plausible development cells <e2>cancer</e2>
D001152_D009369 CID <e1>ias</e1> exposure development <e2>cancer</e2>
1359137
D014150_D006966 CID <e1>neuroleptic-associated</e1> <e2>hyperprolactinemia</e2>
D014150_D006966 CID <e1>medications</e1> associated outpatients <e2>hyperprolactinemia</e2>
D014150_D006966 CID <e1>neuroleptic-associated</e1> <e2>hyperprolactinemia</e2>
D014150_D000568 CID <e1>medications</e1> associated outpatients hyperprolactinemia <e2>amenorrhea/oligomenorrhea</e2>
D014150_D000568 CID <e1>neuroleptic-associated</e1> hyperprolactinemia <e2>amenorrhea/galactorrhea</e2>
D014150_D009839 CID <e1>medications</e1> associated outpatients hyperprolactinemia <e2>amenorrhea/oligomenorrhea</e2>
D001971_D006966 NONE <e1>bromocriptine</e1> treated outpatients <e2>hyperprolactinemia</e2>
D001971_D006966 NONE <e1>bromocriptine</e1> evaluated therapy <e2>hyperprolactinemia</e2>
D001971_D000568 NONE <e1>bromocriptine</e1> treated outpatients hyperprolactinemia <e2>amenorrhea/oligomenorrhea</e2>
D001971_D000568 NONE <e1>bromocriptine</e1> evaluated therapy hyperprolactinemia <e2>amenorrhea/galactorrhea</e2>
D001971_D009839 NONE <e1>bromocriptine</e1> treated outpatients hyperprolactinemia <e2>amenorrhea/oligomenorrhea</e2>
D001971_D011618 CID <e1>bromocriptine</e1> taking worsened <e2>symptoms</e2>
D001971_D005687 NONE <e1>bromocriptine</e1> evaluated therapy hyperprolactinemia <e2>amenorrhea/galactorrhea</e2>
D014150_D005687 NONE <e1>neuroleptic-associated</e1> hyperprolactinemia <e2>amenorrhea/galactorrhea</e2>
24067251
C418563_D007674 NONE <e1>fumarate</e1> investigation pattern <e2>injury</e2>
C418563_D007674 NONE <e1>tdf-related</e1> <e2>disease</e2>
C418563_D007674 NONE <e1>tdf-related</e1> disease criteria analysed had features <e2>dysfunction</e2>
C418563_D007674 NONE <e1>tdf-related</e1> disease criteria analysed found have features <e2>dysfunction</e2>
C418563_D005198 CID <e1>tdf-related</e1> disease criteria analysed had <e2>syndrome</e2>
C418563_D005198 CID <e1>tdf</e1> kidney effects hospitalisation incidence high patients features <e2>syndrome</e2>
8659767
D002045_D001145 NONE <e1>bupivacaine</e1> <e2>dysrhythmias</e2>
D002045_D001145 NONE <e1>bupivacaine</e1> <e2>dysrhythmias</e2>
D002045_D001145 NONE <e1>bupivacaine</e1> antagonizes dysrhythmogenicity dogs susceptible dogs <e2>dysrhythmias</e2>
D004837_D001145 NONE <e1>epinephrine</e1> bupivacaine <e2>dysrhythmias</e2>
D004837_D001145 NONE <e1>epinephrine</e1> effects potentiate <e2>dysrhythmias</e2>
D004837_D001145 NONE <e1>epinephrine</e1> dysrhythmogenicity dogs susceptible dogs <e2>dysrhythmias</e2>
D002045_D009203 NONE <e1>bupivacaine</e1> alters dysrhythmogenicity dogs dogs <e2>infarction</e2>
D004837_D009203 NONE <e1>epinephrine</e1> administration dysrhythmogenicity dogs dogs <e2>infarction</e2>
D004837_D009203 NONE <e1>epinephrine</e1> received day <e2>infarction</e2>
D006221_D009203 NONE <e1>halothane-anesthetized</e1> dogs received day <e2>infarction</e2>
D006221_D017180 NONE <e1>halothane-anesthetized</e1> dogs received appeared <e2>vt</e2>
D004837_D017180 CID <e1>epinephrine</e1> received appeared <e2>vt</e2>
D004837_D017180 CID <e1>epinephrine</e1> dysrhythmogenicity dogs susceptible <e2>vt</e2>
D002045_D017180 NONE <e1>bupivacaine</e1> antagonizes dysrhythmogenicity dogs susceptible <e2>vt</e2>
12678199
D000638_D016171 CID <e1>amiodarone-induced</e1> torsade <e2>pointes</e2>
D000638_D016171 CID <e1>amiodarone</e1> therapy associated development torsade <e2>pointes</e2>
D000638_D016171 CID <e1>amiodarone</e1> therapy associated development <e2>tdp</e2>
D000638_D016171 CID <e1>amiodarone</e1> therapy context resulted speculate prompted episode <e2>tdp.</e2>
D000638_D016171 CID <e1>amiodarone</e1> therapy context resulted speculate prompted known acquired <e2>tdp.</e2>
D000638_D016171 CID <e1>amiodarone-induced</e1> proarrhythmia resulted speculate prompted episode <e2>tdp.</e2>
D000638_D016171 CID <e1>amiodarone-induced</e1> proarrhythmia resulted speculate prompted known acquired <e2>tdp.</e2>
D000638_D016171 CID <e1>amiodarone</e1> therapy absence induce <e2>tdp</e2>
D004077_D016171 NONE <e1>digoxin</e1> hypokalemia factors context occurred case <e2>tdp</e2>
D004077_D007008 NONE <e1>digoxin</e1> <e2>hypokalemia</e2>
D000638_D001919 NONE <e1>amiodarone</e1> therapy context resulted speculate prompted known acquired exacerbates <e2>bradycardia</e2>
D000638_D001919 NONE <e1>amiodarone-induced</e1> proarrhythmia resulted speculate prompted known acquired exacerbates <e2>bradycardia</e2>
D000638_-1 NONE <e1>amiodarone</e1> therapy context resulted <e2>proarrhythmia</e2>
D000638_-1 NONE <e1>amiodarone-induced</e1> <e2>proarrhythmia</e2>
D000638_D007008 NONE <e1>amiodarone</e1> therapy absence induce <e2>hypokalemia</e2>
D000638_C537153 NONE <e1>amiodarone</e1> therapy absence induce hypokalemia <e2>hypomagnesemia</e2>
20828385
C401859_D020522 NONE <e1>temsirolimus</e1> effects cytostatic <e2>lymphoma</e2>
C401859_D020522 NONE <e1>temsirolimus</e1> treated <e2>mcl</e2>
C401859_D020522 NONE <e1>temsirolimus</e1> treatment had case <e2>mcl</e2>
C401859_D020522 NONE <e1>temsirolimus</e1> effect contribute efficiency <e2>mcl</e2>
C401859_D009369 NONE <e1>temsirolimus</e1> treatment had regression <e2>tumor</e2>
C401859_D009369 NONE <e1>temsirolimus</e1> inhibited proliferation <e2>tumor</e2>
C401859_D009369 NONE <e1>temsirolimus</e1> inhibited induce change number cells <e2>tumor</e2>
C401859_D009369 NONE <e1>temsirolimus</e1> had effect decrease density <e2>tumor</e2>
C401859_D009369 NONE <e1>temsirolimus</e1> reduced burden <e2>tumor</e2>
C401859_D009369 NONE <e1>temsirolimus</e1> effect tissue <e2>tumor</e2>
C401859_D009336 CID <e1>temsirolimus</e1> therapy found areas compatible repair tissue <e2>post-necrotic</e2>
15696449
D008558_D058186 CID <e1>melphalan</e1> <e2>insufficiency</e2>
D008558_D058186 CID <e1>melphalan</e1> conditioning noted development <e2>insufficiency</e2>
D008558_D058186 CID <e1>melphalan</e1> <e2>insufficiency</e2>
D008558_D058186 CID <e1>melphalan</e1> insufficiency <e2>ari</e2>
D008558_D058186 CID <e1>melphalan</e1> patients % developed <e2>ari</e2>
D008558_D058186 CID <e1>melphalan</e1> had <e2>ari</e2>
D008558_D058186 CID <e1>melphalan</e1> suggests timing <e2>injury</e2>
D008558_D058186 CID <e1>melphalan</e1> <e2>injury</e2>
D008558_C531616 NONE <e1>melphalan</e1> patients <e2>amyloidosis</e2>
D003404_D058186 NONE <e1>creatinine</e1> level increase defined <e2>insufficiency</e2>
D003404_D058186 NONE <e1>creatinine</e1> level increase defined insufficiency <e2>ari</e2>
D008558_-1 NONE <e1>melphalan</e1> injury prerequisite <e2>injury</e2>
19139825
D019772_D005909 NONE <e1>topotecan</e1> combination radiotherapy <e2>glioblastoma</e2>
D019772_D005909 NONE <e1>topotecan</e1> radiotherapy combination adults <e2>gbm</e2>
D019772_D005910 NONE <e1>topotecan</e1> option exhibits inhibition <e2>glioma</e2>
3383127
D002945_D007022 CID <e1>cisplatin</e1> receiving patients manifestation <e2>hypotension</e2>
D002945_D007022 CID <e1>cisplatin</e1> treated developed symptoms <e2>hypotension</e2>
D002945_D007022 CID <e1>cddp</e1> cisplatin treated developed symptoms <e2>hypotension</e2>
D002945_D066126 NONE <e1>cisplatin</e1> receiving patients manifestation <e2>cardiotoxicity</e2>
D002945_D066126 NONE <e1>cddp</e1> influenced manifestations <e2>cardiotoxicity</e2>
D005472_D007022 CID <e1>5-fluorouracil</e1> cisplatin receiving patients manifestation <e2>hypotension</e2>
D005472_D007022 CID <e1>5-fluorouracil</e1> cisplatin treated developed symptoms <e2>hypotension</e2>
D005472_D007022 CID <e1>5-fu</e1> 5-fluorouracil cisplatin treated developed symptoms <e2>hypotension</e2>
D005472_D066126 NONE <e1>5-fluorouracil</e1> cisplatin receiving patients manifestation <e2>cardiotoxicity</e2>
D005472_D066126 NONE <e1>5-fu</e1> <e2>cardiotoxicity</e2>
D002945_D015179 NONE <e1>cisplatin</e1> treated developed patients <e2>carcinoma</e2>
D002945_D015179 NONE <e1>cddp</e1> cisplatin treated developed patients <e2>carcinoma</e2>
D005472_D015179 NONE <e1>5-fluorouracil</e1> cisplatin treated developed patients <e2>carcinoma</e2>
D005472_D015179 NONE <e1>5-fu</e1> 5-fluorouracil cisplatin treated developed patients <e2>carcinoma</e2>
20431083
D014859_D002543 CID <e1>warfarin</e1> users increased frequent analysis <e2>ich</e2>
D014859_D002543 CID <e1>warfarin</e1> users increased frequent <e2>ich</e2>
D014859_D002543 CID <e1>warfarin</e1> users nonusers <e2>ich</e2>
D014859_D002543 CID <e1>warfarin</e1> users none was excess users nonusers <e2>ich</e2>
D014859_D002543 CID <e1>warfarin</e1> users <e2>ich</e2>
D014859_D002543 CID <e1>warfarin</e1> users mb excess suggests increase risk <e2>ich</e2>
D014859_D002543 CID <e1>warfarin-associated</e1> ich risk increase suggests excess mb users <e2>ich</e2>
D014859_D002543 CID <e1>warfarin-associated</e1> <e2>ich</e2>
D014859_D002544 NONE <e1>warfarin</e1> users increased frequent analysis ich <e2>is/tia</e2>
D014859_D002544 NONE <e1>warfarin</e1> users increased frequent ich <e2>is/tia</e2>
D014859_D002544 NONE <e1>warfarin</e1> users excess was none users <e2>is/tia</e2>
D014859_D002544 NONE <e1>warfarin</e1> users <e2>is/tia</e2>
D014859_D002546 NONE <e1>warfarin</e1> users increased frequent analysis ich <e2>is/tia</e2>
D014859_D002546 NONE <e1>warfarin</e1> users increased frequent ich <e2>is/tia</e2>
D014859_D002546 NONE <e1>warfarin</e1> users excess was none users <e2>is/tia</e2>
D014859_D002546 NONE <e1>warfarin</e1> users <e2>is/tia</e2>
D014859_-1 NONE <e1>warfarin</e1> users increased frequent <e2>mb</e2>
D014859_-1 NONE <e1>warfarin</e1> users excess <e2>mb</e2>
D014859_-1 NONE <e1>warfarin</e1> users none was excess <e2>mb</e2>
D014859_-1 NONE <e1>warfarin</e1> users <e2>mb</e2>
D014859_-1 NONE <e1>warfarin</e1> users mb excess suggests increase <e2>mb</e2>
D014859_-1 NONE <e1>warfarin-associated</e1> ich risk increase suggests excess <e2>mb</e2>
D014859_-1 NONE <e1>warfarin-associated</e1> ich risk increase <e2>mb</e2>
16920333
C416835_D012640 NONE <e1>acetate</e1> effect <e2>seizures</e2>
C416835_D012640 NONE <e1>093</e1> bia acetate effect <e2>seizures</e2>
C416835_D012640 NONE <e1>acetate</e1> model elicited <e2>seizures</e2>
C416835_D012640 NONE <e1>acetate</e1> model elicited changes threshold <e2>seizure</e2>
D010852_D012640 CID <e1>picrotoxin</e1> microperfusion induced <e2>seizures</e2>
D010852_D012640 CID <e1>picrotoxin</e1> doses treated animals 2.3+/-1.2 number <e2>seizures</e2>
D010852_D012640 CID <e1>picrotoxin</e1> doses treated animals 2.3+/-1.2 39.5+/-8.4s duration <e2>seizure</e2>
D010852_D012640 CID <e1>picrotoxin</e1> microperfusion dose pre-treatment prevented <e2>seizures</e2>
15482540
D012254_D000740 NONE <e1>ribavirin-induced</e1> <e2>anemia</e2>
D012254_D000740 NONE <e1>ribavirin-induced</e1> <e2>anemia</e2>
D012254_D000740 NONE <e1>ribavirin-induced</e1> <e2>anemia</e2>
D012254_D000740 NONE <e1>ribavirin-induced</e1> <e2>anemia</e2>
D016898_D019698 NONE <e1>interferon</e1> therapy <e2>c</e2>
D016898_D019698 NONE <e1>interferon-alpha-2b</e1> received patients <e2>c</e2>
D016898_D000743 CID <e1>interferon</e1> therapy background produces <e2>anemia</e2>
D012254_D019698 NONE <e1>ribavirin</e1> interferon therapy <e2>c</e2>
D012254_D019698 NONE <e1>ribavirin</e1> combination weeks administered mu dose received patients <e2>c</e2>
D012254_D000743 CID <e1>ribavirin</e1> interferon therapy background produces <e2>anemia</e2>
19549709
C107135_D002289 NONE <e1>everolimus</e1> efficacy patients <e2>nsclc</e2>
C107135_D002289 NONE <e1>rad001</e1> everolimus efficacy patients <e2>nsclc</e2>
C107135_D002289 NONE <e1>rad001</e1> shown efficacy <e2>nsclc</e2>
C107135_D002289 NONE <e1>rad001</e1> received iiib patients <e2>nsclc</e2>
C107135_D002289 NONE <e1>rad001</e1> tolerated showing activity <e2>nsclc</e2>
C107135_D002289 NONE <e1>rad001</e1> evaluation therapy <e2>nsclc</e2>
D020123_D002289 NONE <e1>rapamycin</e1> target inhibitor rad001 shown efficacy <e2>nsclc</e2>
D010984_D002289 NONE <e1>platinum</e1> based iiib patients <e2>nsclc</e2>
D010984_D064420 NONE <e1>platinum</e1> based iiib received progression <e2>toxicity</e2>
D014443_D002289 NONE <e1>tyrosine</e1> inhibitors chemotherapy iiib patients <e2>nsclc</e2>
D014443_D064420 NONE <e1>tyrosine</e1> inhibitors chemotherapy iiib received progression <e2>toxicity</e2>
C107135_D064420 NONE <e1>rad001</e1> received progression <e2>toxicity</e2>
7671401
D000806_D000799 CID <e1>inhibitor</e1> therapy related <e2>angio-oedema</e2>
D000806_D000799 CID <e1>inhibitors</e1> bouts <e2>angio-oedema</e2>
D000806_D000799 CID <e1>inhibitors</e1> reactions possibility patients <e2>angio-oedema</e2>
D000806_D006973 NONE <e1>inhibitors</e1> used treat <e2>hypertension</e2>
D000806_D006333 NONE <e1>inhibitors</e1> used treat hypertension <e2>failure</e2>
24464946
D015251_D066126 CID <e1>epirubicine-based</e1> chemotherapy prediction <e2>cardiotoxicity</e2>
D015251_D009202 NONE <e1>epirubicin</e1> exposure patients dysfunction predict alterations <e2>strain</e2>
D015251_D006331 NONE <e1>epirubicin</e1> exposure patients <e2>dysfunction</e2>
D015251_D008228 NONE <e1>epirubicin</e1> treated patients <e2>lymphoma</e2>
D018943_D006331 NONE <e1>anthracycline-based</e1> chemotherapy receiving patients <e2>dysfunction</e2>
1756784
D010862_D001930 CID <e1>pilocarpine-induced</e1> epilepticus <e2>reticulata</e2>
D010862_D013226 CID <e1>pilocarpine-induced</e1> <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine</e1> injection induced <e2>epilepticus</e2>
D002118_D009422 NONE <e1>calcium-binding</e1> protein nissl-staining served detect <e2>damage</e2>
9570197
D003042_D018487 CID <e1>cocaine</e1> amount causes deterioration <e2>function</e2>
D003042_D018487 CID <e1>cocaine</e1> sufficient infusion causes deterioration <e2>performance</e2>
D003042_D002637 NONE <e1>hydrochloride</e1> mg/min saline infusion minutes measured methods referred catheterization evaluation <e2>pain</e2>
24691439
D003907_D012173 NONE <e1>dexamethasone</e1> treatment led elevation loss cells <e2>ganglion</e2>
D003907_D009410 CID <e1>dexamethasone</e1> treatment led <e2>degeneration</e2>
D003907_D005901 CID <e1>dexamethasone</e1> treatment led resembling <e2>glaucoma</e2>
D003907_D009798 CID <e1>dexamethasone-induced</e1> <e2>hypertension</e2>
D003907_D009798 CID <e1>dexamethasone</e1> induced reduced prevented <e2>hypertension</e2>
D003907_D009798 CID <e1>dexamethasone-induced</e1> <e2>hypertension</e2>
D003907_D009798 CID <e1>dexamethasone-induced</e1> <e2>hypertension</e2>
C075773_D009798 NONE <e1>4-phenylbutyrate</e1> tm reduction prevented <e2>hypertension</e2>
24971338
D020123_D007674 NONE <e1>sirolimus</e1> conversion ameliorates <e2>nephropathy</e2>
D020123_D007674 NONE <e1>sirolimus</e1> conversion protocols used transplantation prevent <e2>nephropathy</e2>
D020123_D007674 NONE <e1>srl</e1> sirolimus conversion protocols used transplantation prevent <e2>nephropathy</e2>
D020123_D007674 NONE <e1>srl-treated</e1> rats presented proteinuria markers <e2>impairment</e2>
D020123_D007674 NONE <e1>srl</e1> conversion prevented evolution <e2>damage</e2>
D020123_D007674 NONE <e1>srl</e1> replacement biomarker seems prevented evolution <e2>damage</e2>
D016572_D007674 CID <e1>cyclosporine-induced</e1> <e2>nephropathy</e2>
D016572_D007674 CID <e1>a</e1> conversion protocols used transplantation prevent <e2>nephropathy</e2>
D016572_D007674 CID <e1>csa</e1> a conversion protocols used transplantation prevent <e2>nephropathy</e2>
D016572_D007674 CID <e1>csa-induced</e1> <e2>nephropathy</e2>
D016572_D007674 CID <e1>csa</e1> treatment presented slight <e2>lesions</e2>
D016572_D007674 CID <e1>csa</e1> exposure aggravated <e2>damage</e2>
D016572_D007674 CID <e1>csa-induced</e1> evolution <e2>damage</e2>
D016572_D007674 CID <e1>csa</e1> replacement biomarker seems prevented evolution <e2>damage</e2>
D006416_D007674 NONE <e1>hematoxylin</e1> analyzed <e2>lesions</e2>
D004801_D007674 NONE <e1>eosin</e1> hematoxylin analyzed <e2>lesions</e2>
D020123_D011507 CID <e1>srl-treated</e1> rats presented <e2>proteinuria</e2>
24671324
C400082_D019115 CID <e1>bortezomib</e1> regimen <e2>fasciitis</e2>
C400082_D019115 CID <e1>bortezomib</e1> treatment case man suffered <e2>fasciitis</e2>
C400082_D008258 NONE <e1>bortezomib</e1> regimen patient <e2>macroglobulinaemia</e2>
C400082_D008258 NONE <e1>bortezomib</e1> treatment case man <e2>macroglobulinaemia</e2>
D003907_D019115 CID <e1>dexamethasone-containing</e1> bortezomib regimen <e2>fasciitis</e2>
D003907_D019115 CID <e1>dexamethasone</e1> bortezomib treatment case man suffered <e2>fasciitis</e2>
D003907_D008258 NONE <e1>dexamethasone-containing</e1> bortezomib regimen patient <e2>macroglobulinaemia</e2>
D003907_D008258 NONE <e1>dexamethasone</e1> bortezomib treatment case man <e2>macroglobulinaemia</e2>
C400082_D001424 NONE <e1>bortezomib</e1> considered tolerable <e2>infections</e2>
C400082_D001424 NONE <e1>bortezomib</e1> related <e2>infections</e2>
C400082_D009369 NONE <e1>bortezomib</e1> considered tolerable infections patients <e2>malignancies</e2>
D003907_D001424 NONE <e1>dexamethasone-containing</e1> regimens bortezomib considered tolerable <e2>infections</e2>
D003907_D001424 NONE <e1>dexamethasone</e1> bortezomib related <e2>infections</e2>
D003907_D009369 NONE <e1>dexamethasone-containing</e1> regimens bortezomib considered tolerable infections patients <e2>malignancies</e2>
C400082_D009503 NONE <e1>bortezomib</e1> treatment case man suffered <e2>neutropenia</e2>
D003907_D009503 NONE <e1>dexamethasone</e1> bortezomib treatment case man suffered <e2>neutropenia</e2>
16801510
D008691_D008133 CID <e1>methadone</e1> receiving users <e2>syndrome</e2>
D008691_D008133 CID <e1>methadone</e1> treatment <e2>prolongation</e2>
D008691_D008133 CID <e1>methadone</e1> dose considered factors <e2>prolongation</e2>
D008691_D008133 CID <e1>methadone</e1> patients <e2>prolongation</e2>
D008691_D008133 CID <e1>methadone</e1> dose contribute <e2>prolongation</e2>
D008691_D008133 CID <e1>methadone</e1> doses occur <e2>syndrome</e2>
D008691_D016171 NONE <e1>methadone</e1> group patients presented torsades <e2>pointes</e2>
D008691_D007008 NONE <e1>methadone</e1> dose <e2>hypokalemia</e2>
D011188_D008133 NONE <e1>potassium</e1> level inhibitors dose contribute <e2>prolongation</e2>
24158386
C056507_D006689 NONE <e1>gem-p</e1> chemotherapy active treatment <e2>lymphoma</e2>
C056507_D006689 NONE <e1>gemcitabine</e1> have activity toxicity <e2>hl</e2>
C056507_D006689 NONE <e1>gemcitabine</e1> mg/m(2 treated patients relapsed <e2>hl</e2>
C056507_D006689 NONE <e1>gem-p</e1> days patients relapsed <e2>hl</e2>
C056507_D006689 NONE <e1>gem-p</e1> chemotherapy treatment relapsed <e2>hl</e2>
C056507_D064420 NONE <e1>gemcitabine</e1> have activity <e2>toxicity</e2>
D002945_D006689 NONE <e1>cisplatin</e1> gemcitabine have activity toxicity <e2>hl</e2>
D002945_D006689 NONE <e1>cisplatin</e1> d15 methylprednisolone patients relapsed <e2>hl</e2>
D002945_D064420 NONE <e1>cisplatin</e1> gemcitabine have activity <e2>toxicity</e2>
D008775_D006689 NONE <e1>methylprednisolone</e1> patients relapsed <e2>hl</e2>
2931989
D015474_D000152 NONE <e1>isotretinoin</e1> received patients drug treatment <e2>acne</e2>
D015474_D000013 NONE <e1>isotretinoin</e1> contraindicated <e2>abnormalities</e2>
D015474_D008850 NONE <e1>isotretinoin</e1> contraindicated abnormalities use <e2>microphthalmos</e2>
D015474_D006972 NONE <e1>isotretinoin</e1> contraindicated abnormalities use microphthalmos <e2>hypertelorism</e2>
D015474_C563492 NONE <e1>isotretinoin</e1> contraindicated abnormalities use microphthalmos <e2>hypoplasia</e2>
18987260
D004317_D007674 NONE <e1>adriamycin</e1> progression <e2>nephropathy</e2>
D004317_D007674 NONE <e1>adriamycin</e1> slowing progression <e2>disease</e2>
D004317_D007674 NONE <e1>adriamycin</e1> slowing potential <e2>nephropathy</e2>
D004317_D007674 NONE <e1>adr</e1> adriamycin slowing progression <e2>disease</e2>
D004317_D007674 NONE <e1>adr</e1> adriamycin slowing potential <e2>nephropathy</e2>
D004317_D007674 NONE <e1>adr</e1> <e2>nephropathy</e2>
D004317_D007674 NONE <e1>adr</e1> <e2>nephropathy</e2>
D004317_D006973 NONE <e1>adriamycin</e1> progression nephropathy rats <e2>hypertensive</e2>
D004317_D006973 NONE <e1>adriamycin</e1> slowing progression rats <e2>hypertensive</e2>
D004317_D006973 NONE <e1>adr</e1> adriamycin slowing progression rats <e2>hypertensive</e2>
D019808_D007674 NONE <e1>losartan</e1> treated rats <e2>nephropathy</e2>
D019808_D007674 NONE <e1>losartan</e1> blocker effects investigate was background nephropathy potential slowing progression <e2>disease</e2>
D019808_D007674 NONE <e1>losartan</e1> blocker effects investigate was background <e2>nephropathy</e2>
D019808_D007674 NONE <e1>losartan</e1> reduced clearance <e2>nephropathy</e2>
D019808_D007674 NONE <e1>losartan</e1> prevent <e2>nephropathy</e2>
D019808_D006973 NONE <e1>losartan</e1> treated rats <e2>hypertensive</e2>
D019808_D006973 NONE <e1>losartan</e1> blocker effects investigate was background nephropathy potential slowing progression rats <e2>hypertensive</e2>
D000804_D007674 NONE <e1>ii</e1> type-1 receptor blocker effects investigate was background nephropathy potential slowing progression <e2>disease</e2>
D000804_D007674 NONE <e1>ii</e1> type-1 receptor blocker effects investigate was background <e2>nephropathy</e2>
D000804_D006973 NONE <e1>ii</e1> type-1 receptor blocker effects investigate was background nephropathy potential slowing progression rats <e2>hypertensive</e2>
D019808_D005921 NONE <e1>losartan</e1> treatment results rate <e2>glomerulosclerosis</e2>
D019808_D005921 NONE <e1>losartan</e1> treatment showed reduction <e2>glomerulosclerosis</e2>
D019808_D011507 NONE <e1>losartan</e1> treatment results rate resulting <e2>proteinuria</e2>
D019808_D011507 NONE <e1>losartan</e1> treatment showed preventing <e2>proteinuria</e2>
D019808_D001284 NONE <e1>losartan</e1> treatment showed reduction glomerulosclerosis associated progression <e2>atrophy</e2>
D019808_D001284 NONE <e1>losartan</e1> prevent <e2>atrophy</e2>
D019808_D005355 NONE <e1>losartan</e1> treatment showed reduction glomerulosclerosis associated progression atrophy <e2>fibrosis</e2>
D019808_D005355 NONE <e1>losartan</e1> prevent atrophy <e2>fibrosis</e2>
D019808_D007676 NONE <e1>losartan</e1> treatment showed preventing proteinuria <e2>failure</e2>
D019808_D007676 NONE <e1>losartan</e1> reduces rate <e2>disease</e2>
D019808_D014511 NONE <e1>losartan</e1> reduced <e2>uraemia</e2>
D014508_D014511 NONE <e1>urea</e1> clearance reduced <e2>uraemia</e2>
D014508_D007674 NONE <e1>urea</e1> clearance <e2>nephropathy</e2>
D004317_D014511 CID <e1>adr</e1> nephropathy clearance reduced <e2>uraemia</e2>
D004317_D001284 NONE <e1>adr</e1> nephropathy prevent <e2>atrophy</e2>
D004317_D005355 NONE <e1>adr</e1> nephropathy prevent atrophy <e2>fibrosis</e2>
D019808_D005923 NONE <e1>losartan</e1> reduces rate progression <e2>glomerulosclerosis</e2>
D004317_D005923 CID <e1>adr-induced</e1> <e2>glomerulosclerosis</e2>
D004317_D007676 NONE <e1>adr-induced</e1> glomerulosclerosis progression rate <e2>disease</e2>
1522360
D012293_D006461 CID <e1>rifampin</e1> therapy <e2>hemolysis</e2>
D012293_D006461 CID <e1>rifampin</e1> therapy failure leading <e2>hemolysis</e2>
D012293_D006461 CID <e1>rifampin</e1> developed <e2>hemolysis</e2>
D012293_D058186 CID <e1>rifampin</e1> therapy hemolysis <e2>failure</e2>
D012293_D058186 CID <e1>rifampin</e1> therapy <e2>failure</e2>
D012293_D058186 CID <e1>rifampin</e1> developed hemolysis <e2>failure</e2>
D012293_D051437 NONE <e1>rifampin</e1> use associated complication <e2>failure</e2>
D012293_D007918 NONE <e1>rifampin</e1> developed patients <e2>leprosy</e2>
24283660
D016559_D012640 CID <e1>tacrolimus-related</e1> <e2>seizure</e2>
D016559_D012640 CID <e1>tac</e1> level included factors associated <e2>seizures</e2>
D016559_D012640 CID <e1>tac</e1> level factor associated <e2>seizures</e2>
D016559_D012640 CID <e1>tac</e1> level factor contributed <e2>seizures</e2>
D016559_D012640 CID <e1>tac-related</e1> <e2>seizures</e2>
D001663_D012640 NONE <e1>bilirubin</e1> included factors associated <e2>seizures</e2>
D001663_D058625 NONE <e1>bilirubin</e1> included score <e2>disease</e2>
D016559_D058625 NONE <e1>tac</e1> level included score <e2>disease</e2>
2453942
D001556_D020258 NONE <e1>lindane</e1> organochlorine insecticide effects <e2>neurotoxic</e2>
D001556_D020258 NONE <e1>gamma-hexachlorocyclohexane</e1> lindane organochlorine insecticide effects <e2>neurotoxic</e2>
D001556_D012640 CID <e1>lindane</e1> effect studied measuring concentration areas onset <e2>seizures</e2>
D001556_D012640 CID <e1>lindane</e1> administration min suffered <e2>convulsions</e2>
D005680_D012640 NONE <e1>gaba</e1> concentration areas onset <e2>seizures</e2>
D004298_D012640 NONE <e1>dopamine</e1> gaba concentration areas onset <e2>seizures</e2>
20009434
D008727_D058186 CID <e1>methotrexate</e1> therapy <e2>failure</e2>
D008727_D058186 CID <e1>hd-mtx</e1> therapy case <e2>failure</e2>
D008727_D058186 CID <e1>hd-mtx</e1> therapy caused <e2>failure</e2>
D008727_D002051 NONE <e1>methotrexate</e1> treatment <e2>lymphoma</e2>
D008727_D002051 NONE <e1>hd-mtx</e1> methotrexate treatment <e2>lymphoma</e2>
D008727_D056486 NONE <e1>methotrexate</e1> treatment cause <e2>toxicity</e2>
D008727_D056486 NONE <e1>hd-mtx</e1> methotrexate treatment cause <e2>toxicity</e2>
D008727_D007674 NONE <e1>methotrexate</e1> treatment cause <e2>toxicity</e2>
D008727_D007674 NONE <e1>hd-mtx</e1> methotrexate treatment cause <e2>toxicity</e2>
D008727_D001656 NONE <e1>hd-mtx</e1> therapy case report boy received transplantation <e2>atresia</e2>
14616590
D015742_D010146 CID <e1>disoprivan</e1> occurred <e2>pain</e2>
D015742_D013924 CID <e1>disoprivan</e1> occurred pain <e2>thrombophlebitis</e2>
23846525
C055162_D056486 CID <e1>clopidogrel</e1> associated <e2>hepatitis</e2>
C055162_D056486 CID <e1>clopidogrel-related</e1> <e2>hepatitis</e2>
C055162_D056486 CID <e1>clopidogrel</e1> reports cases <e2>hepatotoxicity</e2>
C055162_D056486 CID <e1>clopidogrel</e1> prescribed consider risk <e2>injury</e2>
1779253
D002211_D051474 NONE <e1>capsaicin</e1> <e2>neuralgia</e2>
D002211_D051474 NONE <e1>capsaicin</e1> response action time-course evaluate , patients <e2>neuralgia</e2>
D002211_D051474 NONE <e1>capsaicin</e1> response action time-course evaluate , patients neuralgia <e2>phn</e2>
D002211_D051474 NONE <e1>capsaicin</e1> cream treated order evaluate , patients <e2>neuralgia</e2>
D002211_D051474 NONE <e1>capsaicin</e1> cream treated order evaluate , patients neuralgia <e2>phn</e2>
D002211_D051474 NONE <e1>capsaicin</e1> effect <e2>phn</e2>
D002211_D008413 CID <e1>capsaicin-induced</e1> sensations <e2>mastitis</e2>
573555
D011433_D007003 NONE <e1>propranolol</e1> therapy correlated invariable <e2>hypoglycemia</e2>
D011433_D006932 NONE <e1>propranolol</e1> therapy correlated invariable hypoglycemia <e2>hyperbilirubinemia</e2>
D011433_D011086 NONE <e1>propranolol</e1> therapy correlated invariable hypoglycemia <e2>polycythemia</e2>
D011433_D001049 NONE <e1>propranolol</e1> therapy correlated invariable hypoglycemia <e2>apnea</e2>
D011433_D001919 NONE <e1>propranolol</e1> therapy correlated invariable hypoglycemia <e2>bradycardia</e2>
7173007
C025504_D009325 CID <e1>dimer-x</e1> group had incidence <e2>nausea</e2>
C025504_D004244 CID <e1>dimer-x</e1> group had incidence nausea <e2>dizziness</e2>
C006753_D015746 CID <e1>endografine</e1> group had incidence <e2>pain</e2>
D007485_D064420 NONE <e1>hexabrix</e1> polyvidone considered preferred <e2>toxicity</e2>
D007485_D064420 NONE <e1>hexabrix</e1> preferred <e2>toxicity</e2>
D000100_D064420 NONE <e1>polyvidone</e1> considered preferred <e2>toxicity</e2>
D003287_D064420 NONE <e1>media</e1> considered preferred <e2>toxicity</e2>
1449452
D004077_D001281 NONE <e1>digoxin</e1> <e2>fibrillation</e2>
D004077_D001145 CID <e1>digoxin</e1> has causing <e2>arrhythmias</e2>
D004077_D009203 NONE <e1>digoxin</e1> increase <e2>infarction</e2>
D004077_D009203 NONE <e1>digoxin</e1> increase infarction <e2>mi</e2>
9197951
D003042_D001714 NONE <e1>cocaine-dependent</e1> man became <e2>manic</e2>
D004053_D001714 CID <e1>diethylpropion</e1> efficacy evaluating study subject man became <e2>manic</e2>
D004053_D001714 CID <e1>dep</e1> diethylpropion efficacy evaluating study subject man became <e2>manic</e2>
D004053_D001714 CID <e1>dep</e1> changes changes different those observed subjects become <e2>manic</e2>
D004053_D011681 NONE <e1>dep</e1> changes changes power <e2>oscillation</e2>
25006961
D008094_D018500 CID <e1>lithium-induced</e1> <e2>insipidus</e2>
D008094_D018500 CID <e1>lithium</e1> induces <e2>insipidus</e2>
D008094_D018500 CID <e1>lithium</e1> induces insipidus <e2>ndi</e2>
D008094_D018500 CID <e1>lithium-induced</e1> <e2>ndi</e2>
D008094_D018500 CID <e1>lithium</e1> therapy associated polyuria development prevents preserves <e2>ndi</e2>
D008094_D011141 CID <e1>lithium-induced</e1> <e2>polyuria</e2>
D008094_D011141 CID <e1>lithium-induced</e1> ndi preserves prevents development <e2>polyuria</e2>
D008094_D011141 CID <e1>lithium</e1> therapy associated <e2>polyuria</e2>
6316193
D010852_D012640 CID <e1>picrotoxin-induced</e1> <e2>seizures</e2>
D010852_D012640 CID <e1>picrotoxin</e1> induced <e2>seizures</e2>
D010852_D012640 CID <e1>picrotoxin-induced</e1> <e2>seizures</e2>
D002766_D012640 NONE <e1>cholecystokinin</e1> antagonism <e2>seizures</e2>
D002766_D012640 NONE <e1>cholecystokinin</e1> analogues cholecystokinin antagonism <e2>seizures</e2>
D012844_D012640 NONE <e1>octapeptide</e1> ester administration enhanced latency <e2>seizures</e2>
D012844_D012640 NONE <e1>cck-8-se</e1> ester administration enhanced latency <e2>seizures</e2>
D012844_D012640 NONE <e1>octapeptide</e1> ester administration enhanced latency <e2>seizures</e2>
D012844_D012640 NONE <e1>cck-8-ns</e1> octapeptide ester administration enhanced latency <e2>seizures</e2>
D003975_D012640 NONE <e1>diazepam</e1> had prevented <e2>seizures</e2>
4631913
D014750_D011552 CID <e1>sulfate</e1> effect <e2>infections</e2>
D014750_D007970 CID <e1>sulfate</e1> mg inoculation followed <e2>leukopenia</e2>
D014750_D007239 NONE <e1>sulfate</e1> given resulted <e2>infection</e2>
19681452
D003042_D002543 NONE <e1>cocaine</e1> intoxication infarction <e2>pallidus</e2>
D003042_D020520 NONE <e1>cocaine</e1> intoxication infarction <e2>pallidus</e2>
D003042_D020520 NONE <e1>cocaine</e1> use <e2>infarcts</e2>
D000431_D002543 NONE <e1>alcohol</e1> cocaine intoxication infarction <e2>pallidus</e2>
D000431_D020520 NONE <e1>alcohol</e1> cocaine intoxication infarction <e2>pallidus</e2>
D003042_D002544 NONE <e1>cocaine</e1> factor <e2>stroke</e2>
D003042_D020521 NONE <e1>cocaine</e1> factor <e2>stroke</e2>
D000431_D002545 NONE <e1>alcohol</e1> case man ischemia <e2>pallidus</e2>
D003042_D002545 CID <e1>cocaine</e1> use alcohol case man ischemia <e2>pallidus</e2>
D003932_D020520 CID <e1>heroin</e1> associated <e2>infarctions</e2>
D003932_D020520 CID <e1>heroin</e1> use <e2>infarcts</e2>
D003042_D001145 NONE <e1>cocaine</e1> related patient <e2>arrhythmia</e2>
D003042_D012131 NONE <e1>cocaine</e1> related patient arrhythmia <e2>dysfunction</e2>
D003042_-1 NONE <e1>cocaine</e1> related patient causes <e2>hypoperfusion</e2>
D000431_D001145 NONE <e1>ethanol</e1> cocaine related patient <e2>arrhythmia</e2>
D000431_D012131 NONE <e1>ethanol</e1> cocaine related patient arrhythmia <e2>dysfunction</e2>
D000431_-1 NONE <e1>ethanol</e1> cocaine related patient causes <e2>hypoperfusion</e2>
2320485
D008750_D000743 CID <e1>methyldopa-induced</e1> <e2>anemia</e2>
D008750_D000743 CID <e1>methyldopa-induced</e1> <e2>anemia</e2>
D008750_D013575 NONE <e1>methyldopa-induced</e1> anemia <e2>near-syncope</e2>
D008750_D013575 NONE <e1>methyldopa-induced</e1> anemia presented <e2>near-syncope</e2>
D008750_D000744 NONE <e1>methyldopa</e1> causes <e2>anemia</e2>
D008750_D004630 NONE <e1>methyldopa-induced</e1> anemia presented <e2>department</e2>
D008750_D014947 NONE <e1>methyldopa</e1> treated weeks admission <e2>trauma</e2>
16092435
D012266_D066126 NONE <e1>d-ribose</e1> effect <e2>cardiotoxicity</e2>
D012266_D066126 NONE <e1>d-ribose</e1> influence <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>adriamycin-evoked</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>adriamycin</e1> evoked developed <e2>toxicity</e2>
D004317_D066126 NONE <e1>adr</e1> <e2>cardiotoxicity</e2>
D012266_D009202 NONE <e1>d-ribose</e1> <e2>myocardiopathy</e2>
D004317_D009202 CID <e1>adriamycin-induced</e1> <e2>myocardiopathy</e2>
2782734
D000420_D001249 NONE <e1>salbutamol</e1> therapy responses <e2>asthmatics</e2>
D000420_D001249 NONE <e1>salbutamol</e1> doses produce improvements response patients <e2>asthma</e2>
D000420_D001249 NONE <e1>salbutamol</e1> treatment given patients <e2>asthmatic</e2>
D000420_D001249 NONE <e1>salbutamol</e1> salbutamol treatment given patients <e2>asthmatic</e2>
D011188_D014202 NONE <e1>k</e1> responses fev1 <e2>tremor</e2>
D005947_D014202 NONE <e1>glu</e1> k responses fev1 <e2>tremor</e2>
24675088
D004317_D066126 NONE <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2>
D004317_D009202 CID <e1>doxorubicin</e1> model (dox)-induced <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>(dox)-induced</e1> <e2>cardiomyopathy</e2>
D004317_D064420 NONE <e1>doxorubicin</e1> model utilized provide events underlying <e2>toxicity</e2>
D004317_D064420 NONE <e1>(dox)-induced</e1> model utilized provide events underlying <e2>toxicity</e2>
D005682_D018754 NONE <e1>gadolinium</e1> enhancement <e2>dysfunction</e2>
24100055
D006493_D013921 CID <e1>heparin-induced</e1> type <e2>ii</e2>
D006493_D013921 CID <e1>heparin-induced</e1> type <e2>ii</e2>
D006493_D013921 CID <e1>heparin-induced</e1> type type <e2>ii</e2>
D006493_D013921 CID <e1>heparin-induced</e1> type impact cause <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> use avoided reduction type <e2>ii</e2>
D006493_D013921 CID <e1>heparin</e1> performed avoided reduction type <e2>ii</e2>
1837756
D012701_D010259 NONE <e1>serotonin</e1> inhibitors <e2>paranoia</e2>
D012701_D010259 NONE <e1>serotonin</e1> inhibitors cases exacerbation <e2>paranoid</e2>
D012701_D010259 NONE <e1>serotonin</e1> inhibitors associated exacerbations <e2>paranoid</e2>
D012701_D010259 NONE <e1>serotonin</e1> blockers exacerbations <e2>paranoid</e2>
D012701_D010259 NONE <e1>serotonin</e1> blockers exacerbations call raise <e2>paranoia</e2>
D005473_D010259 CID <e1>fluoxetine</e1> inhibitors cases exacerbation <e2>paranoid</e2>
D000639_D010259 CID <e1>amitriptyline</e1> fluoxetine inhibitors cases exacerbation <e2>paranoid</e2>
D012701_D003866 NONE <e1>serotonin</e1> inhibitors associated exacerbations vulnerability present <e2>disorders</e2>
D012701_D011605 NONE <e1>serotonin</e1> inhibitors associated exacerbations vulnerability present disorders atypicality chronicity <e2>psychosis</e2>
D012701_D011605 NONE <e1>serotonin</e1> inhibitors associated exacerbations vulnerability present disorders atypicality course <e2>psychosis</e2>
D004298_D010259 NONE <e1>dopamine</e1> release mechanisms remain pharmacology <e2>paranoia</e2>
3297909
D013827_D001649 NONE <e1>thiabendazole</e1> administration <e2>injury</e2>
D013827_D007565 NONE <e1>thiabendazole</e1> exposure wk <e2>jaundice</e2>
6106951
D005479_D064420 NONE <e1>fzp</e1> <e2>toxocity</e2>
D005479_D012798 NONE <e1>fzp</e1> toxocity signs included <e2>salivation</e2>
D005479_D014202 NONE <e1>fzp</e1> toxocity signs included salivation retching <e2>tremors</e2>
D005479_D012640 CID <e1>fzp</e1> toxocity signs included salivation retching tremors <e2>convulsions</e2>
D005479_D012640 CID <e1>fzp</e1> dose protected <e2>convulsions</e2>
D005479_D012640 CID <e1>fzp</e1> doses lower those cause <e2>convulsions</e2>
D005479_D004827 NONE <e1>fzp</e1> use situations is <e2>epilepsy</e2>
44072
C024986_D001145 CID <e1>bacl2</e1> used types <e2>arrhythmia</e2>
C024986_D001145 CID <e1>bacl2</e1> chloroform-adrenaline induced arrhythmia inhibition causing manifests activity models <e2>arrhythmia</e2>
C024986_D001145 CID <e1>bacl2</e1> chloroform-adrenaline induced <e2>arrhythmia</e2>
D002725_D001145 CID <e1>chloroform-adrenaline</e1> used types <e2>arrhythmia</e2>
D002725_D001145 CID <e1>chloroform-adrenaline</e1> induced arrhythmia inhibition causing manifests activity models <e2>arrhythmia</e2>
D002725_D001145 CID <e1>chloroform-adrenaline</e1> induced <e2>arrhythmia</e2>
D004837_D001145 CID <e1>chloroform-adrenaline</e1> used types <e2>arrhythmia</e2>
D004837_D001145 CID <e1>chloroform-adrenaline</e1> induced arrhythmia inhibition causing manifests activity models <e2>arrhythmia</e2>
D004837_D001145 CID <e1>chloroform-adrenaline</e1> induced <e2>arrhythmia</e2>
D010042_D001145 CID <e1>g</e1> used types <e2>arrhythmia</e2>
D000157_D001145 CID <e1>aconitine</e1> g used types <e2>arrhythmia</e2>
10087562
D004280_D016171 CID <e1>dobutamine</e1> treatment <e2>pointes</e2>
D004280_D016171 CID <e1>dobutamine</e1> describe <e2>pointes</e2>
D004280_D016171 CID <e1>dobutamine</e1> <e2>pointes</e2>
D004280_D017180 NONE <e1>dobutamine</e1> treatment pointes <e2>tachycardia</e2>
D004280_D017180 NONE <e1>dobutamine</e1> describe pointes <e2>tachycardia</e2>
D004280_D017180 NONE <e1>dobutamine</e1> pointes <e2>tachycardia</e2>
D004280_D002311 NONE <e1>dobutamine</e1> treatment patient <e2>cardiomyopathy</e2>
D004280_D002311 NONE <e1>dobutamine</e1> describe case woman failure secondary <e2>cardiomyopathy</e2>
D004280_D006333 NONE <e1>dobutamine</e1> treatment patient <e2>failure</e2>
D004280_D006333 NONE <e1>dobutamine</e1> describe case woman <e2>failure</e2>
D004280_D001145 NONE <e1>dobutamine</e1> describe case woman failure secondary cardiomyopathy <e2>arrhythmias</e2>
D004280_D001145 NONE <e1>dobutamine</e1> pointes supports hypothesis occur <e2>arrhythmias</e2>
D004280_D008133 NONE <e1>dobutamine</e1> describe case woman failure secondary cardiomyopathy arrhythmias developed <e2>prolongation</e2>
3083835
D010406_D000707 CID <e1>penicillin</e1> <e2>anaphylaxis</e2>
D010406_D000707 CID <e1>penicillin</e1> <e2>anaphylaxis</e2>
D010406_D000707 CID <e1>penicillin</e1> anaphylaxis case described reviewed terminology treatment <e2>anaphylaxis</e2>
D010406_D000707 CID <e1>penicillin</e1> <e2>anaphylaxis</e2>
2767010
C043114_D012640 NONE <e1>acc-9653</e1> sodium have activity <e2>seizures</e2>
C043114_D012640 NONE <e1>sodium</e1> have activity <e2>seizures</e2>
C043114_D017180 NONE <e1>acc-9653</e1> sodium have activity <e2>tachycardia</e2>
C043114_D017180 NONE <e1>sodium</e1> have activity <e2>tachycardia</e2>
D010042_D017180 CID <e1>ouabain-induced</e1> <e2>tachycardia</e2>
C043114_D001145 NONE <e1>acc-9653</e1> doses necessary convert <e2>arrhythmia</e2>
C043114_D001145 NONE <e1>sodium</e1> acc-9653 doses necessary convert <e2>arrhythmia</e2>
C043114_D001145 NONE <e1>sodium</e1> displayed activity <e2>arrhythmias</e2>
D013327_D001145 CID <e1>strophanthidin-induced</e1> <e2>arrhythmias</e2>
C043114_D064420 NONE <e1>acc-9653</e1> sodium studies <e2>toxicity</e2>
C043114_D064420 NONE <e1>sodium</e1> studies <e2>toxicity</e2>
9272404
D002245_D010146 NONE <e1>co2</e1> pulses means applied <e2>pain</e2>
D002245_D010146 NONE <e1>co2</e1> pulses means applied induced <e2>pain</e2>
D002245_D010146 NONE <e1>co2</e1> stimuli response obtained csseps correlates <e2>pain</e2>
D007052_D010146 CID <e1>ibuprofen</e1> administration followed decrease <e2>pain</e2>
D007052_D010146 CID <e1>ibuprofen</e1> administration followed decrease but-relative increase correlates <e2>pain</e2>
D007052_D010146 CID <e1>ibuprofen</e1> administration followed indicating effect ibuprofen interaction stimuli <e2>pain</e2>
D007052_D010146 CID <e1>ibuprofen</e1> effect indicating followed decrease <e2>pain</e2>
D007052_D010146 CID <e1>ibuprofen</e1> effect indicating followed decrease but-relative increase correlates <e2>pain</e2>
D007052_D010146 CID <e1>ibuprofen</e1> interaction stimuli <e2>pain</e2>
18340638
D001379_D000740 CID <e1>azathioprine</e1> include <e2>anemia</e2>
D001379_D000740 CID <e1>azathioprine</e1> triggers death effect contributing <e2>anemia</e2>
D001379_D000740 CID <e1>azathioprine-induced</e1> <e2>anemia</e2>
D010718_D000740 NONE <e1>phosphatidylserine</e1> exposure characterized death result <e2>anemia</e2>
D010718_D000740 NONE <e1>ps</e1> phosphatidylserine exposure characterized death result <e2>anemia</e2>
10726030
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> therapy effects aspects <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> therapy effects include <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> therapy effects include thrombocytopenia other <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> thrombocytopenia other <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-associated</e1> osteoporosis <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-associated</e1> osteoporosis thrombocytopenia other <e2>thrombocytopenia</e2>
D006493_D013921 NONE <e1>heparin</e1> use rare common <e2>hitt</e2>
D006493_D013927 NONE <e1>heparin-induced</e1> thrombocytopenia <e2>thrombosis</e2>
D006493_D013927 NONE <e1>heparin</e1> therapy effects aspects thrombocytopenia <e2>thrombosis</e2>
D006493_D013927 NONE <e1>heparin</e1> used used treat <e2>thrombosis</e2>
D006493_D013927 NONE <e1>heparin</e1> remains treat episodes <e2>thrombotic</e2>
D006493_D013927 NONE <e1>heparin</e1> use rare common <e2>hitt</e2>
D006493_D006470 NONE <e1>heparin</e1> effect <e2>bleeding</e2>
D006493_D006470 NONE <e1>heparin</e1> therapy receiving patients concern <e2>bleeding</e2>
D006493_D010024 CID <e1>heparin</e1> therapy effects include thrombocytopenia <e2>osteoporosis</e2>
D006493_D010024 CID <e1>heparin-induced</e1> thrombocytopenia <e2>osteoporosis</e2>
D006493_D010024 CID <e1>heparin-associated</e1> <e2>osteoporosis</e2>
D006493_D010024 CID <e1>heparin</e1> use rare common hitt <e2>osteoporosis</e2>
D006493_D004802 CID <e1>heparin</e1> therapy effects include thrombocytopenia <e2>eosinophilia</e2>
D006493_D004802 CID <e1>heparin-induced</e1> thrombocytopenia <e2>eosinophilia</e2>
D006493_D004802 CID <e1>heparin-associated</e1> osteoporosis thrombocytopenia <e2>eosinophilia</e2>
D006493_D012871 CID <e1>heparin</e1> therapy effects include thrombocytopenia <e2>reactions</e2>
D006493_D012871 CID <e1>heparin-induced</e1> thrombocytopenia <e2>reactions</e2>
D006493_D012871 CID <e1>heparin-associated</e1> osteoporosis thrombocytopenia <e2>reactions</e2>
D006493_D004342 CID <e1>heparin</e1> therapy effects include thrombocytopenia <e2>reactions</e2>
D006493_D004342 CID <e1>heparin-induced</e1> thrombocytopenia <e2>reactions</e2>
D006493_D004342 CID <e1>heparin-associated</e1> osteoporosis thrombocytopenia <e2>reactions</e2>
D006493_D000505 CID <e1>heparin</e1> therapy effects include thrombocytopenia <e2>alopecia</e2>
D006493_D000505 CID <e1>heparin-induced</e1> thrombocytopenia <e2>alopecia</e2>
D006493_D000505 CID <e1>heparin-associated</e1> osteoporosis thrombocytopenia <e2>alopecia</e2>
D006493_D006947 CID <e1>heparin</e1> therapy effects include thrombocytopenia <e2>hyperkalemia</e2>
D006493_D006947 CID <e1>heparin-induced</e1> thrombocytopenia <e2>hyperkalemia</e2>
D006493_D006947 CID <e1>heparin-associated</e1> osteoporosis thrombocytopenia <e2>hyperkalemia</e2>
D006493_D006994 CID <e1>heparin</e1> therapy effects include thrombocytopenia <e2>hypoaldosteronism</e2>
D006493_D006994 CID <e1>heparin-induced</e1> thrombocytopenia <e2>hypoaldosteronism</e2>
D006493_D006994 CID <e1>heparin-associated</e1> osteoporosis thrombocytopenia <e2>hypoaldosteronism</e2>
D006493_D011317 CID <e1>heparin</e1> therapy effects include thrombocytopenia <e2>priapism</e2>
D006493_D011317 CID <e1>heparin-induced</e1> thrombocytopenia <e2>priapism</e2>
D006493_D011317 CID <e1>heparin-associated</e1> osteoporosis thrombocytopenia <e2>priapism</e2>
10427794
C065757_D056486 CID <e1>meloxicam-induced</e1> <e2>toxicity</e2>
C065757_D056486 CID <e1>meloxicam</e1> developed <e2>hepatitis</e2>
C065757_D056486 CID <e1>meloxicam</e1> administration occurred <e2>hepatitis</e2>
C065757_D056486 CID <e1>meloxicam</e1> related <e2>toxicity</e2>
C065757_D056486 CID <e1>meloxicam</e1> related toxicity case demonstrates potential induce <e2>damage</e2>
C065757_D001172 NONE <e1>meloxicam</e1> developed patient <e2>arthritis</e2>
C065757_D004342 CID <e1>meloxicam</e1> administration occurred associated suggesting mechanism <e2>hypersensitivity</e2>
19184102
D014635_D065626 CID <e1>valproate</e1> therapy <e2>disease</e2>
D014635_D065626 CID <e1>vpa</e1> treatment developed child arising <e2>disease</e2>
D014635_D065626 CID <e1>vpa</e1> treatment developed child arising disease <e2>nafld</e2>
D014635_D065626 CID <e1>vpa</e1> treatment obesity associated development <e2>nafld</e2>
D014635_D065626 CID <e1>vpa</e1> withdrawal reversible suggests associated development <e2>nafld</e2>
D014635_D004827 NONE <e1>acid</e1> effective treatment types <e2>epilepsy</e2>
D014635_D004827 NONE <e1>vpa</e1> acid effective treatment types <e2>epilepsy</e2>
D014635_D009765 CID <e1>vpa</e1> treatment developed <e2>obesity</e2>
D014635_D009765 CID <e1>vpa</e1> treatment <e2>obesity</e2>
D014635_D009765 CID <e1>vpa</e1> withdrawal reversible suggests associated <e2>obesity</e2>
D014635_D015431 NONE <e1>vpa</e1> therapy withdrawal showed <e2>loss</e2>
D014635_D006946 CID <e1>vpa</e1> treatment obesity <e2>hyperinsulinemia</e2>
D014635_D006946 CID <e1>vpa</e1> withdrawal reversible suggests associated obesity <e2>hyperinsulinemia</e2>
D014635_D007333 CID <e1>vpa</e1> treatment obesity <e2>resistance</e2>
D014635_D007333 CID <e1>vpa</e1> withdrawal reversible suggests associated obesity <e2>resistance</e2>
18399341
D004837_D007022 NONE <e1>epinephrine</e1> infusion required treat <e2>hypotension</e2>
24742750
D016593_D016171 CID <e1>terfenadine</e1> blockers reported cause <e2>pointes</e2>
D016593_D016171 CID <e1>terfenadine</e1> blockers reported cause pointes <e2>tdp</e2>
D015283_D016171 CID <e1>citalopram</e1> terfenadine blockers reported cause <e2>pointes</e2>
D015283_D016171 CID <e1>citalopram</e1> terfenadine blockers reported cause pointes <e2>tdp</e2>
2358093
D003613_D054179 NONE <e1>danazol</e1> safety women <e2>angioedema</e2>
D003613_D054179 NONE <e1>danazol</e1> safety investigated performing review patients <e2>angioedema</e2>
D003613_D054179 NONE <e1>danazol</e1> treated <e2>angioedema</e2>
15859361
C105934_D003875 NONE <e1>celecoxib</e1> safety patients <e2>reactions</e2>
C105934_D003875 NONE <e1>ce</e1> tolerability group patients history <e2>reactions</e2>
D000082_D003875 CID <e1>acetaminophen</e1> safety patients <e2>reactions</e2>
D000082_D003875 CID <e1>paracetamol</e1> safety patients <e2>reactions</e2>
D000082_D003875 CID <e1>p</e1> <e2>reactions</e2>
D000082_D003875 CID <e1>p</e1> <e2>reactions</e2>
C012655_D003875 CID <e1>nimesulide</e1> safety patients <e2>reactions</e2>
C012655_D003875 CID <e1>n</e1> p <e2>reactions</e2>
C012655_D003875 CID <e1>n-induced</e1> <e2>reactions</e2>
D000082_D004342 NONE <e1>p</e1> studied patients <e2>hypersensitivity</e2>
D000082_D004342 NONE <e1>p</e1> documented reaction <e2>hypersensitivity</e2>
C012655_D004342 NONE <e1>n</e1> p studied patients <e2>hypersensitivity</e2>
C012655_D004342 NONE <e1>n-highly</e1> p documented reaction <e2>hypersensitivity</e2>
C105934_D004342 NONE <e1>ce</e1> reaction <e2>hypersensitivity</e2>
3088653
D012601_D000647 CID <e1>scopolamine-induced</e1> <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine</e1> induced <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine-induced</e1> <e2>amnesia</e2>
D009270_D000647 NONE <e1>naloxone</e1> reversal <e2>amnesia</e2>
D009270_D000647 NONE <e1>naloxone</e1> administration attenuated <e2>amnesia</e2>
D009270_D008569 NONE <e1>naloxone</e1> role <e2>deficit</e2>
D009270_D008569 NONE <e1>naloxone</e1> injected attenuated <e2>deficit</e2>
D009270_D008569 NONE <e1>naloxone</e1> sensitivity increase appear responsible influence <e2>deficit</e2>
D009270_D008569 NONE <e1>naloxone</e1> state sensitivity increase appear responsible influence <e2>deficit</e2>
D009270_D008569 NONE <e1>naloxone</e1> influence <e2>deficit</e2>
D012601_D008569 NONE <e1>scopolamine-induced</e1> <e2>deficit</e2>
D012601_D008569 NONE <e1>scopolamine-induced</e1> <e2>deficit</e2>
D019832_D000647 NONE <e1>scopolamine</e1> scopolamine induced <e2>amnesia</e2>
D009270_D010146 NONE <e1>naloxone</e1> sensitivity <e2>pain</e2>
D009270_D010146 NONE <e1>naloxone</e1> state sensitivity <e2>pain</e2>
D009270_D010146 NONE <e1>naloxone</e1> influence responsible appear increase sensitivity <e2>pain</e2>
D012601_D010146 NONE <e1>scopolamine-induced</e1> deficit influence responsible appear increase sensitivity <e2>pain</e2>
8808730
D009569_D001745 NONE <e1>oxide</e1> synthase expression <e2>irritation</e2>
D009569_D014570 NONE <e1>oxide</e1> synthase expression irritation <e2>tract</e2>
D003520_D003556 CID <e1>cyclophosphamide</e1> induced <e2>cystitis</e2>
D003520_D003556 CID <e1>cyp</e1> cyclophosphamide induced <e2>cystitis</e2>
D000171_D003556 NONE <e1>acrolein</e1> metabolized cyclophosphamide induced <e2>cystitis</e2>
24753331
C106487_D020964 CID <e1>s-53482</e1> herbicides produced <e2>embryolethality</e2>
C106487_D064793 CID <e1>s-53482</e1> herbicides produced embryolethality <e2>teratogenicity</e2>
C106487_D064793 CID <e1>s-53482</e1> <e2>teratogenic</e2>
C106487_D006345 CID <e1>s-53482</e1> herbicides <e2>defects</e2>
C106487_D005317 CID <e1>s-53482</e1> herbicides <e2>retardation</e2>
C106487_D064420 NONE <e1>s-53482</e1> herbicides studies <e2>toxicity</e2>
C106487_D064420 NONE <e1>s-53482</e1> rats exposure produced patterns <e2>toxicity</e2>
C083440_D020964 CID <e1>s-23121</e1> s-53482 herbicides produced <e2>embryolethality</e2>
C083440_D020964 CID <e1>s-23121</e1> administration resulted incidence <e2>death</e2>
C083440_D020964 CID <e1>s-23121</e1> exposure following observed resulted incidence <e2>death</e2>
C083440_D064793 CID <e1>s-23121</e1> s-53482 herbicides produced embryolethality <e2>teratogenicity</e2>
C083440_D064793 CID <e1>s-23121</e1> s-53482 <e2>teratogenic</e2>
C083440_D006345 CID <e1>s-23121</e1> s-53482 herbicides <e2>defects</e2>
C083440_D006345 CID <e1>s-23121</e1> administration resulted incidence death <e2>defect</e2>
C083440_D006345 CID <e1>s-23121</e1> exposure following observed resulted incidence death <e2>defect</e2>
C083440_D005317 CID <e1>s-23121</e1> s-53482 herbicides <e2>retardation</e2>
C083440_D064420 NONE <e1>s-23121</e1> s-53482 herbicides studies <e2>toxicity</e2>
24209900
D007069_D001927 NONE <e1>ifosfamide</e1> related <e2>encephalopathy</e2>
D007069_D001927 NONE <e1>ifosfamide</e1> receiving patients % reported <e2>encephalopathy</e2>
D007069_D001927 NONE <e1>ifosfamide</e1> related <e2>encephalopathy</e2>
D007069_D001927 NONE <e1>ifosfamide</e1> related <e2>encephalopathy</e2>
D007069_D001927 NONE <e1>ifosfamide</e1> receiving experienced symptoms <e2>encephalopathy</e2>
D007069_D001927 NONE <e1>ifosfamide</e1> related <e2>encephalopathy</e2>
D007069_D001927 NONE <e1>ifosfamide</e1> develop features <e2>encephalopathy</e2>
D007069_D009369 NONE <e1>ifosfamide</e1> is agent useful treatment range <e2>cancers</e2>
D007069_D009369 NONE <e1>ifosfamide</e1> is agent useful treatment range cancers sarcomas <e2>cancers</e2>
D007069_D009369 NONE <e1>ifosfamide</e1> related encephalopathy developed admitted center <e2>cancer</e2>
D007069_D012509 NONE <e1>ifosfamide</e1> is agent useful treatment range cancers <e2>sarcomas</e2>
D007069_D008223 NONE <e1>ifosfamide</e1> is agent useful treatment range cancers sarcomas <e2>lymphoma</e2>
24733133
C031942_D055499 NONE <e1>argatroban</e1> <e2>thrombolysis</e2>
C031942_D055499 NONE <e1>argatroban</e1> <e2>thrombolysis</e2>
C031942_D013921 NONE <e1>argatroban</e1> thrombolysis use patient <e2>thrombocytopenia</e2>
C031942_D013921 NONE <e1>argatroban</e1> treated developed <e2>thrombocytopenia</e2>
C031942_D013921 NONE <e1>argatroban</e1> treated developed thrombosis <e2>hitt</e2>
C031942_D013921 NONE <e1>argatroban</e1> treated man amyloidosis secondary <e2>hitt</e2>
C031942_D013927 NONE <e1>argatroban</e1> thrombolysis use patient <e2>thrombosis</e2>
C031942_D013927 NONE <e1>argatroban</e1> treated developed <e2>thrombosis</e2>
C031942_D013927 NONE <e1>argatroban</e1> treated developed thrombosis <e2>hitt</e2>
C031942_D013927 NONE <e1>argatroban</e1> treated man amyloidosis secondary <e2>hitt</e2>
D006493_D055499 NONE <e1>heparin-induced</e1> thrombocytopenia patient use <e2>thrombolysis</e2>
D006493_D055499 NONE <e1>heparin-induced</e1> thrombocytopenia developed treated argatroban <e2>thrombolysis</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 NONE <e1>heparin-induced</e1> thrombocytopenia developed thrombosis <e2>hitt</e2>
D006493_D013927 NONE <e1>heparin-induced</e1> thrombocytopenia patient <e2>thrombosis</e2>
D006493_D013927 NONE <e1>heparin-induced</e1> thrombocytopenia developed <e2>thrombosis</e2>
D006493_D013927 NONE <e1>heparin-induced</e1> thrombocytopenia developed thrombosis <e2>hitt</e2>
D006493_D000686 NONE <e1>heparin-induced</e1> thrombocytopenia secondary thrombosis upper-extremity developed summary man <e2>amyloidosis</e2>
D006493_D056824 NONE <e1>heparin-induced</e1> thrombocytopenia secondary <e2>thrombosis</e2>
D006493_D020246 CID <e1>heparin-induced</e1> thrombocytopenia secondary thrombosis <e2>dvt</e2>
D006493_D011655 CID <e1>heparin-induced</e1> thrombocytopenia secondary thrombosis <e2>embolism</e2>
C031942_D004844 NONE <e1>argatroban</e1> restarted resolved <e2>epistaxis</e2>
C031942_D000686 NONE <e1>argatroban</e1> treated man <e2>amyloidosis</e2>
C031942_D013479 NONE <e1>argatroban</e1> treated man amyloidosis <e2>syndrome</e2>
24928523
C400082_D009101 NONE <e1>bortezomib</e1> combination therapy transplantation <e2>myeloma</e2>
C400082_D009101 NONE <e1>bortezomib</e1> regimen safety patients <e2>mm</e2>
D013792_D009101 NONE <e1>thalidomide</e1> bortezomib combination therapy transplantation <e2>myeloma</e2>
D013792_D009101 NONE <e1>thalidomide</e1> regimen safety patients <e2>mm</e2>
D003907_D009101 NONE <e1>dexamethasone</e1> bortezomib combination therapy transplantation <e2>myeloma</e2>
D003907_D009101 NONE <e1>dexamethasone</e1> safety patients <e2>mm</e2>
2904523
D004837_D006973 CID <e2><e1>adrenaline-hypertension</e1></e2>
D004837_D006973 CID <e1>adrenaline</e1> infusion support hypothesis <e2>adrenaline-hypertension</e2>
D004837_D006973 CID <e2><e1>adrenaline-hypertension</e1></e2>
24114426
D018817_D003866 CID <e1>3,4-methylenedioxymethamphetamine</e1> users <e2>depression</e2>
D018817_D003866 CID <e1>mdma</e1> users <e2>depression</e2>
D018817_D003866 CID <e1>ecstasy</e1> mdma users <e2>depression</e2>
D018817_D003866 CID <e1>ecstasy</e1> users generation prognosis cause record levels <e2>depression</e2>
D018817_D010554 CID <e1>3,4-methylenedioxymethamphetamine</e1> users depression <e2>impulsiveness</e2>
D018817_D010554 CID <e1>mdma</e1> users depression <e2>impulsiveness</e2>
D018817_D010554 CID <e1>ecstasy</e1> mdma users depression <e2>impulsiveness</e2>
D018817_D010554 CID <e1>ecstasy</e1> users generation prognosis cause record levels depression <e2>impulsiveness</e2>
D018817_D008569 NONE <e1>ecstasy</e1> users generation prognosis cause record <e2>memory</e2>
D018817_D020920 CID <e1>ecstasy</e1> users generation prognosis cause record levels depression <e2>disturbance</e2>
978847
D006145_D006973 NONE <e1>guanethidine</e1> injection reduced inhibited enlargement <e2>pressure</e2>
D006145_D013610 NONE <e1>guanethidine</e1> injection reduced inhibited enlargement <e2>tachycardia</e2>
D018738_D006973 NONE <e1>hexamethonium</e1> injection reduced inhibited enlargement <e2>pressure</e2>
D018738_D013610 NONE <e1>hexamethonium</e1> injection reduced inhibited enlargement <e2>tachycardia</e2>
D010646_D006973 NONE <e1>phentolamine</e1> injection reduced inhibited enlargement <e2>pressure</e2>
D010646_D013610 NONE <e1>phentolamine</e1> injection reduced inhibited enlargement <e2>tachycardia</e2>
D003891_D006973 CID <e1>desmethylimipramine</e1> potentiated reduced inhibited enlargement <e2>pressure</e2>
D003891_D013610 NONE <e1>desmethylimipramine</e1> potentiated reduced inhibited enlargement <e2>tachycardia</e2>
D011433_D006973 NONE <e1>propranolol</e1> inhibited enlargement <e2>pressure</e2>
D011433_D013610 NONE <e1>propranolol</e1> inhibited enlargement <e2>tachycardia</e2>
D002217_D006973 CID <e1>carbachol</e1> tachycardia enlargement <e2>pressure</e2>
D002217_D013610 CID <e1>carbachol</e1> <e2>tachycardia</e2>
8392553
C056595_D006331 NONE <e1>clentiazem</e1> <e2>injury</e2>
C056595_D006331 NONE <e1>clentiazem</e1> attenuated <e2>injury</e2>
D004837_D006331 NONE <e1>epinephrine-induced</e1> <e2>injury</e2>
D004837_D006331 NONE <e1>epinephrine-induced</e1> <e2>injury</e2>
C056595_D009202 NONE <e1>clentiazem</e1> effects <e2>cardiomyopathy</e2>
C106746_D009202 NONE <e1>1,5-benzothiazepine</e1> antagonist clentiazem effects <e2>cardiomyopathy</e2>
D002118_D009202 NONE <e1>calcium</e1> antagonist clentiazem effects <e2>cardiomyopathy</e2>
D004837_D009202 CID <e1>epinephrine-induced</e1> <e2>cardiomyopathy</e2>
D004837_D007511 NONE <e1>epinephrine</e1> infusion died <e2>lesions</e2>
D004837_D007511 NONE <e1>epinephrine-induced</e1> death prevented attenuated <e2>lesions</e2>
D004837_D005355 NONE <e1>epinephrine</e1> infusion died lesions <e2>fibrosis</e2>
D004837_D005355 NONE <e1>epinephrine-induced</e1> death prevented attenuated lesions <e2>fibrosis</e2>
C056595_D007511 NONE <e1>clentiazem</e1> treatment prevented attenuated <e2>lesions</e2>
C056595_D005355 NONE <e1>clentiazem</e1> treatment prevented attenuated lesions <e2>fibrosis</e2>
7369302
D011803_D000550 CID <e1>quinine</e1> <e2>amblyopia</e2>
D011803_D001766 CID <e1>sulfate</e1> use developed <e2>blindness</e2>
D011803_D015845 CID <e1>sulfate</e1> use developed blindness response <e2>pupillary</e2>
D011803_D015845 CID <e1>quinine</e1> toxicity potentials supersensitivity response <e2>pupillary</e2>
D011803_D009120 NONE <e1>sulfate</e1> <e2>cramps</e2>
D011803_D064420 NONE <e1>quinine</e1> <e2>toxicity</e2>
3812624
D002220_D009759 NONE <e1>carbamazepine</e1> associated cases <e2>nystagmus</e2>
D002220_D009759 NONE <e1>carbamazepine</e1> therapy related <e2>nystagmus</e2>
D002220_D009759 NONE <e1>carbamazepine</e1> levels reduction resolved patients <e2>nystagmus</e2>
D002220_D015835 CID <e1>carbamazepine</e1> associated cases nystagmus <e2>oscillopsia</e2>
3798047
D008775_D001919 CID <e1>methylprednisolone</e1> therapy <e2>bradycardia</e2>
D008775_D001172 NONE <e1>methylprednisolone</e1> high-dose therapy received patients <e2>arthritis</e2>
D008775_D001172 NONE <e1>mp</e1> therapy received patients <e2>arthritis</e2>
D008775_D006331 NONE <e1>mp</e1> contraindicated patients <e2>disease</e2>
17721298
D016578_D003320 CID <e1>cocaine</e1> use associated <e2>ulcers</e2>
D016578_D003320 CID <e1>cocaine</e1> use associated <e2>ulcers</e2>
D016578_D003320 CID <e1>cocaine</e1> use associated development <e2>ulcers</e2>
1655018
D000728_D006528 CID <e1>androgen</e1> treated anemia <e2>carcinoma</e2>
D000728_D005199 NONE <e1>androgen</e1> treated <e2>anemia</e2>
D000728_D005199 NONE <e1>androgens</e1> treated known have <e2>anemia</e2>
D000728_D005199 NONE <e1>androgen-</e1> <e2>anemia</e2>
D000305_D006528 CID <e1>corticosteroid</e1> androgen treated anemia <e2>carcinoma</e2>
D000305_D005199 NONE <e1>corticosteroid</e1> androgen treated <e2>anemia</e2>
D000305_D005199 NONE <e1>corticosteroids</e1> androgens treated known have <e2>anemia</e2>
D000305_D005199 NONE <e1>corticosteroid-treated</e1> androgen- <e2>anemia</e2>
D000728_D008113 NONE <e1>androgen-</e1> patients develop <e2>neoplasms</e2>
D000728_D010382 CID <e1>androgen-</e1> patients develop neoplasms <e2>peliosis</e2>
D000305_D008113 NONE <e1>corticosteroid-treated</e1> androgen- patients develop <e2>neoplasms</e2>
D000305_D010382 CID <e1>corticosteroid-treated</e1> androgen- patients develop neoplasms <e2>peliosis</e2>
10975596
C118667_D009203 NONE <e1>dronedarone</e1> amiodarone animals <e2>infarction</e2>
C118667_D009203 NONE <e1>dronedarone</e1> effects compared those rest stimulation dogs <e2>infarction</e2>
D000638_D009203 NONE <e1>amiodarone</e1> animals <e2>infarction</e2>
D000638_D009203 NONE <e1>amiodarone</e1> related compound dronedarone effects compared those rest stimulation dogs <e2>infarction</e2>
D000638_D009203 NONE <e1>amiodarone</e1> those rest stimulation dogs <e2>infarction</e2>
C118667_D013610 NONE <e1>dronedarone</e1> reduced <e2>tachycardia</e2>
C118667_D013610 NONE <e1>dronedarone</e1> reduced decreased <e2>tachycardia</e2>
D000638_D013610 NONE <e1>amiodarone</e1> dronedarone reduced <e2>tachycardia</e2>
D000638_D013610 NONE <e1>amiodarone</e1> dronedarone reduced decreased <e2>tachycardia</e2>
D007545_D013610 CID <e1>isoproterenol-induced</e1> tachycardia decreased reduced <e2>tachycardia</e2>
D007545_D013610 CID <e1>isoproterenol-induced</e1> <e2>tachycardia</e2>
C118667_D001145 NONE <e1>dronedarone</e1> suitable treatment <e2>arrhythmias</e2>
24618873
D008614_D002526 NONE <e1>pethidine</e1> infusion induced <e2>dysfunction</e2>
D008614_D005128 NONE <e1>pethidine</e1> infusion induced <e2>dysfunction</e2>
D008614_D010146 NONE <e1>pethidine</e1> opioid gains popularity control <e2>pain</e2>
D008614_D010146 NONE <e1>pethidine</e1> cause patients function those need control <e2>pain</e2>
D008614_D051437 NONE <e1>pethidine</e1> cause patients <e2>function</e2>
D008614_D017093 NONE <e1>pethidine</e1> cause patients <e2>function</e2>
D008614_D020258 NONE <e1>pethidine</e1> cause metabolite <e2>neurotoxic</e2>
D008614_D001523 NONE <e1>pethidine</e1> cause resulting <e2>irritability</e2>
D008614_D012640 NONE <e1>pethidine</e1> cause resulting irritability attack <e2>seizure</e2>
C002752_D051437 NONE <e1>norpethidine</e1> metabolite cause patients <e2>function</e2>
C002752_D017093 NONE <e1>norpethidine</e1> metabolite cause patients <e2>function</e2>
C002752_D010146 NONE <e1>norpethidine</e1> metabolite cause patients function those need control <e2>pain</e2>
C002752_D020258 NONE <e1>norpethidine</e1> metabolite <e2>neurotoxic</e2>
C002752_D001523 NONE <e1>norpethidine</e1> metabolite cause resulting <e2>irritability</e2>
C002752_D012640 CID <e1>norpethidine</e1> metabolite cause resulting irritability attack <e2>seizure</e2>
7411769
D007213_D006947 CID <e1>indomethacin-induced</e1> <e2>hyperkalemia</e2>
D007213_D006947 CID <e1>indomethacin</e1> treatment developed patients severe <e2>hyperkalemia</e2>
D007213_D015210 NONE <e1>indomethacin-induced</e1> hyperkalemia patients <e2>arthritis</e2>
D007213_D015210 NONE <e1>indomethacin</e1> treatment <e2>arthritis</e2>
D007213_D051437 CID <e1>indomethacin</e1> treatment developed patients severe hyperkalemia <e2>insufficiency</e2>
D011453_D006994 NONE <e1>prostaglandin</e1> synthesis <e2>hypoaidosteronism</e2>
D011188_D003920 NONE <e1>potassium</e1> balance function attention patients <e2>mellitus</e2>
D011188_D007674 NONE <e1>potassium</e1> balance function attention patients mellitus <e2>disease</e2>
D007213_D003920 NONE <e1>indomethacin</e1> receiving patients function attention patients <e2>mellitus</e2>
D007213_D007674 NONE <e1>indomethacin</e1> receiving patients function attention patients mellitus <e2>disease</e2>
9061777
D016291_D012640 CID <e1>mk-801</e1> augments <e2>seizure</e2>
D016291_D012640 CID <e1>mk-801</e1> effects model <e2>seizure</e2>
D016291_D012640 CID <e1>mk-801</e1> <e2>seizure</e2>
D016291_D012640 CID <e1>mk-801</e1> treatment augmented blocked <e2>seizure</e2>
D016291_D012640 CID <e1>mk-801</e1> treatment augmented <e2>seizure</e2>
D016291_D001930 NONE <e1>mk-801</e1> augments protects <e2>damage</e2>
D016291_D001930 NONE <e1>mk-801</e1> pentobarbital protected <e2>damage</e2>
D016291_D001930 NONE <e1>mk-801-treated</e1> group appeared protected <e2>damage</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> electrographic <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> model <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine</e1> injection induced <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine-treated</e1> group appeared <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> electrographic blocked <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> electrographic blocked augmented <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine</e1> induced seizure augmented blocked <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine</e1> induced <e2>seizure</e2>
D010862_D001930 NONE <e1>pilocarpine-induced</e1> electrographic seizure augments protects <e2>damage</e2>
D010862_D001930 NONE <e1>pilocarpine</e1> protected <e2>damage</e2>
D010862_D001930 NONE <e1>pilocarpine</e1> induced epilepticus initiated cause <e2>damage</e2>
D012601_D012640 NONE <e1>scopolamine</e1> prevented development <e2>seizure</e2>
D012601_D012640 NONE <e1>scopolamine</e1> blocked <e2>seizure</e2>
D012601_D012640 NONE <e1>scopolamine</e1> blocked augmented <e2>seizure</e2>
D010424_D012640 NONE <e1>pentobarbital</e1> scopolamine prevented development <e2>seizure</e2>
D010424_D012640 NONE <e1>pentobarbital</e1> scopolamine blocked <e2>seizure</e2>
D010424_D012640 NONE <e1>pentobarbital</e1> scopolamine blocked augmented <e2>seizure</e2>
D010862_D009410 CID <e1>pilocarpine</e1> produced <e2>death</e2>
D010424_D001930 NONE <e1>pentobarbital</e1> protected <e2>damage</e2>
D012601_D001930 NONE <e1>scopolamine</e1> pentobarbital protected <e2>damage</e2>
D010862_D013226 CID <e1>pilocarpine</e1> induced <e2>epilepticus</e2>
D016202_D013226 NONE <e1>nmda</e1> receptor-mediated mechanism cause initiated <e2>epilepticus</e2>
D016202_D001930 NONE <e1>nmda</e1> receptor-mediated mechanism cause <e2>damage</e2>
24881749
D013747_D009459 CID <e1>tetrabenazine</e1> therapy induced <e2>syndrome</e2>
D013747_D009459 CID <e1>tetrabenazine</e1> tiapride therapy initiation describe case woman <e2>syndrome</e2>
D013747_D009459 CID <e1>tetrabenazine</e1> therapy occurrence <e2>syndrome</e2>
D013747_D006816 NONE <e1>tetrabenazine</e1> therapy patient <e2>disease</e2>
D013747_D006816 NONE <e1>tetrabenazine</e1> tiapride therapy initiation <e2>disease</e2>
D013747_D001943 NONE <e1>tetrabenazine</e1> therapy induced stage <e2>cancer</e2>
D063325_D009459 CID <e1>tiapride</e1> tetrabenazine therapy induced <e2>syndrome</e2>
D063325_D009459 CID <e1>tiapride</e1> therapy initiation describe case woman <e2>syndrome</e2>
D063325_D009459 CID <e1>tiapride</e1> tetrabenazine therapy occurrence <e2>syndrome</e2>
D063325_D006816 NONE <e1>tiapride</e1> tetrabenazine therapy patient <e2>disease</e2>
D063325_D006816 NONE <e1>tiapride</e1> therapy initiation <e2>disease</e2>
D063325_D001943 NONE <e1>tiapride</e1> tetrabenazine therapy induced stage <e2>cancer</e2>
3155884
D007545_D066126 NONE <e1>isoproterenol</e1> effect <e2>cardiotoxic</e2>
D007545_D066126 NONE <e1>isoproterenol</e1> doses effect <e2>cardiotoxic</e2>
D007545_D066126 NONE <e1>iso</e1> isoproterenol doses effect <e2>cardiotoxic</e2>
D007545_D003920 NONE <e1>isoproterenol</e1> effect rats <e2>diabetic</e2>
D007545_D003920 NONE <e1>isoproterenol</e1> doses effect effect <e2>diabetes</e2>
D007545_D003920 NONE <e1>iso</e1> isoproterenol doses effect effect <e2>diabetes</e2>
D007545_D003920 NONE <e1>iso</e1> resistance causes points effect sensitivity rats <e2>diabetic</e2>
D013311_D066126 NONE <e1>streptozotocin</e1> rats effect <e2>cardiotoxic</e2>
D013311_D066126 NONE <e1>streptozotocin</e1> diabetes effect effect <e2>cardiotoxic</e2>
D013311_D003920 CID <e1>streptozotocin</e1> rats <e2>diabetic</e2>
D013311_D003920 CID <e1>streptozotocin</e1> <e2>diabetes</e2>
D013311_D003920 CID <e1>streptozotocin</e1> causes points effect sensitivity rats <e2>diabetic</e2>
D007545_D005355 CID <e1>isoproterenol</e1> induced <e2>fibrosis</e2>
D007545_D005355 CID <e1>iso</e1> given induced <e2>fibrosis</e2>
D007545_D005355 CID <e1>iso</e1> induced <e2>fibrosis</e2>
D005947_D005355 NONE <e1>glucose</e1> slope = correlation appeared given induced <e2>fibrosis</e2>
D002395_D003920 NONE <e1>catecholamines</e1> content estimated rats <e2>diabetic</e2>
D002395_D003920 NONE <e1>catecholamine</e1> sensitivity rats <e2>diabetic</e2>
25096313
D013256_D009422 NONE <e1>steroid</e1> injection <e2>neuropathy</e2>
D013256_D009422 NONE <e1>steroid</e1> injection occurred case <e2>neuropathy</e2>
D013256_D013716 NONE <e1>steroid</e1> injection occurred treat <e2>epicondylitis</e2>
D013256_D013716 NONE <e1>steroid</e1> injection treatment <e2>epicondylitis</e2>
D013256_D010292 CID <e1>steroid</e1> injection occurred material woman presented <e2>paresthesia</e2>
D013256_D010292 CID <e1>steroid</e1> injection occurred <e2>paresthesia</e2>
24664478
C104457_D020258 NONE <e1>nelarabine</e1> <e2>neurotoxicity</e2>
C104457_D020258 NONE <e1>nelarabine</e1> <e2>neurotoxicity</e2>
C104457_D020258 NONE <e1>nelarabine</e1> caused report <e2>neurotoxicity</e2>
24659727
D008130_D008223 NONE <e1>lomustine</e1> tolerability combination dogs <e2>lymphoma</e2>
D008130_D008223 NONE <e1>lomustine</e1> protocol dogs <e2>lymphoma</e2>
D008130_D008223 NONE <e1>ccnu</e1> lomustine protocol dogs <e2>lymphoma</e2>
D003520_D008223 NONE <e1>cyclophosphamide</e1> combination dogs <e2>lymphoma</e2>
D003520_D008223 NONE <e1>cyclophosphamide</e1> lomustine protocol dogs <e2>lymphoma</e2>
D003520_D008223 NONE <e1>ctx</e1> cyclophosphamide lomustine protocol dogs <e2>lymphoma</e2>
D008130_D064420 NONE <e1>lomustine</e1> protocol associated <e2>toxicity</e2>
D008130_D064420 NONE <e1>ccnu</e1> lomustine protocol associated <e2>toxicity</e2>
D003520_D064420 NONE <e1>cyclophosphamide</e1> lomustine protocol associated <e2>toxicity</e2>
D003520_D064420 NONE <e1>ctx</e1> cyclophosphamide lomustine protocol associated <e2>toxicity</e2>
D008130_D009503 CID <e1>ccnu/ctx</e1> treatment frequency effect <e2>neutropenia</e2>
D008130_D009503 CID <e1>ccnu/ctx</e1> treatment frequency <e2>neutropenia</e2>
D003520_D009503 CID <e1>ccnu/ctx</e1> treatment frequency effect <e2>neutropenia</e2>
D003520_D009503 CID <e1>ccnu/ctx</e1> treatment frequency <e2>neutropenia</e2>
D008130_D009369 NONE <e1>ccnu</e1> dose tolerable dogs <e2>tumor-bearing</e2>
D003520_D009369 NONE <e1>ctx</e1> combined ccnu dose tolerable dogs <e2>tumor-bearing</e2>
15991002
D009538_D001008 NONE <e1>nicotine</e1> effects <e2>anxiety</e2>
D009538_D001008 NONE <e1>nicotine</e1> pretreatment blocked caffeine- <e2>anxiety</e2>
D009538_D001008 NONE <e1>nicotine</e1> effect <e2>anxiety</e2>
D002110_D001008 CID <e1>caffeine</e1> induced <e2>anxiety</e2>
D002110_D001008 CID <e1>caffeine-</e1> <e2>anxiety</e2>
D002110_D001008 CID <e1>caffeine-induced</e1> <e2>anxiety</e2>
D002110_D001008 CID <e1>caffeine</e1> specific effect <e2>anxiety</e2>
D010433_D001008 CID <e1>pentylenetetrazole</e1> caffeine induced <e2>anxiety</e2>
D010433_D001008 CID <e1>pentylenetetrazole-induced</e1> <e2>anxiety</e2>
3987172
D011433_D006973 NONE <e1>propranolol</e1> antagonism <e2>hypertension</e2>
D011433_D006973 NONE <e1>propranolol</e1> efficacy studied treatment <e2>hypertension</e2>
D010665_D006973 CID <e1>phenylpropanolamine-induced</e1> <e2>hypertension</e2>
D010665_D006973 CID <e1>phenylpropanolamine</e1> overdose cause <e2>hypertension</e2>
D010665_D006973 CID <e1>ppa</e1> phenylpropanolamine overdose cause <e2>hypertension</e2>
D010665_D006973 CID <e1>ppa-induced</e1> <e2>hypertension</e2>
D010665_D062787 NONE <e1>phenylpropanolamine</e1> <e2>overdose</e2>
D010665_D062787 NONE <e1>ppa</e1> phenylpropanolamine <e2>overdose</e2>
D010665_D002543 NONE <e1>phenylpropanolamine</e1> overdose cause hypertension <e2>hemorrhage</e2>
D010665_D002543 NONE <e1>ppa</e1> phenylpropanolamine overdose cause hypertension <e2>hemorrhage</e2>
D010665_D020521 NONE <e1>ppa</e1> increased % volume <e2>stroke</e2>
20408947
D000082_D017114 CID <e1>acetaminophen-induced</e1> <e2>failure</e2>
D000082_D017114 CID <e1>acetaminophen-induced</e1> hepatotoxicity cause <e2>failure</e2>
D000082_D017114 CID <e1>acetaminophen-induced</e1> hepatotoxicity cause failure <e2>alf</e2>
D000082_D017114 CID <e1>acetaminophen-induced</e1> <e2>alf</e2>
D000082_D017114 CID <e1>acetaminophen-induced</e1> alf 1999 undergone patients undergoing lt <e2>alf</e2>
D000082_D017114 CID <e1>non-acetaminophen-induced</e1> alf lt undergoing patients undergone 1999 <e2>alf</e2>
D000082_D017114 CID <e1>non-acetaminophen-induced</e1> <e2>alf</e2>
D000082_D017114 CID <e1>acetaminophen-induced</e1> patients <e2>alf</e2>
D000082_D017114 CID <e1>acetaminophen-induced</e1> patients <e2>alf</e2>
D000082_D017114 CID <e1>acetaminophen-induced</e1> patients had diagnosis lt <e2>alf=0/35</e2>
D000082_D017114 CID <e1>non-acetaminophen-induced</e1> alf=0/35 lt diagnosis had patients <e2>alf</e2>
D000082_D017114 CID <e1>non-acetaminophen-induced</e1> <e2>alf=0/35</e2>
D000082_D017114 CID <e1>acetaminophen-induced</e1> <e2>alf</e2>
D000082_D017114 CID <e1>acetaminophen-induced</e1> alf groups rejection differences were % <e2>alf</e2>
D000082_D017114 CID <e1>non-acetaminophen-induced</e1> % were differences rejection groups <e2>alf</e2>
D000082_D017114 CID <e1>non-acetaminophen-induced</e1> % <e2>alf</e2>
D000082_D017114 CID <e1>acetaminophen-induced</e1> patients <e2>alf</e2>
D000082_D017114 CID <e1>acetaminophen-induced</e1> <e2>alf</e2>
D000082_D017114 CID <e1>acetaminophen-induced</e1> alf transplanted patients outcomes comparable those transplanted <e2>alf</e2>
D000082_D017114 CID <e1>non-acetaminophen-induced</e1> alf transplanted those comparable outcomes patients transplanted <e2>alf</e2>
D000082_D017114 CID <e1>non-acetaminophen-induced</e1> <e2>alf</e2>
D000082_D056486 CID <e1>acetaminophen-induced</e1> <e2>hepatotoxicity</e2>
D000082_D008107 NONE <e1>acetaminophen-induced</e1> alf 1999 undergone patients undergoing lt alf lt <e2>disease</e2>
D000082_D008107 NONE <e1>acetaminophen-induced</e1> alf 1999 undergone patients undergoing lt alf lt disease <e2>cld</e2>
D000082_D008107 NONE <e1>non-acetaminophen-induced</e1> alf lt <e2>disease</e2>
D000082_D008107 NONE <e1>non-acetaminophen-induced</e1> alf lt disease <e2>cld</e2>
D000082_D008107 NONE <e1>acetaminophen-induced</e1> patients had diagnosis lt alf=0/35 <e2>cld=2/34</e2>
D000082_D008107 NONE <e1>non-acetaminophen-induced</e1> alf=0/35 <e2>cld=2/34</e2>
D000082_D008107 NONE <e1>acetaminophen-induced</e1> alf groups rejection differences were <e2>cld</e2>
D000082_D008107 NONE <e1>non-acetaminophen-induced</e1> % were <e2>cld</e2>
D000082_D008107 NONE <e1>acetaminophen-induced</e1> alf transplanted patients outcomes comparable those transplanted alf <e2>cld</e2>
D000082_D008107 NONE <e1>non-acetaminophen-induced</e1> alf <e2>cld</e2>
1423336
D007980_D007022 CID <e1>levodopa</e1> effect <e2>hypotensive</e2>
D007980_D007022 CID <e1>levodopa</e1> effect <e2>hypotensive</e2>
D007980_D007022 CID <e1>levodopa</e1> competing phenylalanine reduced effects <e2>hypotensive</e2>
D007980_D007022 CID <e1>levodopa</e1> effects <e2>hypotensive</e2>
D007980_D007022 CID <e1>levodopa</e1> has action <e2>hypotensive</e2>
D007980_D010300 NONE <e1>levodopa</e1> effect patients <e2>parkinsonian</e2>
D007980_D010300 NONE <e1>levodopa</e1> effects examined patients <e2>parkinsonian</e2>
D007980_D010300 NONE <e1>levodopa</e1> responses patients <e2>parkinsonian</e2>
D010649_D007022 NONE <e1>phenylalanine</e1> reduced effects <e2>hypotensive</e2>
D000596_D007022 NONE <e1>acid</e1> phenylalanine reduced effects <e2>hypotensive</e2>
16906379
D008911_D014657 NONE <e1>minocycline-induced</e1> <e2>vasculitis</e2>
D008911_D014657 NONE <e1>minocycline-induced</e1> <e2>vasculitis</e2>
D008911_D010488 CID <e1>minocycline-induced</e1> vasculitis fulfilling criteria <e2>nodosa</e2>
D008911_D011565 NONE <e1>minocycline</e1> taking fever <e2>pustulosis</e2>
D008911_D005334 NONE <e1>minocycline</e1> taking <e2>fever</e2>
D008911_D063806 NONE <e1>minocycline</e1> taking fever <e2>myalgias</e2>
D008911_D011115 NONE <e1>minocycline</e1> taking fever myalgias <e2>polyneuropathy</e2>
D008911_D013733 NONE <e1>minocycline</e1> taking fever myalgias <e2>pain</e2>
12523489
D003042_D006948 NONE <e1>cocaine-induced</e1> <e2>hyperactivity</e2>
D003042_D006948 NONE <e1>cocaine-induced</e1> hyperactivity influenced <e2>hyperactivity</e2>
D003042_D006948 NONE <e1>cocaine-and</e1> amphetamine-induced <e2>hyperactivity</e2>
D003042_D006948 NONE <e1>cocaine-induced</e1> hyperactivity active those doses decreased <e2>hyperactivity</e2>
D003042_D006948 NONE <e1>cocaine-induced</e1> <e2>hyperactivity</e2>
D003042_D006948 NONE <e1>cocaine-</e1> activity reduce shown indicate influenced <e2>hyperactivity</e2>
D003042_D006948 NONE <e1>cocaine-</e1> activity reduce shown indicate influenced <e2>hyperactivity</e2>
D003042_D006948 NONE <e1>cocaine-induced</e1> <e2>hyperactivity</e2>
D003042_D006948 NONE <e1>cocaine-induced</e1> hyperactivity influenced <e2>hyperactivity</e2>
D000241_D006948 NONE <e1>adenosine</e1> agonists influenced <e2>hyperactivity</e2>
D000241_D006948 NONE <e1>adenosine</e1> agonists influenced <e2>hyperactivity</e2>
D000241_D006948 NONE <e1>adenosine</e1> agonists antagonists <e2>hyperactivity</e2>
D000241_D006948 NONE <e1>adenosine</e1> agonists decreased <e2>hyperactivity</e2>
D000241_D006948 NONE <e1>adenosine</e1> agonists decreased doses those active <e2>hyperactivity</e2>
D000241_D006948 NONE <e1>adenosine</e1> agonists reduce shown indicate influenced <e2>hyperactivity</e2>
D000241_D006948 NONE <e1>adenosine</e1> agonists reduce shown indicate influenced <e2>hyperactivity</e2>
D000241_D006948 NONE <e1>adenosine</e1> agonists influenced <e2>hyperactivity</e2>
D000241_D006948 NONE <e1>adenosine</e1> agonists influenced <e2>hyperactivity</e2>
D000661_D006948 NONE <e1>amphetamine-induced</e1> hyperactivity influenced <e2>hyperactivity</e2>
D000661_D006948 NONE <e1>amphetamine-induced</e1> <e2>hyperactivity</e2>
D000661_D006948 NONE <e1>amphetamine-induced</e1> <e2>hyperactivity</e2>
D000661_D006948 NONE <e1>amphetamine-induced</e1> <e2>hyperactivity</e2>
D000661_D006948 NONE <e1>amphetamine-induced</e1> hyperactivity decreased doses those active <e2>hyperactivity</e2>
D000661_D006948 NONE <e1>amphetamine-induced</e1> cocaine- activity reduce shown indicate influenced <e2>hyperactivity</e2>
D000661_D006948 NONE <e1>amphetamine-induced</e1> cocaine- activity reduce shown indicate influenced <e2>hyperactivity</e2>
D000661_D006948 NONE <e1>amphetamine-induced</e1> hyperactivity influenced <e2>hyperactivity</e2>
D000661_D006948 NONE <e1>amphetamine-induced</e1> <e2>hyperactivity</e2>
D000241_D004409 NONE <e1>adenosine</e1> receptor agonists decreased <e2>activity</e2>
6453500
D004221_D056486 CID <e1>disulfiram</e1> induced <e2>hepatitis</e2>
D004221_D056486 CID <e1>disulfiram</e1> treated woman observed <e2>damage</e2>
146391
D010672_D012010 CID <e1>diphenylhydantoin</e1> taking patient <e2>aplasia</e2>
D010672_D012010 CID <e1>diphenylhydantoin</e1> taking patient developed rash <e2>aplasia</e2>
D010672_D012010 CID <e1>diphenylhydantoin</e1> medication associated <e2>aplasia</e2>
D010672_D012010 CID <e1>diphenylhydantoin</e1> ingestion <e2>aplasia</e2>
D010672_D003875 CID <e1>diphenylhydantoin</e1> taking patient aplasia <e2>dermatitis</e2>
D010672_D008206 CID <e1>diphenylhydantoin</e1> taking patient aplasia dermatitis <e2>lymphadenopathy</e2>
D010672_D008206 CID <e1>diphenylhydantoin</e1> taking patient developed rash <e2>lymphadenopathy</e2>
D010672_D008206 CID <e1>diphenylhydantoin</e1> treatment complication benign <e2>lymphadenopathy</e2>
D010672_D008206 CID <e1>diphenylhydantoin</e1> ingestion <e2>lymphadenopathy</e2>
D010672_D005076 NONE <e1>diphenylhydantoin</e1> taking patient developed <e2>rash</e2>
D010672_D005076 NONE <e1>diphenylhydantoin</e1> treatment complication <e2>rash</e2>
D010672_D005076 NONE <e1>diphenylhydantoin</e1> ingestion occurrence <e2>rash</e2>
6673474
D009599_D007022 CID <e1>nitroprusside</e1> dogs studied deliberate <e2>hypotension</e2>
D009599_D007022 CID <e1>snp</e1> nitroprusside dogs studied deliberate <e2>hypotension</e2>
D009599_D007022 CID <e1>nitroprusside</e1> hypotension used confirm effects <e2>hypotension</e2>
D009599_D007022 CID <e1>nitroprusside</e1> <e2>hypotension</e2>
D009599_D007022 CID <e1>nitroprusside</e1> hypotension used confirm decrease <e2>hypotension</e2>
D009599_D007022 CID <e1>snp</e1> <e2>hypotension</e2>
D014294_D007022 CID <e1>trimetaphan</e1> nitroprusside dogs studied deliberate <e2>hypotension</e2>
D014294_D007022 CID <e1>tmp</e1> trimetaphan nitroprusside dogs studied deliberate <e2>hypotension</e2>
D014294_D007022 CID <e1>trimetaphan</e1> hypotension decrease confirm effects <e2>hypotension</e2>
D014294_D007022 CID <e1>trimetaphan</e1> hypotension decrease confirm used <e2>hypotension</e2>
D014294_D007022 CID <e1>trimetaphan</e1> <e2>hypotension</e2>
20046642
D008668_D003072 NONE <e1>mt</e1> induction <e2>dysfunction</e2>
D002330_D003072 CID <e1>carmustine</e1> (bcnu)-induced <e2>dysfunction</e2>
D002330_D003072 CID <e1>(bcnu)-induced</e1> <e2>dysfunction</e2>
D019287_D007859 NONE <e1>)</e1> dose received revealed resulted deterioration learning <e2>memory</e2>
D019287_D008569 NONE <e1>)</e1> dose received revealed resulted deterioration learning <e2>memory</e2>
D002330_D007859 CID <e1>bcnu</e1> received revealed resulted deterioration learning <e2>memory</e2>
D002330_D007859 CID <e1>bcnu</e1> administration resulted deterioration learning <e2>memory</e2>
D002330_D008569 CID <e1>bcnu</e1> received revealed resulted deterioration learning <e2>memory</e2>
D002330_D008569 CID <e1>bcnu</e1> administration resulted deterioration learning <e2>memory</e2>
D005978_D007859 NONE <e1>glutathione</e1> reductase activity accompanied received revealed resulted deterioration learning <e2>memory</e2>
D005978_D007859 NONE <e1>glutathione</e1> content activity accompanied received revealed resulted deterioration learning <e2>memory</e2>
D005978_D007859 NONE <e1>gsh</e1> glutathione content activity accompanied received revealed resulted deterioration learning <e2>memory</e2>
D005978_D008569 NONE <e1>glutathione</e1> reductase activity accompanied received revealed resulted deterioration learning <e2>memory</e2>
D005978_D008569 NONE <e1>glutathione</e1> content activity accompanied received revealed resulted deterioration learning <e2>memory</e2>
D005978_D008569 NONE <e1>gsh</e1> glutathione content activity accompanied received revealed resulted deterioration learning <e2>memory</e2>
D002330_D009369 NONE <e1>bcnu</e1> administration increased factor-alpha <e2>tumor</e2>
D002330_D009336 NONE <e1>bcnu</e1> administration increased factor-alpha <e2>necrosis</e2>
D008668_D009369 NONE <e1>mt</e1> hippocampal contents factor-alpha <e2>tumor</e2>
D008668_D009336 NONE <e1>mt</e1> hippocampal contents factor-alpha <e2>necrosis</e2>
D008315_D009369 NONE <e1>malondialdehyde</e1> mt hippocampal contents factor-alpha <e2>tumor</e2>
D008315_D009369 NONE <e1>mda</e1> malondialdehyde mt hippocampal contents factor-alpha <e2>tumor</e2>
D008315_D009336 NONE <e1>malondialdehyde</e1> mt hippocampal contents factor-alpha <e2>necrosis</e2>
D008315_D009336 NONE <e1>mda</e1> malondialdehyde mt hippocampal contents factor-alpha <e2>necrosis</e2>
D008668_D064420 NONE <e1>mt</e1> induction halts <e2>toxicity</e2>
D002330_D064420 NONE <e1>bcnu-induced</e1> <e2>toxicity</e2>
D005978_D064420 NONE <e1>gsh</e1> depletion inhibition prevented halts <e2>toxicity</e2>
D008315_D064420 NONE <e1>mda</e1> tnfalpha levels counteracted prevented halts <e2>toxicity</e2>
24438483
D002045_D002318 NONE <e1>bupivacaine-induced</e1> <e2>depression</e2>
D015742_D002318 NONE <e1>propofol</e1> formulations using pre-treatment <e2>depression</e2>
D002045_D066126 CID <e1>bupivacaine</e1> doses increase shown alleviate <e2>cardiotoxicity</e2>
D002045_D066126 CID <e1>bupivacaine-induced</e1> <e2>cardiotoxicity</e2>
D002045_D066126 CID <e1>bupivacaine-induced</e1> <e2>cardiotoxicity</e2>
D002045_D066126 CID <e1>bupivacaine</e1> dose higher conclude delayed onset effects <e2>cardiotoxic</e2>
D002045_D066126 CID <e1>bupivacaine</e1> levels higher conclude delayed onset effects <e2>cardiotoxic</e2>
D002045_D066126 CID <e1>bupivacaine</e1> levels lower higher conclude delayed onset effects <e2>cardiotoxic</e2>
D002045_D066126 CID <e1>bupivacaine-induced</e1> effects <e2>cardiotoxic</e2>
D002045_D066126 CID <e1>bupivacaine</e1> levels delayed onset effects <e2>cardiotoxic</e2>
D015742_D066126 NONE <e1>propofol</e1> content alleviate <e2>cardiotoxicity</e2>
D015742_D066126 NONE <e1>propofol</e1> effects <e2>cardiotoxicity</e2>
D015742_D066126 NONE <e1>propofol</e1> pre-treatment delayed onset effects <e2>cardiotoxic</e2>
D015742_D066126 NONE <e1>propofol</e1> compared pre-treatment delayed onset effects <e2>cardiotoxic</e2>
D002045_D001145 NONE <e1>bupivacaine</e1> consumption amount asystole time mean recorded occurrence <e2>dysrhythmia</e2>
D002045_D006323 CID <e1>bupivacaine</e1> consumption amount <e2>asystole</e2>
6695685
D014700_D001145 CID <e1>verapamil</e1> therapy <e2>rhythms</e2>
D014700_D001145 CID <e1>verapamil</e1> receiving patients <e2>rhythms</e2>
D014700_D002637 NONE <e1>verapamil</e1> increased patients syndromes <e2>pain</e2>
7176945
D013390_D010146 CID <e1>post-suxamethonium</e1> <e2>pains</e2>
D013390_D010146 CID <e1>scoline</e1> <e2>pain</e2>
D013390_D010146 CID <e1>scoline</e1> <e2>pain</e2>
D013390_D010146 CID <e1>scoline</e1> <e2>pain</e2>
D013390_D010146 CID <e1>suxamethonium</e1> preparation type affected incidence <e2>pain</e2>
D013390_D010146 CID <e1>scoline</e1> <e2>pain</e2>
C084773_D005207 NONE <e1>fazadinium</e1> dose abolition <e2>fasciculations</e2>
C084773_D010146 NONE <e1>fazadinium</e1> dose abolition influence occurrence <e2>pain</e2>
D013390_D005207 CID <e1>scoline</e1> pain occurrence influence abolition <e2>fasciculations</e2>
D000530_D010146 NONE <e1>althesin</e1> agent type affected incidence <e2>pain</e2>
D013874_D010146 NONE <e1>thiopentone</e1> althesin agent type affected incidence <e2>pain</e2>
D002712_D010146 NONE <e1>chloride</e1> used type affected incidence <e2>pain</e2>
D001965_D010146 NONE <e1>bromide</e1> chloride used type affected incidence <e2>pain</e2>
26033014
C051786_D009369 NONE <e1>metolachlor</e1> use incidence <e2>cancer</e2>
C051786_D009369 NONE <e1>metolachlor</e1> using reported % evaluated incidence <e2>cancer</e2>
C051786_D009369 NONE <e1>metolachlor</e1> use metrics incidence <e2>cancer</e2>
C051786_D009369 NONE <e1>metolachlor</e1> use incidence <e2>cancers</e2>
C051786_D009369 NONE <e1>metolachlor</e1> use incidence cancers <e2>cancers</e2>
C051786_D008113 CID <e1>metolachlor</e1> unassigned classified <e2>neoplasms</e2>
C051786_D008113 CID <e1>metolachlor</e1> <e2>cancer</e2>
C051786_D008113 CID <e1>metolachlor</e1> association suggestion finding echoes observation <e2>neoplasms</e2>
C051786_D008113 CID <e1>metolachlor</e1> use effects differentiate follow-up findings <e2>cancer</e2>
C051786_D008175 NONE <e1>metolachlor</e1> use levels suggestion risk <e2>cancer</e2>
C051786_D008223 NONE <e1>metolachlor</e1> use effects differentiate follow-up findings cancer warrant <e2>lymphoma</e2>
3895875
D008012_D009203 NONE <e1>lidocaine</e1> phase <e2>infarction</e2>
D008012_D009203 NONE <e1>lidocaine</e1> trial entered patients <e2>infarction</e2>
D008012_D009203 NONE <e1>lidocaine</e1> level minutes administration patients <e2>infarction</e2>
D008012_D009203 NONE <e1>lidocaine</e1> administration advocate hours <e2>infarction</e2>
D008012_D017180 NONE <e1>lidocaine</e1> prevent <e2>tachycardia</e2>
D008012_D017180 NONE <e1>lidocaine</e1> administration was prevent <e2>tachycardia</e2>
D008012_D001145 NONE <e1>lidocaine</e1> prevent was reduction number patients <e2>arrhythmias</e2>
D008012_D001145 NONE <e1>lidocaine</e1> administration was reduction number patients <e2>arrhythmias</e2>
D008012_D007238 NONE <e1>lidocaine</e1> level minutes higher that patients <e2>infarction</e2>
D008012_D007022 CID <e1>lidocaine</e1> group greater occurred <e2>hypotension</e2>
D008012_D007022 CID <e1>lidocaine</e1> received patients occurred <e2>hypotension</e2>
D008012_D007022 CID <e1>lidocaine</e1> had greater occurred <e2>hypotension</e2>
D008012_D006323 NONE <e1>lidocaine</e1> group greater occurred died <e2>asystole</e2>
D008012_D006323 NONE <e1>lidocaine</e1> received patients occurred died <e2>asystole</e2>
D008012_D006323 NONE <e1>lidocaine</e1> had greater occurred died <e2>asystole</e2>
16880771
D004298_D020521 NONE <e1>dopamine</e1> levodopa administration enhances subjects patients <e2>stroke</e2>
D004298_D020521 NONE <e1>dopamine</e1> enhances subjects patients <e2>stroke</e2>
D007980_D020521 NONE <e1>levodopa</e1> administration enhances subjects patients <e2>stroke</e2>
D004298_D007859 NONE <e1>dopamine</e1> agonist impaired <e2>learning</e2>
7248895
D003520_D010386 NONE <e1>cyclophosphamide</e1> therapy carcinoma <e2>pelvis</e2>
D003520_D010386 NONE <e1>cyclophosphamide</e1> treatment association reported carcinoma <e2>pelvis</e2>
D003520_D006869 NONE <e1>cyclophosphamide</e1> treated had woman <e2>hydroureteronephrosis</e2>
D003520_D006869 NONE <e1>cyclophosphamide</e1> exposure intensified suggests association <e2>hydroureteronephrosis</e2>
D003520_D006417 CID <e1>cyclophosphamide</e1> treated had <e2>hematuria</e2>
D003520_D020293 NONE <e1>cyclophosphamide</e1> <e2>vasculitis</e2>
D003520_D006470 NONE <e1>cyclophosphamide</e1> ability cause <e2>cystitis</e2>
D003520_D003556 NONE <e1>cyclophosphamide</e1> ability cause <e2>cystitis</e2>
D003520_D002277 CID <e1>cyclophosphamide</e1> ability cause indistinguishable <e2>carcinoma</e2>
D003520_D014571 NONE <e1>cyclophosphamide</e1> ability known appreciated associated carcinoma <e2>tract</e2>
D003520_D014571 NONE <e1>cyclophosphamide</e1> treatment association reported <e2>cancer</e2>
D003520_D009369 NONE <e1>cyclophosphamide</e1> exposure intensified suggests association <e2>tumor</e2>
D003520_-1 NONE <e1>cyclophosphamide</e1> treatment candidates patients evaluated <e2>uropathy</e2>
24345882
D008727_D054198 NONE <e1>methotrexate</e1> consequence effects children treated p9605 protocols <e2>leukemia</e2>
D008727_D054198 NONE <e1>methotrexate</e1> neurotoxicity concerns led modifications therapy frequency administration children <e2>leukemia</e2>
D008727_D054198 NONE <e1>mtx</e1> neurotoxicity concerns led modifications therapy frequency administration children <e2>leukemia</e2>
D008727_D054198 NONE <e1>mtx</e1> administration children <e2>leukemia</e2>
D008727_D020258 NONE <e1>methotrexate</e1> <e2>neurotoxicity</e2>
D008727_D020258 NONE <e1>mtx</e1> <e2>neurotoxicity</e2>
D008727_D020258 NONE <e1>mtx</e1> administration frequency therapy modifications led concerns <e2>neurotoxicity</e2>
18945509
-1_D003324 NONE <e1>sulphonylurea</e1> treatment associated <e2>disease</e2>
-1_D003324 NONE <e1>sulphonylureas</e1> treatment associated <e2>disease</e2>
-1_D003324 NONE <e1>sulphonylureas</e1> treatment associated disease <e2>cad</e2>
-1_D003924 NONE <e1>sulphonylurea</e1> treatment patients <e2>diabetes</e2>
-1_D003924 NONE <e1>sulphonylureas</e1> treatment <e2>diabetes</e2>
D005905_D003324 CID <e1>glibenclamide</e1> increased hazard developing <e2>cad</e2>
D005905_D003324 CID <e1>glibenclamide</e1> treatment initiating associated risk <e2>cad</e2>
D005913_D003324 NONE <e1>glipizide</e1> increased hazard developing <e2>cad</e2>
D005913_D003324 NONE <e1>glipizide</e1> glibenclamide treatment initiating associated risk <e2>cad</e2>
D008687_D003324 NONE <e1>metformin</e1> unchanged increased hazard developing <e2>cad</e2>
D005905_D003924 NONE <e1>glibenclamide</e1> treatment <e2>diabetes</e2>
D005913_D003924 NONE <e1>glipizide</e1> glibenclamide treatment <e2>diabetes</e2>
D005907_D003924 NONE <e1>gliclazide</e1> comparison associated initiating treatment <e2>diabetes</e2>
D005907_D003324 NONE <e1>gliclazide</e1> comparison associated risk <e2>cad</e2>
C057619_D003924 NONE <e1>glimepiride</e1> gliclazide comparison associated initiating treatment <e2>diabetes</e2>
C057619_D003324 NONE <e1>glimepiride</e1> gliclazide comparison associated risk <e2>cad</e2>
15627798
D005839_D009395 CID <e1>gentamicin</e1> induced <e2>nephritis</e2>
D005839_D009395 CID <e1>gentamicin</e1> induced <e2>nephritis</e2>
D005839_D005355 NONE <e1>gentamicin</e1> treated animals show areas <e2>fibrosis</e2>
16731636
D007545_D006332 CID <e1>isoproterenol-induced</e1> <e2>hypertrophy</e2>
D007545_D006332 CID <e1>iso</e1> treatment induced <e2>hypertrophy</e2>
6985498
D008733_D056486 CID <e1>methoxyflurane</e1> anesthesia acidosis <e2>hepatitis</e2>
D008733_D000141 CID <e1>methoxyflurane</e1> anesthesia <e2>acidosis</e2>
D008733_D000141 CID <e1>methoxyflurane</e1> anesthesia operated developed syndrome <e2>acidosis</e2>
D008733_D041881 NONE <e1>methoxyflurane</e1> anesthesia operated <e2>cholecystitis</e2>
D008733_D048550 NONE <e1>methoxyflurane</e1> anesthesia operated developed <e2>syndrome</e2>
8819482
D002118_D017202 NONE <e1>calcium</e1> antagonist effects <e2>ischemia</e2>
D002118_D023921 NONE <e1>calcium</e1> antagonist effects ischemia dogs <e2>stenosis</e2>
C082828_D017202 NONE <e1>cd-832</e1> antagonist effects <e2>ischemia</e2>
C082828_D017202 NONE <e1>cd-832</e1> effects <e2>ischemia</e2>
C082828_D017202 NONE <e1>cd-832</e1> improves <e2>ischemia</e2>
C082828_D017202 NONE <e1>cd-832</e1> property plays suggest show improves <e2>ischemia</e2>
C082828_D017202 NONE <e1>cd-832</e1> effects plays suggest show improves <e2>ischemia</e2>
C082828_D023921 NONE <e1>cd-832</e1> antagonist effects ischemia dogs <e2>stenosis</e2>
C082828_D023921 NONE <e1>cd-832</e1> effects studied dogs <e2>stenosis</e2>
D007545_D017202 CID <e1>isoproterenol-induced</e1> <e2>ischemia</e2>
D007545_D017202 CID <e1>isoproterenol</e1> <e2>ischemia</e2>
D007545_D017202 CID <e1>(iso)-induced</e1> <e2>ischemia</e2>
D007545_D017202 CID <e1>iso</e1> infusion <e2>ischemia</e2>
D007545_D023921 NONE <e1>isoproterenol-induced</e1> ischemia dogs <e2>stenosis</e2>
D007545_D023921 NONE <e1>isoproterenol</e1> ischemia effects studied dogs <e2>stenosis</e2>
D007545_D023921 NONE <e1>(iso)-induced</e1> ischemia effects studied dogs <e2>stenosis</e2>
D007545_D023921 NONE <e1>iso</e1> infusion periods increased presence <e2>stenosis</e2>
D009543_D017202 NONE <e1>nifedipine</e1> those compared studied effects <e2>ischemia</e2>
D009543_D023921 NONE <e1>nifedipine</e1> those compared studied dogs <e2>stenosis</e2>
D004110_D017202 NONE <e1>diltiazem</e1> nifedipine those compared studied effects <e2>ischemia</e2>
D004110_D023921 NONE <e1>diltiazem</e1> nifedipine those compared studied dogs <e2>stenosis</e2>
D007545_D003251 NONE <e1>iso</e1> infusion <e2>stenosis</e2>
D007545_D003251 NONE <e1>iso</e1> infusion infused performed infusion <e2>stenosis</e2>
D007545_D003251 NONE <e1>iso</e1> infusion <e2>stenosis</e2>
D007545_D003251 NONE <e1>iso</e1> infusion <e2>stenosis</e2>
D007545_D003251 NONE <e1>iso</e1> infusion ischemia improves <e2>stenosis</e2>
C082828_D003251 NONE <e1>cd-832</e1> doses performed infusion <e2>stenosis</e2>
C082828_D003251 NONE <e1>cd-832</e1> nifedipine contrast prevented min infusion <e2>stenosis</e2>
C082828_D003251 NONE <e1>cd-832</e1> improves <e2>stenosis</e2>
C082828_D003251 NONE <e1>cd-832</e1> property plays suggest show improves <e2>stenosis</e2>
C082828_D003251 NONE <e1>cd-832</e1> effects plays suggest show improves <e2>stenosis</e2>
D009543_D003251 NONE <e1>nifedipine</e1> performed infusion <e2>stenosis</e2>
D009543_D003251 NONE <e1>nifedipine</e1> contrast prevented min infusion <e2>stenosis</e2>
D004110_D003251 NONE <e1>diltiazem</e1> performed infusion <e2>stenosis</e2>
D004110_D003251 NONE <e1>diltiazem</e1> prevented min infusion <e2>stenosis</e2>
12165618
D019469_-1 NONE <e1>indinavir</e1> treated children function associated <e2>leukocyturia</e2>
D019469_-1 NONE <e1>indinavir</e1> level h found incidence <e2>leukocyturia</e2>
D019469_-1 NONE <e1>indinavir</e1> discontinued found incidence <e2>leukocyturia</e2>
D019469_-1 NONE <e1>indinavir</e1> treated children have incidence <e2>leukocyturia</e2>
D019469_-1 NONE <e1>indinavir-associated</e1> nephrotoxicity monitored children factors <e2>leukocyturia</e2>
D019469_-1 NONE <e1>indinavir</e1> curve area years monitored children factors <e2>leukocyturia</e2>
D019469_D007674 CID <e1>indinavir</e1> treated children <e2>function</e2>
D019469_D007674 CID <e1>indinavir-related</e1> <e2>nephrotoxicity</e2>
D019469_D007674 CID <e1>indinavir</e1> treated children cohort <e2>nephrotoxicity</e2>
D019469_D007674 CID <e1>indinavir</e1> level h found discontinued <e2>nephrotoxicity</e2>
D019469_D007674 CID <e1>indinavir</e1> discontinued <e2>nephrotoxicity</e2>
D019469_D007674 CID <e1>indinavir-associated</e1> <e2>nephrotoxicity</e2>
D019469_D007674 CID <e1>indinavir</e1> curve area years monitored <e2>nephrotoxicity</e2>
D019469_D015658 NONE <e1>indinavir</e1> treated children <e2>1-infected</e2>
D019469_D015658 NONE <e1>indinavir-related</e1> nephrotoxicity cohort children <e2>1-infected</e2>
D019469_D015658 NONE <e1>indinavir</e1> treated children <e2>1-infected</e2>
D003404_-1 NONE <e1>albumin/creatinine</e1> ratio increase associated <e2>leukocyturia</e2>
D003404_-1 NONE <e1>creatinine</e1> levels had children <e2>leukocyturia</e2>
D003404_-1 NONE <e1>creatinine</e1> levels % normal children <e2>leukocyturia</e2>
D003404_-1 NONE <e1>creatinine</e1> levels decreased returned disappeared <e2>leukocyturia</e2>
D003404_-1 NONE <e1>albumin/creatinine</e1> ratios returned disappeared <e2>leukocyturia</e2>
D003404_-1 NONE <e1>creatinine</e1> levels increase had children <e2>leukocyturia</e2>
D003404_D006417 NONE <e1>albumin/creatinine</e1> ratio increase <e2>hematuria</e2>
16083708
D001663_D017114 NONE <e1>bilirubin</e1> value sex factors associated development <e2>failure</e2>
D019980_D056486 CID <e1>amoxicillin-clavulanate</e1> stands drug related <e2>dili</e2>
23872883
D007545_D066126 CID <e1>isoproterenol-induced</e1> <e2>cardiotoxicity</e2>
3833372
D013999_D006973 NONE <e1>maleate</e1> mg containing combination safety determine administered patients <e2>hypertensive</e2>
D006852_D006973 NONE <e1>hydrochlorothiazide</e1> safety determine administered patients <e2>hypertensive</e2>
25041770
D019821_D012206 CID <e1>simvastatin</e1> increment association <e2>rhabdomyolysis</e2>
D019821_D012206 CID <e1>statin</e1> induced <e2>rhabdomyolysis</e2>
D017291_D012206 CID <e1>clarithromycin</e1> increment association <e2>rhabdomyolysis</e2>
D017291_D012206 CID <e1>clarithromycin</e1> dose increase occurred interest <e2>rhabdomyolysis</e2>
11835460
D007980_D015835 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D015835 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D015835 CID <e1>levodopa</e1> effect patient report hypothesize needed appearance <e2>dyskinesias</e2>
D007980_D015835 CID <e1>levodopa-induce</e1> <e2>dyskinesias</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias <e2>disease</e2>
9759693
D018170_D017091 CID <e1>sumatriptan</e1> use <e2>colitis</e2>
D018170_D017091 CID <e1>sumatriptan</e1> treated migraine patients cases <e2>colitis</e2>
D018170_D003329 NONE <e1>sumatriptan</e1> use occurring published <e2>vasospasm</e2>
D018170_D017202 NONE <e1>sumatriptan</e1> use occurring published vasospasm <e2>ischemia</e2>
D018170_D009203 NONE <e1>sumatriptan</e1> use occurring published vasospasm <e2>infarction</e2>
D018170_D008881 NONE <e1>sumatriptan</e1> treated <e2>migraine</e2>
9382023
D004280_D006973 CID <e1>dobutamine</e1> echocardiography response <e2>hypertensive</e2>
D004280_D006973 CID <e1>dobutamine</e1> studies response <e2>hypertensive</e2>
D004280_D006973 CID <e1>dobutamine</e1> infusion had had history <e2>hypertension</e2>
9125676
D013015_-1 NONE <e1>l-sotalol</e1> d use <e2>proarrhythmia</e2>
D013015_D017180 NONE <e1>l-sotalol</e1> d use <e2>tachyarrhythmias</e2>
D013015_D017180 NONE <e1>l-sotalol</e1> d <e2>tachyarrhythmias</e2>
D013015_D017180 NONE <e1>l-sotalol</e1> d received patients <e2>tachycardia</e2>
D013015_D017180 NONE <e1>l-sotalol</e1> d received prevent induction <e2>tachyarrhythmia</e2>
D013015_D017180 NONE <e1>l-sotalol</e1> prevented induction <e2>tachycardia</e2>
D013015_D017180 NONE <e1>l-sotalol</e1> d prevented induction <e2>tachyarrhythmia</e2>
D013015_D017180 NONE <e1>l-sotalol</e1> d prevented remained <e2>tachyarrhythmia</e2>
D013015_D017180 NONE <e1>l-sotalol</e1> tolerate prevented induction <e2>tachyarrhythmia</e2>
D013015_D017180 NONE <e1>l-sotalol</e1> tolerate prevented remained <e2>tachyarrhythmia</e2>
D013015_D016171 CID <e1>l-sotalol</e1> d treated patients pointes torsades factors efficacy incidence torsades <e2>pointes</e2>
D013015_D016171 CID <e1>l-sotalol</e1> d treated patients <e2>pointes</e2>
D013015_D016171 CID <e1>l-sotalol</e1> d treatment had torsades <e2>pointes</e2>
D013015_D016171 CID <e1>l-sotalol</e1> lower patients torsades <e2>pointes</e2>
D013015_D016171 CID <e1>l-sotalol</e1> d treatment years had torsades <e2>pointes</e2>
D013015_D016171 CID <e1>l-sotalol</e1> d doses treatment occurred <e2>pointes</e2>
D013015_D016171 CID <e1>l-sotalol</e1> identify subgroup patients risk torsades <e2>pointes</e2>
D013015_D016171 CID <e1>l-sotalol</e1> identify patients risk torsades <e2>pointes</e2>
D013015_D003324 NONE <e1>l-sotalol</e1> d received patients 54 <e2>disease</e2>
D013015_D002311 NONE <e1>l-sotalol</e1> d received patients 54 20 <e2>cardiomyopathy</e2>
D013015_D014693 NONE <e1>l-sotalol</e1> d received patients tachycardia <e2>fibrillation</e2>
D013015_D014693 NONE <e1>l-sotalol</e1> prevented induction tachycardia <e2>fibrillation</e2>
D013015_D006331 NONE <e1>l-sotalol</e1> d treatment years had patient <e2>disease</e2>
1735570
D014294_D007022 CID <e1>trimethaphan-induced</e1> <e2>hypotension</e2>
D014294_D001919 NONE <e1>trimethaphan-induced</e1> hypotension accompanied <e2>bradycardia</e2>
D014294_D013610 CID <e1>trimethaphan-induced</e1> hypotension accompanied <e2>tachycardia</e2>
20169779
D015632_D010302 NONE <e1>mptp</e1> model <e2>disease</e2>
D015632_D010302 NONE <e1>mptp-lesioned</e1> marmoset used model symptoms patients <e2>pd</e2>
D015632_D010302 NONE <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1> administered resulting <e2>parkinsonism</e2>
D007980_D001523 NONE <e1>levodopa-treated</e1> marmoset used model <e2>symptoms</e2>
D007980_D001523 NONE <e1>levodopa-induced</e1> fluctuations <e2>behaviors</e2>
D007980_D001523 NONE <e1>levodopa</e1> prior <e2>behaviors</e2>
D007980_D001523 NONE <e1>levodopa-induced</e1> <e2>behaviors</e2>
D007980_D001523 NONE <e1>levodopa</e1> treatment 1 day present <e2>behaviors</e2>
D007980_D001523 NONE <e1>levodopa</e1> interaction likely <e2>disorders</e2>
D007980_D010302 NONE <e1>levodopa-treated</e1> marmoset used model symptoms patients <e2>pd</e2>
D007980_D010302 NONE <e1>levodopa</e1> interaction likely disorders <e2>pd</e2>
D015632_D001523 NONE <e1>mptp-lesioned</e1> marmoset used model <e2>symptoms</e2>
D007980_D020734 NONE <e1>levodopa</e1> prior behaviors evaluated <e2>disability</e2>
D007980_D004409 CID <e1>levodopa</e1> prior behaviors evaluated disability <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> fluctuations <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> therapy duration correlated exhibited increase fluctuations <e2>dyskinesia</e2>
24641119
D007654_-1 NONE <e1>ketoconazole</e1> induced <e2>syndrome</e2>
D007654_-1 NONE <e1>ketoconazole</e1> sensitivity included diagnosed <e2>syndrome</e2>
D007654_-1 NONE <e1>ketoconazole-induced</e1> <e2>syndrome</e2>
D007654_D003875 CID <e1>ketoconazole</e1> using patient presented <e2>eruption</e2>
24840785
D000157_D001145 CID <e1>aconitine-induced</e1> ca2 causes <e2>arrhythmia</e2>
D000157_D001145 CID <e1>aconitine</e1> aggravates causes <e2>arrhythmia</e2>
D002118_D001145 NONE <e1>ca2</e1> causes <e2>arrhythmia</e2>
D002118_D001145 NONE <e1>ca(2</e1> overload lead caused <e2>arrhythmia</e2>
D002118_D001145 NONE <e1>ca(2</e1> aggravates causes <e2>arrhythmia</e2>
D012964_D066126 NONE <e1>na(+</e1> channels have <e2>cardiotoxicity</e2>
D000157_D066126 CID <e1>aconitine</e1> <e2>cardiotoxicity</e2>
D002118_D011041 NONE <e1>ca(2</e1> role <e2>poisoning</e2>
D002118_D011041 NONE <e1>ca(2</e1> importance signaling <e2>poisoning</e2>
D000157_D011041 CID <e1>aconitine</e1> <e2>poisoning</e2>
D000157_D011041 CID <e1>aconitine</e1> <e2>poisoning</e2>
D000157_D009202 NONE <e1>aconitine</e1> effects <e2>injury</e2>
D000157_D009202 NONE <e1>aconitine</e1> resulted <e2>injury</e2>
D000157_D064420 NONE <e1>aconitine</e1> effects investigate performed assay <e2>cytotoxicity</e2>
D019344_D009202 NONE <e1>lactate</e1> level measured performed investigate effects <e2>injury</e2>
D019344_D064420 NONE <e1>lactate</e1> level measured performed assay <e2>cytotoxicity</e2>
24975837
D002945_D058186 CID <e1>cisplatin-induced</e1> <e2>injury</e2>
D002945_D058186 CID <e1>cisplatin</e1> treatment adopted induce <e2>injury</e2>
D002945_D058186 CID <e1>cisplatin-induced</e1> <e2>injury</e2>
D002945_D058186 CID <e1>cisplatin</e1> challenged examine role <e2>injury</e2>
D002945_D058186 CID <e1>cisplatin-induced</e1> <e2>injury</e2>
D002945_D007683 CID <e1>cisplatin</e1> treatment adopted induce increase score <e2>necrosis</e2>
D003404_D058186 NONE <e1>creatinine</e1> levels augment induce <e2>injury</e2>
D003404_D007683 NONE <e1>creatinine</e1> levels augment induce increase score <e2>necrosis</e2>
D014508_D058186 NONE <e1>urea</e1> creatinine levels augment induce <e2>injury</e2>
D014508_D007683 NONE <e1>urea</e1> creatinine levels augment induce increase score <e2>necrosis</e2>
D002945_D009336 NONE <e1>cisplatin-induced</e1> injury involved mediating process <e2>necrotic</e2>
D002945_D007674 NONE <e1>cisplatin</e1> therapy induced <e2>nephrotoxicity</e2>
1556529
D015215_D056486 CID <e1>zidovudine-induced</e1> <e2>hepatitis</e2>
D015215_D056486 CID <e1>zidovudine</e1> induced <e2>hepatitis</e2>
D015215_D000163 NONE <e1>zidovudine</e1> induced patient <e2>aids</e2>
8667442
D002117_D006934 CID <e1>1,25(oh)2d</e1> induced <e2>syndrome</e2>
D002117_D006934 CID <e1>calcitriol</e1> carbonate treated hypoparathyroidism patient resulting admissions hospital <e2>syndrome</e2>
D002117_D007011 NONE <e1>1,25(oh)2d</e1> induced patient <e2>hypoparathyroidism</e2>
D002117_D007011 NONE <e1>calcitriol</e1> carbonate treated <e2>hypoparathyroidism</e2>
D002118_D006934 CID <e1>calcium</e1> amounts treatment context described <e2>syndrome</e2>
D002118_D010437 NONE <e1>calcium</e1> amounts treatment <e2>disease</e2>
D000468_D006934 CID <e1>alkali</e1> calcium amounts treatment context described <e2>syndrome</e2>
D000468_D010437 NONE <e1>alkali</e1> calcium amounts treatment <e2>disease</e2>
D009853_D014456 NONE <e1>omeprazole</e1> blockers therapy <e2>ulcer</e2>
D009853_D006934 NONE <e1>omeprazole</e1> blockers therapy decreased frequency <e2>syndrome</e2>
D009853_D006934 NONE <e1>omeprazole</e1> blockers therapy decreased triad <e2>hypercalcemia</e2>
D009853_D000471 NONE <e1>omeprazole</e1> blockers therapy decreased triad hypercalcemia <e2>alkalosis</e2>
D009853_D051437 NONE <e1>omeprazole</e1> blockers therapy decreased triad hypercalcemia <e2>impairment</e2>
D013392_D014456 NONE <e1>sucralfate</e1> blockers therapy <e2>ulcer</e2>
D013392_D006934 NONE <e1>sucralfate</e1> blockers therapy decreased frequency <e2>syndrome</e2>
D013392_D006934 NONE <e1>sucralfate</e1> blockers therapy decreased triad <e2>hypercalcemia</e2>
D013392_D000471 NONE <e1>sucralfate</e1> blockers therapy decreased triad hypercalcemia <e2>alkalosis</e2>
D013392_D051437 NONE <e1>sucralfate</e1> blockers therapy decreased triad hypercalcemia <e2>impairment</e2>
D002119_D007011 NONE <e1>carbonate</e1> treated <e2>hypoparathyroidism</e2>
D002119_D006934 CID <e1>carbonate</e1> treated hypoparathyroidism patient resulting admissions hospital <e2>syndrome</e2>
C019248_D006934 NONE <e1>pamidronate</e1> illustrates presents <e2>syndrome</e2>
C019248_D006934 NONE <e1>pamidronate</e1> illustrates presents <e2>emergency</e2>
10986547
C076029_D001714 NONE <e1>olanzapine</e1> efficacy <e2>mania</e2>
C076029_D001714 NONE <e1>olanzapine</e1> efficacy compared placebo treatment <e2>mania</e2>
C076029_D001714 NONE <e1>olanzapine</e1> randomized total patients diagnosis <e2>disorder</e2>
C076029_D001714 NONE <e1>olanzapine</e1> randomized total <e2>manic</e2>
C076029_D001714 NONE <e1>olanzapine</e1> demonstrated efficacy placebo treatment <e2>mania</e2>
C076029_D015430 CID <e1>olanzapine-treated</e1> patients had <e2>gain</e2>
C076029_D006970 CID <e1>olanzapine-treated</e1> patients had experienced <e2>somnolence</e2>
17356399
C042705_D020803 NONE <e1>peg-asparaginase</e1> <e2>encephalopathy</e2>
C042705_D020301 CID <e1>peg-asparaginase</e1> encephalopathy <e2>vasospasm</e2>
C042705_D054198 NONE <e1>peg-asparaginase</e1> encephalopathy treatment <e2>leukemia</e2>
D003561_D020803 NONE <e1>cytarabine</e1> peg-asparaginase <e2>encephalopathy</e2>
D003561_D020803 NONE <e1>cytarabine</e1> administration developed <e2>encephalopathy</e2>
D003561_D020301 CID <e1>cytarabine</e1> peg-asparaginase encephalopathy <e2>vasospasm</e2>
D003561_D020301 CID <e1>cytarabine</e1> administration developed encephalopathy evidenced changes weakness <e2>vasospasm</e2>
D003561_D054198 NONE <e1>cytarabine</e1> peg-asparaginase encephalopathy treatment <e2>leukemia</e2>
D003561_D001037 CID <e1>cytarabine</e1> administration developed encephalopathy evidenced changes <e2>aphasia</e2>
D003561_D014549 CID <e1>cytarabine</e1> administration developed encephalopathy evidenced changes aphasia <e2>incontinence</e2>
D003561_D006212 CID <e1>cytarabine</e1> administration developed encephalopathy evidenced changes aphasia incontinence <e2>hallucinations</e2>
D003561_D018908 CID <e1>cytarabine</e1> administration developed encephalopathy evidenced changes <e2>weakness</e2>
3533179
D003520_D066126 NONE <e1>cyclophosphamide</e1> <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> doses occur <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> doses occur described factors development <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> dose calculated determine correlated incidence <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> doses receiving days had symptoms consistent <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> related thought <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> cardiotoxicity correlates prepared days incidence <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> dosage correlates <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> dosage correlates prepared days incidence <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> dose grafting marrow prepared correlates <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> dose grafting marrow prepared days incidence <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> dosage calculated patients cardiotoxicity incidence days prepared correlates <e2>cardiotoxicity</e2>
D003520_D066126 NONE <e1>cya</e1> dosage calculated patients <e2>cardiotoxicity</e2>
D003520_D064420 NONE <e1>cya</e1> dose calculated correlates <e2>toxicity</e2>
D003520_D064420 NONE <e1>cya</e1> cardiotoxicity incidence correlated determine calculated correlates <e2>toxicity</e2>
D003520_D000741 NONE <e1>cya</e1> mg/kg/d receive patients underwent total transplants <e2>anemia</e2>
D003520_D000741 NONE <e1>cya</e1> cardiotoxicity correlates prepared patients <e2>anemia</e2>
D003520_D000741 NONE <e1>cya</e1> dosage correlates prepared patients <e2>anemia</e2>
D003520_D000741 NONE <e1>cya</e1> dose grafting marrow prepared patients <e2>anemia</e2>
D003520_D000741 NONE <e1>cya</e1> dosage calculated patients cardiotoxicity incidence days prepared patients <e2>anemia</e2>
D003520_D014923 NONE <e1>cya</e1> mg/kg/d receive patients underwent total transplants anemia <e2>syndrome</e2>
D003520_D016511 NONE <e1>cya</e1> mg/kg/d receive patients underwent total transplants anemia <e2>syndrome</e2>
D003520_D007153 NONE <e1>cya</e1> cardiotoxicity correlates prepared patients anemia <e2>immunodeficiencies</e2>
D003520_D007153 NONE <e1>cya</e1> dosage correlates prepared patients anemia <e2>immunodeficiencies</e2>
D003520_D007153 NONE <e1>cya</e1> dose grafting marrow prepared patients anemia <e2>immunodeficiencies</e2>
D003520_D007153 NONE <e1>cya</e1> dosage calculated patients cardiotoxicity incidence days prepared patients anemia <e2>immunodeficiencies</e2>
20589632
D014295_D000743 CID <e1>trimethoprim-induced</e1> <e2>anemia</e2>
15018178
D015662_D000743 CID <e1>trimethoprim-sulfomethoxazole</e1> induced crisis <e2>anemia</e2>
D015662_D002534 NONE <e1>trimethoprim-sulfomethoxazole</e1> induced crisis had findings present resulting <e2>anoxia</e2>
23666265
D003520_D003556 CID <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>cyclophosphamide</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>(cyp)-induced</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>cyp-induced</e1> <e2>cystitis</e2>
D003520_D010146 CID <e1>cyp</e1> administration behaviors <e2>pain</e2>
D003520_D010146 CID <e1>cyclophosphamide</e1> treatment increased scores behaviors <e2>pain</e2>
9578276
15366550
D008094_D059606 NONE <e1>lithium</e1> use <e2>polydipsia</e2>
D008094_D018500 CID <e1>lithium</e1> implicated <e2>di</e2>
D008094_D018500 CID <e1>lithium</e1> implicated changed focus <e2>di</e2>
D008094_D018500 CID <e1>lithium</e1> received implicated <e2>di</e2>
D008094_D018500 CID <e1>lithium</e1> received implicated changed focus <e2>di</e2>
D008094_D018500 CID <e1>lithium-induced</e1> <e2>di</e2>
D008094_D018500 CID <e1>lithium-induced</e1> di self-treating developed <e2>di</e2>
D008094_D001930 NONE <e1>lithium-induced</e1> di self-treating developed di secondary <e2>trauma</e2>
10713017
D005277_D006976 CID <e1>fenfluramines</e1> had association <e2>pph</e2>
D005277_D006976 CID <e1>fenfluramines</e1> specificity magnitude association <e2>pph</e2>
D005277_D006976 CID <e1>fenfluramines</e1> specificity magnitude consistent indicating related <e2>pph</e2>
D005277_D006976 CID <e1>fenfluramines</e1> related indicating consistent magnitude association <e2>pph</e2>
D005277_D006976 CID <e1>fenfluramines</e1> related <e2>pph</e2>
2818777
D010672_D056486 NONE <e1>phenytoin</e1> induced <e2>injury</e2>
D010672_D017093 CID <e1>phenytoin</e1> administration <e2>failure</e2>
25986755
D002110_D005921 NONE <e1>caffeine</e1> exposure induced offspring <e2>glomerulosclerosis</e2>
D002110_D005317 CID <e1>caffeine</e1> exposure induce <e2>retardation</e2>
D002110_D005317 CID <e1>caffeine</e1> exposure induce retardation <e2>iugr</e2>
D003404_D005921 NONE <e1>creatinine</e1> levels accompanied revealed exhibited <e2>glomerulosclerosis</e2>
D003404_D005355 NONE <e1>creatinine</e1> levels accompanied revealed exhibited glomerulosclerosis <e2>fibrosis</e2>
2217015
D008528_D009503 CID <e1>acid-induced</e1> <e2>neutropenia</e2>
D008528_D009503 CID <e1>acid-induced</e1> failure <e2>neutropenia</e2>
D008528_D051437 CID <e1>acid-induced</e1> neutropenia <e2>failure</e2>
D008528_D051437 CID <e1>acid-induced</e1> <e2>failure</e2>
D008528_D007037 NONE <e1>acid-induced</e1> neutropenia females <e2>hypothyroidism</e2>
D008528_D007037 NONE <e1>acid</e1> use patients <e2>hypothyroid</e2>
D008528_D007037 NONE <e1>acid</e1> use corrected <e2>hypothyroidism</e2>
15609701
D013015_D003329 CID <e1>sotalol-induced</e1> <e2>spasm</e2>
D013015_D003329 CID <e1>sotalol</e1> properties induced <e2>vasospasm</e2>
D013015_D002311 NONE <e1>sotalol-induced</e1> spasm patient <e2>cardiomyopathy</e2>
D013015_D017180 NONE <e1>sotalol-induced</e1> spasm patient cardiomyopathy associated <e2>tachycardia</e2>
D013015_D017180 NONE <e1>sotalol</e1> agent effective prevention <e2>vt</e2>
C076259_D017180 NONE <e1>hydrochloride</e1> administration terminated <e2>vt</e2>
23433219
D008694_D011605 CID <e1>methamphetamine</e1> <e2>psychosis</e2>
D008694_D011605 CID <e1>methamphetamine-dependent</e1> patients <e2>psychosis</e2>
D008694_D011605 CID <e1>methamphetamine-induced</e1> lifetime <e2>psychosis</e2>
D008694_D011605 CID <e1>methamphetamine</e1> dependence patients <e2>psychosis</e2>
D008694_D011605 CID <e1>methamphetamine-induced</e1> <e2>psychosis</e2>
D008694_D011605 CID <e1>methamphetamine</e1> diagnosis patients interviewed using interview <e2>psychosis</e2>
D008694_D011605 CID <e1>methamphetamine-induced</e1> <e2>psychosis</e2>
D008694_D011605 CID <e1>methamphetamine</e1> uses disorder disorder associated <e2>psychosis</e2>
D008694_D011605 CID <e1>methamphetamine-induced</e1> <e2>psychosis</e2>
D008694_D011605 CID <e1>methamphetamine</e1> dependence patients <e2>psychosis</e2>
D008694_D011605 CID <e1>methamphetamine</e1> dependence cases screened <e2>symptoms</e2>
D008694_D001523 NONE <e1>methamphetamine</e1> diagnosis patients interviewed using interview psychosis <e2>disorders</e2>
D008694_D001523 NONE <e1>methamphetamine-induced</e1> psychosis <e2>disorders</e2>
D008694_D003866 NONE <e1>methamphetamine</e1> uses disorder <e2>disorder</e2>
D008694_D003866 NONE <e1>methamphetamine-induced</e1> psychosis associated <e2>disorder</e2>
D008694_D001714 CID <e1>methamphetamine</e1> uses disorder disorder <e2>disorder</e2>
D008694_D001714 CID <e1>methamphetamine-induced</e1> psychosis associated disorder <e2>disorder</e2>
D008694_D000987 CID <e1>methamphetamine</e1> uses <e2>disorder</e2>
D008694_D000987 CID <e1>methamphetamine-induced</e1> psychosis associated disorder <e2>disorder</e2>
D008694_D000987 CID <e1>methamphetamine</e1> use disorder <e2>personality</e2>
D008694_D019964 NONE <e1>methamphetamine</e1> use <e2>disorder</e2>
16112787
D014640_D007674 CID <e1>vancomycin-induced</e1> <e2>nephrotoxicity</e2>
D014640_D007674 CID <e1>vancomycin</e1> stress promotes investigate role tissue <e2>impairment</e2>
D014640_D007674 CID <e1>(vcm)-induced</e1> stress promotes investigate role tissue <e2>impairment</e2>
D014640_D007674 CID <e1>vcm-induced</e1> <e2>impairment</e2>
D014640_D007674 CID <e1>vcm</e1> administration increased malondialdehyde nag marker <e2>injury</e2>
D014640_D007674 CID <e1>vcm-induced</e1> <e2>nephrotoxicity</e2>
D014640_D007674 CID <e1>vcm-induced</e1> <e2>nephrotoxicity</e2>
D014640_D007674 CID <e1>vcm-induced</e1> nephrotoxicity plays reduces <e2>damage</e2>
D014640_D007674 CID <e1>vcm-induced</e1> damage reduces plays <e2>nephrotoxicity</e2>
D014640_D007674 CID <e1>vcm-induced</e1> <e2>damage</e2>
C048498_D007674 NONE <e1>erdosteine</e1> protection evidences suggesting role stress pathogenesis <e2>nephrotoxicity</e2>
C048498_D007674 NONE <e1>erdosteine</e1> role tissue <e2>impairment</e2>
C048498_D007674 NONE <e1>erdosteine</e1> showed protection <e2>nephrotoxicity</e2>
C048498_D007674 NONE <e1>erdosteine</e1> modulation <e2>nephrotoxicity</e2>
C048498_D007674 NONE <e1>erdosteine</e1> modulation nephrotoxicity plays reduces <e2>damage</e2>
D010100_D007674 NONE <e1>oxygen</e1> species production promotes investigate role tissue <e2>impairment</e2>
D008315_D007674 NONE <e1>malondialdehyde</e1> nag marker <e2>injury</e2>
D008315_D007674 NONE <e1>mda</e1> malondialdehyde nag marker <e2>injury</e2>
D013481_D007674 NONE <e1>superoxide</e1> dismutase increased malondialdehyde nag marker <e2>injury</e2>
D014640_D001284 NONE <e1>vcm-treated</e1> rats necrosis lumens <e2>atrophy</e2>
D014640_-1 NONE <e1>vcm-treated</e1> rats necrosis lumens atrophy <e2>desquamation</e2>
D014640_D009336 NONE <e1>vcm-treated</e1> rats <e2>necrosis</e2>
C048498_D001284 NONE <e1>erdosteine</e1> groups dilatation lumens <e2>atrophy</e2>
C048498_-1 NONE <e1>erdosteine</e1> groups dilatation lumens atrophy <e2>desquamation</e2>
C048498_D009336 NONE <e1>erdosteine</e1> groups dilatation lumens <e2>necrosis</e2>
11439380
D013792_D009422 NONE <e1>thalidomide</e1> <e2>neuropathy</e2>
D013792_D009422 NONE <e1>thalidomide-induced</e1> <e2>neuropathy</e2>
D013792_D009422 NONE <e1>thalidomide</e1> complication <e2>neuropathy</e2>
D013792_D011471 NONE <e1>thalidomide</e1> neuropathy patients treated <e2>cancer</e2>
D013792_D011471 NONE <e1>thalidomide</e1> trial men <e2>cancer</e2>
D000728_D011471 NONE <e1>androgen-independent</e1> <e2>cancer</e2>
24842192
D008687_D018487 NONE <e1>metformin</e1> treatment suppresses attenuates <e2>dysfunction</e2>
D008687_D018487 NONE <e1>metformin</e1> 25 treated groups lower <e2>dysfunction</e2>
D008687_D009203 NONE <e1>metformin</e1> treatment suppresses attenuates dysfunction <e2>infarction</e2>
D008687_D009203 NONE <e1>metformin</e1> treatment has effect <e2>infarction</e2>
D008687_D009203 NONE <e1>metformin</e1> effect activities <e2>infarction</e2>
D008687_D009203 NONE <e1>metformin</e1> pre-treatment reduces dysfunction <e2>infarction</e2>
D000667_D009203 NONE <e1>amp-activated</e1> kinase activation suppression has effect <e2>infarction</e2>
D008687_D006331 NONE <e1>metformin</e1> effect <e2>dysfunction</e2>
D007545_D009203 CID <e1>isoproterenol</e1> injected induce <e2>infarction</e2>
D007545_D009369 NONE <e1>isoproterenol-induced</e1> elevation lowered factor-alpha <e2>tumor</e2>
D007545_D009336 NONE <e1>isoproterenol-induced</e1> elevation lowered factor-alpha <e2>necrosis</e2>
9646784
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> therapy effects <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> therapy effects <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin</e1> therapy effects other <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-induced</e1> thrombocytopenia effects other <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-associated</e1> osteoporosis <e2>thrombocytopenia</e2>
D006493_D013921 CID <e1>heparin-associated</e1> osteoporosis thrombocytopenia effects other <e2>thrombocytopenia</e2>
D006493_D013923 CID <e1>heparin-induced</e1> thrombocytopenia <e2>thromboembolism</e2>
D006493_D013923 CID <e1>heparin</e1> therapy effects thrombocytopenia <e2>thromboembolism</e2>
D006493_D010024 CID <e1>heparin</e1> therapy effects thrombocytopenia <e2>osteoporosis</e2>
D006493_D010024 CID <e1>heparin-induced</e1> thrombocytopenia <e2>osteoporosis</e2>
D006493_D010024 CID <e1>heparin-associated</e1> <e2>osteoporosis</e2>
D006493_D004802 CID <e1>heparin</e1> therapy effects thrombocytopenia <e2>eosinophilia</e2>
D006493_D004802 CID <e1>heparin-induced</e1> thrombocytopenia <e2>eosinophilia</e2>
D006493_D004802 CID <e1>heparin-associated</e1> osteoporosis thrombocytopenia <e2>eosinophilia</e2>
D006493_D012871 CID <e1>heparin</e1> therapy effects thrombocytopenia <e2>reactions</e2>
D006493_D012871 CID <e1>heparin-induced</e1> thrombocytopenia <e2>reactions</e2>
D006493_D012871 CID <e1>heparin-associated</e1> osteoporosis thrombocytopenia <e2>reactions</e2>
D006493_D004342 CID <e1>heparin</e1> therapy effects thrombocytopenia <e2>reactions</e2>
D006493_D004342 CID <e1>heparin-induced</e1> thrombocytopenia <e2>reactions</e2>
D006493_D004342 CID <e1>heparin-associated</e1> osteoporosis thrombocytopenia <e2>reactions</e2>
D006493_D000505 CID <e1>heparin</e1> therapy effects other <e2>alopecia</e2>
D006493_D000505 CID <e1>heparin-induced</e1> thrombocytopenia effects other <e2>alopecia</e2>
D006493_D000505 CID <e1>heparin-associated</e1> osteoporosis thrombocytopenia effects other <e2>alopecia</e2>
24582773
C069541_D011595 CID <e1>quetiapine</e1> induced <e2>agitation</e2>
C069541_D011595 CID <e1>quetiapine</e1> introduction h presented <e2>agitation</e2>
C069541_D011595 CID <e1>quetiapine</e1> reintroduction withdrawal led <e2>agitation</e2>
C069541_D011595 CID <e1>quetiapine</e1> reintroduction withdrawal enabled attribute <e2>agitation</e2>
C069541_D011595 CID <e1>quetiapine</e1> attribute enabled withdrawal led <e2>agitation</e2>
C069541_D011595 CID <e1>quetiapine</e1> attribute <e2>agitation</e2>
C069541_D011618 NONE <e1>quetiapine</e1> induced <e2>disorder</e2>
D003006_D011618 NONE <e1>zuclopenthixol</e1> antipsychotics combination treated report case suffering <e2>disorder</e2>
D008094_D011618 NONE <e1>lithium</e1> zuclopenthixol antipsychotics combination treated report case suffering <e2>disorder</e2>
D008094_D011618 NONE <e1>lithium=0.85</e1> meq/l combination treated report case suffering <e2>disorder</e2>
C069541_D010554 NONE <e1>quetiapine</e1> introduction h presented contrasting absence history <e2>aggressiveness</e2>
C069541_D010554 NONE <e1>quetiapine</e1> introduction h presented contrasting absence history aggressiveness <e2>disorder</e2>
24459006
D015725_D000380 CID <e1>fluconazole</e1> associated <e2>agranulocytosis</e2>
D015725_D000380 CID <e1>fluconazole</e1> <e2>agranulocytosis</e2>
D015725_D000380 CID <e1>fluconazole</e1> therapy result occurred <e2>agranulocytosis</e2>
D015725_D013921 CID <e1>fluconazole</e1> associated agranulocytosis <e2>thrombocytopenia</e2>
D015725_D013921 CID <e1>fluconazole</e1> agranulocytosis <e2>thrombocytopenia</e2>
D015725_D013921 CID <e1>fluconazole</e1> therapy result occurred agranulocytosis <e2>thrombocytopenia</e2>
D015725_D001855 NONE <e1>fluconazole</e1> initiation relationship <e2>suppression</e2>
24234943
C086816_D007177 CID <e1>desvenlafaxine</e1> associated secretion <e2>hormone</e2>
C086816_D007177 CID <e1>desvenlafaxine</e1> associated secretion <e2>hormone</e2>
C086816_D007177 CID <e1>desvenlafaxine</e1> associated secretion hormone <e2>siadh</e2>
C086816_D009325 CID <e1>desvenlafaxine</e1> included included <e2>nausea</e2>
C086816_D001008 CID <e1>desvenlafaxine</e1> included included nausea <e2>anxiety</e2>
C086816_D003221 CID <e1>desvenlafaxine</e1> included included nausea anxiety <e2>confusion</e2>
D012964_D007177 NONE <e1>sodium</e1> mmol/l consistent diagnosis <e2>siadh</e2>
D012964_D007177 NONE <e1>sodium</e1> mmol/l mosmol/kg mmol/l consistent diagnosis <e2>siadh</e2>
C086816_D007010 CID <e1>desvenlafaxine</e1> cause <e2>hyponatremia</e2>
8829135
C058876_D000647 NONE <e1>nefiracetam</e1> reverses <e2>amnesia</e2>
C058876_D000647 NONE <e1>dm-9384</e1> nefiracetam reverses <e2>amnesia</e2>
C058876_D000647 NONE <e1>nefiracetam</e1> ability attenuate <e2>amnesia</e2>
C058876_D000647 NONE <e1>nefiracetam</e1> administration reversed <e2>amnesia</e2>
D001058_D000647 CID <e1>apomorphine-induced</e1> <e2>amnesia</e2>
D001058_D000647 CID <e1>apomorphine</e1> inhibits evaluated ability attenuate <e2>amnesia</e2>
D001058_D000647 CID <e1>apomorphine</e1> induced <e2>amnesia</e2>
C058876_D007859 NONE <e1>nefiracetam</e1> derivative attenuates learning <e2>deficits</e2>
D011760_D007859 NONE <e1>pyrrolidone</e1> derivative attenuates learning <e2>deficits</e2>
D012601_D007859 CID <e1>scopolamine-induced</e1> learning <e2>deficits</e2>
24709919
D036145_D006930 NONE <e1>ginsenosides</e1> <e2>hyperalgesia</e2>
C049864_D006930 NONE <e1>ginsenosides</e1> <e2>oih</e2>
C049864_D006930 NONE <e1>re</e1> inhibited <e2>oih</e2>
C049864_D006930 NONE <e1>re</e1> ginsenoside contribute reversal <e2>oih</e2>
C035054_D006930 NONE <e1>ginsenosides</e1> <e2>oih</e2>
C035054_D006930 NONE <e1>ginsenosides</e1> failed prevent <e2>oih</e2>
C035054_D006930 NONE <e1>rg1</e1> showed tendency aggravate <e2>oih</e2>
C035054_D006930 NONE <e1>rg1</e1> ginsenoside contribute reversal <e2>oih</e2>
C442759_D006930 NONE <e1>ginsenosides</e1> <e2>oih</e2>
C442759_D006930 NONE <e1>ginsenosides</e1> failed prevent <e2>oih</e2>
C442759_D006930 NONE <e1>rb1</e1> rg1 ginsenoside contribute reversal <e2>oih</e2>
D009020_D006930 CID <e1>morphine</e1> administration achieved <e2>oih</e2>
D019342_D006930 NONE <e1>acid-induced</e1> test test inhibited <e2>oih</e2>
D019342_D006930 NONE <e1>acid-induced</e1> test aggravate <e2>oih</e2>
689020
D005280_D014202 CID <e1>fenoterol-hydrobromide</e1> infusion end decreased amplitudes <e2>tremor</e2>
D012312_D014202 CID <e1>ritodrin-hcl</e1> infusion those faster decreased amplitudes <e2>tremor</e2>
19392810
D003932_D012206 CID <e1>heroin-dependent</e1> male stroke <e2>rhabdomyolysis</e2>
D003932_D012206 CID <e1>heroin</e1> presented <e2>rhabdomyolysis</e2>
D003932_D012206 CID <e1>heroin</e1> methadone using increase risk <e2>rhabdomyolysis</e2>
D003932_D012206 CID <e1>heroin-related</e1> <e2>rhabdomyolysis</e2>
D003932_D012206 CID <e1>heroin</e1> abusers stroke hypotheses <e2>rhabdomyolysis</e2>
D003932_D002544 NONE <e1>heroin-dependent</e1> male <e2>stroke</e2>
D003932_D002544 NONE <e1>heroin</e1> presented rhabdomyolysis <e2>stroke</e2>
D003932_D002544 NONE <e1>heroin</e1> methadone using increase risk rhabdomyolysis <e2>stroke</e2>
D008691_D012206 CID <e1>methadone</e1> therapy male stroke <e2>rhabdomyolysis</e2>
D008691_D012206 CID <e1>methadone</e1> using increase risk <e2>rhabdomyolysis</e2>
D008691_D002544 NONE <e1>methadone</e1> therapy male <e2>stroke</e2>
D008691_D002544 NONE <e1>methadone</e1> using increase risk rhabdomyolysis <e2>stroke</e2>
D003932_D020521 CID <e1>heroin-related</e1> rhabdomyolysis hypotheses <e2>stroke</e2>
D003932_D020521 CID <e1>heroin</e1> abusers <e2>stroke</e2>
24451297
C065180_D056486 CID <e1>fluvastatin</e1> therapy <e2>injury</e2>
C065180_D056486 CID <e1>fluvastatin</e1> treatment beginning appeared man reported <e2>damage</e2>
D019161_D056486 NONE <e1>statins</e1> drugs reported cases <e2>injury</e2>
15229250
D008694_D001930 CID <e1>methamphetamine</e1> abuse associated <e2>brain</e2>
D008694_D001930 CID <e1>ma</e1> methamphetamine abuse associated <e2>brain</e2>
D008694_D001930 CID <e1>ma</e1> used subjects <e2>ventricles</e2>
D008694_D001930 CID <e1>ma</e1> abuse symptoms account help providing targets <e2>injury</e2>
D008694_D008659 NONE <e1>ma</e1> used studies revealed systems <e2>abnormalities</e2>
D008694_D003072 NONE <e1>ma</e1> abuse associated alterations pattern determined related <e2>impairment</e2>
D008694_D006984 NONE <e1>ma</e1> abusers had <e2>hypertrophy</e2>
D008694_D008569 CID <e1>methamphetamine</e1> abuse causes pattern contributes <e2>performance</e2>
16867246
D002746_D001480 CID <e1>chlorpromazine-induced</e1> <e2>syndrome</e2>
D002746_D001480 CID <e1>chlorpromazine-induced</e1> <e2>eps</e2>
D002746_D001480 CID <e1>chlorpromazine</e1> treated scale identified inpatients 59 <e2>eps</e2>
D002746_D001480 CID <e1>chlorpromazine</e1> treated scale identified inpatients <e2>eps</e2>
D002746_D012559 NONE <e1>chlorpromazine-induced</e1> syndrome polymorphisms association patients <e2>schizophrenic</e2>
D002746_D012559 NONE <e1>chlorpromazine-induced</e1> eps plays patients <e2>schizophrenic</e2>
D002746_D012559 NONE <e1>chlorpromazine</e1> treated scale identified inpatients <e2>schizophrenic</e2>
D002746_D012559 NONE <e1>chlorpromazine</e1> induced effect plays view lend patients <e2>schizophrenia</e2>
611664
D011433_C544351 NONE <e1>propranolol</e1> use treatment <e2>hypotension</e2>
D011433_C544351 NONE <e1>propranolol</e1> drug patients <e2>hypotension</e2>
D002395_D004342 NONE <e1>catecholamines</e1> exhibited had <e2>hypersensitivity</e2>
D009638_D004342 NONE <e1>norepinephrine</e1> effects had <e2>hypersensitivity</e2>
D011433_D006973 CID <e1>propranolol</e1> induced <e2>hypertension</e2>
20513036
C542870_D010243 NONE <e1>botox</e1> injection <e2>paralysis</e2>
C542870_D010243 NONE <e1>botox</e1> injections cases <e2>paralysis</e2>
C542870_D010243 NONE <e1>botox</e1> dose <e2>paralysis</e2>
C542870_D010243 NONE <e1>botox</e1> dose paralysis patients noted <e2>paralysis</e2>
C542870_D010243 NONE <e1>botox</e1> dose <e2>paralysis</e2>
C542870_D010243 NONE <e1>botox</e1> dose paralysis patients noted <e2>paralysis</e2>
C542870_D010243 NONE <e1>botox</e1> injection incidence <e2>paralysis</e2>
C542870_D010243 NONE <e1>botox</e1> injections complication <e2>paralysis</e2>
C542870_D010243 NONE <e1>botox</e1> diffusion mechanism <e2>paralysis</e2>
C542870_D014826 CID <e1>botox</e1> injection <e2>dysphonia</e2>
C542870_D014826 CID <e1>botox</e1> toxin injections standard <e2>dysphonia</e2>
C542870_D014826 CID <e1>botox</e1> toxin injections standard dysphonia <e2>adsd</e2>
C542870_D014826 CID <e1>botox</e1> injections <e2>adsd</e2>
C542870_D014826 CID <e1>botox</e1> receiving patients database diagnosed <e2>adsd</e2>
C542870_D014826 CID <e1>botox</e1> injection <e2>adsd</e2>
C542870_D014826 CID <e1>botox</e1> injections <e2>adsd</e2>
C542870_D055154 NONE <e1>botox</e1> injections received <e2>dysphonia</e2>
2614930
D009543_D001919 CID <e1>nifedipine</e1> induced <e2>bradycardia</e2>
D009543_D009422 NONE <e1>nifedipine</e1> induced patient <e2>neuropathy</e2>
D009543_D001282 NONE <e1>nifedipine</e1> slowed rate have <e2>flutter</e2>
D009543_D013610 CID <e1>nifedipine</e1> induces <e2>tachycardia</e2>
24614773
D014635_D001927 NONE <e1>valproate</e1> <e2>encephalopathy</e2>
D014635_D001927 NONE <e1>valproate-induced</e1> <e2>encephalopathy</e2>
D014635_D010291 NONE <e1>valproate</e1> started had number admissions <e2>hemiparesis</e2>
D014635_D020325 NONE <e1>valproate</e1> <e2>migraine</e2>
D016202_D001927 NONE <e1>n-methyl-d-aspartate</e1> antibodies changes consistent <e2>encephalopathy</e2>
D016202_D001927 NONE <e1>nmda</e1> antibodies changes consistent <e2>encephalopathy</e2>
D016202_D001927 NONE <e1>nmda</e1> receptor-associated encephalitis <e2>encephalopathy</e2>
D014635_D004660 NONE <e1>valproate-induced</e1> encephalopathy <e2>encephalitis</e2>
D016202_D004660 NONE <e1>nmda</e1> receptor-associated <e2>encephalitis</e2>
17042797
D010862_D013226 CID <e1>pilocarpine-induced</e1> <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine-induced</e1> <e2>epilepticus</e2>
D010862_D004833 CID <e1>pilocarpine</e1> model <e2>epilepsy</e2>
7378868
D013390_D014313 CID <e1>suxamethonium-induced</e1> <e2>stiffness</e2>
D013390_D014313 CID <e1>suxamethonium</e1> occur <e2>rigidity</e2>
D013390_D063806 CID <e1>suxamethonium-induced</e1> stiffness <e2>myalgia</e2>
D013390_D063806 CID <e1>suxamethonium</e1> occur rigidity <e2>myalgia</e2>
D010197_D014313 NONE <e1>pancuronium</e1> pretreatment occur <e2>rigidity</e2>
D010197_D063806 NONE <e1>pancuronium</e1> pretreatment occur rigidity <e2>myalgia</e2>
9869655
D004997_D002780 CID <e1>17alpha-ethinylestradiol</e1> (ee)-induced <e2>cholestasis</e2>
D004997_D002780 CID <e1>(ee)-induced</e1> <e2>cholestasis</e2>
D001647_D002780 NONE <e1>salt</e1> synthesis pathway inhibition associated shows (ee)-induced <e2>cholestasis</e2>
D001647_D002780 NONE <e1>bs</e1> salt synthesis pathway inhibition associated shows (ee)-induced <e2>cholestasis</e2>
11366874
D019888_D001145 NONE <e1>viracept</e1> warning <e2>heartbeat</e2>
D019888_D001145 NONE <e1>viracept</e1> cause <e2>beat</e2>
D019888_D001919 CID <e1>viracept</e1> cause beat known <e2>bradycardia</e2>
D019888_D001919 CID <e1>viracept</e1> patient occurred <e2>bradycardia</e2>
11423811
D004280_D002637 NONE <e1>dobutamine</e1> echocardiography safety evaluation <e2>pain</e2>
D004280_D002637 NONE <e1>dobutamine</e1> administration concern conducted study assess <e2>pain</e2>
D004280_D002637 NONE <e1>dobutamine</e1> administered patients <e2>pain</e2>
D003042_D002637 CID <e1>cocaine-associated</e1> <e2>pain</e2>
D003042_D002637 CID <e1>cocaine</e1> use setting <e2>pain</e2>
D003042_D002637 CID <e1>cocaine</e1> use setting administration concern conducted study assess <e2>pain</e2>
D003042_D002637 CID <e1>cocaine-associated</e1> <e2>pain</e2>
D003042_D002637 CID <e1>cocaine</e1> used preceding onset <e2>pain</e2>
D003042_D002637 CID <e1>cocaine-related</e1> <e2>pain</e2>
D004280_D007511 NONE <e1>dobutamine</e1> echocardiography available test evaluating <e2>ischemia</e2>
D003042_D064420 NONE <e1>cocaine</e1> <e2>toxicity</e2>
17255138
D052246_D009203 CID <e1>inhibitors</e1> risk <e2>infarction</e2>
D052246_D009203 CID <e1>inhibitors</e1> risk infarction <e2>ami</e2>
D052246_D009203 CID <e1>inhibitors</e1> using risks <e2>ami</e2>
D000894_D009203 CID <e1>drugs</e1> offset risk <e2>infarction</e2>
D000894_D009203 CID <e1>drugs</e1> offset risk infarction <e2>ami</e2>
D052246_D006471 NONE <e1>inhibitors</e1> using risks ami <e2>bleeding</e2>
D000082_D009203 NONE <e1>acetaminophen</e1> ns-nsaids inhibitors using risks <e2>ami</e2>
D000082_D009203 NONE <e1>acetaminophen</e1> rofecoxib , ratios hospitalization <e2>ami/gi</e2>
D000082_D009203 NONE <e1>acetaminophen</e1> that similar toxicity <e2>ami/gi</e2>
D000082_D006471 NONE <e1>acetaminophen</e1> ns-nsaids inhibitors using risks ami <e2>bleeding</e2>
D001241_D009203 NONE <e1>aspirin</e1> non-users rofecoxib , ratios hospitalization <e2>ami/gi</e2>
D001241_D009203 NONE <e1>aspirin</e1> group acetaminophen rofecoxib , ratios hospitalization <e2>ami/gi</e2>
D001241_D009203 NONE <e1>aspirin</e1> non-users seemed carry bleeding <e2>ami/gi</e2>
C116926_D009203 CID <e1>rofecoxib</e1> , ratios hospitalization <e2>ami/gi</e2>
C116926_D009203 CID <e1>rofecoxib</e1> those better seemed similar toxicity <e2>ami/gi</e2>
C105934_D009203 NONE <e1>celecoxib</e1> rofecoxib , ratios hospitalization <e2>ami/gi</e2>
C105934_D009203 NONE <e1>celecoxib</e1> toxicity <e2>ami/gi</e2>
D009288_D009203 CID <e1>naproxen</e1> celecoxib rofecoxib , ratios hospitalization <e2>ami/gi</e2>
D009288_D009203 CID <e1>naproxen</e1> seemed carry bleeding <e2>ami/gi</e2>
D004008_D009203 NONE <e1>diclofenac</e1> rofecoxib , ratios hospitalization <e2>ami/gi</e2>
D007052_D009203 NONE <e1>ibuprofen</e1> diclofenac rofecoxib , ratios hospitalization <e2>ami/gi</e2>
D001241_D006471 NONE <e1>aspirin</e1> non-users seemed carry <e2>bleeding</e2>
D009288_D006471 CID <e1>naproxen</e1> seemed carry <e2>bleeding</e2>
C105934_D064420 NONE <e1>celecoxib</e1> <e2>toxicity</e2>
D000082_D064420 NONE <e1>acetaminophen</e1> that similar <e2>toxicity</e2>
C116926_D064420 NONE <e1>rofecoxib</e1> those better seemed similar <e2>toxicity</e2>
15953230
C012052_D062787 NONE <e1>amisulpride</e1> <e2>overdose</e2>
C012052_D008133 CID <e1>amisulpride</e1> overdose cases cause <e2>syndrome</e2>
C012052_D011041 NONE <e1>amisulpride</e1> cases <e2>self-poisoning</e2>
D002125_D008133 NONE <e1>gluconate</e1> administration respond appeared <e2>prolongation</e2>
12498738
C043211_D009202 NONE <e1>carvedilol</e1> protects <e2>cardiomyopathy</e2>
C043211_D009202 NONE <e1>carvedilol</e1> protection afford minimizing dysfunction <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>doxorubicin-induced</e1> <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>doxorubicin</e1> caused cumulative <e2>cardiomyopathy</e2>
D004317_D009202 CID <e1>doxorubicin</e1> therapy accompanies dysfunction <e2>cardiomyopathy</e2>
C043211_D064420 NONE <e1>carvedilol</e1> protects cardiac associated <e2>toxicity</e2>
D004317_D064420 NONE <e1>doxorubicin</e1> <e2>toxicity</e2>
C043211_D028361 NONE <e1>carvedilol</e1> protection afford minimizing <e2>dysfunction</e2>
C043211_D009369 NONE <e1>carvedilol</e1> protection afford minimizing dysfunction accompanies therapy patients <e2>cancer</e2>
D004317_D028361 NONE <e1>doxorubicin</e1> therapy accompanies <e2>dysfunction</e2>
D004317_D009369 NONE <e1>doxorubicin</e1> therapy patients <e2>cancer</e2>
19515070
D019343_D064420 NONE <e1>citrate</e1> anticoagulation unsafe carries risk <e2>toxicity</e2>
D019343_D064420 NONE <e1>citrate</e1> <e2>toxicity</e2>
D019343_D064420 NONE <e1>citrate</e1> <e2>toxicity</e2>
D000082_D017114 CID <e1>acetaminophen-induced</e1> <e2>failure</e2>
D000082_D058186 CID <e1>acetaminophen-induced</e1> failure <e2>aki</e2>
D019343_D017114 NONE <e1>citrate</e1> dialysate anticoagulated transplantation underwent <e2>failure</e2>
D019343_D017114 NONE <e1>citrate</e1> dialysate alternative support transplantation <e2>failure</e2>
D019343_D058186 NONE <e1>citrate</e1> dialysate anticoagulated transplantation underwent failure <e2>aki</e2>
9889429
D009543_D006973 NONE <e1>nifedipine</e1> tablets event <e2>hypertension</e2>
D009543_D006973 NONE <e1>nifedipine</e1> blocker months treated patients <e2>hypertension</e2>
D009543_D006973 NONE <e1>nifedipine</e1> useful patients <e2>hypertensive</e2>
D009543_D011565 NONE <e1>nifedipine</e1> tablets event hypertension patients <e2>psoriasis</e2>
D009543_D011565 NONE <e1>nifedipine</e1> blocker months treated patients <e2>psoriatic</e2>
D009543_D011565 NONE <e1>nifedipine</e1> useful patients <e2>psoriatic</e2>
D016572_D006973 CID <e1>a-induced</e1> <e2>hypertension</e2>
D016572_D006973 CID <e1>a</e1> therapy course patients <e2>hypertension</e2>
D016572_D006973 CID <e1>a</e1> therapy exhibited state <e2>hypertensive</e2>
D016572_D006973 CID <e1>a</e1> treatment useful patients <e2>hypertensive</e2>
D016572_D011565 NONE <e1>a-induced</e1> hypertension patients <e2>psoriasis</e2>
D016572_D011565 NONE <e1>a</e1> therapy course patients <e2>psoriatic</e2>
D016572_D011565 NONE <e1>a</e1> treatment useful patients <e2>psoriatic</e2>
D002118_D011565 NONE <e1>calcium</e1> channel blocker months treated patients <e2>psoriatic</e2>
D002118_D006973 NONE <e1>calcium</e1> channel blocker months treated patients <e2>hypertension</e2>
D016572_D005885 CID <e1>a</e1> therapy events included increase 9 development <e2>hyperplasia</e2>
D016572_D005885 CID <e1>a</e1> treatment useful monitored <e2>hyperplasia</e2>
D009543_D005885 CID <e1>nifedipine</e1> a therapy events included increase 9 development <e2>hyperplasia</e2>
D009543_D005885 CID <e1>nifedipine</e1> useful monitored <e2>hyperplasia</e2>
D001806_D005885 NONE <e1>nitrogen</e1> levels increase 9 development <e2>hyperplasia</e2>
17554526
D003042_D001925 CID <e1>cocaine</e1> users <e2>recognition</e2>
D003042_D001925 CID <e1>cocaine</e1> effects explained deficit accuracy <e2>recognition</e2>
D018817_D001925 NONE <e1>ecstasy</e1> effects explained deficit accuracy <e2>recognition</e2>
920167
D014859_D005315 NONE <e1>warfarin-induced</e1> <e2>embryopathy</e2>
D014859_-1 NONE <e1>warfarin-induced</e1> embryopathy <e2>hypoplasia</e2>
D014859_-1 NONE <e1>warfarin</e1> treated mothers born infants reported <e2>hypoplasia</e2>
D014859_D002806 CID <e1>warfarin-induced</e1> embryopathy showed <e2>epiphyses</e2>
D014859_D002806 CID <e1>warfarin-induced</e1> embryopathy showed epiphyses <e2>punctata</e2>
D014859_D002806 CID <e1>warfarin</e1> treated mothers born infants reported hypoplasia <e2>epiphyses</e2>
25054547
D013390_D001049 CID <e1>suxamethonium</e1> loss activity <e2>apnea</e2>
D013390_D001049 CID <e1>suxamethonium</e1> relaxants use characterized <e2>apnea</e2>
D013390_C537417 CID <e1>suxamethonium</e1> relaxants use characterized <e2>deficiency</e2>
C049430_C537417 CID <e1>mivacurium</e1> suxamethonium relaxants use characterized <e2>deficiency</e2>
C049430_D001049 CID <e1>mivacurium</e1> suxamethonium relaxants use characterized <e2>apnea</e2>
10677406
D004280_D018487 CID <e1>dobutamine</e1> occurs <e2>dysfunction</e2>
D004280_D018487 CID <e1>dobutamine</e1> induced results <e2>dysfunction</e2>
D004280_D003324 NONE <e1>dobutamine</e1> occurs patients <e2>disease</e2>
D004280_D003324 NONE <e1>dobutamine</e1> induced results patients <e2>disease</e2>
D004280_D003324 NONE <e1>dobutamine</e1> induced ischaemia used study patients <e2>disease</e2>
D004280_D017202 NONE <e1>dobutamine</e1> <e2>ischaemia</e2>
D004280_D007511 NONE <e1>dobutamine</e1> exercise <e2>ischaemia</e2>
D004280_D007511 NONE <e1>dobutamine</e1> induced results <e2>ischaemia</e2>
D004280_D007511 NONE <e1>dobutamine</e1> induced <e2>ischaemia</e2>
D004280_D017682 CID <e1>dobutamine</e1> induced results presumed <e2>stunning</e2>
1361574
D002243_D012640 NONE <e1>beta-carboline</e1> mg/kg reduced increase binding <e2>convulsions</e2>
C037476_D012640 NONE <e1>[35s]tbps</e1> binding <e2>convulsions</e2>
D007538_D012640 CID <e1>isoniazid</e1> induced <e2>convulsions</e2>
6687006
D003913_D006948 CID <e1>d-amphetamine</e1> induced <e2>hyperactivity</e2>
C012102_D006948 NONE <e1>dsp4</e1> pretreatment reduced <e2>hyperactivity</e2>
C012102_D006948 NONE <e1>dsp4</e1> induced <e2>hyperactivity</e2>
C012102_D006948 NONE <e1>dsp4</e1> action prevents agent pretreatment blocked reduction <e2>hyperactivity</e2>
D000661_D019956 NONE <e1>amphetamine-induced</e1> <e2>stereotypies</e2>
C012102_D019956 NONE <e1>dsp4</e1> pretreatment blocked <e2>stereotypies</e2>
D000661_D006948 NONE <e1>amphetamine</e1> <e2>hyperactivity</e2>
D000661_D020258 NONE <e1>amphetamine</e1> hyperactivity reduction blocked pretreatment agent prevents action <e2>neurotoxic</e2>
C012102_D020258 NONE <e1>dsp4</e1> induced hyperactivity reduction blocked pretreatment agent prevents action <e2>neurotoxic</e2>
C012102_D020258 NONE <e1>dsp4</e1> action <e2>neurotoxic</e2>
D009638_D006948 NONE <e1>noradrenaline-uptake</e1> agent pretreatment blocked reduction <e2>hyperactivity</e2>
D009638_D020258 NONE <e1>noradrenaline-uptake</e1> agent prevents action <e2>neurotoxic</e2>
D003891_D006948 NONE <e1>desipramine</e1> agent pretreatment blocked reduction <e2>hyperactivity</e2>
D003891_D020258 NONE <e1>desipramine</e1> agent prevents action <e2>neurotoxic</e2>
10770468
D008094_D001714 NONE <e1>lithium</e1> therapy receiving patient <e2>bipolar</e2>
D008094_D001714 NONE <e1>lithium</e1> therapy developed prompted conduct study patients <e2>bipolar</e2>
D008094_D001714 NONE <e1>lithium-associated</e1> hypercalcemia patients study conduct prompted developed therapy receiving patient <e2>bipolar</e2>
D008094_D001714 NONE <e1>lithium-associated</e1> hypercalcemia patients <e2>bipolar</e2>
D008094_D001714 NONE <e1>lithium-treated</e1> patients <e2>bipolar</e2>
D008094_D001714 NONE <e1>lithium-treated</e1> patients included c1 included patients <e2>bipolar</e2>
D008094_D001714 NONE <e1>lithium-associated</e1> hypercalcemia patients <e2>bipolar</e2>
D008094_D006934 CID <e1>lithium</e1> therapy developed <e2>hypercalcemia</e2>
D008094_D006934 CID <e1>lithium</e1> therapy developed prompted conduct study patients <e2>hypercalcemia</e2>
D008094_D006934 CID <e1>lithium-associated</e1> hypercalcemia patients study conduct prompted developed <e2>hypercalcemia</e2>
D008094_D006934 CID <e1>lithium-associated</e1> <e2>hypercalcemia</e2>
D008094_D006934 CID <e1>non-lithium-treated</e1> patients identified eliminating <e2>hypercalcemias</e2>
D008094_D006934 CID <e1>non-lithium-treated</e1> patients <e2>hypercalcemias</e2>
D008094_D006934 CID <e1>non-lithium-treated</e1> patients hypercalcemias related malignancies patients <e2>hypercalcemia</e2>
D008094_D006934 CID <e1>lithium-associated</e1> hypercalcemia patients malignancies related hypercalcemias patients identified eliminating <e2>hypercalcemias</e2>
D008094_D006934 CID <e1>lithium-associated</e1> hypercalcemia patients malignancies related <e2>hypercalcemias</e2>
D008094_D006934 CID <e1>lithium-associated</e1> <e2>hypercalcemia</e2>
D008094_D006934 CID <e1>lithium-associated</e1> hypercalcemia patients diseases resulting patients <e2>hypercalcemia</e2>
D008094_D006934 CID <e1>lithium-associated</e1> <e2>hypercalcemia</e2>
D008094_D001919 NONE <e1>lithium</e1> therapy developed hypercalcemia <e2>bradyarrhythmia</e2>
D008094_D001919 NONE <e1>lithium-associated</e1> hypercalcemia patients study conduct prompted developed hypercalcemia <e2>bradyarrhythmia</e2>
D008094_D009369 NONE <e1>non-lithium-treated</e1> patients hypercalcemias related <e2>malignancies</e2>
D008094_D009369 NONE <e1>lithium-associated</e1> hypercalcemia patients <e2>malignancies</e2>
18025637
D005473_D012170 CID <e1>fluoxetine</e1> <e2>occlusion</e2>
D005473_D012170 CID <e1>fluoxetine-induced</e1> hypertension associated <e2>occlusion</e2>
D005473_D006973 CID <e1>fluoxetine-induced</e1> <e2>hypertension</e2>
D012701_D006973 NONE <e1>serotonin</e1> therapy complication important aware cause <e2>hypertension</e2>
16309808
D004294_D012148 NONE <e1>domperidone</e1> potentiate <e2>syndrome</e2>
D004294_D012148 NONE <e1>domperidone</e1> induce symptoms <e2>rls</e2>
D004294_D012148 NONE <e1>domperidone</e1> therapy added report comorbid dyspepsia developed <e2>rls</e2>
D004294_D012148 NONE <e1>domperione</e1> effect support relationship use symptoms <e2>rls</e2>
D004294_D012148 NONE <e1>domperione</e1> effect <e2>rls</e2>
C035133_D012148 CID <e1>mirtazapine-associated</e1> <e2>syndrome</e2>
C035133_D012148 CID <e1>mirtazapine</e1> associated <e2>rls</e2>
C035133_D012148 CID <e1>mirtazapine</e1> developed <e2>rls</e2>
C035133_D012148 CID <e1>mirtazapine</e1> treated started have symptoms <e2>rls</e2>
C035133_D012148 CID <e1>mirtazapine</e1> treated started resolved symptoms <e2>rls</e2>
C035133_D012148 CID <e1>mirtazapine</e1> discontinuation resolved started have symptoms <e2>rls</e2>
C035133_D012148 CID <e1>mirtazapine</e1> discontinuation resolved symptoms <e2>rls</e2>
C035133_D012148 CID <e1>mirtazapine</e1> use symptoms <e2>rls</e2>
C035133_D012148 CID <e1>mirtazapine</e1> use relationship support effect <e2>rls</e2>
C035133_D012148 CID <e1>mirtazapine-associated</e1> rls effect support relationship use symptoms <e2>rls</e2>
C035133_D012148 CID <e1>mirtazapine-associated</e1> <e2>rls</e2>
C035133_D012148 CID <e1>mirtazapine</e1> associated <e2>rls</e2>
D007980_D012148 NONE <e1>levodopa</e1> improved symptoms <e2>rls</e2>
D007980_D012148 NONE <e1>levodopa</e1> improved induce symptoms <e2>rls</e2>
D004298_D012148 NONE <e1>dopamine</e1> levodopa improved symptoms <e2>rls</e2>
D004298_D012148 NONE <e1>dopamine</e1> levodopa improved induce symptoms <e2>rls</e2>
D004298_D012148 NONE <e1>dopamine</e1> antagonists induce improved symptoms <e2>rls</e2>
D004298_D012148 NONE <e1>dopamine</e1> antagonists induce symptoms <e2>rls</e2>
D004298_D012148 NONE <e1>dopamine</e1> antagonist domperidone induce symptoms <e2>rls</e2>
D004298_D012148 NONE <e1>dopamine</e1> receptor antagonists receiving those aware possibility associated <e2>rls</e2>
C035133_D004415 NONE <e1>mirtazapine</e1> developed <e2>dyspepsia</e2>
D004294_D004415 NONE <e1>domperidone</e1> therapy added report comorbid <e2>dyspepsia</e2>
3832950
D002998_D004827 NONE <e1>clonazepam</e1> monotherapy <e2>epilepsy</e2>
D002998_D004827 NONE <e1>clonazepam</e1> treated patients types <e2>epilepsy</e2>
D002998_D013036 NONE <e1>clonazepam</e1> treated patients types <e2>spasms</e2>
4010471
D009538_D012640 CID <e1>nicotine-induced</e1> <e2>seizures</e2>
D009538_D012640 CID <e1>nicotine-induced</e1> <e2>seizures</e2>
D009538_D012640 CID <e1>nicotine</e1> effects sensitive mice had <e2>seizure</e2>
D004229_D012640 NONE <e1>dithiothreitol</e1> treatment affected sites mice <e2>seizure</e2>
7644931
D017239_D002289 NONE <e1>paclitaxel</e1> combined carboplatin study directed patients <e2>cancer</e2>
D017239_D002289 NONE <e1>taxol</e1> company paclitaxel combined carboplatin study directed patients <e2>cancer</e2>
D016190_D002289 NONE <e1>carboplatin</e1> study directed patients <e2>cancer</e2>
D017239_D064420 NONE <e1>paclitaxel</e1> trial patients cohort compared <e2>toxicities</e2>
D016190_D006402 NONE <e1>carboplatin</e1> appear add <e2>toxicities</e2>
D016190_D006402 NONE <e1>paclitaxel/carboplatin</e1> combination dosed appear add <e2>toxicities</e2>
D017239_D006402 CID <e1>paclitaxel/carboplatin</e1> combination dosed appear add <e2>toxicities</e2>
1280054
D014750_D001927 CID <e1>vincristine</e1> administration <e2>myeloencephalopathy</e2>
D014750_D001927 CID <e1>vincristine</e1> given producing dysfunction followed <e2>encephalopathy</e2>
D014750_D007938 NONE <e1>vincristine</e1> given child <e2>leukaemia</e2>
D014750_D007049 CID <e1>vincristine</e1> given producing <e2>dysfunction</e2>
895432
D007545_D009203 CID <e1>isoproterenol-induced</e1> <e2>infarction</e2>
D007545_D009203 CID <e1>isoproterenol-induced</e1> <e2>infarction</e2>
D007545_D007238 NONE <e1>isoproterenol</e1> dosages effects associated mortality reduced had severity <e2>infarction</e2>
19815465
D020888_D014786 CID <e1>vigabatrin</e1> specific <e2>defects</e2>
D020888_D014786 CID <e1>vigabatrin</e1> associated <e2>defects</e2>
D020888_D014786 CID <e1>vgb</e1> vigabatrin associated <e2>defects</e2>
D020888_D004827 NONE <e1>vgb</e1> exposure current therapy basis grouped people <e2>epilepsy</e2>
D020888_D012164 CID <e1>vgb</e1> associated <e2>toxicity</e2>
16565833
C522803_D066126 NONE <e1>monoher</e1> interval administration protection <e2>cardiotoxicity</e2>
C522803_D066126 NONE <e1>monohydroxyethylrutoside</e1> showed cardioprotection <e2>cardiotoxicity</e2>
C522803_D066126 NONE <e1>monoher</e1> monohydroxyethylrutoside showed cardioprotection <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> monoher interval administration protection <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>dox</e1> doxorubicin <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>dox-induced</e1> <e2>cardiotoxicity</e2>
D004317_D006331 NONE <e1>dox-induced</e1> <e2>damage</e2>
D004317_D006331 NONE <e1>dox</e1> formation results <e2>damage</e2>
D004317_D006331 NONE <e1>dox</e1> treatment induced <e2>damage</e2>
D005419_D066126 NONE <e1>flavonoid</e1> monohydroxyethylrutoside showed cardioprotection <e2>cardiotoxicity</e2>
D007501_D066126 NONE <e1>iron</e1> properties scavenging showed cardioprotection <e2>cardiotoxicity</e2>
20682692
D013311_D003928 CID <e1>streptozotocin-induced</e1> <e2>nephropathy</e2>
D013311_D003928 CID <e1>stz-induced</e1> <e2>nephropathy</e2>
D013311_D003928 CID <e1>stz-induced</e1> <e2>nephropathy</e2>
D000804_D003922 NONE <e1>renin-angiotensin</e1> system patients <e2>diabetes</e2>
D000804_D007674 NONE <e1>renin-angiotensin</e1> system blockade retard progression <e2>nephropathy</e2>
D000804_D003928 NONE <e1>renin-angiotensin</e1> system blockade retard showed suggesting involved pathogenesis <e2>nephropathy</e2>
D000804_D003928 NONE <e1>renin-angiotensin</e1> system blockade retard showed suggesting involved pathogenesis nephropathy diabetic <e2>nephropathy</e2>
D013311_D005355 NONE <e1>streptozotocin</e1> diabetes mice development <e2>fibrosis</e2>
D013311_D005355 NONE <e1>(stz)-induced</e1> diabetes mice development <e2>fibrosis</e2>
D013311_D003920 NONE <e1>streptozotocin</e1> <e2>diabetes</e2>
D013311_D003920 NONE <e1>(stz)-induced</e1> <e2>diabetes</e2>
18189308
D003520_D003556 CID <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>cyclophosphamide</e1> induced <e2>inflammation</e2>
D003520_D003556 CID <e1>cyp</e1> cyclophosphamide induced <e2>inflammation</e2>
D003520_D003556 CID <e1>cyp-induced</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>cyp-induced</e1> <e2>cystitis</e2>
D003520_D003556 CID <e1>cyp-induced</e1> <e2>cystitis</e2>
D014443_D003556 NONE <e1>tyrosine</e1> receptors expression <e2>inflammation</e2>
9428298
D000420_D001249 NONE <e1>albuterol</e1> exacerbations <e2>asthma</e2>
D000420_D001249 NONE <e1>albuterol</e1> received exacerbations <e2>asthma</e2>
D000420_D001249 NONE <e1>albuterol</e1> treatments albuterol received exacerbations <e2>asthma</e2>
16369751
D005472_D066126 NONE <e1>5-fluorouracil</e1> <e2>cardiotoxicity</e2>
D005472_D066126 NONE <e1>5-fluorouracil</e1> treatment occurring complication <e2>cardiotoxicity</e2>
D005472_D066126 NONE <e1>5-fu</e1> 5-fluorouracil treatment occurring complication <e2>cardiotoxicity</e2>
D005472_D066126 NONE <e1>5-fu-induced</e1> <e2>cardiotoxicity</e2>
D005472_D066126 NONE <e1>5-fu-induced</e1> <e2>cardiotoxicity</e2>
D005472_D066126 NONE <e1>5-fu</e1> administration abandoned considered <e2>cardiotoxicity</e2>
D005472_D066126 NONE <e1>5-fu-induced</e1> <e2>cardiotoxicity</e2>
D005472_D066126 NONE <e1>5-fu-induced</e1> <e2>cardiotoxicity</e2>
C032348_D066126 NONE <e1>alpha-fluoro-beta-alanine</e1> induced <e2>cardiotoxicity</e2>
C032348_D066126 NONE <e1>alpha-fluoro-beta-alanine</e1> level observed case man <e2>cardiotoxicity</e2>
C032348_D066126 NONE <e1>fbal</e1> level observed case man <e2>cardiotoxicity</e2>
C032348_D066126 NONE <e1>fbal</e1> related <e2>cardiotoxicity</e2>
D005472_D009369 NONE <e1>5-fluorouracil</e1> treatment <e2>malignancies</e2>
D005472_D009369 NONE <e1>5-fu</e1> 5-fluorouracil treatment <e2>malignancies</e2>
D005472_D002637 CID <e1>5-fu</e1> infusion occurred <e2>pain</e2>
D005472_D002637 CID <e1>5-fu</e1> discontinuation disappeared <e2>pain</e2>
D005472_D002637 CID <e1>5-fu-induced</e1> cardiotoxicity considered <e2>pain</e2>
D005472_D002637 CID <e1>5-fu</e1> administration abandoned considered <e2>pain</e2>
D005472_D002037 CID <e1>5-fu</e1> infusion occurred pain <e2>block</e2>
C032348_D002637 NONE <e1>fbal</e1> concentration occurred <e2>pain</e2>
C032348_D002037 NONE <e1>fbal</e1> concentration occurred pain <e2>block</e2>
3708328
D010862_D012640 CID <e1>pilocarpine</e1> produced <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> given reproduces provides model studying mechanisms buildup activity <e2>convulsive</e2>
D010862_D012640 CID <e1>pilocarpine</e1> given reproduces provides model studying mechanisms operative generalization propagation <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> produced <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> doses reticulata resulted <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>convulsions</e2>
D010862_D012640 CID <e1>pilocarpine</e1> observed revealed damage <e2>seizure-related</e2>
D010862_D012640 CID <e1>pilocarpine</e1> produced <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> produced <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> produced <e2>convulsions</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>seizures</e2>
D007538_D012640 NONE <e1>isoniazid</e1> microinjection produced <e2>seizures</e2>
D007538_D012640 NONE <e1>isoniazid</e1> microinjections pretreated animals reticulata resulted <e2>seizures</e2>
D007538_D012640 NONE <e1>isoniazid</e1> injections augment <e2>seizures</e2>
D020888_D012640 NONE <e1>gamma-vinyl-gaba</e1> isoniazid microinjection produced <e2>seizures</e2>
D020888_D012640 NONE <e1>gamma-vinyl-gaba</e1> inhibitor application suppressed appearance <e2>seizures</e2>
D020888_D012640 NONE <e1>acid</e1> d gamma-vinyl-gaba inhibitor application suppressed appearance <e2>seizures</e2>
D020888_D012640 NONE <e1>gamma-vinyl-gaba</e1> microinjections failed prevent development <e2>convulsions</e2>
D010862_D004833 NONE <e1>pilocarpine</e1> given reproduces sequelae <e2>epilepsy</e2>
D005680_D012640 NONE <e1>acid</e1> inhibition nigra <e2>seizures</e2>
D005680_D012640 NONE <e1>(gaba)-mediated</e1> acid inhibition nigra <e2>seizures</e2>
D005680_D012640 NONE <e1>gaba-synthesizing</e1> enzyme activity inhibitor micrograms isoniazid microinjections pretreated animals reticulata resulted <e2>seizures</e2>
D005680_D012640 NONE <e1>gaba</e1> transaminase inhibitor application suppressed appearance <e2>seizures</e2>
D005680_D012640 NONE <e1>gaba-mediated</e1> inhibition regulation subjected threshold <e2>seizures</e2>
D007538_D013226 NONE <e1>isoniazid</e1> microinjections pretreated animals reticulata resulted seizures <e2>epilepticus</e2>
D005680_D013226 NONE <e1>gaba-synthesizing</e1> enzyme activity inhibitor micrograms isoniazid microinjections pretreated animals reticulata resulted seizures <e2>epilepticus</e2>
D018698_D012640 NONE <e1>acid</e1> decarboxylase isoniazid microinjections pretreated animals reticulata resulted <e2>seizures</e2>
D018698_D013226 NONE <e1>acid</e1> decarboxylase isoniazid microinjections pretreated animals reticulata resulted seizures <e2>epilepticus</e2>
D010862_D013226 NONE <e1>pilocarpine</e1> doses reticulata resulted seizures <e2>epilepticus</e2>
4082466
D009020_D012640 CID <e1>morphine-induced</e1> <e2>seizures</e2>
D009020_D012640 CID <e1>sulfate</e1> course suffered <e2>seizures</e2>
D009020_D012640 CID <e1>morphine</e1> received doses micrograms/kg/hr larger group neonates received had <e2>seizures</e2>
D009020_D012640 CID <e1>morphine</e1> cessation stopped ruled reasons <e2>seizures</e2>
D009020_D012640 CID <e1>morphine</e1> cessation stopped <e2>convulsions</e2>
2933998
D017265_D001249 NONE <e1>procaterol</e1> terbutaline <e2>asthma</e2>
D017265_D001249 NONE <e1>procaterol</e1> studied trial patients <e2>asthma</e2>
D017265_D001249 NONE <e1>procaterol</e1> effects <e2>anti-asthmatic</e2>
D013726_D001249 NONE <e1>terbutaline</e1> <e2>asthma</e2>
D017265_D014202 CID <e1>procaterol</e1> effects anti-asthmatic <e2>tremorgenic</e2>
24778426
D002945_D007674 NONE <e1>cisplatin</e1> <e2>toxicity</e2>
D002945_D007674 NONE <e1>cisplatin</e1> use complications one <e2>nephrotoxicity</e2>
D002945_D007674 NONE <e1>cisplatin-induced</e1> <e2>nephrotoxicity</e2>
D002945_D007674 NONE <e1>cisplatin</e1> receiving patients <e2>nephrotoxicity</e2>
D002945_D007674 NONE <e1>cisplatin</e1> risk <e2>nephrotoxicity</e2>
D002945_D009369 NONE <e1>cisplatin</e1> patients <e2>cancer</e2>
D002945_D009369 NONE <e1>cisplatin-induced</e1> nephrotoxicity patients <e2>cancer</e2>
D002945_D009369 NONE <e1>cisplatin</e1> receiving patients <e2>cancer</e2>
D002945_D009369 NONE <e1>cisplatin</e1> receiving patients <e2>cancer</e2>
D002945_D009369 NONE <e1>cisplatin</e1> received patients evaluated had <e2>malignancy</e2>
D008353_D007674 NONE <e1>mannitol</e1> with rates <e2>toxicity</e2>
D008353_D007674 NONE <e1>mannitol</e1> receiving patients <e2>nephrotoxicity</e2>
D008353_D007674 NONE <e1>mannitol</e1> receive patients likely develop <e2>nephrotoxicity</e2>
D008353_D007674 NONE <e1>mannitol</e1> quantities available given patients risk <e2>nephrotoxicity</e2>
D008353_D007674 NONE <e1>mannitol</e1> addition benefit risk <e2>nephrotoxicity</e2>
D008353_D009369 NONE <e1>mannitol</e1> with rates toxicity cisplatin patients <e2>cancer</e2>
D008353_D009369 NONE <e1>mannitol</e1> receiving patients <e2>cancer</e2>
D008353_D064420 NONE <e1>mannitol</e1> use strategies prevent <e2>toxicity</e2>
D002945_D006258 NONE <e1>cisplatin</e1> received patients evaluated had <e2>cancer</e2>
D002945_D006973 NONE <e1>cisplatin</e1> those <e2>hypertension</e2>
D008353_D006973 NONE <e1>mannitol</e1> addition benefit risk cisplatin those <e2>hypertension</e2>
20447294
D009020_D009437 NONE <e1>morphine</e1> synergy studies models <e2>pain</e2>
D009020_D009437 NONE <e1>morphine</e1> models <e2>pain</e2>
D012964_D009437 NONE <e1>sodium</e1> channel blocker morphine synergy studies models <e2>pain</e2>
D012964_D009437 NONE <e1>sodium</e1> channel blocker cnsb002 combinations morphine models <e2>pain</e2>
C401121_D009437 NONE <e1>cnsb002</e1> morphine synergy studies models <e2>pain</e2>
C401121_D009437 NONE <e1>cnsb002</e1> combinations morphine models <e2>pain</e2>
D009020_D010146 NONE <e1>morphine</e1> doses curves constructed using models <e2>pain</e2>
D009020_D007249 NONE <e1>morphine</e1> doses curves constructed <e2>inflammation</e2>
D009020_D003929 NONE <e1>morphine</e1> doses curves constructed <e2>neuropathy</e2>
C401121_D010146 NONE <e1>cnsb002</e1> morphine doses curves constructed using models <e2>pain</e2>
C401121_D007249 NONE <e1>cnsb002</e1> morphine doses curves constructed <e2>inflammation</e2>
C401121_D003929 NONE <e1>cnsb002</e1> morphine doses curves constructed <e2>neuropathy</e2>
D002351_D010146 NONE <e1>carrageenan-induced</e1> inflammation constructed using models <e2>pain</e2>
D002351_D007249 CID <e1>carrageenan-induced</e1> <e2>inflammation</e2>
D002351_D003929 NONE <e1>carrageenan-induced</e1> inflammation constructed <e2>neuropathy</e2>
D013311_D010146 NONE <e1>streptozotocin</e1> inflammation constructed using models <e2>pain</e2>
D013311_D010146 NONE <e1>(stz)-induced</e1> diabetic neuropathy constructed using models <e2>pain</e2>
D013311_D007249 NONE <e1>streptozotocin</e1> <e2>inflammation</e2>
D013311_D007249 NONE <e1>(stz)-induced</e1> diabetic neuropathy constructed <e2>inflammation</e2>
D013311_D003929 CID <e1>streptozotocin</e1> inflammation constructed <e2>neuropathy</e2>
D013311_D003929 CID <e1>(stz)-induced</e1> diabetic <e2>neuropathy</e2>
D002351_D006930 CID <e1>carrageenan</e1> model doses calculated cause reversal <e2>hyperalgesia</e2>
D002351_D009422 NONE <e1>carrageenan</e1> model doses model <e2>neuropathy</e2>
D002351_D009422 NONE <e1>carrageenan</e1> model less model <e2>neuropathy</e2>
D013311_D006930 CID <e1>stz-induced</e1> model doses calculated cause reversal <e2>hyperalgesia</e2>
D013311_D009422 NONE <e1>stz-induced</e1> model <e2>neuropathy</e2>
C401121_D006930 NONE <e1>cnsb002</e1> model doses calculated cause reversal <e2>hyperalgesia</e2>
C401121_D006930 NONE <e1>cnsb002</e1> co-administration increased reversal <e2>hyperalgesia</e2>
C401121_D009422 NONE <e1>cnsb002</e1> model <e2>neuropathy</e2>
C401121_D009422 NONE <e1>cnsb002</e1> combination given values less model <e2>neuropathy</e2>
C401121_D009422 NONE <e1>cnsb002</e1> co-administration increased reversal models inflammatory <e2>neuropathic</e2>
D009020_D006930 NONE <e1>morphine</e1> cnsb002 model doses calculated cause reversal <e2>hyperalgesia</e2>
D009020_D006930 NONE <e1>morphine</e1> antinociception increased reversal <e2>hyperalgesia</e2>
D009020_D009422 NONE <e1>morphine</e1> cnsb002 model <e2>neuropathy</e2>
D009020_D009422 NONE <e1>morphine</e1> values less model <e2>neuropathy</e2>
D009020_D009422 NONE <e1>morphine</e1> antinociception increased reversal models inflammatory <e2>neuropathic</e2>
22836123
D016559_D007674 NONE <e1>tacrolimus</e1> induced <e2>crisis</e2>
D016559_D007674 NONE <e1>tacrolimus</e1> induced <e2>src</e2>
D011239_D007674 NONE <e1>prednisolone</e1> tacrolimus induced <e2>crisis</e2>
D000305_D007674 NONE <e1>corticosteroid</e1> use moderate recognized factor <e2>src</e2>
D000305_D007674 NONE <e1>corticosteroids</e1> tacrolimus induced <e2>src</e2>
D016572_D057049 CID <e1>cyclosporine</e1> precipitated <e2>microangiopathy</e2>
D016572_D012595 NONE <e1>cyclosporine</e1> precipitated patients <e2>ssc</e2>
D016559_D012595 CID <e1>tacrolimus</e1> use patients <e2>ssc</e2>
12559315
D007213_D018856 CID <e1>indomethacin</e1> resulted findings typical <e2>cystitis</e2>
D007213_D008415 CID <e1>indomethacin</e1> resulted findings epithelium <e2>mastocytosis</e2>
753803
D014810_D009135 NONE <e1>e</e1> lack <e2>myopathy</e2>
D014810_D009135 NONE <e1>e</e1> <e2>myopathy</e2>
D014810_D009135 NONE <e1>e.</e1> deficient myopathic rendered rats doses effects investigate encouraged results obtained departments patients <e2>myopathic</e2>
D014810_D009135 NONE <e1>e.</e1> deficient <e2>myopathic</e2>
D014810_D009135 NONE <e1>e.</e1> deficient myopathic rendered rats doses effects investigate encouraged changes maintained characteristics <e2>myopathic</e2>
D014810_D009135 NONE <e1>e</e1> lack conclude affirming efficacy steroids <e2>disease</e2>
D014810_D009136 CID <e1>e.</e1> characteristics lacking diet giving induced <e2>myodystrophy</e2>
D014810_D009136 CID <e1>e</e1> characteristics lacking diet giving induced <e2>myodystrophy</e2>
D013256_D009135 NONE <e1>steroids</e1> using obtained departments patients <e2>myopathic</e2>
D013256_D009135 NONE <e1>steroids</e1> using obtained results encouraged investigate effects doses rats rendered <e2>myopathic</e2>
D013256_D009135 NONE <e1>steroids</e1> using obtained results encouraged changes maintained characteristics <e2>myopathic</e2>
D013256_D009135 NONE <e1>steroids</e1> <e2>disease</e2>
D008696_D009135 NONE <e1>dianabol</e1> agent effects investigate encouraged results obtained departments patients <e2>myopathic</e2>
D008696_D009135 NONE <e1>dianabol</e1> agent effects doses rats rendered <e2>myopathic</e2>
D008696_D009135 NONE <e1>dianabol</e1> agent effects investigate encouraged changes maintained characteristics <e2>myopathic</e2>
-1_D009135 NONE <e1>ciba</e1> dianabol agent effects investigate encouraged results obtained departments patients <e2>myopathic</e2>
-1_D009135 NONE <e1>ciba</e1> dianabol agent effects doses rats rendered <e2>myopathic</e2>
-1_D009135 NONE <e1>ciba</e1> dianabol agent effects investigate encouraged changes maintained characteristics <e2>myopathic</e2>
1760851
D004317_D066126 CID <e1>doxorubicin</e1> <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>doxorubicin</e1> <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>dox</e1> doxorubicin <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>dox</e1> received animals observed deaths related <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>dox</e1> received animals observed revealed changes consistent <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>dox</e1> dox received animals observed deaths related <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>dox</e1> dox received animals observed revealed changes consistent <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>dox-induced</e1> cardiotoxicity consistent changes revealed observed deaths related <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>dox-induced</e1> <e2>cardiotoxicity</e2>
C032976_D066126 NONE <e1>n-(2-hydroxypropyl)methacrylamide</e1> conjugates form <e2>cardiotoxicity</e2>
C032976_D066126 NONE <e1>n-(2-hydroxypropyl)methacrylamide</e1> conjugates form drug toxicity <e2>cardiotoxicity</e2>
C032976_D066126 NONE <e1>hpma</e1> conjugates form drug toxicity <e2>cardiotoxicity</e2>
C032976_D066126 NONE <e1>hpma</e1> copolymer mixture dox received animals observed deaths related <e2>cardiotoxicity</e2>
C032976_D066126 NONE <e1>hpma</e1> copolymer mixture dox received animals observed revealed changes consistent <e2>cardiotoxicity</e2>
D004317_D064420 NONE <e1>doxorubicin</e1> cardiotoxicity <e2>toxicity</e2>
D004317_D064420 NONE <e1>dox</e1> doxorubicin cardiotoxicity <e2>toxicity</e2>
C032976_D064420 NONE <e1>n-(2-hydroxypropyl)methacrylamide</e1> conjugates form drug <e2>toxicity</e2>
C032976_D064420 NONE <e1>hpma</e1> conjugates form drug <e2>toxicity</e2>
17879217
D012293_D005921 CID <e1>rifampicin-associated</e1> segmental necrotizing <e2>glomerulonephritis</e2>
D012293_D005921 CID <e1>rifampicin</e1> therapy complication reported <e2>glomerulonephritis</e2>
D012293_D005921 CID <e1>rifampicin</e1> treated developed failure secondary <e2>glomerulonephritis</e2>
D012293_D005921 CID <e1>rifampicin</e1> therapy complication review describe case patient developed failure secondary <e2>glomerulonephritis</e2>
D012293_D013203 NONE <e1>rifampicin-associated</e1> segmental <e2>endocarditis</e2>
D012293_D013203 NONE <e1>rifampicin</e1> use <e2>infections</e2>
D012293_D013203 NONE <e1>rifampicin</e1> treated developed patient <e2>ie</e2>
D012293_D013203 NONE <e1>rifampicin</e1> therapy complication review describe case patient <e2>ie</e2>
D012293_D004696 NONE <e1>rifampicin-associated</e1> segmental <e2>endocarditis</e2>
D012293_D004696 NONE <e1>rifampicin</e1> use increase led changing epidemiology infections <e2>endocarditis</e2>
D012293_D004696 NONE <e1>rifampicin</e1> use increase led changing epidemiology infections endocarditis <e2>ie</e2>
D012293_D004696 NONE <e1>rifampicin</e1> treated developed patient <e2>ie</e2>
D012293_D004696 NONE <e1>rifampicin</e1> therapy complication review describe case patient <e2>ie</e2>
D012293_D014376 NONE <e1>rifampicin</e1> therapy complication patients receiving treatment <e2>tuberculosis</e2>
D012293_D007239 NONE <e1>rifampicin</e1> use increase led changing epidemiology <e2>infections</e2>
D012293_D058186 CID <e1>rifampicin</e1> treated developed <e2>failure</e2>
D012293_D058186 CID <e1>rifampicin</e1> therapy complication review describe case patient developed <e2>failure</e2>
8957205
D000324_D006935 NONE <e1>corticotropin-releasing</e1> hormone modulate response <e2>hypercapnic</e2>
D013972_D006935 NONE <e1>thyrotropin-releasing</e1> hormone modulate response <e2>hypercapnic</e2>
24816962
D008795_D001927 CID <e1>metronidazole-induced</e1> <e2>encephalopathy</e2>
D008795_D001927 CID <e1>metronidazole</e1> intake features <e2>encephalopathy</e2>
D008795_D064420 NONE <e1>metronidazole</e1> <e2>toxicity</e2>
12950111
D006024_D013547 NONE <e1>glycopyrrolate</e1> treatment <e2>hyperhidrosis</e2>
D006024_D013547 NONE <e1>glycopyrrolate</e1> applying excellent <e2>sweating</e2>
D006024_D013547 NONE <e1>glycopyrrolate</e1> applying excellent patients <e2>sweating</e2>
D006024_D013547 NONE <e1>glycopyrrolate</e1> pad application appeared method treatment moderate symptoms <e2>hyperhidrosis</e2>
D006024_D014987 NONE <e1>glycopyrrolate</e1> throat <e2>mouth</e2>
D006024_D014987 NONE <e1>glycopyrrolate</e1> headache <e2>mouth</e2>
D006024_D010612 CID <e1>glycopyrrolate</e1> <e2>throat</e2>
D006024_D010612 CID <e1>glycopyrrolate</e1> headache mouth <e2>throat</e2>
D006024_D006261 CID <e1>glycopyrrolate</e1> throat mouth <e2>headache</e2>
D006024_D006261 CID <e1>glycopyrrolate</e1> <e2>headache</e2>
20024739
D000431_D015658 NONE <e1>alcohol</e1> use association progression <e2>disease</e2>
D000431_D015658 NONE <e1>alcohol</e1> consumption association evaluated effects progression <e2>disease</e2>
D000431_D003866 CID <e1>alcohol</e1> consumption <e2>depression</e2>
D000431_D003866 CID <e1>alcohol</e1> use had counts measurement symptoms <e2>depression</e2>
D000431_D003866 CID <e1>alcohol</e1> use had using center scale <e2>studies-depression</e2>
D000431_D003866 CID <e1>alcohol</e1> consumption <e2>depression</e2>
D000431_D003866 CID <e1>alcohol</e1> consumption has association <e2>depression</e2>
24717468
D020927_D007022 CID <e1>dexmedetomidine</e1> receive patients prevalence occur <e2>hypotension</e2>
D020927_D007022 CID <e1>dexmedetomidine</e1> receive patients prevalence occur conclusions consider likelihood <e2>hypotension</e2>
D020927_D001919 CID <e1>dexmedetomidine</e1> receive patients prevalence occur hypotension <e2>bradycardia</e2>
D020927_D001919 CID <e1>dexmedetomidine</e1> receive patients prevalence occur conclusions consider likelihood hypotension <e2>bradycardia</e2>
D015742_D007022 CID <e1>propofol</e1> dexmedetomidine receive patients prevalence occur <e2>hypotension</e2>
D015742_D007022 CID <e1>propofol</e1> dexmedetomidine receive patients prevalence occur conclusions consider likelihood <e2>hypotension</e2>
D015742_D001919 CID <e1>propofol</e1> dexmedetomidine receive patients prevalence occur hypotension <e2>bradycardia</e2>
D015742_D001919 CID <e1>propofol</e1> dexmedetomidine receive patients prevalence occur conclusions consider likelihood hypotension <e2>bradycardia</e2>
8985298
D019259_D006509 NONE <e1>lamivudine</e1> effective suppressing dna <e2>b</e2>
D019259_D006509 NONE <e1>lamivudine</e1> analogue has replication <e2>b</e2>
D019259_D006509 NONE <e1>cytosine</e1> analogue has replication <e2>b</e2>
D019259_D006509 NONE <e1>lamivudine</e1> receiving patients had decrease values virus <e2>b</e2>
D006514_D006509 CID <e1>antigen</e1> carriers dna <e2>b</e2>
24927617
C486464_D012206 CID <e1>telaprevir</e1> treated patient <e2>rhabdomyolysis</e2>
C486464_D006526 NONE <e1>telaprevir</e1> treated patient <e2>infected</e2>
C486464_D006526 NONE <e1>telaprevir</e1> interferon ribavirin received man <e2>infection</e2>
D019821_D012206 CID <e1>simvastatin</e1> telaprevir treated patient <e2>rhabdomyolysis</e2>
D019821_D006526 NONE <e1>simvastatin</e1> telaprevir treated patient <e2>infected</e2>
D012254_D006526 NONE <e1>ribavirin</e1> received man <e2>infection</e2>
C417083_D006526 NONE <e1>interferon</e1> ribavirin received man <e2>infection</e2>
D019821_D064420 NONE <e1>simvastatin</e1> discontinued suspected <e2>toxicity</e2>
D019821_D009135 CID <e1>simvastatin</e1> concentration increased patient <e2>toxicity</e2>
D019821_D009135 CID <e1>statin</e1> induced <e2>toxicity</e2>
D019821_D009135 CID <e1>statin</e1> concentration related increased patient <e2>toxicity</e2>
11474137
D003300_D034381 NONE <e1>copper/zinc-superoxide</e1> dismutase overexpression protects <e2>loss</e2>
D015032_D034381 NONE <e1>copper/zinc-superoxide</e1> dismutase overexpression protects <e2>loss</e2>
D013481_D034381 NONE <e1>copper/zinc-superoxide</e1> dismutase overexpression protects <e2>loss</e2>
D007612_D034381 CID <e1>kanamycin-induced</e1> <e2>loss</e2>
D010100_D006311 NONE <e1>oxygen</e1> species participation <e2>ototoxicity</e2>
D010100_D006311 NONE <e1>oxygen</e1> species participation deduced observations catalyze attenuate <e2>ototoxicity</e2>
D000617_D006311 NONE <e1>aminoglycoside-induced</e1> <e2>ototoxicity</e2>
D000617_D006311 NONE <e1>aminoglycoside-induced</e1> ototoxicity participation deduced observations catalyze attenuate <e2>ototoxicity</e2>
D000617_D006311 NONE <e1>aminoglycoside-iron</e1> complexes catalyze observations deduced participation <e2>ototoxicity</e2>
D000617_D006311 NONE <e1>aminoglycoside-iron</e1> complexes catalyze attenuate <e2>ototoxicity</e2>
D000617_D006311 NONE <e1>aminoglycoside-induced</e1> <e2>ototoxicity</e2>
D007501_D006311 NONE <e1>aminoglycoside-iron</e1> complexes catalyze observations deduced participation <e2>ototoxicity</e2>
D007501_D006311 NONE <e1>aminoglycoside-iron</e1> complexes catalyze attenuate <e2>ototoxicity</e2>
D013481_D006311 NONE <e1>superoxide</e1> radicals formation catalyze observations deduced participation <e2>ototoxicity</e2>
D013481_D006311 NONE <e1>superoxide</e1> radicals formation catalyze attenuate <e2>ototoxicity</e2>
D013481_D006311 NONE <e1>cu/zn-superoxide</e1> dismutase overexpression protect <e2>ototoxicity</e2>
D013481_D006311 NONE <e1>superoxide</e1> dismutase overexpression protection supports hypothesis plays <e2>ototoxicity</e2>
D003300_D006311 NONE <e1>cu/zn-superoxide</e1> dismutase overexpression protect <e2>ototoxicity</e2>
D015032_D006311 NONE <e1>cu/zn-superoxide</e1> dismutase overexpression protect <e2>ototoxicity</e2>
24897009
D004977_D010523 NONE <e1>ethambutol</e1> overtreatment due <e2>neuropathy</e2>
D004977_D009901 CID <e1>ethambutol</e1> known cause <e2>neuropathy</e2>
D004977_D011115 CID <e1>ethambutol</e1> known <e2>polyneuropathy</e2>
D004977_D014786 CID <e1>ethambutol</e1> dose exposure weeks developed <e2>loss</e2>
D004977_D010292 CID <e1>ethambutol</e1> dose exposure weeks developed loss <e2>paresthesias</e2>
D004977_D064420 NONE <e1>ethambutol</e1> <e2>toxicity</e2>
25071004
C039726_D000740 NONE <e1>artesunate</e1> treatment <e2>anemia</e2>
C039726_D000743 CID <e1>artesunate</e1> treatment described cases <e2>anemia</e2>
C039726_D008288 NONE <e1>artesunate</e1> treatment described organization drug treatment <e2>malaria</e2>
C039726_D008288 NONE <e1>artesunate</e1> <e2>malaria</e2>
19914299
D005473_D008569 NONE <e1>fluoxetine</e1> improves <e2>deficits</e2>
D005472_D008569 CID <e1>5-fluorouracil</e1> agent caused <e2>deficits</e2>
11745287
D016190_D002294 NONE <e1>carboplatin</e1> patients carcinoma <e2>cervix</e2>
D016190_D002294 NONE <e1>carboplatin</e1> combination administered patients <e2>carcinoma</e2>
D016190_D002583 NONE <e1>carboplatin</e1> patients carcinoma <e2>cervix</e2>
D016190_D002583 NONE <e1>carboplatin</e1> combination activity tested study patients <e2>carcinoma</e2>
D016190_D002583 NONE <e1>carboplatin</e1> combination administered patients <e2>carcinoma</e2>
D016190_D002583 NONE <e1>carboplatin</e1> combination has activity patients <e2>carcinoma</e2>
D004317_D002294 NONE <e1>doxorubicin</e1> carboplatin patients carcinoma <e2>cervix</e2>
D004317_D002294 NONE <e1>doxorubicin</e1> combination administered patients <e2>carcinoma</e2>
D004317_D002294 NONE <e1>doxil</e1> combination administered patients <e2>carcinoma</e2>
D004317_D002583 NONE <e1>doxorubicin</e1> carboplatin patients carcinoma <e2>cervix</e2>
D004317_D002583 NONE <e1>doxorubicin</e1> carboplatin combination activity tested study patients <e2>carcinoma</e2>
D004317_D002583 NONE <e1>doxorubicin</e1> combination administered patients <e2>carcinoma</e2>
D004317_D002583 NONE <e1>doxil</e1> combination administered patients <e2>carcinoma</e2>
D004317_D002583 NONE <e1>doxorubicin</e1> carboplatin combination has activity patients <e2>carcinoma</e2>
D016190_D064420 NONE <e1>carboplatin</e1> combination administered determine activity profile <e2>toxicity</e2>
D004317_D064420 NONE <e1>doxorubicin</e1> combination administered determine activity profile <e2>toxicity</e2>
D004317_D064420 NONE <e1>doxil</e1> combination administered determine activity profile <e2>toxicity</e2>
10510854
D006220_D002375 CID <e1>haloperidol</e1> induced <e2>catalepsy</e2>
1943082
D005978_D007511 NONE <e1>glutathione</e1> change was injury <e2>ischemia-reperfusion</e2>
D005978_D015427 NONE <e1>glutathione</e1> change was <e2>injury</e2>
3074291
C017590_D001249 NONE <e1>bromide</e1> theophylline <e2>asthma</e2>
C017590_D001249 NONE <e1>bromide</e1> drug preparation <e2>asthma</e2>
C017590_D001249 NONE <e1>oxitropium</e1> proves alternative theophylline <e2>asthma</e2>
D013806_D001249 NONE <e1>theophylline</e1> <e2>asthma</e2>
D013806_D001249 NONE <e1>theophylline</e1> preparation <e2>asthma</e2>
D013806_D001249 NONE <e1>theophylline</e1> <e2>asthma</e2>
C017590_D009325 NONE <e1>oxitropium</e1> effects reported compared subjects reporting <e2>nausea</e2>
C017590_D014839 NONE <e1>oxitropium</e1> effects reported compared subjects reporting nausea <e2>vomiting</e2>
C017590_D014202 NONE <e1>oxitropium</e1> effects reported compared subjects reporting nausea vomiting <e2>tremors</e2>
D013806_D009325 CID <e1>theophylline</e1> <e2>nausea</e2>
D013806_D014839 CID <e1>theophylline</e1> nausea <e2>vomiting</e2>
D013806_D014202 CID <e1>theophylline</e1> nausea vomiting <e2>tremors</e2>
19263707
D002231_D056648 CID <e1>carbimazole</e1> induced <e2>vasculitis</e2>
D013956_D006980 NONE <e1>drugs</e1> prescribed treatment <e2>hyperthyroidism</e2>
D002231_D006980 NONE <e1>carbimazole</e1> drugs prescribed treatment <e2>hyperthyroidism</e2>
D011441_D006980 NONE <e1>propylthiouracil</e1> carbimazole drugs prescribed treatment <e2>hyperthyroidism</e2>
D011441_D006980 NONE <e1>ptu</e1> carbimazole drugs prescribed treatment <e2>hyperthyroidism</e2>
D013956_D056648 CID <e1>medications.</e1> antibody effects aware effect <e2>vasculitis</e2>
D013956_D056648 CID <e1>antithyroidmedications</e1> effect <e2>vasculitis</e2>
D002231_D006111 NONE <e1>carbimazole</e1> vasculitis developed <e2>disease</e2>
D002231_D014657 NONE <e1>carbimazole</e1> <e2>vasculitis</e2>
D002231_D014657 NONE <e1>carbimazole</e1> case <e2>vasculitis</e2>
816141
D002512_D000743 CID <e1>cephalothin-induced</e1> <e2>anemia</e2>
D002512_D000743 CID <e1>cephalothin</e1> therapy receiving developed <e2>anemia</e2>
D002512_D007674 NONE <e1>cephalothin</e1> therapy receiving developed patient <e2>disease</e2>
10960401
D009020_D009759 CID <e1>morphine</e1> administration associated <e2>nystagmus</e2>
D009020_D009759 CID <e1>morphine</e1> dose receiving developed dizziness <e2>nystagmus</e2>
D009020_D004244 CID <e1>morphine</e1> dose receiving developed <e2>dizziness</e2>
891494
D010672_D001927 CID <e1>phenytoin</e1> <e2>encephalopathy</e2>
D010672_D001927 CID <e1>phenytoin</e1> dph case <e2>encephalopathy</e2>
D010672_D001927 CID <e1>dph</e1> case <e2>encephalopathy</e2>
D010672_D012640 NONE <e1>phenytoin</e1> dph case encephalopathy <e2>seizures</e2>
D010672_D012640 NONE <e1>dph</e1> case encephalopathy <e2>seizures</e2>
D010672_D012640 NONE <e1>dph</e1> treatment starting increase <e2>seizures</e2>
D010672_D012640 NONE <e1>dph</e1> eliminating need alert patient starting increase <e2>seizures</e2>
D010672_D005076 NONE <e1>dph</e1> concentration normal presented <e2>rash</e2>
D010672_D005076 NONE <e1>dph</e1> treatment presented <e2>rash</e2>
D010672_D005076 NONE <e1>dph</e1> injection had normal presented <e2>rash</e2>
11915580
D005996_D004412 NONE <e1>trinitrate</e1> diclofenac treatment <e2>dysmenorrhea</e2>
D005996_D004412 NONE <e1>trinitrate</e1> efficacy determine resolution <e2>dysmenorrhea</e2>
D005996_D004412 NONE <e1>gtn</e1> trinitrate efficacy determine resolution <e2>dysmenorrhea</e2>
D005996_D004412 NONE <e1>gtn</e1> has comparison treatment <e2>dysmenorrhea</e2>
D004008_D004412 NONE <e1>diclofenac</e1> treatment <e2>dysmenorrhea</e2>
D004008_D004412 NONE <e1>diclofenac</e1> comparison resolution <e2>dysmenorrhea</e2>
D004008_D004412 NONE <e1>dcf</e1> diclofenac comparison resolution <e2>dysmenorrhea</e2>
D004008_D004412 NONE <e1>dcf</e1> comparison treatment <e2>dysmenorrhea</e2>
D011453_D004412 NONE <e1>prostaglandins</e1> hypersecretion caused contractility characterized syndrome <e2>dysmenorrhea</e2>
D009569_D004412 NONE <e1>no</e1> donor trinitrate efficacy determine resolution <e2>dysmenorrhea</e2>
D004008_D017699 NONE <e1>dcf</e1> continued effective reducing <e2>pain</e2>
D005996_D017699 NONE <e1>gtn</e1> scores remained continued effective reducing <e2>pain</e2>
D005996_D017699 NONE <e1>gtn</e1> hour ( dfc those higher remained continued effective reducing <e2>pain</e2>
D005996_D017699 NONE <e1>gtn</e1> gtn hour ( dfc those higher remained continued effective reducing <e2>pain</e2>
D005996_D006261 CID <e1>gtn</e1> increased <e2>headache</e2>
D005996_D006261 CID <e1>gtn</e1> using stopped <e2>headache</e2>
D004008_D006261 NONE <e1>dcf</e1> gtn increased <e2>headache</e2>
24190587
D018817_D008107 NONE <e1>ecstasy</e1> rationale drug associated <e2>dysfunction</e2>
D018817_D008107 NONE <e1>mdma</e1> ecstasy rationale drug associated <e2>dysfunction</e2>
D018817_D001008 NONE <e1>ecstasy-polydrug</e1> users observations line increases <e2>anxiety</e2>
D018817_D003866 CID <e1>ecstasy-polydrug</e1> users observations line increases anxiety <e2>depression</e2>
35781
D003000_D002375 CID <e1>clonidine</e1> effect analgesia induced effect <e2>cataleptic</e2>
D003000_D002375 CID <e1>clonidine</e1> increased <e2>catalepsy</e2>
D009278_D002375 CID <e1>naphazoline</e1> clonidine effect analgesia induced effect <e2>cataleptic</e2>
D009278_D002375 CID <e1>naphazoline</e1> decreased increased <e2>catalepsy</e2>
C009695_D002375 CID <e1>xylometazoline</e1> clonidine effect analgesia induced effect <e2>cataleptic</e2>
C009695_D002375 CID <e1>xylometazoline</e1> naphazoline decreased increased <e2>catalepsy</e2>
D009020_D002375 CID <e1>morphine</e1> induced effect <e2>cataleptic</e2>
D009020_D002375 CID <e1>morphine</e1> effect <e2>cataleptic</e2>
D009020_D002375 CID <e1>morphine</e1> induced <e2>catalepsy</e2>
D003061_D002375 CID <e1>codeine</e1> morphine induced effect <e2>cataleptic</e2>
D003061_D002375 CID <e1>codine</e1> morphine effect <e2>cataleptic</e2>
D003061_D002375 CID <e1>codeine</e1> <e2>catalepsy</e2>
D005283_D002375 CID <e1>fentanyl</e1> morphine induced effect <e2>cataleptic</e2>
D005283_D002375 CID <e1>fentanyl</e1> morphine effect <e2>cataleptic</e2>
D005283_D002375 CID <e1>fentanyl</e1> morphine induced <e2>catalepsy</e2>
D010423_D002375 NONE <e1>pentazocine</e1> fentanyl morphine induced effect <e2>cataleptic</e2>
D009638_D002375 NONE <e1>na</e1> receptors stimulating drugs failed enhanced <e2>catalepsy</e2>
6310832
D016572_D007239 CID <e1>cyclosporine</e1> recipients kidney <e2>infections</e2>
D016572_D007239 CID <e1>cyclosporine</e1> patients had <e2>infections</e2>
D016572_D007239 CID <e1>cyclosporine</e1> patients had infections <e2>infections</e2>
D016572_D007239 CID <e1>cyclosporine</e1> patients <e2>infections</e2>
D016572_D007239 CID <e1>cyclosporine</e1> patients infections had <e2>infections</e2>
D016572_D007239 CID <e1>cyclosporine</e1> patients deaths were played <e2>infection</e2>
D016572_D007239 CID <e1>cyclosporine-treated</e1> patients common <e2>infections</e2>
D001379_D007239 CID <e1>aza</e1> patients had <e2>infections</e2>
D001379_D007239 CID <e1>aza</e1> patients had infections <e2>infections</e2>
D001379_D007239 CID <e1>aza</e1> patients infections had <e2>infections</e2>
D001379_D007239 CID <e1>aza</e1> patients <e2>infections</e2>
D001379_D007239 CID <e1>aza</e1> cyclosporine patients deaths were played <e2>infection</e2>
D001379_D007239 CID <e1>aza-treated</e1> patients patients common <e2>infections</e2>
D016572_D016470 NONE <e1>cyclosporine</e1> patients had <e2>bacteremias</e2>
D001379_D013203 NONE <e1>aza</e1> patients had <e2>infections</e2>
D001379_D009181 NONE <e1>aza</e1> patients had occurred <e2>infections</e2>
D016572_D003586 NONE <e1>cyclosporine</e1> patients had symptoms related <e2>infection</e2>
D016572_D020031 NONE <e1>cyclosporine</e1> patients % found evidence <e2>infection</e2>
8096565
D018170_D009203 CID <e1>sumatriptan</e1> <e2>infarction</e2>
D018170_D009203 CID <e1>sumatriptan</e1> administration <e2>infarction</e2>
D018170_D003027 NONE <e1>sumatriptan</e1> administration infarction woman describe <e2>headache</e2>
16876986
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> injections induced <e2>seizures</e2>
946593
D008727_D010264 CID <e1>methotrexate</e1> <e2>paraplegia</e2>
D008727_D010264 CID <e1>methotrexate</e1> instillation developed <e2>paraplegia</e2>
D008727_D002493 NONE <e1>methothexate</e1> concentration dynamics related presence <e2>leukemia</e2>
D008727_D002493 NONE <e1>methotrexate</e1> doses dynamics related concentration dynamics related presence <e2>leukemia</e2>
D008727_D002493 NONE <e1>methotrexate</e1> available preparations presence appear dynamics related presence <e2>leukemia</e2>
D008727_D002493 NONE <e1>methotrexate</e1> diluents use presence appear dynamics related presence <e2>leukemia</e2>
D008727_D002493 NONE <e1>methotrexate</e1> presence <e2>leukemia</e2>
D008727_D020258 NONE <e1>methothexate</e1> concentration dynamics appear presence preservatives <e2>neurotoxic</e2>
D008727_D020258 NONE <e1>methotrexate</e1> doses dynamics related concentration dynamics appear presence preservatives <e2>neurotoxic</e2>
D008727_D020258 NONE <e1>methotrexate</e1> available preparations presence preservatives <e2>neurotoxic</e2>
D008727_D020258 NONE <e1>methotrexate</e1> diluents use presence preservatives <e2>neurotoxic</e2>
D008727_D020258 NONE <e1>methotrexate</e1> doses employing reduced incidence <e2>neurotoxicity</e2>
D008727_D020258 NONE <e1>methotrexate</e1> fluid levels monitoring predictive development <e2>neurotoxicity</e2>
D008727_C536409 NONE <e1>methotrexate</e1> contaminants <e2>deficiency</e2>
D008727_C536409 NONE <e1>methotrexate</e1> toxicity pathogenesis role contaminants <e2>deficiency</e2>
D008727_D064420 NONE <e1>methotrexate</e1> contaminants role pathogenesis <e2>toxicity</e2>
D008727_D064420 NONE <e1>methotrexate</e1> <e2>toxicity</e2>
16034922
D004967_D020521 CID <e1>oestrogen-only</e1> ht increased risk disease <e2>stroke</e2>
D004967_D005705 CID <e1>oestrogen-only</e1> ht increased risk <e2>disease</e2>
17445520
D002110_D016584 CID <e1>caffeine</e1> challenge test <e2>disorder</e2>
D002110_D016584 CID <e1>caffeine</e1> challenge test disorder depression <e2>attacks</e2>
D002110_D016584 CID <e1>caffeine</e1> challenge test induction way respond patients <e2>disorder</e2>
D002110_D016584 CID <e1>caffeine</e1> challenge test induction way respond patients disorder <e2>pd</e2>
D002110_D016584 CID <e1>caffeine</e1> challenge test induction way respond patients patients depression <e2>attacks</e2>
D002110_D016584 CID <e1>caffeine</e1> challenge test induction <e2>attacks</e2>
D002110_D016584 CID <e1>caffeine</e1> challenge test attack had total patients <e2>pd</e2>
D002110_D016584 CID <e1>caffeine</e1> challenge test <e2>attack</e2>
D002110_D016584 CID <e1>caffeine</e1> sensitive patients <e2>pd</e2>
D002110_D016584 CID <e1>caffeine-free</e1> intake observed <e2>attack</e2>
D002110_D016584 CID <e1>caffeine</e1> challenge test hyperreactivity associated matter is association <e2>attacks</e2>
D002110_D016584 CID <e1>caffeine</e1> challenge test hyperreactivity associated <e2>pd</e2>
D002110_D016584 NONE <e1>caffeine</e1> challenge test induction way respond patients patients depression attacks <e2>mdp</e2>
D002110_D016584 NONE <e1>caffeine</e1> challenge test attack had % patients <e2>mdp</e2>
D002110_D016584 NONE <e1>caffeine</e1> sensitive patients pd <e2>mdp</e2>
D002110_D016584 NONE <e1>caffeine</e1> challenge test hyperreactivity associated pd <e2>mdp</e2>
D002110_D003866 NONE <e1>caffeine</e1> challenge test disorder <e2>depression</e2>
D002110_D003865 NONE <e1>caffeine</e1> challenge test induction way respond patients patients <e2>depression</e2>
D002110_D003865 NONE <e1>caffeine</e1> challenge test induction way respond patients patients depression attacks <e2>mdp</e2>
D002110_D003865 NONE <e1>caffeine</e1> challenge test attack had % patients <e2>mdp</e2>
D002110_D003865 NONE <e1>caffeine</e1> challenge test attack had % % patients <e2>md</e2>
D002110_D003865 NONE <e1>caffeine</e1> sensitive patients pd <e2>mdp</e2>
D002110_D003865 NONE <e1>caffeine</e1> sensitive patients <e2>md</e2>
D002110_D003865 NONE <e1>caffeine</e1> challenge test hyperreactivity associated pd <e2>mdp</e2>
D002110_D001523 NONE <e1>caffeine</e1> challenge test induction way respond patients diagnostic <e2>disorders</e2>
D002110_D001008 NONE <e1>caffeine</e1> experiment administered form scales <e2>anxiety</e2>
D002110_D001008 NONE <e1>caffeine-free</e1> placebo solution caffeine experiment administered form scales <e2>anxiety</e2>
10462057
D017330_D000741 CID <e1>remoxipride</e1> metabolites induction relevance <e2>anemia</e2>
D017330_D000741 CID <e1>remoxipride-induced</e1> <e2>anemia</e2>
D017330_D000741 CID <e1>remoxipride</e1> agent associated <e2>anemia</e2>
D017330_D000741 CID <e1>amide</e1> agent associated <e2>anemia</e2>
D017330_D000741 CID <e1>remoxipride</e1> induce <e2>anemia</e2>
D017330_D000741 CID <e1>remoxipride</e1> induce contribute mechanism underlying <e2>anemia</e2>
D017330_D000741 CID <e1>remoxipride</e1> associated anemia underlying mechanism contribute induce <e2>anemia</e2>
D017330_D000741 CID <e1>remoxipride</e1> associated <e2>anemia</e2>
C084325_D009336 NONE <e1>ncq436</e1> treated cells observed <e2>necrosis</e2>
C084325_D009336 NONE <e1>ncq436</e1> treated cells observed had inducing concentrations <e2>necrosis</e2>
C112341_D009336 NONE <e1>ncq344</e1> had observed <e2>necrosis</e2>
C112341_D009336 NONE <e1>ncq344</e1> had inducing concentrations <e2>necrosis</e2>
D001554_D000741 CID <e1>benzene</e1> remoxipride induce <e2>anemia</e2>
D001554_D000741 CID <e1>benzene</e1> remoxipride induce contribute mechanism underlying <e2>anemia</e2>
C084325_D000741 NONE <e1>ncq436</e1> ability contribute induce <e2>anemia</e2>
C084325_D000741 NONE <e1>ncq436</e1> ability contribute mechanism underlying <e2>anemia</e2>
C112341_D000741 NONE <e1>ncq344</e1> ncq436 ability contribute induce <e2>anemia</e2>
C112341_D000741 NONE <e1>ncq344</e1> ncq436 ability contribute mechanism underlying <e2>anemia</e2>
6627074
D013390_D001049 CID <e1>succinylcholine</e1> <e2>apnoea</e2>
D013390_D001049 CID <e1>succinylcholine</e1> <e2>apnoea</e2>
D013390_D020879 NONE <e1>succinylcholine</e1> administration antagonize <e2>blockade</e2>
3323599
D011692_D009401 NONE <e1>aminonucleoside</e1> <e2>nephrosis</e2>
D011692_D005923 CID <e1>puromycin-aminonucleoside</e1> administration rats developed model <e2>sclerosis</e2>
D011692_D005923 CID <e1>puromycin-aminonucleoside</e1> administration rats developed model sclerosis <e2>fsgs</e2>
D011692_D005923 CID <e1>amns</e1> puromycin-aminonucleoside administration rats developed model <e2>sclerosis</e2>
D011692_D005923 CID <e1>amns</e1> puromycin-aminonucleoside administration rats developed model sclerosis <e2>fsgs</e2>
D011692_D005923 CID <e1>amns</e1> toxicity enhances produces <e2>fsgs</e2>
D011479_D005923 NONE <e1>sulfate</e1> puromycin-aminonucleoside administration rats developed model <e2>sclerosis</e2>
D011479_D005923 NONE <e1>sulfate</e1> puromycin-aminonucleoside administration rats developed model sclerosis <e2>fsgs</e2>
D011479_D005923 NONE <e1>ps</e1> sulfate puromycin-aminonucleoside administration rats developed model <e2>sclerosis</e2>
D011479_D005923 NONE <e1>ps</e1> sulfate puromycin-aminonucleoside administration rats developed model sclerosis <e2>fsgs</e2>
D011479_D005923 NONE <e1>ps</e1> administration enhances produces <e2>fsgs</e2>
D011479_D064420 NONE <e1>ps</e1> administration enhances <e2>toxicity</e2>
D011479_D007676 NONE <e1>ps</e1> administration enhances produces rats resulting <e2>disease</e2>
D011692_D064420 NONE <e1>amns</e1> <e2>toxicity</e2>
D011692_D007676 CID <e1>amns</e1> toxicity enhances produces rats resulting <e2>disease</e2>
24658375
D014212_D009220 CID <e1>acid-induced</e1> <e2>myositis</e2>
D014212_D009220 CID <e1>atra-induced</e1> <e2>myositis</e2>
D014212_D015473 NONE <e1>acid-induced</e1> myositis patient <e2>leukemia</e2>
D014212_D015473 NONE <e1>acid</e1> component therapy <e2>leukemia</e2>
D014212_D015473 NONE <e1>acid</e1> component therapy leukemia <e2>apl</e2>
D014212_D015473 NONE <e1>atra</e1> acid component therapy <e2>leukemia</e2>
D014212_D015473 NONE <e1>atra</e1> acid component therapy leukemia <e2>apl</e2>
12535818
D000638_D001919 CID <e1>amiodarone</e1> risk <e2>bradyarrhythmia</e2>
D000638_D001919 CID <e1>amiodarone</e1> use increases risk <e2>bradyarrhythmia</e2>
D000638_D001919 CID <e1>amiodarone</e1> therapy reports <e2>bradyarrhythmia</e2>
D000638_D001919 CID <e1>amiodarone</e1> use increases risk <e2>bradyarrhythmia</e2>
D000638_D001281 NONE <e1>amiodarone</e1> risk bradyarrhythmia requiring pacemaker patients <e2>fibrillation</e2>
D000638_D001281 NONE <e1>amiodarone</e1> patients <e2>fibrillation</e2>
D000638_D001281 NONE <e1>amiodarone</e1> patients fibrillation <e2>af</e2>
D000638_D001281 NONE <e1>amiodarone</e1> use patients <e2>af</e2>
D000638_D009203 NONE <e1>amiodarone</e1> risk bradyarrhythmia requiring pacemaker patients fibrillation <e2>infarction</e2>
D000638_D009203 NONE <e1>amiodarone</e1> use patients <e2>mi</e2>
D000638_D001145 NONE <e1>amiodarone</e1> therapy reports infrequent limited studies assessing use management patients <e2>arrhythmias</e2>
2429800
D006632_D007022 NONE <e1>histamine</e1> antagonists <e2>hypotension</e2>
D014403_D007022 CID <e1>d-tubocurarine-induced</e1> <e2>hypotension</e2>
2765447
D019793_D012640 NONE <e1>fluorescein</e1> angiography <e2>convulsion</e2>
D019793_D004830 CID <e1>fluorescein</e1> injection followed <e2>seizures</e2>
3685052
D005481_D012640 NONE <e1>flurothyl</e1> <e2>seizure</e2>
D005481_D012640 NONE <e1>flurothyl</e1> seizure thresholds mice treated injection evaluation testing <e2>seizure</e2>
D005481_D012640 NONE <e1>flurothyl</e1> testing evaluation injection treated mice thresholds <e2>seizure</e2>
D005481_D012640 NONE <e1>flurothyl</e1> testing <e2>seizure</e2>
D005481_D012640 NONE <e1>flurothyl</e1> ether <e2>seizure</e2>
D005481_D012640 NONE <e1>flurothyl</e1> ether seizure used evaluate susceptibility <e2>seizure</e2>
D005481_D012640 NONE <e1>flurothyl</e1> ether produced unclear relationship <e2>seizure</e2>
D005481_D012640 NONE <e1>flurothyl</e1> exposure duration correlated hypothermia produced unclear relationship <e2>seizure</e2>
D005481_D012640 NONE <e1>flurothyl</e1> testing <e2>seizure</e2>
D005481_D012640 NONE <e1>flurothyl</e1> testing proved technique evaluate susceptibility <e2>seizure</e2>
D012970_D012640 NONE <e1>glutamate</e1> evaluation injection treated mice thresholds <e2>seizure</e2>
D012970_D012640 NONE <e1>glutamate</e1> evaluation testing <e2>seizure</e2>
D012970_D012640 NONE <e1>msg</e1> evaluation injection treated mice thresholds <e2>seizure</e2>
D012970_D012640 NONE <e1>msg</e1> evaluation testing <e2>seizure</e2>
D012970_D012640 NONE <e1>glutamate</e1> administration produces <e2>convulsions</e2>
D012970_D012640 NONE <e1>msg</e1> glutamate administration produces <e2>convulsions</e2>
D012970_D012640 NONE <e1>msg</e1> administration produced alterations susceptibility <e2>seizure</e2>
D012970_D012640 NONE <e1>msg</e1> injections received mice susceptibility evaluate used <e2>seizure</e2>
D012970_D012640 NONE <e1>msg</e1> injections received mice susceptibility <e2>seizure</e2>
D012970_D012640 NONE <e1>msg</e1> treatment resulted alter threshold <e2>seizure</e2>
D012970_D012640 NONE <e1>msg-treated</e1> mice control thresholds <e2>seizure</e2>
D004986_D012640 NONE <e1>ether</e1> <e2>seizure</e2>
D004986_D012640 NONE <e1>ether</e1> seizure used evaluate susceptibility <e2>seizure</e2>
D004986_D012640 NONE <e1>ether</e1> produced unclear relationship <e2>seizure</e2>
D009270_D012640 NONE <e1>naloxone</e1> challenge ineffective altering thresholds <e2>seizure</e2>
D005481_D007035 CID <e1>flurothyl</e1> ether produced <e2>hypothermia</e2>
D005481_D007035 CID <e1>flurothyl</e1> ether produced unclear relationship <e2>hypothermia</e2>
D005481_D007035 CID <e1>flurothyl</e1> exposure duration correlated <e2>hypothermia</e2>
D005481_D007035 CID <e1>flurothyl</e1> exposure duration correlated hypothermia produced unclear relationship <e2>hypothermia</e2>
D004986_D007035 NONE <e1>ether</e1> produced <e2>hypothermia</e2>
D004986_D007035 NONE <e1>ether</e1> produced unclear relationship <e2>hypothermia</e2>
1360900
D004976_D012640 CID <e1>acid-induced</e1> <e2>convulsions</e2>
D004976_D012640 CID <e1>acid</e1> injection dose <e2>convulsive</e2>
D004976_D012640 CID <e1>acid-induced</e1> <e2>convulsions</e2>
D012701_D012640 NONE <e1>5-hydroxytryptamine</e1> synthesis/turnover accelerated injection dose <e2>convulsive</e2>
D012701_D012640 NONE <e1>5-ht</e1> 5-hydroxytryptamine synthesis/turnover accelerated injection dose <e2>convulsive</e2>
D005680_D012640 NONE <e1>acid</e1> synthesis suppressed accelerated injection dose <e2>convulsive</e2>
D000109_D012640 NONE <e1>acetylcholine</e1> acid synthesis suppressed accelerated injection dose <e2>convulsive</e2>
11026989
D014331_D015878 CID <e1>tropicamide</e1> <e2>dilation</e2>
D014331_D015878 CID <e1>tropicamide</e1> using <e2>dilation</e2>
24729111
D000638_D007037 CID <e1>amiodarone-induced</e1> <e2>coma</e2>
D000638_D007037 CID <e1>amiodarone-induced</e1> <e2>coma</e2>
D000638_D007037 CID <e1>amiodarone-induced</e1> <e2>coma</e2>
D000638_D003128 CID <e1>amiodarone-induced</e1> <e2>coma</e2>
D000638_D003128 CID <e1>amiodarone-induced</e1> <e2>coma</e2>
D000638_D003128 CID <e1>amiodarone-induced</e1> <e2>coma</e2>
D000638_D001919 CID <e1>amiodarone</e1> therapy initiation have <e2>bradycardia</e2>
D000638_D007035 CID <e1>amiodarone</e1> therapy initiation have bradycardia <e2>hypothermia</e2>
D000638_D012131 CID <e1>amiodarone</e1> therapy initiation have bradycardia <e2>failure</e2>
D000638_D001281 NONE <e1>amiodarone</e1> therapy <e2>fibrillation</e2>
D000638_D013959 NONE <e1>amiodarone-induced</e1> coma case history significant <e2>disease</e2>
15282950
D010936_D009202 NONE <e1>chebula</e1> <e2>injury</e2>
D010936_D009202 NONE <e1>fruits</e1> extract effect examined induced <e2>damage</e2>
D007545_D009202 CID <e1>isoproterenol</e1> induced <e2>injury</e2>
D007545_D009202 CID <e1>isoproterenol</e1> examined induced <e2>damage</e2>
11105626
D015474_D065817 CID <e1>isotretinoin</e1> exposure report infant anomalies <e2>anotia</e2>
D015474_D004310 CID <e1>isotretinoin</e1> exposure report infant anomalies anotia <e2>malformation</e2>
1420650
D002220_D020820 NONE <e1>carbamazepine</e1> therapy induced <e2>asterixis</e2>
D002220_D020820 NONE <e1>carbamazepine</e1> adding triggered <e2>asterixis</e2>
D002220_D020820 NONE <e1>cbz</e1> carbamazepine adding triggered <e2>asterixis</e2>
D002220_D020820 NONE <e1>cbz</e1> combination used consider <e2>asterixis</e2>
D008094_D020820 CID <e1>lithium</e1> drugs used consider <e2>asterixis</e2>
D008094_D020258 NONE <e1>lithium</e1> drugs used consider sign <e2>neurotoxicity</e2>
D003024_D020820 CID <e1>clozapine</e1> lithium drugs used consider <e2>asterixis</e2>
D003024_D020258 NONE <e1>clozapine</e1> lithium drugs used consider sign <e2>neurotoxicity</e2>
D002220_D020258 NONE <e1>cbz</e1> combination used consider sign <e2>neurotoxicity</e2>
3746148
D004176_D003324 NONE <e1>dipyridamole</e1> infusion detection <e2>disease</e2>
D004176_D003324 NONE <e1>dipyridamole</e1> infusion changes studied patients <e2>disease</e2>
D004176_D003324 NONE <e1>dipyridamole</e1> useful test assessment <e2>disease</e2>
D004176_D007511 NONE <e1>dipyridamole</e1> depression <e2>ischemic</e2>
D004176_D003866 NONE <e1>dipyridamole</e1> <e2>depression</e2>
D004176_D009203 NONE <e1>dipyridamole</e1> observed % group <e2>non-mi</e2>
D004176_D056988 NONE <e1>dipyridamole</e1> observed % group <e2>ant-mi</e2>
D004176_D056989 NONE <e1>dipyridamole</e1> observed % % group <e2>inf-mi</e2>
D004176_D017202 CID <e1>dipyridamole-induced</e1> <e2>ischemia</e2>
24055495
D005690_D003072 CID <e1>galactose</e1> oral prevents <e2>deficits</e2>
D005690_D003072 CID <e1>galactose</e1> effects treatment <e2>deficits</e2>
D005690_D003072 CID <e1>galactose</e1> treatment month prevented development <e2>deficits</e2>
D005690_D003072 CID <e1>galactose</e1> exposure have worth investigating improvement <e2>deficits</e2>
D013311_D003072 CID <e1>streptozotocin</e1> treated rats <e2>deficits</e2>
D013311_D003072 CID <e1>streptozotocin-induced</e1> model <e2>deficits</e2>
D013311_D003072 CID <e1>stz-icv</e1> model <e2>deficits</e2>
D013311_D003072 CID <e1>stz-icv</e1> administration initiated treatment month prevented development <e2>deficits</e2>
D013311_D003072 CID <e1>stz-icv-induced</e1> <e2>deficits</e2>
D005947_D003704 NONE <e1>glucose</e1> transport followed system dysfunction associated <e2>dementia</e2>
D005947_D003704 NONE <e1>glucose</e1> transporter glut4 transport followed system dysfunction associated <e2>dementia</e2>
D005947_D003704 NONE <e1>glucose</e1> metabolism decreased associated <e2>dementia</e2>
D005947_D000544 CID <e1>glucose</e1> transport followed system dysfunction associated dementia type <e2>disease</e2>
D005947_D000544 CID <e1>glucose</e1> transporter glut4 transport followed system dysfunction associated dementia type <e2>disease</e2>
D005947_D000544 CID <e1>glucose</e1> metabolism decreased associated dementia type <e2>disease</e2>
D005690_D008569 NONE <e1>galactose</e1> <e2>deterioration</e2>
D005690_D008569 NONE <e1>galactose</e1> oral treatment effects tested used injections <e2>deterioration</e2>
D005690_D018149 NONE <e1>galactose</e1> exposure have worth investigating improvement deficits associated <e2>hypometabolism</e2>
D005690_D000544 NONE <e1>galactose</e1> exposure have worth investigating improvement deficits associated hypometabolism <e2>ad</e2>
24220752
D003287_D007674 CID <e1>contrast-induced</e1> <e2>nephropathy</e2>
D003287_D007674 CID <e1>contrast-induced</e1> <e2>nephropathy</e2>
D003287_D007674 CID <e1>contrast-induced</e1> <e2>nephropathy</e2>
D003287_D009369 NONE <e1>contrast-induced</e1> nephropathy patients <e2>cancer</e2>
D003287_D009369 NONE <e1>contrast-induced</e1> nephropathy patients <e2>cancer</e2>
-1_D006973 NONE <e1>bevacizumab/irinotecan</e1> treatment patients <e2>hypertension</e2>
-1_D006973 NONE <e1>bevacizumab/irinotecan</e1> combination <e2>hypertension</e2>
-1_D006973 NONE <e1>bevacizumab</e1> <e2>hypertension</e2>
C051890_D006973 NONE <e1>bevacizumab/irinotecan</e1> treatment patients <e2>hypertension</e2>
C051890_D006973 NONE <e1>bevacizumab/irinotecan</e1> combination <e2>hypertension</e2>
17069550
D005702_D001321 NONE <e1>galantamine</e1> trial <e2>disorder</e2>
D005702_D001321 NONE <e1>galantamine</e1> use assess treatment behaviors children <e2>autism</e2>
D005702_D001321 NONE <e1>galantamine</e1> trial 12-week participated children <e2>autism</e2>
D005702_D001321 NONE <e1>galantamine</e1> well-tolerated appeared beneficial treatment behaviors children <e2>autism</e2>
D005702_D006261 CID <e1>galantamine</e1> well-tolerated effects apart <e2>headaches</e2>
D005702_D001523 NONE <e1>galantamine</e1> well-tolerated appeared beneficial treatment behaviors children autism <e2>aggression</e2>
D005702_D002653 NONE <e1>galantamine</e1> well-tolerated appeared beneficial treatment behaviors children autism aggression <e2>dyscontrol</e2>
D005702_D019958 NONE <e1>galantamine</e1> well-tolerated appeared beneficial treatment behaviors children autism aggression dyscontrol <e2>inattention</e2>
20595935
D014700_D006966 NONE <e1>verapamil</e1> stimulation test <e2>hyperprolactinemia</e2>
D014700_D006966 NONE <e1>verapamil</e1> test investigated tool diagnosis <e2>hyperprolactinemia</e2>
D014700_D006966 NONE <e1>verapamil</e1> patients <e2>hyperprolactinemia</e2>
D014700_D006966 NONE <e1>verapamil</e1> increased <e2>hyperprolactinemia</e2>
D014700_D006966 NONE <e1>verapamil</e1> unresponsiveness sensitivity associated pseudoprolactinoma <e2>hyperprolactinemia</e2>
D014700_D006966 NONE <e1>verapamil</e1> responsiveness finding diagnosis <e2>hyperprolactinemia</e2>
D014700_D006966 NONE <e1>verapamil</e1> unresponsiveness discriminates inhibited causes <e2>hyperprolactinemia</e2>
D014700_D015175 NONE <e1>verapamil</e1> value population screened <e2>macroprolactinemia</e2>
D014700_D015175 NONE <e1>verapamil</e1> increased controls <e2>macroprolactinoma</e2>
D014700_D015175 NONE <e1>verapamil</e1> increased controls <e2>microprolactinoma</e2>
D014700_D015175 NONE <e1>verapamil</e1> increased controls <e2>macroprolactinemia</e2>
D014700_-1 NONE <e1>verapamil</e1> increased controls <e2>pseudoprolactinoma</e2>
D014700_-1 NONE <e1>verapamil</e1> unresponsiveness sensitivity associated <e2>pseudoprolactinoma</e2>
D018967_D015175 NONE <e1>risperidone-induced</e1> hyperprolactinemia increased controls <e2>macroprolactinoma</e2>
D018967_D015175 NONE <e1>risperidone-induced</e1> hyperprolactinemia increased controls <e2>microprolactinoma</e2>
D018967_D015175 NONE <e1>risperidone-induced</e1> hyperprolactinemia increased controls <e2>macroprolactinemia</e2>
D018967_-1 NONE <e1>risperidone-induced</e1> hyperprolactinemia increased controls <e2>pseudoprolactinoma</e2>
D018967_-1 NONE <e1>risperidone-induced</e1> hyperprolactinemia <e2>pseudoprolactinoma</e2>
D018967_D006966 CID <e1>risperidone-induced</e1> <e2>hyperprolactinemia</e2>
D018967_D006966 CID <e1>risperidone-induced</e1> <e2>hyperprolactinemia</e2>
3339945
D013806_D020258 NONE <e1>theophylline</e1> <e2>neurotoxicity</e2>
D013806_D020258 NONE <e1>theophylline</e1> <e2>neurotoxicity</e2>
D013806_D020258 NONE <e1>theophylline</e1> response <e2>neurotoxic</e2>
D000628_D012640 CID <e1>aminophylline</e1> infusions received onset <e2>seizures</e2>
6893265
D011441_D056486 CID <e1>propylthiouracil-induced</e1> <e2>damage</e2>
D011441_D056486 CID <e1>propylthiouracil-induced</e1> <e2>damage</e2>
16810074
D009569_D006973 CID <e1>oxide</e1> deficiency induced <e2>hypertension</e2>
D009569_D006973 CID <e1>no</e1> deficiency induced <e2>hypertension</e2>
D009569_D006973 CID <e1>oxide</e1> loss <e2>hypertension</e2>
D009569_D006973 CID <e1>no</e1> oxide loss <e2>hypertension</e2>
D009569_D006973 CID <e1>no</e1> removal created <e2>hypertension</e2>
D009569_D006973 CID <e1>no</e1> deficiency increases make contribution form <e2>hypertension</e2>
D009569_D018754 NONE <e1>oxide</e1> loss hallmark <e2>dysfunction</e2>
D009569_D018754 NONE <e1>no</e1> oxide loss hallmark <e2>dysfunction</e2>
D019335_D006973 NONE <e1>nomega-nitro-l-arginine</e1> <e2>hypertension</e2>
D019335_D006973 NONE <e1>lnna</e1> <e2>hypertension</e2>
D019335_D006973 NONE <e1>lnna</e1> <e2>hypertension</e2>
D019335_D006973 NONE <e1>lnna</e1> weeks elevated <e2>hypertension</e2>
D019335_D006973 NONE <e1>lnna</e1> <e2>hypertensive</e2>
D018738_D006973 NONE <e1>hexamethonium</e1> blockade caused fall rats <e2>hypertensive</e2>
1563460
D014859_D020758 CID <e1>coumadin</e1> therapy secondary <e2>hematomyelia</e2>
6529939
D011433_D001146 CID <e1>propranolol</e1> induced <e2>rhythm</e2>
D011433_D001146 CID <e1>propranolol</e1> angina treatment observed block <e2>rhythm</e2>
D011433_D012848 CID <e1>propranolol</e1> induced rhythm <e2>block</e2>
D011433_D012848 CID <e1>propranolol</e1> angina treatment observed <e2>block</e2>
D011433_D012848 CID <e1>propranolol</e1> withdrawal disappeared seen <e2>block</e2>
D011433_D000787 NONE <e1>propranolol</e1> <e2>angina</e2>
D011433_D019955 NONE <e1>propranolol</e1> evidence accepted cause <e2>disorder</e2>
24812279
D018943_D066126 NONE <e1>anthracycline</e1> <e2>cardiotoxicity</e2>
D004317_D009369 NONE <e1>doxorubicin</e1> therapeutic <e2>anti-cancer</e2>
D004317_D009369 NONE <e1>dox</e1> doxorubicin therapeutic <e2>anti-cancer</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> therapeutic associated <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>dox</e1> doxorubicin therapeutic associated <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>dox</e1> <e2>cardiotoxicity</e2>
D004317_D006333 CID <e1>dox-induced</e1> <e2>failure</e2>
3538855
D000617_D007674 CID <e1>aminoglycoside</e1> <e2>nephrotoxicity</e2>
D000617_D007674 CID <e1>aminoglycoside-induced</e1> <e2>nephrotoxicity</e2>
D000617_D007674 CID <e1>aminoglycosides</e1> cause indicate cause <e2>dysfunction</e2>
D000617_D007674 CID <e1>aminoglycoside</e1> levels therapy duration increase risk <e2>nephrotoxicity</e2>
D000617_D007674 CID <e1>aminoglycoside-induced</e1> <e2>nephrotoxicity</e2>
D000617_D058186 NONE <e1>aminoglycosides</e1> trials indicate ranges risk developing <e2>failure</e2>
D000617_D008107 NONE <e1>aminoglycoside</e1> levels therapy <e2>disease</e2>
D003404_D008107 NONE <e1>creatinine</e1> clearance therapy <e2>disease</e2>
D003404_D007674 NONE <e1>creatinine</e1> clearance therapy duration increase risk <e2>nephrotoxicity</e2>
15817013
D014859_D001281 NONE <e1>warfarin</e1> <e2>fibrillation</e2>
D014859_D001281 NONE <e1>warfarin</e1> <e2>fibrillation</e2>
D014859_D001281 NONE <e1>warfarin</e1> <e2>fibrillation</e2>
D014859_D006470 CID <e1>warfarin</e1> fibrillation aged rate <e2>hemorrhage</e2>
D014859_D006470 CID <e1>warfarin</e1> fibrillation older aged people stroke determine incidence <e2>hemorrhage</e2>
D014859_D006470 CID <e1>warfarin</e1> use episodes <e2>bleeding</e2>
D014859_D006470 CID <e1>warfarin</e1> rate low resulted high rate <e2>hemorrhage</e2>
D014859_D006470 CID <e1>warfarin</e1> treatment is demonstrating resulted high rate <e2>hemorrhage</e2>
D014859_D020521 NONE <e1>warfarin</e1> fibrillation aged rate <e2>stroke</e2>
D014859_D020521 NONE <e1>warfarin</e1> fibrillation older aged people <e2>stroke</e2>
D014859_D020521 NONE <e1>warfarin</e1> use episodes <e2>strokes</e2>
D014859_D020521 NONE <e1>warfarin</e1> initiation rate <e2>stroke</e2>
D014859_D020521 NONE <e1>warfarin</e1> rate <e2>stroke</e2>
D014859_D020521 NONE <e1>warfarin</e1> treatment is demonstrating resulted low rate <e2>stroke</e2>
19178808
D015742_D006470 NONE <e1>propofol-remifentanil</e1> total anesthesia induced anesthesia maintaining using background was compare conditions amount <e2>bleeding</e2>
D015742_D007022 CID <e1>propofol-remifentanil</e1> total anesthesia induced anesthesia <e2>hypotension</e2>
D015742_D007022 CID <e1>propofol-remifentanil-tiva</e1> caused patients undergoing anesthesia <e2>hypotension</e2>
C071741_D006470 NONE <e1>propofol-remifentanil</e1> total anesthesia induced anesthesia maintaining using background was compare conditions amount <e2>bleeding</e2>
C071741_D007022 CID <e1>propofol-remifentanil</e1> total anesthesia induced anesthesia <e2>hypotension</e2>
C071741_D007022 CID <e1>propofol-remifentanil-tiva</e1> caused patients undergoing anesthesia <e2>hypotension</e2>
C071741_D007022 CID <e1>remifentanil</e1> infusion rates using period achieved <e2>hypotension</e2>
C071741_D007022 CID <e1>remifentanil</e1> dose infusion rates using period achieved <e2>hypotension</e2>
C071741_D007022 CID <e1>remifentanil</e1> doses hypotension allowed provided management using anesthesia <e2>hypotension</e2>
C071741_D007022 CID <e1>remifentanil</e1> doses <e2>hypotension</e2>
7121659
D012293_D051437 NONE <e1>rifampicin-associated</e1> <e2>failure</e2>
D012293_D058186 NONE <e1>rifampicin</e1> reintroduction induced patients <e2>failure</e2>
D012293_D013921 CID <e1>rifampicin</e1> reintroduction induced patients 3 <e2>thrombopenia</e2>
D012293_D006461 CID <e1>rifampicin</e1> reintroduction induced patients 3 thrombopenia <e2>hemolysis</e2>
12644816
D013792_D011471 NONE <e1>thalidomide</e1> study <e2>cancer</e2>
D013792_D011471 NONE <e1>thalidomide</e1> using months men <e2>cancer</e2>
D000728_D011471 NONE <e1>androgen-independent</e1> <e2>cancer</e2>
D000728_D011471 NONE <e1>androgen-independent</e1> <e2>cancer</e2>
D013792_D019337 NONE <e1>thalidomide</e1> effects assessed trials patients solid <e2>malignancies</e2>
D013792_D010523 CID <e1>thalidomide</e1> completed men found evidence <e2>neuropathy</e2>
D013792_D010523 CID <e1>thalidomide</e1> option maintained development <e2>neuropathy</e2>
3990093
D011692_D007674 NONE <e1>aminonucleoside</e1> nephrosis rats function <e2>sclerosis</e2>
D011692_D007674 NONE <e1>aminonucleoside</e1> model studied relationship <e2>dysfunction</e2>
D011692_D007674 NONE <e1>aminonucleoside</e1> model studied relationship dysfunction <e2>sclerosis</e2>
D011692_D007674 NONE <e1>pan</e1> aminonucleoside model studied relationship <e2>dysfunction</e2>
D011692_D007674 NONE <e1>pan</e1> aminonucleoside model studied relationship dysfunction <e2>sclerosis</e2>
D011692_D007674 NONE <e1>pan</e1> rats glomeruli % found <e2>sclerosis</e2>
D011692_D007674 NONE <e1>pan</e1> nephrosis model similar development <e2>sclerosis</e2>
D011692_D009401 NONE <e1>aminonucleoside</e1> <e2>nephrosis</e2>
D011692_D009401 NONE <e1>pan</e1> <e2>nephrosis</e2>
D011692_D011507 CID <e1>pan</e1> rats <e2>proteinuric</e2>
D002244_D011507 NONE <e1>carbon</e1> given <e2>proteinuric</e2>
D011692_D012598 NONE <e1>pan</e1> treatment change conclude caused injection areas develop <e2>sclerosis</e2>
17346443
D010396_D017512 CID <e1>penicillamine-related</e1> <e2>dermatitis</e2>
D010396_D017512 CID <e1>penicillamine</e1> interrupted appearance <e2>dermatitis</e2>
D010396_D006527 NONE <e1>penicillamine-related</e1> dermatitis patient <e2>disease</e2>
D010396_D006527 NONE <e1>penicillamine-related</e1> effects appeared patient <e2>disease</e2>
D010396_D006527 NONE <e1>penicillamine-treated</e1> <e2>disease</e2>
D010396_D001008 NONE <e1>penicillamine-related</e1> dermatitis patient presentation <e2>anxiety</e2>
D019345_D017512 NONE <e1>acetate</e1> utility <e2>dermatitis</e2>
D019345_D017512 NONE <e1>acetate</e1> permitted interrupted appearance <e2>dermatitis</e2>
D019345_D006527 NONE <e1>acetate</e1> utility dermatitis patient <e2>disease</e2>
D019345_D006527 NONE <e1>acetate</e1> therapy represented treatment patient <e2>disease</e2>
D019345_D006527 NONE <e1>acetate</e1> safety allowed line evidence efficacy treatment <e2>disease</e2>
D019345_D001008 NONE <e1>acetate</e1> utility dermatitis patient presentation <e2>anxiety</e2>
D003300_D006527 NONE <e1>copper</e1> metabolism disorder <e2>disease</e2>
D003300_D006527 NONE <e1>copper</e1> accumulation metabolism disorder <e2>disease</e2>
D003300_D064420 NONE <e1>copper</e1> metabolism accumulation <e2>toxicity</e2>
D003300_D064420 NONE <e1>copper</e1> accumulation <e2>toxicity</e2>
D003300_D056486 NONE <e1>copper</e1> metabolism disorder tissues <e2>disorders</e2>
D003300_D056486 NONE <e1>copper</e1> accumulation metabolism disorder tissues <e2>disorders</e2>
D003300_D009422 NONE <e1>copper</e1> metabolism disorder tissues <e2>disorders</e2>
D003300_D009422 NONE <e1>copper</e1> accumulation metabolism disorder tissues <e2>disorders</e2>
D003300_D001523 NONE <e1>copper</e1> metabolism disorder tissues <e2>disorders</e2>
D003300_D001523 NONE <e1>copper</e1> accumulation metabolism disorder tissues <e2>disorders</e2>
D010396_D012871 NONE <e1>penicillamine-treated</e1> patients most seem develop <e2>lesion</e2>
3975902
D010424_D002318 NONE <e1>pentobarbital</e1> <e2>dysfunction</e2>
D010424_D004342 NONE <e1>pentobarbital</e1> dysfunction <e2>hypersensitivity</e2>
D010424_D004342 NONE <e1>pentobarbital</e1> <e2>hypersensitivity</e2>
D010424_D004342 NONE <e1>pentobarbital</e1> system <e2>hypersensitivity</e2>
C024986_D002318 NONE <e1>chloride</e1> ingestion induced pentobarbital <e2>dysfunction</e2>
C024986_D004342 NONE <e1>chloride</e1> ingestion induced pentobarbital dysfunction <e2>hypersensitivity</e2>
D001464_D006973 NONE <e1>barium-supplemented</e1> long-evans hooded rats characterized <e2>hypertension</e2>
D001464_D006973 NONE <e1>barium</e1> month evident <e2>hypertension</e2>
D001464_D002318 NONE <e1>barium-induced</e1> disturbances <e2>system</e2>
D001464_D004342 NONE <e1>barium</e1> effect aspect <e2>hypersensitivity</e2>
D001464_D004342 NONE <e1>barium</e1> exposure induced disorder existence suggest contractility <e2>hypersensitivity</e2>
D010424_D008659 NONE <e1>pentobarbital</e1> system hypersensitivity contractility <e2>disturbances</e2>
D010424_D009202 NONE <e1>pentobarbital</e1> system hypersensitivity contractility suggest existence <e2>disorder</e2>
D001464_D008659 NONE <e1>barium</e1> exposure induced disorder existence suggest contractility <e2>disturbances</e2>
D001464_D009202 NONE <e1>barium</e1> exposure induced <e2>disorder</e2>
17379047
C081489_D006973 NONE <e1>valsartan/hydrochlorothiazide</e1> therapy comparison study followed therapy adults <e2>hypertensive</e2>
D006852_D006973 NONE <e1>valsartan/hydrochlorothiazide</e1> therapy comparison study followed therapy adults <e2>hypertensive</e2>
C081489_C562386 NONE <e1>valsartan</e1> combinations patients <e2>hypertension</e2>
C081489_C562386 NONE <e1>val</e1> valsartan combinations patients <e2>hypertension</e2>
C081489_C562386 NONE <e1>val</e1> groups randomized patients <e2>hypertension</e2>
C081489_C562386 NONE <e1>val/hctz</e1> 160/12.5 val groups randomized patients <e2>hypertension</e2>
D006852_C562386 NONE <e1>hydrochlorothiazide</e1> (hctz)-monotherapy valsartan combinations patients <e2>hypertension</e2>
D006852_C562386 NONE <e1>(hctz)-monotherapy</e1> valsartan combinations patients <e2>hypertension</e2>
D006852_C562386 NONE <e1>hctz</e1> val groups randomized patients <e2>hypertension</e2>
D006852_C562386 NONE <e1>val/hctz</e1> 160/12.5 val groups randomized patients <e2>hypertension</e2>
C081489_D007008 NONE <e1>val/hctz</e1> combinations lower incidence <e2>hypokalemia</e2>
C081489_D007008 NONE <e1>val/hctz</e1> therapies associated associated <e2>hypokalemia</e2>
D006852_D007008 CID <e1>val/hctz</e1> combinations lower incidence <e2>hypokalemia</e2>
D006852_D007008 CID <e1>hctz</e1> monotherapies lower incidence <e2>hypokalemia</e2>
D006852_D007008 CID <e1>val/hctz</e1> therapies associated associated <e2>hypokalemia</e2>
D006852_D007008 CID <e1>hctz</e1> <e2>hypokalemia</e2>
24068571
D013874_D003693 CID <e1>thiopentone</e1> use associated risk <e2>delirium</e2>
D015742_D003693 NONE <e1>propofol</e1> compared risk <e2>delirium</e2>
10933650
D000666_D007674 NONE <e1>b.</e1> incorporating lipid attenuation <e2>nephrotoxicity</e2>
D000666_D007674 NONE <e1>b</e1> incorporation attenuates <e2>nephrotoxicity</e2>
D000666_D007674 NONE <e1>b.</e1> attenuates <e2>nephrotoxicity</e2>
D000666_D064420 NONE <e1>b</e1> incorporating lipid ns-718 effective has <e2>toxicity</e2>
D000666_D064420 NONE <e1>fungizone</e1> that <e2>toxicity</e2>
D000666_D064420 NONE <e1>b</e1> study study compared <e2>toxicity</e2>
C059765_D064420 NONE <e1>deoxycholate</e1> that <e2>toxicity</e2>
C059765_D064420 NONE <e1>d-amb</e1> compared <e2>toxicity</e2>
C059765_D007683 CID <e1>d-amb-treated</e1> rats <e2>necrosis</e2>
9881641
D005905_D007022 NONE <e1>glibenclamide-sensitive</e1> <e2>hypotension</e2>
D005905_D007022 NONE <e1>glibenclamide</e1> attenuated <e2>hypotension</e2>
D005905_D007022 NONE <e1>glibenclamide-sensitive</e1> channels activation attributable <e2>hypotension</e2>
C040442_D007022 CID <e1>helodermin</e1> produced <e2>hypotension</e2>
C040442_D007022 CID <e1>helodermin</e1> produced <e2>hypotension</e2>
C040442_D007022 CID <e1>helodermin-induced</e1> <e2>hypotension</e2>
C040442_D007022 CID <e1>helodermin-induced</e1> hypotension affect shortened duration <e2>hypotension</e2>
C040442_D007022 CID <e1>helodermin-produced</e1> <e2>hypotension</e2>
D019806_D007022 CID <e1>levcromakalim-produced</e1> decrease abolished attenuated <e2>hypotension</e2>
D000109_D007022 CID <e1>acetylcholine</e1> hypotension duration shortened affect <e2>hypotension</e2>
D000109_D007022 CID <e1>acetylcholine</e1> <e2>hypotension</e2>
D000109_D007022 CID <e1>(ach)-produced</e1> hypotension duration shortened affect <e2>hypotension</e2>
D000109_D007022 CID <e1>(ach)-produced</e1> <e2>hypotension</e2>
D011188_D007022 NONE <e1>k+</e1> channels activation attributable <e2>hypotension</e2>
D011188_D007022 NONE <e1>k(atp</e1> channels activation attributable <e2>hypotension</e2>
D000255_D007022 NONE <e1>k(atp</e1> channels activation attributable <e2>hypotension</e2>
D009569_D007022 NONE <e1>oxide</e1> seem play <e2>hypotension</e2>
1158089
D013752_D005234 CID <e1>tetracycline</e1> induced <e2>liver</e2>
D013752_D005234 CID <e1>tetracycline</e1> induced <e2>liver</e2>
D013752_D005234 CID <e1>tetracycline</e1> production <e2>liver</e2>
D019301_D003866 NONE <e1>acid</e1> provision observed dose accumulation <e2>depression</e2>
D013752_D003866 NONE <e1>tetracycline</e1> dose accumulation <e2>depression</e2>
D013752_D003866 NONE <e1>tetracycline</e1> effects <e2>depression</e2>
D014280_D003866 NONE <e1>triglyceride</e1> accumulation <e2>depression</e2>
D014280_D003866 NONE <e1>triglyceride</e1> output <e2>depression</e2>
D014280_D003866 NONE <e1>triglyceride</e1> output <e2>depression</e2>
D014280_D005234 NONE <e1>triglyceride</e1> secretion accounted indicating involved production <e2>liver</e2>
D014280_D005234 NONE <e1>triglyceride</e1> % accounted indicating involved production <e2>liver</e2>
D014280_D005234 NONE <e1>triglyceride-rich</e1> <e2>liver</e2>
1289188
D003676_D058186 NONE <e1>desferrioxamine</e1> therapy occurring <e2>failure</e2>
D003676_D058186 NONE <e1>desferrioxamine</e1> caused <e2>failure</e2>
D003676_D013789 NONE <e1>desferrioxamine</e1> treatment undergoing patient <e2>thalassemia</e2>
D003676_D013789 NONE <e1>dfx</e1> desferrioxamine treatment undergoing patient <e2>thalassemia</e2>
24309294
D012844_D000647 NONE <e1>cck-8</e1> alleviated <e2>amnesia</e2>
D009020_D000647 CID <e1>morphine-induced</e1> <e2>amnesia</e2>
D009020_D000647 CID <e1>morphine-treated</e1> animals hippocampus region decreases alleviated <e2>amnesia</e2>
D012844_D008569 NONE <e1>cck-8</e1> attenuates suggest function <e2>impairment</e2>
D012844_D008569 NONE <e1>cck-8</e1> function <e2>impairment</e2>
D009020_D008569 NONE <e1>morphine</e1> effect attenuates suggest function <e2>impairment</e2>
D009020_D008569 NONE <e1>morphine-induced</e1> <e2>impairment</e2>
15630069
D005947_D012559 NONE <e1>glucose</e1> metabolism patients <e2>schizophrenia</e2>
D005947_D012559 NONE <e1>glucose</e1> test metabolism patients <e2>schizophrenia</e2>
D005947_D012559 NONE <e1>glucose</e1> metabolism affecting unclear remains increasing patients <e2>schizophrenia</e2>
D005947_D012559 NONE <e1>glucose</e1> test using design patients <e2>schizophrenia</e2>
D005947_D003920 NONE <e1>glucose</e1> metabolism affecting unclear remains increasing incidence <e2>mellitus</e2>
D005947_D003920 NONE <e1>glucose</e1> metabolism affecting increasing factors <e2>diabetes</e2>
D003024_D012559 NONE <e1>clozapine</e1> treated matched subjects <e2>schizophrenia</e2>
D003024_D011618 NONE <e1>clozapine</e1> treated matched subjects schizophrenia <e2>disorder</e2>
C076029_D012559 NONE <e1>olanzapine</e1> clozapine treated matched subjects <e2>schizophrenia</e2>
C076029_D011618 NONE <e1>olanzapine</e1> clozapine treated matched subjects schizophrenia <e2>disorder</e2>
D018967_D012559 NONE <e1>risperidone</e1> clozapine treated matched subjects <e2>schizophrenia</e2>
D018967_D011618 NONE <e1>risperidone</e1> clozapine treated matched subjects schizophrenia <e2>disorder</e2>
D005947_D007333 NONE <e1>glucose</e1> fasting index <e2>sensitivity</e2>
D005947_D007333 NONE <e1>glucose</e1> fasting measures assessment <e2>resistance</e2>
D005947_D007333 NONE <e1>glucose</e1> effectiveness assessment measures fasting index <e2>sensitivity</e2>
D005947_D007333 NONE <e1>glucose</e1> effectiveness assessment <e2>resistance</e2>
D005947_D007333 NONE <e1>glucose</e1> effectiveness impairment <e2>resistance</e2>
D003024_D007333 CID <e1>clozapine</e1> risperidone f(33 difference index <e2>sensitivity</e2>
D003024_D007333 CID <e1>clozapine</e1> risperidone f(33 difference subjects exhibiting <e2>resistance</e2>
D003024_D007333 CID <e1>clozapine</e1> received subjects difference index <e2>sensitivity</e2>
D003024_D007333 CID <e1>clozapine</e1> received subjects exhibiting <e2>resistance</e2>
D003024_D007333 CID <e1>clozapine</e1> risperidone treated subjects resistance exhibiting subjects difference index <e2>sensitivity</e2>
D003024_D007333 CID <e1>clozapine</e1> risperidone treated subjects <e2>resistance</e2>
D003024_D007333 CID <e1>clozapine</e1> risperidone groups differed assessment <e2>resistance</e2>
D003024_D007333 CID <e1>clozapine</e1> groups differed assessment <e2>resistance</e2>
D003024_D007333 CID <e1>clozapine-</e1> groups displayed <e2>resistance</e2>
D003024_D007333 CID <e1>clozapine</e1> taking patients examined <e2>resistance</e2>
C076029_D007333 CID <e1>olanzapine</e1> risperidone f(33 difference index <e2>sensitivity</e2>
C076029_D007333 CID <e1>olanzapine</e1> risperidone f(33 difference subjects exhibiting <e2>resistance</e2>
C076029_D007333 CID <e1>olanzapine</e1> clozapine received subjects difference index <e2>sensitivity</e2>
C076029_D007333 CID <e1>olanzapine</e1> clozapine received subjects exhibiting <e2>resistance</e2>
C076029_D007333 CID <e1>olanzapine</e1> = was difference index <e2>sensitivity</e2>
C076029_D007333 CID <e1>olanzapine</e1> = was difference subjects exhibiting <e2>resistance</e2>
C076029_D007333 CID <e1>olanzapine</e1> risperidone groups differed assessment <e2>resistance</e2>
C076029_D007333 CID <e1>olanzapine</e1> = differed assessment <e2>resistance</e2>
C076029_D007333 CID <e1>olanzapine-treated</e1> clozapine- groups displayed <e2>resistance</e2>
C076029_D007333 CID <e1>olanzapine</e1> clozapine taking patients examined <e2>resistance</e2>
D018967_D007333 NONE <e1>risperidone</e1> f(33 difference index <e2>sensitivity</e2>
D018967_D007333 NONE <e1>risperidone</e1> f(33 difference subjects exhibiting <e2>resistance</e2>
D018967_D007333 NONE <e1>risperidone</e1> treated subjects resistance exhibiting subjects difference index <e2>sensitivity</e2>
D018967_D007333 NONE <e1>risperidone</e1> treated subjects <e2>resistance</e2>
D018967_D007333 NONE <e1>risperidone</e1> clozapine risperidone treated subjects resistance exhibiting subjects difference index <e2>sensitivity</e2>
D018967_D007333 NONE <e1>risperidone</e1> clozapine risperidone treated subjects <e2>resistance</e2>
D018967_D007333 NONE <e1>risperidone</e1> olanzapine = was difference index <e2>sensitivity</e2>
D018967_D007333 NONE <e1>risperidone</e1> olanzapine = was difference subjects exhibiting <e2>resistance</e2>
D018967_D007333 NONE <e1>risperidone</e1> groups differed assessment <e2>resistance</e2>
D018967_D007333 NONE <e1>risperidone</e1> clozapine groups differed assessment <e2>resistance</e2>
D018967_D007333 NONE <e1>risperidone</e1> olanzapine = differed assessment <e2>resistance</e2>
D018967_D007333 NONE <e1>risperidone-treated</e1> subjects displayed <e2>resistance</e2>
19841052
D016578_D015658 NONE <e1>cocaine</e1> smoking factor <e2>infection</e2>
D016578_D015658 NONE <e1>cocaine</e1> has incidence <e2>infection</e2>
D016578_D015658 NONE <e1>cocaine</e1> use sought examine become factor <e2>infection</e2>
D016578_D006679 CID <e1>cocaine</e1> smokers <e2>seroconversion</e2>
D016578_D006679 CID <e1>cocaine</e1> smokers participants <e2>seroconversion</e2>
D016578_D006679 CID <e1>cocaine</e1> smoking found factor <e2>seroconversion</e2>
851038
D007980_D010300 NONE <e1>l-dopa</e1> treatment effect patients <e2>parkinsonian</e2>
D007980_D010300 NONE <e1>l-dopa-treated</e1> patients <e2>parkinsonian</e2>
D007980_D007008 CID <e1>l-dopa-treated</e1> patients observed <e2>hypokalemia</e2>
D007980_D007008 CID <e1>l-dopa</e1> influence studied patients <e2>hypokalemia</e2>
D011188_D007008 NONE <e1>potassium</e1> excretion influence studied patients <e2>hypokalemia</e2>
D011188_D007008 NONE <e1>potassium</e1> concentration determination patients patients <e2>hypokalemia</e2>
D011188_D007008 NONE <e1>potassium</e1> excretion patients <e2>hypokalemia</e2>
D012964_D007008 NONE <e1>sodium</e1> potassium concentration determination patients patients <e2>hypokalemia</e2>
D012964_D007008 NONE <e1>sodium</e1> potassium excretion patients <e2>hypokalemia</e2>
D000450_D007008 NONE <e1>aldosterone</e1> potassium excretion patients <e2>hypokalemia</e2>
20129423
D002220_D004802 CID <e1>carbamazepine</e1> induced myocarditis <e2>eosinophilic</e2>
D002220_D004342 CID <e1>carbamazepine</e1> induced myocarditis <e2>hypersensitivity</e2>
D002220_D004342 CID <e1>carbamazepine</e1> induced myocarditis emphasis characteristics mechanisms <e2>hypersensitivity</e2>
D002220_D004342 CID <e1>carbamazepine</e1> effect necrotizing myocarditis <e2>hypersensitivity</e2>
D002220_D004342 CID <e1>carbamazepine</e1> administration secondary myocarditis <e2>hypersensitivity</e2>
D002220_D009205 CID <e1>carbamazepine</e1> induced <e2>myocarditis</e2>
D002220_D009205 CID <e1>carbamazepine</e1> effect necrotizing <e2>myocarditis</e2>
D002220_D009205 CID <e1>carbamazepine</e1> administration secondary <e2>myocarditis</e2>
D002220_D009205 CID <e1>carbamazepine</e1> <e2>myocarditis</e2>
10327032
D005472_D022124 CID <e1>5-fluorouracil</e1> infusion received patients <e2>encephalopathy</e2>
D005472_D022124 CID <e1>5-fluorouracil</e1> infusion related <e2>encephalopathy</e2>
D005472_D022124 CID <e1>5-fu</e1> 5-fluorouracil infusion related <e2>encephalopathy</e2>
D005472_D022124 CID <e1>5-fu</e1> doses receiving patients patients seen levels onset <e2>hyperammonemia</e2>
D005472_D022124 CID <e1>5-fu</e1> infusion receiving patients occur <e2>encephalopathy</e2>
D005472_D001927 CID <e1>5-fluorouracil</e1> infusion received patients <e2>encephalopathy</e2>
D005472_D001927 CID <e1>5-fluorouracil</e1> infusion related <e2>encephalopathy</e2>
D005472_D001927 CID <e1>5-fu</e1> 5-fluorouracil infusion related <e2>encephalopathy</e2>
D005472_D001927 CID <e1>5-fu</e1> infusion receiving patients occur <e2>encephalopathy</e2>
D005472_D009369 NONE <e1>5-fluorouracil</e1> infusion received patients <e2>cancer</e2>
D005472_D009369 NONE <e1>5-fluorouracil</e1> infusion related encephalopathy episodes had patients <e2>cancer</e2>
D005472_D009369 NONE <e1>5-fu</e1> 5-fluorouracil infusion related encephalopathy episodes had patients <e2>cancer</e2>
D005472_D003681 NONE <e1>5-fluorouracil</e1> infusion received complication <e2>dehydration</e2>
D005472_D007239 NONE <e1>5-fluorouracil</e1> infusion received complication dehydration <e2>infection</e2>
D000644_D022124 NONE <e1>ammonium</e1> levels onset <e2>hyperammonemia</e2>
D000644_D001424 NONE <e1>ammonium</e1> levels seen patients <e2>infections</e2>
D005472_D001424 NONE <e1>5-fu</e1> doses receiving patients patients <e2>infections</e2>
3109094
D003520_D001745 CID <e1>cyclophosphamide-induced</e1> lesions <e2>bladder</e2>
D015080_D001745 NONE <e1>mesna</e1> prevention investigations lesions <e2>bladder</e2>
D003520_D003556 NONE <e1>cyclophosphamide-induced</e1> <e2>cystitis</e2>
D003520_D004487 NONE <e1>cyclophosphamide-induced</e1> cystitis characterized detachment <e2>edema</e2>
D003520_D009336 NONE <e1>cyclophosphamide-induced</e1> cystitis characterized detachment owing damage bed <e2>necroses</e2>
11380496
D011441_D006111 NONE <e1>propylthiouracil</e1> treated patients <e2>disease</e2>
D011441_D006111 NONE <e1>propylthiouracil</e1> treated patients <e2>disease</e2>
D011441_D006111 NONE <e1>ptu</e1> propylthiouracil treated patients <e2>disease</e2>
D011441_D006111 NONE <e1>ptu</e1> therapy vasculitis mpo-anca appearance relationship studies been incidence patients <e2>disease</e2>
D011441_D006111 NONE <e1>ptu</e1> therapy starting investigated <e2>disease</e2>
D011441_D014657 NONE <e1>propylthiouracil</e1> treated patients reported <e2>vasculitis</e2>
D011441_D014657 NONE <e1>ptu</e1> propylthiouracil treated patients reported <e2>vasculitis</e2>
D011441_D014657 NONE <e1>ptu</e1> therapy <e2>vasculitis</e2>
D011441_D014657 NONE <e1>ptu</e1> therapy starting investigated <e2>vasculitis</e2>
D011441_D014657 NONE <e1>ptu</e1> therapy related appear related <e2>vasculitis</e2>
D011441_D006980 NONE <e1>ptu</e1> therapy starting investigated patients <e2>hyperthyroidism</e2>
D011441_D014652 NONE <e1>ptu</e1> therapy increased developed <e2>disorders</e2>
D011441_D005334 CID <e1>ptu</e1> therapy stopping resolved increased developed <e2>fever</e2>
D011441_D005334 CID <e1>ptu</e1> discontinuing decreased resolved increased developed <e2>fever</e2>
D011441_D019226 CID <e1>ptu</e1> therapy stopping resolved increased developed fever <e2>ulcers</e2>
D011441_D019226 CID <e1>ptu</e1> discontinuing decreased resolved increased developed fever <e2>ulcers</e2>
D011441_D018771 CID <e1>ptu</e1> therapy stopping resolved increased developed fever ulcers <e2>polyarthralgia</e2>
D011441_D018771 CID <e1>ptu</e1> discontinuing decreased resolved increased developed fever ulcers <e2>polyarthralgia</e2>
11176729
D000806_D006333 NONE <e1>inhibitors</e1> patients <e2>failure</e2>
D000806_D006333 NONE <e1>inhibitors</e1> treatment reduces mortality patients <e2>failure</e2>
D000806_D006333 NONE <e1>inhibitors</e1> treatment reduces mortality patients failure <e2>chf</e2>
D000806_D006333 NONE <e1>inhibitor</e1> therapy patients <e2>chf</e2>
D017706_D006333 NONE <e1>lisinopril</e1> <e2>chf</e2>
D000806_D007022 NONE <e1>inhibitor</e1> receiving patients titrated symptoms related <e2>hypotension</e2>
D000806_D007674 NONE <e1>inhibitor</e1> receiving patients titrated symptoms <e2>dysfunction</e2>
D000806_D006947 NONE <e1>inhibitor</e1> receiving patients titrated symptoms dysfunction <e2>hyperkalemia</e2>
D000806_D003920 NONE <e1>inhibitor</e1> intolerance risk to presumed age patients <e2>diabetes</e2>
D003404_D003920 NONE <e1>creatinine</e1> pressure intolerance risk to presumed age patients <e2>diabetes</e2>
2383364
C048279_D002056 NONE <e1>diphosphanilate</e1> study agent <e2>burns</e2>
C048279_D002056 NONE <e1>phosphanilate</e1> evaluated dressing wound <e2>burn</e2>
C048279_D002056 NONE <e1>chp</e1> phosphanilate evaluated dressing wound <e2>burn</e2>
C048279_D002056 NONE <e1>chp</e1> concentrations each treated site <e2>burn</e2>
C048279_D002056 NONE <e1>chp</e1> concentrations each treated cream agent used treatment wounds <e2>burn</e2>
D012837_D002056 NONE <e1>sulphadiazine</e1> silver cream treated site <e2>burn</e2>
D012837_D002056 NONE <e1>sulphadiazine</e1> silver cream agent used treatment wounds <e2>burn</e2>
D012837_D002056 NONE <e1>agsd</e1> sulphadiazine silver cream treated site <e2>burn</e2>
D012837_D002056 NONE <e1>agsd</e1> sulphadiazine silver cream agent used treatment wounds <e2>burn</e2>
C048279_D010146 CID <e1>chp</e1> concentration ratings <e2>pain</e2>
C048279_D010146 CID <e1>chp</e1> cream 0.25 closest tolerance <e2>pain</e2>
D012837_D010146 NONE <e1>agsd</e1> closest tolerance <e2>pain</e2>
D012837_D010146 NONE <e1>agsd</e1> differed closest tolerance <e2>pain</e2>
9725303
D019469_D014517 NONE <e1>indinavir</e1> therapy undergoing patients <e2>obstruction</e2>
D019469_D014517 NONE <e1>indinavir</e1> crystals caused <e2>obstruction</e2>
D019469_D014517 NONE <e1>indinavir</e1> therapy receive patients diagnosis stones <e2>obstruction</e2>
D019469_D014514 CID <e1>indinavir</e1> receiving patients features <e2>calculi</e2>
D019469_D014514 NONE <e1>indinavir</e1> therapy receive patients diagnosis stones <e2>obstruction</e2>
D019469_D015658 NONE <e1>indinavir</e1> receiving patients <e2>hiv-infected</e2>
D019469_D015658 NONE <e1>indinavir</e1> therapy receive patients <e2>infection</e2>
D019469_D052878 NONE <e1>indinavir</e1> receiving patients features associated incidence <e2>urolithiasis</e2>
10401555
C096012_D007859 NONE <e1>nociceptin/orphanin</e1> fq nocistatin <e2>impairment</e2>
C096012_D007859 NONE <e1>fq</e1> nocistatin <e2>impairment</e2>
C096012_D007859 NONE <e1>nociceptin/orphanin</e1> fq modulate impairment learning <e2>memory</e2>
C096012_D007859 NONE <e1>fq</e1> modulate impairment learning <e2>memory</e2>
C096012_D008569 NONE <e1>nociceptin/orphanin</e1> fq nocistatin <e2>impairment</e2>
C096012_D008569 NONE <e1>fq</e1> nocistatin <e2>impairment</e2>
C096012_D008569 NONE <e1>nociceptin/orphanin</e1> fq modulate impairment learning <e2>memory</e2>
C096012_D008569 NONE <e1>fq</e1> modulate impairment learning <e2>memory</e2>
C111148_D007859 NONE <e1>nocistatin</e1> <e2>impairment</e2>
C111148_D007859 NONE <e1>nocistatin</e1> fq modulate impairment learning <e2>memory</e2>
C111148_D008569 NONE <e1>nocistatin</e1> <e2>impairment</e2>
C111148_D008569 NONE <e1>nocistatin</e1> fq modulate impairment learning <e2>memory</e2>
D012601_D007859 CID <e1>scopolamine</e1> induced <e2>impairment</e2>
D012601_D007859 CID <e1>scopolamine</e1> induced learning <e2>memory</e2>
D012601_D008569 CID <e1>scopolamine</e1> induced <e2>impairment</e2>
D012601_D008569 CID <e1>scopolamine</e1> induced learning <e2>memory</e2>
C111148_D006930 NONE <e1>nocistatin</e1> isolated blocks <e2>allodynia</e2>
C111148_D006930 NONE <e1>nocistatin</e1> isolated blocks allodynia <e2>hyperalgesia</e2>
C096012_D006930 NONE <e1>nociceptin</e1> precursor isolated blocks <e2>allodynia</e2>
C096012_D006930 NONE <e1>nociceptin</e1> precursor isolated blocks allodynia <e2>hyperalgesia</e2>
C096012_D006930 NONE <e1>nociceptin-induced</e1> <e2>allodynia</e2>
C096012_D006930 NONE <e1>nociceptin-induced</e1> allodynia <e2>hyperalgesia</e2>
3323259
D002118_D002318 NONE <e1>calcium</e1> importance pathogenesis <e2>disease</e2>
D002118_D002318 NONE <e1>calcium</e1> importance recognition stimulated use treatment variety <e2>diseases</e2>
D002121_D002318 NONE <e1>agents</e1> use stimulated recognition importance pathogenesis <e2>disease</e2>
D002121_D002318 NONE <e1>agents</e1> use treatment variety <e2>diseases</e2>
C038806_D000787 NONE <e1>dihydropyridine</e1> controls <e2>angina</e2>
C038806_D006973 NONE <e1>dihydropyridine</e1> controls angina <e2>hypertension</e2>
D009543_D000787 NONE <e1>nifedipine</e1> controls <e2>angina</e2>
D009543_D006973 NONE <e1>nifedipine</e1> controls angina <e2>hypertension</e2>
D009568_D006973 NONE <e1>nitrendipine</e1> possible dosage offers schedule encourages compliance therapy <e2>hypertension</e2>
D015737_D006973 NONE <e1>nisoldipine</e1> nitrendipine possible dosage offers schedule encourages compliance therapy <e2>hypertension</e2>
D015737_D000787 NONE <e1>nisoldipine</e1> properties led investigation agent use <e2>angina</e2>
D009553_D013345 NONE <e1>nimodipine</e1> useful treatment <e2>hemorrhage</e2>
D009553_D008881 NONE <e1>nimodipine</e1> useful treatment hemorrhage <e2>headache</e2>
D009553_D003704 NONE <e1>nimodipine</e1> useful treatment hemorrhage <e2>dementia</e2>
D009553_D020521 NONE <e1>nimodipine</e1> useful treatment hemorrhage <e2>stroke</e2>
C038806_D006261 NONE <e1>dihydropyridine</e1> blockers tolerated <e2>headache</e2>
C038806_D005483 NONE <e1>dihydropyridine</e1> blockers tolerated headache <e2>flushing</e2>
C038806_-1 NONE <e1>dihydropyridine</e1> blockers tolerated headache flushing <e2>palpitations</e2>
C038806_D004487 NONE <e1>dihydropyridine</e1> blockers tolerated headache flushing <e2>edema</e2>
C038806_D009325 NONE <e1>dihydropyridine</e1> blockers tolerated headache flushing edema <e2>nausea</e2>
C038806_D000855 NONE <e1>dihydropyridine</e1> blockers tolerated headache flushing <e2>anorexia</e2>
C038806_D004244 NONE <e1>dihydropyridine</e1> blockers tolerated headache <e2>dizziness</e2>
D002121_D006261 CID <e1>blockers</e1> tolerated <e2>headache</e2>
D002121_D005483 CID <e1>blockers</e1> tolerated headache <e2>flushing</e2>
D002121_-1 NONE <e1>blockers</e1> tolerated headache flushing <e2>palpitations</e2>
D002121_D004487 CID <e1>blockers</e1> tolerated headache flushing <e2>edema</e2>
D002121_D009325 CID <e1>blockers</e1> tolerated headache flushing edema <e2>nausea</e2>
D002121_D000855 CID <e1>blockers</e1> tolerated headache flushing <e2>anorexia</e2>
D002121_D004244 CID <e1>blockers</e1> tolerated headache <e2>dizziness</e2>
2884595
D006632_D014917 NONE <e1>histamine</e1> receptors blockade reduce encephalopathy immunization-induced <e2>pertussis</e2>
D006632_D001927 NONE <e1>histamine</e1> receptors blockade reduce <e2>encephalopathy</e2>
2710809
D001712_D001919 CID <e1>biperiden</e1> <e2>bradycardia</e2>
D001712_D001919 CID <e1>biperiden</e1> induced <e2>bradycardia</e2>
C036432_D006562 NONE <e1>lactate</e1> application patient suffering neuralgia <e2>postzosteric</e2>
C036432_D014277 NONE <e1>lactate</e1> application patient suffering <e2>neuralgia</e2>
C036432_D001919 NONE <e1>lactate</e1> application patient led reaction characterized <e2>bradycardia</e2>
C036432_D004401 NONE <e1>lactate</e1> application patient led reaction characterized bradycardia <e2>dysarthria</e2>
C036432_D003680 NONE <e1>lactate</e1> application patient led reaction characterized bradycardia <e2>dysphagia</e2>
D001285_D001919 NONE <e1>atropine-like</e1> drugs effect speed attributed <e2>bradycardia</e2>
D009116_D001919 NONE <e1>muscarine</e1> receptors effect speed attributed <e2>bradycardia</e2>
12865514
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias bradykinesia patients suffering <e2>disease</e2>
D007980_D018476 NONE <e1>levodopa-induced</e1> dyskinesias <e2>bradykinesia</e2>
D007980_D009127 NONE <e1>levodopa-induced</e1> dyskinesias bradykinesia <e2>rigidity</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa</e1> dose reduction useful controlling <e2>dyskinesias</e2>
16323982
D002784_D011471 NONE <e1>cholesterols</e1> changes follow-up <e2>cancer</e2>
D002784_D011471 NONE <e1>c</e1> cholesterols changes follow-up <e2>cancer</e2>
D014280_D011471 NONE <e1>triglycerides</e1> cholesterols changes follow-up <e2>cancer</e2>
D014280_D011471 NONE <e1>tg</e1> triglycerides cholesterols changes follow-up <e2>cancer</e2>
D017373_D011471 NONE <e1>acetate</e1> treatment follow-up <e2>cancer</e2>
D017373_D011471 NONE <e1>cpa</e1> acetate treatment follow-up <e2>cancer</e2>
D017373_D003327 NONE <e1>cpa</e1> treatment period found affected <e2>disease</e2>
D017373_D003324 CID <e1>cpa</e1> therapy caused <e2>arteriosclerosis</e2>
D017373_D050171 CID <e1>cpa</e1> therapy caused arteriosclerosis mediated other <e2>effect</e2>
D002784_D003324 NONE <e1>cholesterol</e1> changes mediated <e2>arteriosclerosis</e2>
D002784_D050171 NONE <e1>cholesterol</e1> changes mediated other <e2>effect</e2>
D004967_D003324 NONE <e1>estrogen</e1> caused effect other mediated <e2>arteriosclerosis</e2>
D004967_D050171 NONE <e1>estrogen</e1> caused <e2>effect</e2>
16723784
D015764_D001281 NONE <e1>bepridil</e1> administration fibrillation <e2>flutter</e2>
D015764_D001281 NONE <e1>hydrochloride</e1> background attracted drug <e2>fibrillation</e2>
D015764_D001281 NONE <e1>hydrochloride</e1> background attracted drug fibrillation <e2>af</e2>
D015764_D001281 NONE <e1>bpd</e1> hydrochloride background attracted drug <e2>fibrillation</e2>
D015764_D001281 NONE <e1>bpd</e1> hydrochloride background attracted drug fibrillation <e2>af</e2>
D015764_D001281 NONE <e1>bpd</e1> administered patients comprising <e2>af</e2>
D015764_D001282 NONE <e1>bepridil</e1> administration fibrillation <e2>flutter</e2>
D015764_D001282 NONE <e1>hydrochloride</e1> background attracted drug fibrillation <e2>flutter</e2>
D015764_D001282 NONE <e1>hydrochloride</e1> background attracted drug fibrillation flutter <e2>afl</e2>
D015764_D001282 NONE <e1>bpd</e1> hydrochloride background attracted drug fibrillation <e2>flutter</e2>
D015764_D001282 NONE <e1>bpd</e1> hydrochloride background attracted drug fibrillation flutter <e2>afl</e2>
D015764_D001282 NONE <e1>bpd</e1> administered patients comprising af cases <e2>afl</e2>
15321332
D004329_D001008 CID <e1>droperidol</e1> case <e2>anxiety</e2>
D004329_D001008 CID <e1>droperidol-induced</e1> <e2>disturbance</e2>
19920070
D010634_D006529 CID <e1>phenobarbital</e1> administration results proliferation <e2>hepatomegaly</e2>
6806735
D002945_D010051 NONE <e1>cis-platinum</e1> combination treatment <e2>cancer</e2>
D002945_D010051 NONE <e1>cisplatinum</e1> combination treated patients <e2>cancer</e2>
D004317_D010051 NONE <e1>adriamycin</e1> cis-platinum combination treatment <e2>cancer</e2>
D004317_D010051 NONE <e1>adriamycin</e1> cisplatinum combination treated patients <e2>cancer</e2>
D003520_D010051 NONE <e1>cyclophosphamide</e1> cis-platinum combination treatment <e2>cancer</e2>
D003520_D010051 NONE <e1>cyclophosphamide</e1> cisplatinum combination treated patients <e2>cancer</e2>
D006585_D010051 NONE <e1>hexamethylmelamine</e1> cyclophosphamide cis-platinum combination treatment <e2>cancer</e2>
D006585_D010051 NONE <e1>hexamethylmelamine</e1> treated patients <e2>cancer</e2>
D006585_D010051 NONE <e1>hmm</e1> hexamethylmelamine treated patients <e2>cancer</e2>
C034868_D010051 NONE <e1>cpdd</e1> cisplatinum combination treated patients <e2>cancer</e2>
D006585_D005767 NONE <e1>hmm</e1> <e2>toxicity</e2>
24275640
D004317_D066126 CID <e1>doxorubicin</e1> doses single treatment <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>doxorubicin</e1> <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>(dox)-induced</e1> <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>dox</e1> dose induced <e2>cardiotoxicity</e2>
D004317_D006331 NONE <e1>dox</e1> dose associated <e2>disarrangement</e2>
D004317_D009336 CID <e1>dox</e1> dose associated disarrangement <e2>necrosis</e2>
3409843
D002220_D000741 CID <e1>carbamazepine</e1> treated patient <e2>anemia</e2>
D002220_D000741 CID <e1>carbamazepine</e1> treatment case <e2>anemia</e2>
D002220_D004827 NONE <e1>carbamazepine</e1> treatment woman <e2>epileptic</e2>
D002220_D001855 NONE <e1>carbamazepine</e1> concerns <e2>toxicity</e2>
2021990
D002927_D007022 CID <e1>cimetidine</e1> caused <e2>hypotension</e2>
D002927_D007022 CID <e1>cimetidine</e1> activity mediated useful preventing <e2>hypotension</e2>
8996419
D003276_D054556 CID <e1>contraceptives</e1> associated <e2>thromboembolism</e2>
D003276_D054556 CID <e1>contraceptives</e1> used women higher incidence <e2>thromboembolism</e2>
D003276_D054556 CID <e1>contraceptives</e1> used women higher incidence thromboembolism <e2>vte</e2>
D003276_D054556 CID <e1>ocs</e1> contraceptives used women higher incidence <e2>thromboembolism</e2>
D003276_D054556 CID <e1>ocs</e1> contraceptives used women higher incidence thromboembolism <e2>vte</e2>
D003276_D054556 CID <e1>ocs</e1> users higher incidence <e2>thromboembolism</e2>
D003276_D054556 CID <e1>ocs</e1> users higher incidence thromboembolism <e2>vte</e2>
D003276_D054556 CID <e1>oc</e1> use risk <e2>vte</e2>
D003276_D054556 CID <e1>oc</e1> preparations users compare incidence <e2>vte</e2>
D003276_D054556 CID <e1>oc</e1> preparations users compare estimate did study calculate odds ratios <e2>vte</e2>
D003276_D054556 CID <e1>oc</e1> types use associated vte ratios odds calculate study did estimate compare incidence <e2>vte</e2>
D003276_D054556 CID <e1>oc</e1> types use associated <e2>vte</e2>
D003276_D054556 CID <e1>ocs</e1> users met criteria <e2>vte</e2>
D003276_D054556 CID <e1>ocs</e1> use associated <e2>vte</e2>
D003276_D054556 CID <e1>oc</e1> users 4.10 rate <e2>vte</e2>
D003276_D054556 CID <e1>ocs</e1> users 3.10 oc users 4.10 rate <e2>vte</e2>
D003276_D054556 CID <e1>ocs</e1> relative users ratio <e2>vte</e2>
D003276_D054556 CID <e1>ocs</e1> third-generation users risk <e2>vte</e2>
D003276_D054556 CID <e1>ocs</e1> 3.49 odds ratios <e2>vte</e2>
D011374_D054556 NONE <e1>progestagens</e1> containing contraceptives used women higher incidence <e2>thromboembolism</e2>
D011374_D054556 NONE <e1>progestagens</e1> containing contraceptives used women higher incidence thromboembolism <e2>vte</e2>
D011374_D054556 NONE <e1>progestagens</e1> containing ocs users higher incidence <e2>thromboembolism</e2>
D011374_D054556 NONE <e1>progestagens</e1> containing ocs users higher incidence thromboembolism <e2>vte</e2>
D011374_D054556 NONE <e1>progestagens</e1> users higher risk <e2>vte</e2>
D011374_D054556 NONE <e1>progestagens</e1> 3.49 odds ratios <e2>vte</e2>
C033273_D054556 NONE <e1>gestodene</e1> higher incidence <e2>thromboembolism</e2>
C033273_D054556 NONE <e1>gestodene</e1> higher incidence thromboembolism <e2>vte</e2>
C033273_D054556 NONE <e1>gestodene</e1> users higher risk <e2>vte</e2>
D017135_D054556 NONE <e1>desogestrel</e1> gestodene higher incidence <e2>thromboembolism</e2>
D017135_D054556 NONE <e1>desogestrel</e1> gestodene higher incidence thromboembolism <e2>vte</e2>
D017135_D054556 NONE <e1>desogestrel</e1> users higher risk <e2>vte</e2>
D017135_D054556 NONE <e1>desogestrel</e1> users higher risk <e2>vte</e2>
D017135_D054556 NONE <e1>desogestrel</e1> ethinyloestradiol 3.49 odds ratios <e2>vte</e2>
D011372_D054556 NONE <e1>progestagen-only</e1> ocs users met criteria <e2>vte</e2>
D003276_D020246 NONE <e1>ocs</e1> use associated vte cases recorded <e2>thrombosis</e2>
D003276_D020246 NONE <e1>ocs</e1> use associated vte cases recorded five <e2>thrombosis</e2>
D003276_D013927 NONE <e1>ocs</e1> use associated vte cases recorded 35 <e2>thrombosis</e2>
D004997_D054556 NONE <e1>ethinyloestradiol</e1> desogestrel users higher risk <e2>vte</e2>
D004997_D054556 NONE <e1>ethinyloestradiol</e1> desogestrel users higher risk <e2>vte</e2>
D004997_D054556 NONE <e1>ethinyloestradiol</e1> 3.49 odds ratios <e2>vte</e2>
18422462
D000409_D000740 NONE <e1>alanine</e1> aminotransferase jaundice hepatitis patients % observed <e2>anemia</e2>
D000409_D056486 NONE <e1>alanine</e1> aminotransferase jaundice <e2>hepatitis</e2>
D000409_D007565 NONE <e1>alanine</e1> aminotransferase <e2>jaundice</e2>
D019829_D005076 CID <e1>nvp</e1> therapy associated developing <e2>rash</e2>
D019829_D010523 NONE <e1>nvp</e1> therapy associated developing developing <e2>neuropathy</e2>
D018119_D005076 NONE <e1>t</e1> therapy <e2>rash</e2>
D018119_D010523 CID <e1>t</e1> therapy rash developing developing <e2>neuropathy</e2>
18450790
D013792_D010523 CID <e1>thalidomide</e1> <e2>neurotoxicity</e2>
D013792_D010523 CID <e1>thalidomide</e1> doses treated patients <e2>neuropathy</e2>
D013792_D008178 NONE <e1>thalidomide</e1> treated measure variations amplitude patients <e2>erythematosus</e2>
D013792_D008178 NONE <e1>thalidomide</e1> treated measure <e2>cle</e2>
D013792_D008178 NONE <e1>thalidomide</e1> potential identify use treated measure variations amplitude patients <e2>erythematosus</e2>
D013792_D008178 NONE <e1>thalidomide</e1> potential identify use treated measure <e2>cle</e2>
D013792_D008178 NONE <e1>thalidomide</e1> treatment data patients <e2>cle</e2>
D013792_D020258 NONE <e1>thalidomide</e1> treated use identify potential <e2>neurotoxic</e2>
D013792_D020258 NONE <e1>thalidomide</e1> potential <e2>neurotoxic</e2>
D013792_D020258 NONE <e1>thalidomide</e1> dose g. lower dosage <e2>neurotoxic</e2>
D013792_D020258 NONE <e1>thalidomide</e1> potential <e2>neurotoxic</e2>
24894748
D008790_D001919 CID <e1>metoprolol-terbinafine</e1> combination induced <e2>bradycardia</e2>
C041359_D001919 CID <e1>metoprolol-terbinafine</e1> combination induced <e2>bradycardia</e2>
D008790_D012804 NONE <e1>metoprolol</e1> induced <e2>bradycardia</e2>
D008790_D012804 NONE <e1>metoprolol</e1> interaction <e2>bradycardia</e2>
D008790_D012804 NONE <e1>metoprolol</e1> clearance decreased leading accumulation resulted <e2>bradycardia</e2>
D008790_D012804 NONE <e1>metoprolol</e1> accumulation resulted <e2>bradycardia</e2>
C041359_D012804 NONE <e1>terbinafine</e1> metoprolol induced <e2>bradycardia</e2>
C041359_D012804 NONE <e1>terbinafine</e1> metoprolol interaction <e2>bradycardia</e2>
C041359_D012804 NONE <e1>terbinafine</e1> decreased leading accumulation resulted <e2>bradycardia</e2>
D008790_D003324 NONE <e1>metoprolol</e1> man mg/day <e2>disease</e2>
D008790_D014009 NONE <e1>metoprolol</e1> man prescribed <e2>onychomycosis</e2>
C041359_D003324 NONE <e1>terbinafine</e1> course prescribed man mg/day <e2>disease</e2>
C041359_D014009 NONE <e1>terbinafine</e1> course prescribed <e2>onychomycosis</e2>
C041359_D003221 NONE <e1>terbinafine</e1> therapy day brought decrease status <e2>confusion</e2>
D008790_D064420 NONE <e1>metoprolol</e1> interaction bradycardia relationship indicates score scale probability <e2>reaction</e2>
C041359_D064420 NONE <e1>terbinafine</e1> metoprolol interaction bradycardia relationship indicates score scale probability <e2>reaction</e2>
19715529
12051122
D014750_D007010 CID <e1>vincristine</e1> use reported <e2>hyponatremia</e2>
D014750_D007010 CID <e1>vincristine-treated</e1> patients rate <e2>hyponatremia</e2>
D014750_D007010 CID <e1>vincristine</e1> use reported november searched database cases <e2>hyponatremia</e2>
D014750_D007010 CID <e1>vincristine</e1> use associated <e2>hyponatremia</e2>
D014750_D007010 CID <e1>vincristine</e1> use associated <e2>hyponatremia</e2>
D014750_D007177 CID <e1>vincristine</e1> use reported hyponatremia <e2>hormone</e2>
D014750_D007177 CID <e1>vincristine-treated</e1> patients rate hyponatremia secretion <e2>hormone</e2>
D014750_D007177 CID <e1>vincristine-treated</e1> patients rate hyponatremia secretion hormone <e2>siadh</e2>
D014750_D007177 CID <e1>vincristine</e1> use reported november searched database cases hyponatremia <e2>siadh</e2>
D014750_D007177 CID <e1>vincristine</e1> use associated hyponatremia <e2>siadh</e2>
D014750_D007177 CID <e1>vincristine</e1> use associated hyponatremia <e2>siadh</e2>
D014750_D007177 CID <e1>vincristine</e1> associated <e2>siadh</e2>
15605432
D004317_D028361 CID <e1>adriamycin-induced</e1> <e2>injury</e2>
D004317_D028361 CID <e1>adr</e1> adducts showed point appeared <e2>injury</e2>
D010100_D066126 NONE <e1>oxygen</e1> species reported present <e2>cardiotoxicity</e2>
D009584_D066126 NONE <e1>(ros)/nitrogen</e1> species reported present <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>adriamycin</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>(adr)-induced</e1> <e2>cardiotoxicity</e2>
C027576_D028361 NONE <e1>4hne-protein</e1> adducts showed point appeared <e2>injury</e2>
8184922
D007545_D006332 CID <e1>isoproterenol-induced</e1> <e2>hypertrophy</e2>
20959502
D017576_D008581 NONE <e1>daptomycin</e1> penetration <e2>meningitis</e2>
D017576_D008581 NONE <e1>daptomycin</e1> treated <e2>meningitis</e2>
D017576_D008581 NONE <e1>daptomycin</e1> mg/kg daily initiated <e2>meningitis</e2>
D008712_D016470 NONE <e1>methicillin-sensitive</e1> <e2>bacteremia</e2>
D008712_D008581 NONE <e1>methicillin-sensitive</e1> bacteremia <e2>meningitis</e2>
D017576_D016470 NONE <e1>daptomycin</e1> treated meningitis <e2>bacteremia</e2>
D017576_D016470 NONE <e1>daptomycin</e1> initiated patient secondary relapsing <e2>bacteremia</e2>
D017576_D016470 NONE <e1>daptomycin</e1> option <e2>bacteremia</e2>
D003404_D058186 NONE <e1>creatinine</e1> <e2>failure</e2>
D009254_D008581 NONE <e1>nafcillin</e1> discontinued initiated <e2>meningitis</e2>
D017576_D009395 NONE <e1>daptomycin</e1> initiated patient secondary <e2>nephritis</e2>
D009254_D009395 CID <e1>nafcillin-induced</e1> <e2>nephritis</e2>
D009254_D016470 NONE <e1>nafcillin-induced</e1> nephritis secondary relapsing <e2>bacteremia</e2>
89511
D004967_D014591 NONE <e1>oestrogen</e1> therapy receiving prevention <e2>disease</e2>
D004967_D014591 NONE <e1>oestrogen</e1> therapy receiving women patients <e2>disease</e2>
D004967_D006965 CID <e1>oestrogen</e1> therapy associated <e2>hyperplasia</e2>
D004967_D006965 CID <e1>oestrogen</e1> therapy difficulty distinguishing <e2>hyperplasia</e2>
D011372_D006965 NONE <e1>progestagen</e1> therapy associated <e2>hyperplasia</e2>
D009640_D006965 NONE <e1>norethisterone</e1> courses caused reversion normal cases <e2>hyperplasia</e2>
D009640_D006965 NONE <e1>norethisterone</e1> courses caused reversion cases <e2>hyperplasia</e2>
D004967_D016889 NONE <e1>oestrogen</e1> therapy problems demonstrated cases <e2>carcinoma</e2>
D004967_D009369 NONE <e1>oestrogen</e1> therapy difficulty distinguishing <e2>malignancy</e2>
D004967_D004714 NONE <e1>oestrogen</e1> therapy seem increase risk <e2>hyperplasia</e2>
D004967_D002277 NONE <e1>oestrogen</e1> therapy seem increase risk hyperplasia <e2>carcinoma</e2>
D011372_D004714 NONE <e1>progestagen</e1> days therapy seem increase risk <e2>hyperplasia</e2>
D011372_D002277 NONE <e1>progestagen</e1> days therapy seem increase risk hyperplasia <e2>carcinoma</e2>
8748050
D000639_D001927 CID <e1>amitriptyline</e1> therapy <e2>encephalopathy</e2>
D000639_D001927 CID <e1>amitriptyline</e1> therapy course developed case <e2>encephalopathy</e2>
D000639_D009459 NONE <e1>amitriptyline</e1> therapy encephalopathy <e2>syndrome</e2>
D000639_D020230 NONE <e1>amitriptyline</e1> therapy encephalopathy syndrome <e2>syndrome</e2>
D000639_D003866 NONE <e1>amitriptyline</e1> therapy course developed case describes remission <e2>depression</e2>
24535067
D005045_D009207 CID <e1>etomidate-induced</e1> <e2>myoclonus</e2>
D005045_D009207 CID <e1>etomidate-induced</e1> <e2>myoclonus</e2>
D005045_D009207 CID <e1>etomidate-induced</e1> <e2>myoclonus</e2>
D005283_D009207 NONE <e1>fentanyl</e1> superior prevention <e2>myoclonus</e2>
D005283_D009207 NONE <e1>fentanyl</e1> effectiveness prevent <e2>myoclonus</e2>
D005283_D009207 NONE <e1>fentanyl</e1> combination fentanyl effectiveness prevent <e2>myoclonus</e2>
D005283_D009207 NONE <e1>fentanyl</e1> pretreatment effective preventing <e2>myoclonus</e2>
D005283_D009207 NONE <e1>fentanyl</e1> fentanyl pretreatment effective preventing <e2>myoclonus</e2>
D008874_D009207 NONE <e1>midazolam</e1> fentanyl superior prevention <e2>myoclonus</e2>
D008874_D009207 NONE <e1>midazolam</e1> fentanyl effectiveness prevent <e2>myoclonus</e2>
D008874_D009207 NONE <e1>midazolam</e1> fentanyl combination fentanyl effectiveness prevent <e2>myoclonus</e2>
D008874_D009207 NONE <e1>midazolam</e1> fentanyl fentanyl pretreatment effective preventing <e2>myoclonus</e2>
D005045_D009069 NONE <e1>etomidate</e1> injection graded observed evaluated <e2>movements</e2>
D005045_D010146 NONE <e1>etomidate</e1> injection severity <e2>pain</e2>
24802403
D008687_D012640 NONE <e1>metformin</e1> protects <e2>seizures</e2>
D008687_D012640 NONE <e1>metformin</e1> <e2>seizures</e2>
D008687_D012640 NONE <e1>metformin</e1> agent treatment medicine impairment induced <e2>seizures</e2>
D008687_D007859 NONE <e1>metformin</e1> protects <e2>impairments</e2>
D008687_D008569 NONE <e1>metformin</e1> protects <e2>impairments</e2>
D010433_D012640 CID <e1>pentylenetetrazole-induced</e1> kindling induced impairments protects <e2>seizures</e2>
D010433_D012640 CID <e1>pentylenetetrazole-induced</e1> animals observed impairment <e2>seizures</e2>
D010433_D007859 CID <e1>pentylenetetrazole-induced</e1> kindling induced <e2>impairments</e2>
D010433_D008569 CID <e1>pentylenetetrazole-induced</e1> kindling induced <e2>impairments</e2>
D008687_D003072 NONE <e1>metformin</e1> seizures <e2>impairment</e2>
D008687_D003072 NONE <e1>metformin</e1> suppressed ameliorated <e2>impairment</e2>
D008687_D003072 NONE <e1>metformin</e1> agent treatment medicine <e2>impairment</e2>
D010433_D003072 CID <e1>pentylenetetrazole-induced</e1> animals observed <e2>impairment</e2>
D008687_D004827 NONE <e1>metformin</e1> agent treatment <e2>epilepsy</e2>
25006369
C061870_D005207 NONE <e1>rocuronium</e1> dose decrease <e2>fasciculation</e2>
C061870_D005207 NONE <e1>rocuronium</e1> dose identified prevent <e2>fasciculation</e2>
C061870_D005207 NONE <e1>rocuronium</e1> influence evaluated prevent <e2>fasciculation</e2>
C061870_D005207 NONE <e1>rocuronium</e1> dose amount increasing less incidence <e2>fasciculation</e2>
C061870_D005207 NONE <e1>rocuronium</e1> precurarization dose considering reduction incidence <e2>fasciculation</e2>
C061870_D063806 NONE <e1>rocuronium</e1> dose decrease fasciculation <e2>myalgia</e2>
C061870_D063806 NONE <e1>rocuronium</e1> dose identified prevent fasciculation <e2>myalgia</e2>
C061870_D063806 NONE <e1>rocuronium</e1> influence evaluated prevent fasciculation <e2>myalgia</e2>
C061870_D063806 NONE <e1>rocuronium</e1> dose amount increasing decrease tend those <e2>myalgia</e2>
C061870_D063806 NONE <e1>rocuronium</e1> precurarization dose considering reduction incidence fasciculation <e2>myalgia</e2>
D013390_D005207 CID <e1>succinylcholine</e1> administration decrease <e2>fasciculation</e2>
D013390_D005207 CID <e1>succinylcholine</e1> produces effects <e2>fasciculation</e2>
D013390_D005207 CID <e1>succinylcholine-induced</e1> <e2>fasciculation</e2>
D013390_D005207 CID <e1>succinylcholine</e1> produced onset speed influence evaluated prevent <e2>fasciculation</e2>
D013390_D005207 CID <e1>succinylcholine</e1> mg/kg received assessed incidence severity <e2>fasciculations</e2>
D013390_D063806 CID <e1>succinylcholine</e1> administration decrease fasciculation <e2>myalgia</e2>
D013390_D063806 CID <e1>succinylcholine</e1> produces effects fasciculation <e2>myalgia</e2>
D013390_D063806 CID <e1>succinylcholine-induced</e1> fasciculation <e2>myalgia</e2>
D013390_D063806 CID <e1>succinylcholine</e1> produced onset speed influence evaluated prevent fasciculation <e2>myalgia</e2>
D013390_D063806 CID <e1>succinylcholine</e1> mg/kg received assessed assessed <e2>myalgia</e2>
8188982
D001127_D006973 CID <e1>avp</e1> effects normotensive rats <e2>hypertensive</e2>
D001127_D006973 CID <e1>vasopressin</e1> influence normotensive <e2>hypertensive</e2>
D001127_D006973 CID <e1>avp</e1> vasopressin influence normotensive <e2>hypertensive</e2>
D010656_D006973 CID <e1>phenylephrine</e1> <e2>hypertension</e2>
D010656_D006973 CID <e1>(phe)-induced</e1> <e2>hypertension</e2>
D010656_D007022 NONE <e1>phenylephrine</e1> hypertension <e2>hypotension</e2>
D010656_D007022 NONE <e1>(phe)-induced</e1> hypertension <e2>hypotension</e2>
D009599_D006973 NONE <e1>nitroprusside</e1> <e2>hypertension</e2>
D009599_D006973 NONE <e1>(sn)-induced</e1> hypotension <e2>hypertension</e2>
D009599_D007022 CID <e1>nitroprusside</e1> hypertension <e2>hypotension</e2>
D009599_D007022 CID <e1>(sn)-induced</e1> <e2>hypotension</e2>
D009599_D007022 CID <e1>sn-induced</e1> <e2>hypotension</e2>
D001127_D007022 NONE <e1>avp</e1> administration reduced <e2>hypotension</e2>
23892921
C467567_D009101 NONE <e1>lenalidomide</e1> efficacy patients <e2>myeloma</e2>
C467567_D009101 NONE <e1>lenalidomide</e1> efficacy data study group <e2>myeloma</e2>
C467567_D009101 NONE <e1>lenalidomide</e1> standard <e2>myeloma</e2>
C467567_D009101 NONE <e1>lenalidomide</e1> standard myeloma <e2>rrmm</e2>
C467567_D009101 NONE <e1>rd</e1> dexamethasone lenalidomide standard <e2>myeloma</e2>
C467567_D009101 NONE <e1>rd</e1> dexamethasone lenalidomide standard myeloma <e2>rrmm</e2>
C467567_D009101 NONE <e1>rd</e1> received patients <e2>rrmm</e2>
C467567_D009101 NONE <e1>rd</e1> effective safe <e2>rrmm</e2>
D003907_D009101 NONE <e1>dexamethasone</e1> lenalidomide efficacy patients <e2>myeloma</e2>
D003907_D009101 NONE <e1>dexamethasone</e1> lenalidomide efficacy data study group <e2>myeloma</e2>
D003907_D009101 NONE <e1>dexamethasone</e1> lenalidomide standard <e2>myeloma</e2>
D003907_D009101 NONE <e1>dexamethasone</e1> lenalidomide standard myeloma <e2>rrmm</e2>
D003907_D009101 NONE <e1>rd</e1> dexamethasone lenalidomide standard <e2>myeloma</e2>
D003907_D009101 NONE <e1>rd</e1> dexamethasone lenalidomide standard myeloma <e2>rrmm</e2>
D003907_D009101 NONE <e1>rd</e1> received patients <e2>rrmm</e2>
D003907_D009101 NONE <e1>rd</e1> effective safe <e2>rrmm</e2>
12359538
D003042_D002637 NONE <e1>cocaine-associated</e1> <e2>pain</e2>
D003042_D002637 NONE <e1>cocaine-associated</e1> <e2>pain</e2>
D003042_D002637 NONE <e1>cocaine</e1> <e2>pain</e2>
D003042_D002637 NONE <e1>cocaine-associated</e1> <e2>pain</e2>
D003042_D009202 NONE <e1>cocaine-associated</e1> pain patients difficult diagnosis make abnormalities associated <e2>necrosis</e2>
D003042_D009203 CID <e1>cocaine-associated</e1> pain patients difficult diagnosis <e2>infarction</e2>
D003042_D009203 CID <e1>cocaine-associated</e1> pain patients difficult diagnosis infarction <e2>mi</e2>
D003042_D009203 CID <e1>cocaine</e1> pain admitted exclusion <e2>mi</e2>
D003042_D009203 CID <e1>cocaine</e1> use admitted <e2>mi</e2>
D003042_D009203 CID <e1>cocaine-associated</e1> pain patients <e2>mi</e2>
D003042_D009336 NONE <e1>cocaine-associated</e1> pain patients <e2>necrosis</e2>
25080425
D001622_D009202 NONE <e1>betaine</e1> attenuates <e2>injury</e2>
D001622_D009202 NONE <e1>betaine</e1> role <e2>damage</e2>
D007545_D009202 NONE <e1>isoproterenol-induced</e1> <e2>injury</e2>
D001622_D017202 NONE <e1>betaine</e1> effects <e2>ischemia</e2>
D001622_D017202 NONE <e1>betaine</e1> pretreatment attenuated <e2>ischemia</e2>
D007545_D017202 CID <e1>isoproterenol</e1> injection induced <e2>injury</e2>
D007545_D017202 CID <e1>isoproterenol-induced</e1> <e2>ischemia</e2>
D001622_D020257 NONE <e1>betaine</e1> administration reduced prevented <e2>remodeling</e2>
15614572
D014196_D009062 NONE <e1>trazodone</e1> pretreatment effect dexamphetamine- <e2>stereotypies</e2>
D014196_D002375 NONE <e1>trazodone</e1> pretreatment effect <e2>catalepsy</e2>
D014196_D002375 NONE <e1>trazodone</e1> induces <e2>catalepsy</e2>
D014196_D002375 NONE <e1>trazodone</e1> induce <e2>catalepsy</e2>
D014196_D002375 NONE <e1>trazodone</e1> induce results <e2>catalepsy</e2>
D014196_D002375 NONE <e1>trazodone</e1> enhanced antagonized <e2>catalepsy</e2>
D014196_D002375 NONE <e1>trazodone</e1> induced <e2>catalepsy</e2>
D014196_D002375 NONE <e1>trazodone</e1> that releases potentiates antagonizes <e2>catalepsy</e2>
D003913_D009062 NONE <e1>dexamphetamine-</e1> <e2>stereotypies</e2>
D003913_D002375 NONE <e1>dexamphetamine-</e1> effect <e2>catalepsy</e2>
D003913_D002375 NONE <e1>dexamphetamine</e1> stereotypy enhanced antagonized <e2>catalepsy</e2>
D003913_D002375 NONE <e1>dexamphetamine</e1> apomorphine <e2>catalepsy</e2>
D003913_D002375 NONE <e1>dexamphetamine</e1> stereotypy potentiates antagonizes <e2>catalepsy</e2>
D001058_D009062 NONE <e1>apomorphine-induced</e1> dexamphetamine- <e2>stereotypies</e2>
D001058_D009062 NONE <e1>apomorphine</e1> haloperidol induced catalepsy effect dexamphetamine- <e2>stereotypies</e2>
D001058_D002375 CID <e1>apomorphine-induced</e1> dexamphetamine- effect <e2>catalepsy</e2>
D001058_D002375 CID <e1>apomorphine</e1> haloperidol induced <e2>catalepsy</e2>
D001058_D002375 CID <e1>apomorphine</e1> antagonize induce <e2>catalepsy</e2>
D001058_D002375 CID <e1>apomorphine</e1> antagonize induce results <e2>catalepsy</e2>
D001058_D002375 CID <e1>apomorphine</e1> stereotypy results induce <e2>catalepsy</e2>
D001058_D002375 CID <e1>apomorphine</e1> stereotypy results <e2>catalepsy</e2>
D001058_D002375 CID <e1>apomorphine</e1> <e2>catalepsy</e2>
D006220_D009062 NONE <e1>haloperidol</e1> induced catalepsy effect dexamphetamine- <e2>stereotypies</e2>
D006220_D002375 CID <e1>haloperidol</e1> induced <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> <e2>catalepsy</e2>
D004874_D009062 NONE <e1>ergometrine-induced</e1> shake effect dexamphetamine- <e2>stereotypies</e2>
D004874_D002375 NONE <e1>ergometrine-induced</e1> shake effect <e2>catalepsy</e2>
D004874_D002375 NONE <e1>ergometrine-induced</e1> behavior <e2>catalepsy</e2>
D005473_D009062 NONE <e1>fluoxetine-induced</e1> erections behavior shake effect dexamphetamine- <e2>stereotypies</e2>
D005473_D002375 NONE <e1>fluoxetine-induced</e1> erections behavior shake effect <e2>catalepsy</e2>
D005473_D002375 NONE <e1>fluoxetine-induced</e1> erections behavior <e2>catalepsy</e2>
D012701_D002375 NONE <e1>5-ht</e1> receptors blocking releases potentiates antagonizes <e2>catalepsy</e2>
D012701_D002375 NONE <e1>5-ht</e1> caused inhibition neurons releases potentiates antagonizes <e2>catalepsy</e2>
11425091
D003042_D007235 CID <e1>cocaine</e1> exposure <e2>infants</e2>
D003042_D007235 CID <e1>cocaine</e1> exposure increases incidence <e2>infants</e2>
D003042_D007235 CID <e1>cocaine</e1> exposed <e2>infants</e2>
D003042_D006470 NONE <e1>cocaine</e1> exposure linked <e2>hemorrhage</e2>
D003042_D003560 CID <e1>cocaine</e1> exposure linked hemorrhage formation <e2>cysts</e2>
D003042_D003560 CID <e1>cocaine</e1> exposure increases incidence <e2>cysts</e2>
D003042_D003560 CID <e1>cocaine</e1> exposed infants <e2>cysts</e2>
D003042_D003560 CID <e1>cocaine</e1> exposed infants formation <e2>cyst</e2>
D003042_D001927 CID <e1>cocaine</e1> exposure increases incidence <e2>cysts</e2>
D003042_D001927 CID <e1>cocaine</e1> exposed infants <e2>cysts</e2>
D003042_D001927 CID <e1>cocaine</e1> exposed infants formation <e2>cyst</e2>
D003042_D019970 NONE <e1>cocaine-exposed</e1> group assigned was history <e2>abuse</e2>
17954033
D019259_D019694 NONE <e1>lamivudine-untreated</e1> patients <e2>infection</e2>
D019259_D019694 NONE <e1>lamivudine</e1> used treatment patients <e2>b</e2>
D019259_D019694 NONE <e1>lamivudine-untreated</e1> patients <e2>b</e2>
D019259_D019694 NONE <e1>lamivudine-untreated</e1> patients <e2>b</e2>
D019259_D019694 NONE <e1>lamivudine</e1> treated patients <e2>b</e2>
D019259_D019694 NONE <e1>lamivudine-untreated</e1> patients <e2>b</e2>
D019259_D019694 NONE <e1>lamivudine-untreated</e1> patients mutants occurrence reported detected patients <e2>b</e2>
D019259_D019694 NONE <e1>lamivudine-untreated</e1> patients detected reported occurrence mutants patients <e2>b</e2>
D019259_D019694 NONE <e1>lamivudine-untreated</e1> patients <e2>b</e2>
D019259_D006509 NONE <e1>lamivudine-untreated</e1> patients variability occur mutants virus <e2>b</e2>
2484903
D011441_D056486 CID <e1>propylthiouracil-associated</e1> <e2>hepatitis</e2>
D011441_D056486 CID <e1>propylthiouracil-associated</e1> syndrome case case described cases <e2>hepatitis</e2>
D011441_D047508 NONE <e1>propylthiouracil-associated</e1> hepatitis cases described case <e2>necrosis</e2>
D011441_D047508 NONE <e1>propylthiouracil-associated</e1> syndrome case case <e2>necrosis</e2>
D011441_D008180 CID <e1>propylthiouracil-associated</e1> hepatitis cases described case case <e2>syndrome</e2>
D011441_D008180 CID <e1>propylthiouracil-associated</e1> <e2>syndrome</e2>
D008713_D056486 NONE <e1>methimazole-associated</e1> necrosis case described cases <e2>hepatitis</e2>
D008713_D047508 CID <e1>methimazole-associated</e1> <e2>necrosis</e2>
D008713_D008180 NONE <e1>methimazole-associated</e1> necrosis case case <e2>syndrome</e2>
17484470
D011433_D006333 CID <e1>propranolol</e1> induced <e2>failure</e2>
D011433_D008944 NONE <e1>propranolol</e1> induced confirmed absence <e2>mr</e2>
23535177
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesias disease <e2>pd</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> dyskinesias <e2>lids</e2>
6585590
D004317_D066126 NONE <e1>doxorubicin</e1> nephrotoxicity effect <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> induced nephrotoxicity activity <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin/kg</e1> dose observed evidence <e2>cardiotoxicity</e2>
D004317_D007674 NONE <e1>doxorubicin</e1> <e2>nephrotoxicity</e2>
D004317_D007674 NONE <e1>doxorubicin</e1> induced <e2>nephrotoxicity</e2>
D004317_D007674 NONE <e1>doxorubicin/kg</e1> dose seen evidence <e2>damage</e2>
D004317_-1 NONE <e1>doxorubicin</e1> nephrotoxicity effect rat <e2>immunocytoma-bearing</e2>
D004317_-1 NONE <e1>doxorubicin</e1> induced nephrotoxicity activity studied <e2>immunocytoma</e2>
D004317_D009369 NONE <e1>doxorubicin</e1> injections treated animals <e2>tumor</e2>
D004317_D009369 NONE <e1>doxorubicin/kg</e1> observed regression <e2>tumor</e2>
D004317_D009369 NONE <e1>doxorubicin/kg</e1> induced disappearance <e2>tumor</e2>
D004317_D000419 CID <e1>doxorubicin/kg</e1> dose resulted <e2>albuminuria</e2>
2650911
D004967_D002292 NONE <e1>estrogen</e1> sites evidence induced <e2>carcinomas</e2>
D004967_D002292 NONE <e1>estrogen</e1> sites demonstrated transplantable <e2>carcinomas</e2>
D004967_D002292 NONE <e1>estrogen</e1> binding nuclei cells <e2>carcinomas</e2>
D004967_D002292 NONE <e1>estrogen</e1> induced <e2>carcinomas</e2>
D004054_D002292 CID <e1>diethylstilbesterol</e1> nuclei sites evidence induced <e2>carcinomas</e2>
D004054_D002292 CID <e1>diethylstilbesterol</e1> transplantable <e2>carcinomas</e2>
D004958_D009369 NONE <e1>estradiol</e1> injection radiolabelling increased nuclei cells <e2>tumor</e2>
D012834_D009369 NONE <e1>silver</e1> grains concentration revealed increased nuclei cells <e2>tumor</e2>
17297207
D011803_D001145 NONE <e1>quinine-induced</e1> <e2>arrhythmia</e2>
D011803_D001145 NONE <e1>quinine</e1> infusion reported getting presented <e2>arrhythmia</e2>
D011803_D001145 NONE <e1>quinine</e1> alkaloid has property <e2>anti-arrhythmic</e2>
D011803_D001145 NONE <e1>quinine</e1> alkaloid cause <e2>pro-arrhythmic</e2>
D011803_D001145 NONE <e1>quinine</e1> alkaloid cause <e2>arrhythmias</e2>
D011803_D001145 NONE <e1>quinine</e1> alkaloid cause arrhythmias <e2>arrhythmia</e2>
D011803_D001145 NONE <e1>quinine</e1> administration done effect <e2>pro-arrhythmic</e2>
D011803_D016778 NONE <e1>quinine-induced</e1> arrhythmia patient <e2>malaria</e2>
D011803_D016778 NONE <e1>quinine</e1> infusion reported getting presented patient <e2>malaria</e2>
D011803_D016778 NONE <e1>quinine</e1> infusion got diagnosed <e2>malaria</e2>
D011803_D007565 NONE <e1>quinine</e1> infusion reported getting presented patient <e2>jaundice</e2>
D011803_D007565 NONE <e1>quinine</e1> infusion got diagnosed <e2>jaundice</e2>
D011803_D018879 CID <e1>quinine</e1> infusion reported getting presented arrhythmia <e2>contraction</e2>
D011803_D018879 CID <e1>quinine</e1> infusion hours felt showed <e2>contraction</e2>
D011803_D018879 CID <e1>quinine</e1> infusion hours felt showed contraction <e2>pvc</e2>
D011803_D018879 CID <e1>quinine</e1> alkaloid cause arrhythmias arrhythmia <e2>pvc</e2>
D001663_D016778 NONE <e1>bilirubin</e1> showed diagnosed <e2>malaria</e2>
D001663_D016778 NONE <e1>bilirubin</e1> bilirubin showed diagnosed <e2>malaria</e2>
D001663_D016778 NONE <e1>bilirubin</e1> bilirubin showed diagnosed <e2>malaria</e2>
D001663_D007565 NONE <e1>bilirubin</e1> showed diagnosed <e2>jaundice</e2>
D001663_D007565 NONE <e1>bilirubin</e1> bilirubin showed diagnosed <e2>jaundice</e2>
D001663_D007565 NONE <e1>bilirubin</e1> bilirubin showed diagnosed <e2>jaundice</e2>
D011188_D016778 NONE <e1>potassium</e1> patient diagnosed <e2>malaria</e2>
D011188_D007565 NONE <e1>potassium</e1> patient diagnosed <e2>jaundice</e2>
D005947_D016778 NONE <e1>dextrose</e1> hour got diagnosed <e2>malaria</e2>
D005947_D007565 NONE <e1>dextrose</e1> hour got diagnosed <e2>jaundice</e2>
D011803_-1 NONE <e1>quinine</e1> infusion hours felt <e2>palpitation</e2>
D011803_D012848 NONE <e1>quinine</e1> infusion hours felt showed > <e2>block</e2>
D011188_D018879 NONE <e1>potassium</e1> level meq/l. reduced frequency <e2>pvc</e2>
D011802_D001145 NONE <e1>quinidine</e1> alkaloid has property <e2>anti-arrhythmic</e2>
D011802_D001145 NONE <e1>quinidine</e1> alkaloid cause <e2>pro-arrhythmic</e2>
D011802_D001145 NONE <e1>quinidine</e1> alkaloid cause <e2>arrhythmias</e2>
D011802_D001145 NONE <e1>quinidine</e1> alkaloid cause arrhythmias <e2>arrhythmia</e2>
D011802_D018879 NONE <e1>quinidine</e1> alkaloid cause arrhythmias arrhythmia <e2>pvc</e2>
D011803_D006331 NONE <e1>quinine</e1> administration done effect patients have <e2>diseases</e2>
D011803_D014883 NONE <e1>quinine</e1> administration done effect patients have diseases patients <e2>disorder</e2>
D011803_D007008 NONE <e1>quinine</e1> administration done effect patients have diseases patients disorder <e2>hypokalemia</e2>
D011803_D014839 NONE <e1>quinine</e1> administration done effect patients have diseases occurs <e2>vomiting</e2>
D011803_D003967 NONE <e1>quinine</e1> administration done effect patients have diseases occurs vomiting <e2>diarrhea</e2>
D011803_D008288 NONE <e1>quinine</e1> administration done effect patients have diseases occurs vomiting cases <e2>malaria</e2>
3084231
D014635_D003704 CID <e1>acid-induced</e1> <e2>dementia</e2>
D014635_D003704 CID <e1>acid-induced</e1> <e2>dementia</e2>
D014635_D004827 NONE <e1>acid-induced</e1> dementia documented man <e2>epilepsy</e2>
D014635_D022124 CID <e1>acid</e1> effect effect mediated <e2>hyperammonemia</e2>
D014635_D022124 CID <e1>acid-induced</e1> <e2>hyperammonemia</e2>
2083961
D012293_D058186 CID <e1>rifampicin</e1> <e2>failure</e2>
D012293_D009325 NONE <e1>rifampicin</e1> administered time developed effects <e2>nausea</e2>
D012293_D014839 NONE <e1>rifampicin</e1> administered time developed effects nausea <e2>vomiting</e2>
D012293_D005334 NONE <e1>rifampicin</e1> administered time developed effects nausea vomiting <e2>fever</e2>
23949582
D015080_D030342 NONE <e1>mesna</e1> reduces <e2>genotoxicity</e2>
D007069_D030342 NONE <e1>ifo</e1> <e2>genotoxicity</e2>
19154241
D008094_D006961 CID <e1>lithium</e1> therapy leading <e2>hyperparathyroidism</e2>
D008094_D006934 CID <e1>lithium-treated</e1> patient had <e2>hypercalcemia</e2>
D008094_D006934 CID <e1>lithium-treated</e1> patients % implications become <e2>hypercalcemic</e2>
D008094_D049950 NONE <e1>lithium</e1> therapy effect <e2>hyperparathyroidism</e2>
8318674
D003561_D011654 CID <e1>aracytine-c</e1> <e2>edema</e2>
D003561_D012769 CID <e1>aracytine-c</e1> edema <e2>shock</e2>
D003561_D012769 CID <e1>ara-c</e1> associated hypothesize thought involved development <e2>shock</e2>
D003561_D008223 NONE <e1>aracytine-c</e1> <e2>lymphoma</e2>
D003561_D008223 NONE <e1>ara-c</e1> <e2>lymphomas</e2>
D003561_D012128 NONE <e1>ara-c</e1> associated hypothesize thought involved development shock <e2>syndrome</e2>
19338378
C031942_D013921 NONE <e1>argatroban</e1> therapy considerations <e2>thrombocytopenia</e2>
C031942_D013921 NONE <e1>argatroban</e1> inhibitor used prophylaxis <e2>thrombocytopenia</e2>
C031942_D013921 NONE <e1>argatroban</e1> inhibitor used prophylaxis thrombocytopenia <e2>hit</e2>
C031942_D013921 NONE <e1>argatroban</e1> inhibitor used prophylaxis patients risk <e2>hit</e2>
C031942_D013921 NONE <e1>argatroban</e1> therapy considerations <e2>hit</e2>
C031942_D013921 NONE <e1>argatroban</e1> dose <e2>hit</e2>
C031942_D013921 NONE <e1>argatroban</e1> therapy <e2>hit</e2>
C031942_D013921 NONE <e1>argatroban</e1> therapy professionals familiarity facilitate reduction harm associated <e2>hit</e2>
C031942_D013921 NONE <e1>argatroban</e1> medication errors treatment reduction facilitate familiarity professionals therapy <e2>hit</e2>
C031942_D013921 NONE <e1>argatroban</e1> medication errors treatment reduction harm associated <e2>hit</e2>
D006493_D013921 NONE <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 NONE <e1>heparin-induced</e1> <e2>thrombocytopenia</e2>
D006493_D013921 NONE <e1>heparin-induced</e1> thrombocytopenia <e2>hit</e2>
D006493_D013921 NONE <e1>heparin-induced</e1> thrombocytopenia prophylaxis patients risk <e2>hit</e2>
C031942_D013927 NONE <e1>argatroban</e1> inhibitor used prophylaxis <e2>thrombosis</e2>
D006493_D013927 NONE <e1>heparin-induced</e1> thrombocytopenia prophylaxis <e2>thrombosis</e2>
C031942_D008107 NONE <e1>argatroban</e1> dose microg/kg/min reduced patients <e2>impairment</e2>
C031942_D009765 NONE <e1>argatroban</e1> microg/kg/min investigated unnecessary age race/ethnicity <e2>obesity</e2>
C031942_D006470 CID <e1>argatroban</e1> <e2>bleeding</e2>
12948256
D004977_D009901 CID <e1>ethambutol</e1> <e2>neuropathy</e2>
D004977_D009901 CID <e1>ethambutol</e1> association <e2>neuropathy</e2>
D004977_D009901 CID <e1>ethambutol</e1> treated <e2>neuropathy</e2>
D004977_D009901 CID <e1>ethambutol</e1> therapy starting had <e2>neuropathy</e2>
D004977_D009901 CID <e1>ethambutol</e1> therapy patients considered recognition <e2>neuropathy</e2>
D004977_D014397 NONE <e1>ethambutol</e1> treated tuberculosis lung <e2>node</e2>
D004977_D014388 NONE <e1>ethambutol</e1> treated tuberculosis lung <e2>node</e2>
8312343
D004317_D002311 NONE <e1>doxorubicin</e1> cardiomyopathy <e2>cardiomyopathy</e2>
D004317_D006331 NONE <e1>doxorubicin</e1> cardiomyopathy cardiomyopathy <e2>disease</e2>
D004317_D002312 NONE <e1>doxorubicin</e1> cardiomyopathy cardiomyopathy disease <e2>cardiomyopathy</e2>
D004317_D006349 NONE <e1>doxorubicin</e1> cardiomyopathy cardiomyopathy disease <e2>disease</e2>
D004317_D009202 CID <e1>doxorubicin</e1> <e2>cardiomyopathy</e2>
D015774_D003586 NONE <e1>ganciclovir</e1> treated <e2>infections</e2>
11401944
D013015_D016171 CID <e1>dl-sotalol</e1> induced prolongation initiate torsade <e2>pointes</e2>
D013015_D016171 CID <e1>dl-sotalol</e1> induced prolongation initiate torsade <e2>tdp</e2>
D013015_D016171 CID <e1>dl-sotalol</e1> increase facilitated propagation initiated episodes <e2>tdp</e2>
D013015_D008133 CID <e1>dl-sotalol</e1> induced <e2>prolongation</e2>
D013015_D008133 CID <e1>dl-sotalol</e1> prolonged leading <e2>prolongation</e2>
D013015_D008133 CID <e1>dl-sotalol</e1> induced produced rabbits seen <e2>prolongation</e2>
C086123_D016171 NONE <e1>azimilide</e1> dl-sotalol induced prolongation initiate torsade <e2>pointes</e2>
C086123_D016171 NONE <e1>azimilide</e1> dl-sotalol induced prolongation initiate torsade <e2>tdp</e2>
C086123_D008133 NONE <e1>azimilide</e1> dl-sotalol induced <e2>prolongation</e2>
C086123_D008133 NONE <e1>azimilide</e1> dl-sotalol induced produced rabbits seen <e2>prolongation</e2>
6517710
D011796_D003328 CID <e1>hydrochloride</e1> ingesting rats heart involving <e2>thrombosis</e2>
D011796_D003328 CID <e1>hydrochloride</e1> treated rats developed incidence <e2>thrombosis</e2>
D011796_D003328 CID <e1>hydrochloride</e1> nitrite had have <e2>thrombosis</e2>
D011796_D013927 NONE <e1>hydrochloride</e1> nitrite had <e2>thrombosis</e2>
D012977_D013927 NONE <e1>nitrite</e1> had <e2>thrombosis</e2>
D012977_D003328 NONE <e1>nitrite</e1> had have <e2>thrombosis</e2>
7661171
D016595_D007674 NONE <e1>misoprostol</e1> <e2>dysfunction</e2>
D016595_D007674 NONE <e1>misoprostol</e1> shown counteract <e2>dysfunction</e2>
D016595_D005355 NONE <e1>misoprostol</e1> effect <e2>cirrhosis</e2>
D016595_D005355 NONE <e1>misoprostol</e1> shown counteract dysfunction patients <e2>cirrhotic</e2>
D016595_D005355 NONE <e1>misoprostol</e1> doses mg combination assessed techniques patients <e2>cirrhotic</e2>
D016595_D005355 NONE <e1>misoprostol</e1> micrograms ability confirmed prudent avoid therapy patients <e2>cirrhosis</e2>
D007213_D007674 CID <e1>indomethacin-induced</e1> <e2>dysfunction</e2>
D007213_D007674 CID <e1>indomethacin-induced</e1> <e2>dysfunction</e2>
D007213_D005355 NONE <e1>indomethacin-induced</e1> dysfunction misoprostol effect <e2>cirrhosis</e2>
D007213_D005355 NONE <e1>indomethacin-induced</e1> dysfunction patients <e2>cirrhotic</e2>
D007213_D005355 NONE <e1>indomethacin</e1> mg combination assessed techniques patients <e2>cirrhotic</e2>
D007213_D005355 NONE <e1>indomethacin</e1> effects prevent ability confirmed prudent avoid therapy patients <e2>cirrhosis</e2>
D012964_D005355 NONE <e1>sodium</e1> parameters assessed techniques patients <e2>cirrhotic</e2>
11385188
D003042_D006331 NONE <e1>cocaine</e1> users prevalence <e2>disease</e2>
D003042_D006331 NONE <e1>cocaine</e1> users prevalence <e2>disease</e2>
D003042_D006331 NONE <e1>cocaine</e1> users prevalence <e2>disease</e2>
D003042_D003324 CID <e1>cocaine</e1> users common artery <e2>disease</e2>
D003042_D009202 CID <e1>cocaine</e1> users common artery <e2>disease</e2>
24091473
D004837_D066126 NONE <e1>epinephrine</e1> lipid <e2>toxicity</e2>
C476513_D066126 NONE <e1>levobupivacaine-induced</e1> <e2>toxicity</e2>
D004837_D064420 NONE <e1>epinephrine</e1> emulsion regimens determined neonates cases <e2>toxicity</e2>
C476513_D002318 CID <e1>levobupivacaine</e1> received occurred <e2>collapse</e2>
16911931
D019259_D006509 NONE <e1>lamivudine</e1> combined globulin <e2>b</e2>
D019259_D006509 NONE <e1>lamivudine</e1> combined prevention recurrence <e2>b</e2>
D019259_D006509 NONE <e1>lamivudine</e1> globulin <e2>b</e2>
D019259_D006509 NONE <e1>lamivudine</e1> prophylaxis recurrence <e2>b</e2>
D006514_D006509 NONE <e1>hbsag</e1> patients survival improved globulin <e2>b</e2>
D006514_D006509 NONE <e1>hbsag</e1> patients survival improved globulin lamivudine prophylaxis recurrence <e2>b</e2>
20034406
D010862_D013226 CID <e1>pilocarpine-induced</e1> <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine</e1> injection induced <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine</e1> injection induced epilepticus <e2>se</e2>
D010862_D013226 CID <e1>pilocarpine</e1> injection induced <e2>se</e2>
D010862_D013226 CID <e1>pilocarpine-induced</e1> <e2>se</e2>
6985297
D015764_D001919 CID <e1>bepridil</e1> induced <e2>bradycardia</e2>
D015764_D001919 CID <e1>bepridil</e1> induced <e2>bradycardia</e2>
D015764_D000787 NONE <e1>bepridil</e1> compound treatment <e2>attacks</e2>
D015764_D013610 NONE <e1>bepridil</e1> induced bradycardia effect <e2>anti-tachycardial</e2>
7949506
D003000_D054537 CID <e1>clonidine</e1> interaction cases report resulting <e2>block</e2>
D003000_D054537 CID <e1>clonidine</e1> dose addition developed <e2>block</e2>
D003000_D054537 CID <e1>clonidine</e1> mg bid addition developed <e2>block</e2>
D003000_D007022 CID <e1>clonidine</e1> interaction cases report resulting block patients <e2>hypotension</e2>
D003000_D007022 CID <e1>clonidine</e1> dose addition developed block <e2>hypotension</e2>
D014700_D054537 CID <e1>verapamil</e1> clonidine interaction cases report resulting <e2>block</e2>
D014700_D054537 CID <e1>verapamil</e1> extended-release treated developed <e2>block</e2>
D014700_D007022 CID <e1>verapamil</e1> clonidine interaction cases report resulting block patients <e2>hypotension</e2>
D014700_D007022 CID <e1>verapamil</e1> extended-release treated developed block <e2>hypotension</e2>
D014700_D006929 NONE <e1>verapamil</e1> treated woman <e2>hyperaldosteronism</e2>
D013148_D006929 NONE <e1>spironolactone</e1> treated woman <e2>hyperaldosteronism</e2>
11135381
D008729_D014550 NONE <e1>methoxamine</e1> effect pressure women <e2>incontinence</e2>
D008729_D014550 NONE <e1>methoxamine</e1> doses log administered group women <e2>incontinence</e2>
D008729_D006973 CID <e1>methoxamine</e1> evoked caused rise <e2>pressure</e2>
3191389
D010862_D012640 CID <e1>pilocarpine</e1> produced <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> induces <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> produced <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> produced <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> induced damage rats protected prevented <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine</e1> induced damage <e2>seizure-related</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>seizures</e2>
D010862_D013226 CID <e1>pilocarpine</e1> induces seizures <e2>epilepticus</e2>
D012980_D012640 CID <e1>salicylate</e1> drugs effect <e2>seizures</e2>
D010653_D012640 CID <e1>phenylbutazone</e1> drugs effect <e2>seizures</e2>
D007213_D012640 NONE <e1>indomethacin</e1> phenylbutazone drugs effect <e2>seizures</e2>
D007213_D012640 NONE <e1>indomethacin</e1> failed modulate <e2>seizures</e2>
D007052_D012640 NONE <e1>ibuprofen</e1> acid phenylbutazone drugs effect <e2>seizures</e2>
D007052_D012640 NONE <e1>ibuprofen</e1> indomethacin failed modulate <e2>seizures</e2>
D008528_D012640 NONE <e1>acid</e1> phenylbutazone drugs effect <e2>seizures</e2>
D008528_D012640 NONE <e1>acid</e1> mg/kg prevented <e2>seizures</e2>
D008528_D012640 NONE <e1>acid</e1> mg/kg prevented protected rats damage <e2>seizure-related</e2>
D008528_D001930 NONE <e1>acid</e1> mg/kg prevented protected rats <e2>damage</e2>
D010862_D001930 NONE <e1>pilocarpine</e1> induced <e2>damage</e2>
7147232
D000255_D007022 CID <e1>triphosphate</e1> induced <e2>hypotension</e2>
D000255_D007022 CID <e1>triphosphate</e1> administered induce <e2>hypotension</e2>
D000255_D007022 CID <e1>atp</e1> triphosphate administered induce <e2>hypotension</e2>
D000255_D007022 CID <e1>atp</e1> induced <e2>hypotension</e2>
D000255_D007022 CID <e1>atp</e1> stopped returned accompanied <e2>hypotension</e2>
D009599_D007022 CID <e1>nitroprusside</e1> triphosphate induced <e2>hypotension</e2>
D009599_D007022 CID <e1>nitroprusside</e1> triphosphate administered induce <e2>hypotension</e2>
D009599_D007022 CID <e1>snp</e1> nitroprusside triphosphate administered induce <e2>hypotension</e2>
D009599_D007022 CID <e1>snp</e1> decreases produced <e2>hypotension</e2>
D010100_D007022 NONE <e1>oxygen</e1> consumption resistance accompanied <e2>hypotension</e2>
D010100_D007022 NONE <e1>oxygen</e1> difference resistance observed <e2>hypotension</e2>
24665854
D014635_D022124 CID <e1>valproate-induced</e1> encephalopathy <e2>hyperammonemic</e2>
D014635_D022124 CID <e1>valproate-induced</e1> encephalopathy <e2>hyperammonemic</e2>
D014635_D022124 CID <e1>valproate</e1> treatment effect encephalopathy <e2>hyperammonemic</e2>
D014635_D022124 CID <e1>valproate</e1> therapy girl case describe revealed consciousness <e2>hyperammonemia</e2>
D014635_D001927 NONE <e1>valproate-induced</e1> <e2>encephalopathy</e2>
D014635_D001927 NONE <e1>valproate-induced</e1> <e2>encephalopathy</e2>
D014635_D001927 NONE <e1>valproate</e1> treatment effect <e2>encephalopathy</e2>
D014635_D004827 NONE <e1>valproate</e1> therapy <e2>epilepsy</e2>
D014635_D003244 CID <e1>valproate</e1> therapy girl case describe revealed <e2>consciousness</e2>
8603459
D004317_D066126 CID <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2>
D004317_D006984 NONE <e1>doxorubicin-treated</e1> animals hearts sacrifice enlarged <e2>hypertrophic</e2>
D064730_D064420 NONE <e1>icrf-187</e1> protection determined exerted <e2>toxicity</e2>
D064730_D064420 NONE <e1>icrf-187</e1> protection determined using schedule <e2>toxicity</e2>
D004317_D064420 NONE <e1>doxorubicin</e1> doses toxicity schedule using determined exerted <e2>toxicity</e2>
D004317_D064420 NONE <e1>doxorubicin</e1> doses <e2>toxicity</e2>
D064730_D066126 NONE <e1>icrf-187</e1> provided protection demonstrated allows testing protectors <e2>cardiotoxicity</e2>
21195121
D009569_D012640 NONE <e1>oxide</e1> role <e2>convulsions</e2>
D009569_D012640 NONE <e1>no</e1> plays model <e2>seizures</e2>
D001556_D012640 CID <e1>lindane</e1> induced <e2>convulsions</e2>
D001556_D012640 CID <e1>lindane</e1> dose elicited convulsion shortened increased incidence <e2>convulsion</e2>
D001556_D012640 CID <e1>lindane</e1> dose elicited <e2>convulsion</e2>
D001556_D012640 CID <e1>lindane</e1> dose injection incidence <e2>convulsion</e2>
D001556_D012640 CID <e1>lindane</e1> dose injection incidence <e2>convulsion</e2>
D001556_D012640 CID <e1>lindane</e1> dose <e2>convulsive</e2>
D001556_D012640 CID <e1>lindane</e1> <e2>seizures</e2>
D005680_D012640 NONE <e1>gaba(a</e1> receptors blockage trough <e2>convulsions</e2>
D009569_D004827 NONE <e1>oxide</e1> has effects l-name observed models <e2>epilepsy</e2>
D009569_D004827 NONE <e1>no</e1> oxide has effects l-name observed models <e2>epilepsy</e2>
D009569_D004827 NONE <e1>no</e1> precursor l-arginine effects l-name observed models <e2>epilepsy</e2>
D009569_D004827 NONE <e1>no</e1> effects characteristics <e2>epilepsy</e2>
D001120_D004827 NONE <e1>l-arginine</e1> effects l-name observed models <e2>epilepsy</e2>
D019331_D004827 NONE <e1>l-name</e1> observed models <e2>epilepsy</e2>
D001556_D004827 NONE <e1>lindane-induced</e1> <e2>epilepsy</e2>
D001120_D012640 NONE <e1>l-arginine</e1> administration increased incidence <e2>convulsion</e2>
D001120_D012640 NONE <e1>l-arginine</e1> administration increased shortened <e2>convulsion</e2>
D019331_D012640 NONE <e1>l-name</e1> pretreatment decreased incidence <e2>convulsion</e2>
D019331_D012640 NONE <e1>l-name</e1> pretreatment decreased incidence <e2>convulsion</e2>
D019331_D012640 NONE <e1>l-name</e1> pretreatment decreased incidence injection dose <e2>convulsive</e2>
3864191
D012459_D007674 NONE <e1>salicylate</e1> <e2>nephropathy</e2>
D011453_D007674 NONE <e1>prostaglandins</e1> role <e2>nephropathy</e2>
D011453_D007674 NONE <e1>prostaglandins</e1> role development <e2>nephropathy</e2>
D011453_D007674 NONE <e1>prostaglandin</e1> synthesis changes accompanied evidence <e2>damage</e2>
D011453_D007674 NONE <e1>prostaglandin</e1> synthesis contributes lead lesions deterioration <e2>function</e2>
D011453_D007674 NONE <e1>prostaglandin</e1> synthesis inhibition lead lesions deterioration <e2>function</e2>
-1_D006932 NONE <e1>glucuronyl</e1> transferase absence unconjugated <e2>hyperbilirubinemia</e2>
D001663_D006932 NONE <e1>bilirubin</e1> deposition leading unconjugated <e2>hyperbilirubinemia</e2>
D011453_D006417 NONE <e1>prostaglandin</e1> synthesis changes accompanied incidence severity <e2>hematuria</e2>
D001241_D007674 CID <e1>aspirin-treated</e1> jj <e2>damage</e2>
D001241_D007674 CID <e1>aspirin-treated</e1> jj jj compared p accompanied evidence <e2>damage</e2>
D001241_D006417 NONE <e1>aspirin-treated</e1> jj damage evidence accompanied incidence severity <e2>hematuria</e2>
D001241_D006417 NONE <e1>aspirin-treated</e1> jj jj compared p accompanied incidence severity <e2>hematuria</e2>
D003404_D007674 NONE <e1>creatinine</e1> accompanied evidence <e2>damage</e2>
D003404_D006417 NONE <e1>creatinine</e1> accompanied incidence severity <e2>hematuria</e2>
D011453_D058186 NONE <e1>prostaglandin</e1> synthesis contributes lead <e2>lesions</e2>
D011453_D058186 NONE <e1>prostaglandin</e1> synthesis inhibition lead <e2>lesions</e2>
15815446
D010656_D002545 NONE <e1>phenylephrine-induced</e1> hypertension effect <e2>ischemia</e2>
D010656_D006973 CID <e1>phenylephrine-induced</e1> <e2>hypertension</e2>
D010656_D006973 CID <e1>phenylephrine-induced</e1> hypertension effect determined min occlusion rats <e2>hypertensive</e2>
D010656_D006973 CID <e1>phenylephrine-induced</e1> <e2>hypertension</e2>
D010656_D020244 NONE <e1>phenylephrine-induced</e1> hypertension effect determined min <e2>occlusion</e2>
D010656_D001930 NONE <e1>phenylephrine-induced</e1> hypertension effect <e2>injury</e2>
C009591_D001930 NONE <e1>chloride</e1> using evaluated a rats <e2>injury</e2>
C009591_D004487 NONE <e1>chloride</e1> <e2>edema</e2>
D005070_D006973 NONE <e1>blue</e1> greater group <e2>90/htn</e2>
D005070_D006973 NONE <e1>blue</e1> greater group greater group <e2>15/htn</e2>
15276093
C451780_D006937 NONE <e1>extended-release/lovastatin</e1> product approved treatment <e2>hypercholesterolemia</e2>
C451780_D050171 NONE <e1>extended-release/lovastatin</e1> product approved treatment hypercholesterolemia <e2>dyslipidemia</e2>
C451780_D050171 NONE <e1>extended-release/lovastatin</e1> <e2>dyslipidemia</e2>
D003401_D009135 NONE <e1>creatine</e1> phosphokinase increase occurred observed cases <e2>myopathy</e2>
7479194
D015662_D064420 NONE <e1>trimethoprim-sulfamethoxazole</e1> study <e2>toxicity</e2>
D014295_D064420 NONE <e1>trimethoprim</e1> study <e2>toxicity</e2>
D002506_D064420 NONE <e1>cephalexin</e1> trimethoprim study <e2>toxicity</e2>
D015662_D008107 CID <e1>tmp-smz</e1> prescribed persons similar risk <e2>disease</e2>
D015662_D008107 NONE <e1>trimethoprim-sulfamethoxazole</e1> prescribed people study conducted estimate risk <e2>disorders</e2>
D015662_D008107 NONE <e1>tmp-smz</e1> people study conducted estimate risk <e2>disorders</e2>
D015662_D006402 NONE <e1>trimethoprim-sulfamethoxazole</e1> prescribed people study conducted estimate risk <e2>disorders</e2>
D015662_D006402 NONE <e1>tmp-smz</e1> people study conducted estimate risk <e2>disorders</e2>
D015662_D012871 NONE <e1>trimethoprim-sulfamethoxazole</e1> prescribed people study conducted estimate risk <e2>disorders</e2>
D015662_D012871 NONE <e1>tmp-smz</e1> people study conducted estimate risk <e2>disorders</e2>
D015662_D007674 NONE <e1>trimethoprim-sulfamethoxazole</e1> prescribed people study conducted estimate risk <e2>disorders</e2>
D015662_D007674 NONE <e1>tmp-smz</e1> people study conducted estimate risk <e2>disorders</e2>
D014295_D008107 CID <e1>trimethoprim</e1> persons similar risk <e2>disease</e2>
D014295_D008107 NONE <e1>trimethoprim</e1> people study conducted estimate risk <e2>disorders</e2>
D014295_D006402 NONE <e1>trimethoprim</e1> people study conducted estimate risk <e2>disorders</e2>
D014295_D012871 NONE <e1>trimethoprim</e1> people study conducted estimate risk <e2>disorders</e2>
D014295_D007674 NONE <e1>trimethoprim</e1> people study conducted estimate risk <e2>disorders</e2>
D002506_D008107 NONE <e1>cephalexin</e1> trimethoprim people study conducted estimate risk <e2>disorders</e2>
D002506_D006402 NONE <e1>cephalexin</e1> trimethoprim people study conducted estimate risk <e2>disorders</e2>
D002506_D012871 NONE <e1>cephalexin</e1> trimethoprim people study conducted estimate risk <e2>disorders</e2>
D002506_D007674 NONE <e1>cephalexin</e1> trimethoprim people study conducted estimate risk <e2>disorders</e2>
D015662_D004892 NONE <e1>tmp-smz</e1> exposed disorders experienced <e2>multiforme</e2>
D015662_D004892 NONE <e1>tmp-smz</e1> exposed experienced <e2>multiforme</e2>
D015662_D013262 CID <e1>tmp-smz</e1> exposed disorders experienced multiforme <e2>syndrome</e2>
D015662_D013262 CID <e1>tmp-smz</e1> exposed experienced multiforme <e2>syndrome</e2>
D002506_D013262 CID <e1>cephalexin</e1> took patient occurred case <e2>necrolysis</e2>
8511251
D003042_D017202 CID <e1>cocaine</e1> induced <e2>ischemia</e2>
D003042_D017202 CID <e1>cocaine</e1> induced <e2>ischemia</e2>
D005996_D007511 NONE <e1>nitroglycerin</e1> reversed <e2>ischemia</e2>
D005996_D003329 NONE <e1>nitroglycerin</e1> reversed ischemia induced <e2>spasm</e2>
D002118_D007511 NONE <e1>calcium</e1> blocking agents nitroglycerin reversed <e2>ischemia</e2>
D002118_D003329 NONE <e1>calcium</e1> blocking agents nitroglycerin reversed ischemia induced <e2>spasm</e2>
19447152
D010042_D001714 CID <e1>ouabain</e1> induced <e2>mania</e2>
D010042_D001714 CID <e1>ouabain</e1> administration suggested mimic symptoms <e2>mania</e2>
D010042_D001714 CID <e1>ouabain-induced</e1> behavior <e2>mania-like</e2>
D010042_D001714 CID <e1>ouabain-induced</e1> behavior provide model test hypothesis involvement stress <e2>disorder</e2>
D012964_D001714 NONE <e1>na(+)/k(+)-atpase</e1> inhibitor ouabain administration suggested mimic symptoms <e2>mania</e2>
D011188_D001714 NONE <e1>na(+)/k(+)-atpase</e1> inhibitor ouabain administration suggested mimic symptoms <e2>mania</e2>
D010042_D009069 NONE <e1>ouabain</e1> induced <e2>hyperlocomotion</e2>
733189
D000305_D015356 NONE <e1>corticosteroid</e1> suspensions injection <e2>occlusion</e2>
C000873_D015356 CID <e1>acetate</e1> cases <e2>occlusions</e2>
C000873_D001766 NONE <e1>acetate</e1> cases occlusions <e2>blindness</e2>
D008012_D015356 NONE <e1>lidocaine</e1> combination acetate cases <e2>occlusions</e2>
D008012_D001766 NONE <e1>lidocaine</e1> combination acetate cases occlusions <e2>blindness</e2>
D004837_D015356 NONE <e1>epinephrine</e1> lidocaine combination acetate cases <e2>occlusions</e2>
D004837_D001766 NONE <e1>epinephrine</e1> lidocaine combination acetate cases occlusions <e2>blindness</e2>
D010406_D015356 NONE <e1>penicillin</e1> reported cases <e2>occlusions</e2>
D010406_D001766 NONE <e1>penicillin</e1> reported cases occlusions <e2>blindness</e2>
20566328
D003042_D028361 NONE <e1>cocaine-induced</e1> dysfunction contributes <e2>impairment</e2>
D003042_D028361 NONE <e1>cocaine</e1> exposure detectable suggesting late <e2>abnormalities</e2>
D003042_D028361 NONE <e1>cocaine</e1> response event late <e2>abnormalities</e2>
D003042_D028361 NONE <e1>cocaine-induced</e1> dysfunction <e2>defect</e2>
D003042_D006331 CID <e1>cocaine-induced</e1> <e2>dysfunction</e2>
D003042_D006331 CID <e1>cocaine-induced</e1> <e2>dysfunction</e2>
D003042_D006331 CID <e1>cocaine-induced</e1> <e2>dysfunction</e2>
C476756_D028361 NONE <e1>mitoq.</e1> prevention contributes <e2>impairment</e2>
C476756_D028361 NONE <e1>mitoq</e1> shown prevent <e2>abnormalities</e2>
C476756_D006331 NONE <e1>mitoq.</e1> prevention contributes <e2>dysfunction</e2>
C476756_D006331 NONE <e1>mitoq</e1> shown prevent <e2>dysfunction</e2>
C476756_-1 NONE <e1>mitoq</e1> shown prevent dysfunction characterized <e2>dysfunction</e2>
8308951
D014859_D002543 CID <e1>warfarin-like</e1> anticoagulant exposure causing <e2>hemorrhage</e2>
D014859_D006406 NONE <e1>warfarin-induced</e1> coagulopathy case <e2>hematoma</e2>
D014859_D001778 NONE <e1>warfarin-induced</e1> <e2>coagulopathy</e2>
D014859_D001778 NONE <e1>warfarin</e1> absorption causing <e2>coagulopathy</e2>
D010894_D001778 NONE <e1>piroxicam</e1> interaction exacerbated <e2>coagulopathy</e2>
2718706
D007741_D007022 CID <e1>labetalol</e1> induced <e2>hypotension</e2>
D007741_D007022 CID <e1>labetalol</e1> using feasibility agent <e2>hypotensive</e2>
D007741_D007022 CID <e1>labetalol</e1> induces <e2>hypotension</e2>
D006221_D007022 CID <e1>halothane</e1> labetalol induced <e2>hypotension</e2>
D006221_D007022 CID <e1>halothane</e1> anaesthetics combination agent <e2>hypotensive</e2>
D006221_D007022 CID <e1>h</e1> concentration <e2>hypotension</e2>
D004737_D007022 CID <e1>enflurane</e1> labetalol induced <e2>hypotension</e2>
D004737_D007022 CID <e1>enflurane</e1> halothane anaesthetics combination agent <e2>hypotensive</e2>
D004737_D007022 CID <e1>e</e1> concentration vol% concentration <e2>hypotension</e2>
D007530_D007022 CID <e1>isoflurane</e1> labetalol induced <e2>hypotension</e2>
D007530_D007022 CID <e1>isoflurane</e1> halothane anaesthetics combination agent <e2>hypotensive</e2>
D007530_D007022 CID <e1>i</e1> concentration mean vol% vol% concentration <e2>hypotension</e2>
D007530_D007022 CID <e1>isoflurane</e1> group returned rose <e2>hypotension</e2>
D007530_D007022 CID <e1>isoflurane</e1> group returned rose <e2>hypotension</e2>
D003404_D007022 NONE <e1>creatinine</e1> concentration rose <e2>hypotension</e2>
D003404_D007022 NONE <e1>creatinine</e1> concentration rose <e2>hypotension</e2>
D007741_D013610 NONE <e1>labetalol</e1> induces <e2>tachycardia</e2>
D007741_D006973 NONE <e1>labetalol</e1> induces tachycardia rebound <e2>hypertension</e2>
2400986
D002066_D020258 NONE <e1>busulfan</e1> <e2>neurotoxicity</e2>
D002066_D020258 NONE <e1>busulfan</e1> known <e2>neurotoxic</e2>
D002066_D020258 NONE <e1>busulfan</e1> known remains <e2>neurotoxicity</e2>
D002066_D020258 NONE <e1>busulfan</e1> dose taken was terms incidence <e2>neurotoxicity</e2>
D002066_D020258 NONE <e1>busulfan</e1> <e2>neurotoxicity</e2>
D002066_D020258 NONE <e1>busulfan</e1> dose followed <e2>neurotoxicity</e2>
D002066_D020258 NONE <e1>busulfan</e1> dose followed neurotoxicity close incidence <e2>neurotoxicity</e2>
D002066_D009369 NONE <e1>busulfan</e1> receiving transplantation <e2>tumors</e2>
D002066_D001932 NONE <e1>busulfan</e1> receiving children study report excluded <e2>tumors</e2>
D002066_D012640 CID <e1>busulfan</e1> days developed <e2>seizures</e2>
D002066_D009461 NONE <e1>busulfan</e1> given had <e2>symptoms</e2>
D002998_D009461 NONE <e1>clonazepam</e1> infusion dose given had <e2>symptoms</e2>
D002066_D002493 NONE <e1>busulfan</e1> levels measured fluid children <e2>disease</e2>
D002066_D002493 NONE <e1>busulfan</e1> fluid children <e2>disease</e2>
D002066_D002493 NONE <e1>busulfan</e1> fluid measured fluid children <e2>disease</e2>
D002998_D002493 NONE <e1>clonazepam</e1> fluid children <e2>disease</e2>
D002998_D020258 NONE <e1>clonazepam</e1> prevented dose-dependent <e2>neurotoxicity</e2>
9782254
D007980_D010300 NONE <e1>l-dopa-induced</e1> dyskinesias bradykinesia treatment pallidotomy underwent patients <e2>disease</e2>
D007980_D018476 NONE <e1>l-dopa-induced</e1> dyskinesias <e2>bradykinesia</e2>
D007980_D009127 NONE <e1>l-dopa-induced</e1> dyskinesias bradykinesia <e2>rigidity</e2>
D007980_D004409 CID <e1>l-dopa-induced</e1> <e2>dyskinesias</e2>
25907210
D010755_D009369 NONE <e1>organophosphate</e1> diazinon exposed applicators incidence <e2>tumours</e2>
D010755_D009369 NONE <e1>organophosphate</e1> insecticide diazinon associated examined risk <e2>cancer</e2>
D003976_D009369 NONE <e1>diazinon</e1> exposed applicators incidence <e2>tumours</e2>
D003976_D009369 NONE <e1>diazinon</e1> associated examined risk <e2>cancer</e2>
D003976_D009369 NONE <e1>diazinon-associated</e1> risk <e2>cancer</e2>
D003976_D009369 NONE <e1>diazinon</e1> exposure information incidence <e2>cancer</e2>
D003976_D009369 NONE <e1>diazinon</e1> exposure used evaluate risk <e2>tumour</e2>
D003976_D009369 NONE <e1>diazinon</e1> use reported methods assessed incidence <e2>cancer</e2>
D003976_D008175 CID <e1>diazinon</e1> associated <e2>cancer</e2>
D003976_D008175 CID <e1>diazinon-associated</e1> risk examined associated <e2>cancer</e2>
D003976_D008175 CID <e1>diazinon</e1> use days number applicators risks <e2>cancer</e2>
D003976_D008175 CID <e1>diazinon</e1> evaluation provides evidence association risk <e2>cancer</e2>
D010755_D008175 NONE <e1>organophosphate</e1> insecticide diazinon associated <e2>cancer</e2>
2173761
D019806_D007022 CID <e1>cromakalim</e1> induced vessels <e2>hypotension</e2>
D019806_D013610 CID <e1>cromakalim</e1> induced vessels vasodilation affected blockade <e2>tachycardia</e2>
D020110_D007022 CID <e1>pinacidil</e1> cromakalim induced vessels <e2>hypotension</e2>
D020110_D013610 CID <e1>pinacidil</e1> cromakalim induced vessels vasodilation affected blockade <e2>tachycardia</e2>
D000319_D007022 NONE <e1>blockade</e1> affected vasodilation vessels <e2>hypotension</e2>
D018727_D007022 NONE <e1>blockade</e1> affected vasodilation vessels <e2>hypotension</e2>
D000319_D013610 NONE <e1>blockade</e1> <e2>tachycardia</e2>
D018727_D013610 NONE <e1>blockade</e1> <e2>tachycardia</e2>
10390729
D011188_D009069 NONE <e1>k(+)-channel</e1> blockers neither meter measured test affected <e2>hypoactivity</e2>
D011188_D009069 NONE <e1>k(+)-channel</e1> blockers prevented affected <e2>hypoactivity</e2>
D011188_D009069 NONE <e1>k(+)-channels</e1> blockade sufficient prevent <e2>hypoactivity</e2>
D011188_D009069 NONE <e1>k(+)-channels</e1> quinine- connected seems sufficient prevent <e2>hypoactivity</e2>
D011188_D006948 NONE <e1>k(+)-channel</e1> blockers neither meter measured test affected prevented <e2>hyperactivity</e2>
D011188_D006948 NONE <e1>k(+)-channel</e1> blockers prevented <e2>hyperactivity</e2>
D011188_D006948 NONE <e1>k(+)-channels</e1> blockade sufficient seems <e2>hyperactivity</e2>
D011188_D006948 NONE <e1>k(+)-channels</e1> quinine- connected seems <e2>hyperactivity</e2>
D009020_D009069 NONE <e1>morphine-induced</e1> <e2>hypoactivity</e2>
D009020_D009069 NONE <e1>morphine-induced</e1> hyperactivity prevented affected <e2>hypoactivity</e2>
D009020_D009069 NONE <e1>morphine-induced</e1> <e2>hypoactivity</e2>
D009020_D009069 NONE <e1>morphine-induced</e1> hyperactivity seems sufficient prevent <e2>hypoactivity</e2>
D009020_D006948 CID <e1>morphine-induced</e1> hypoactivity affected prevented <e2>hyperactivity</e2>
D009020_D006948 CID <e1>morphine-induced</e1> <e2>hyperactivity</e2>
D009020_D006948 CID <e1>morphine-induced</e1> hypoactivity prevent sufficient seems <e2>hyperactivity</e2>
D009020_D006948 CID <e1>morphine-induced</e1> <e2>hyperactivity</e2>
D011803_D009069 NONE <e1>quinine-</e1> connected seems sufficient prevent <e2>hypoactivity</e2>
D011803_D006948 NONE <e1>quinine-</e1> connected seems <e2>hyperactivity</e2>
D015761_D009069 NONE <e1>4-aminopyridine-sensitive</e1> quinine- connected seems sufficient prevent <e2>hypoactivity</e2>
D015761_D006948 NONE <e1>4-aminopyridine-sensitive</e1> quinine- connected seems <e2>hyperactivity</e2>
25119790
D003474_D007674 NONE <e1>curcumin</e1> prevents <e2>nephrotoxicity</e2>
D003474_D007674 NONE <e1>curcumin</e1> effect <e2>injury</e2>
D003474_D007674 NONE <e1>curcumin</e1> able attenuate <e2>nephropathy</e2>
C030272_D007674 CID <e1>maleate-induced</e1> <e2>nephrotoxicity</e2>
C030272_D007674 CID <e1>maleate</e1> induced <e2>injury</e2>
C030272_D007674 CID <e1>maleate-induced</e1> <e2>injury</e2>
C030272_D007674 CID <e1>maleate-induced</e1> injury included upregulation (kim)-1 molecule <e2>injury</e2>
C030272_D007674 CID <e1>maleate-induced</e1> <e2>nephropathy</e2>
D010100_D007674 NONE <e1>oxygen</e1> consumption alterations relation prevents <e2>nephrotoxicity</e2>
C030272_D011507 CID <e1>maleate</e1> injection induced <e2>proteinuria</e2>
C030272_D009336 CID <e1>maleate-induced</e1> injury included decrease besides <e2>necrosis</e2>
D005947_D007674 NONE <e1>glucose</e1> protein excretion resistance increase included <e2>injury</e2>
D005947_D007674 NONE <e1>glucose</e1> protein excretion resistance increase included upregulation (kim)-1 molecule <e2>injury</e2>
D005947_D009336 NONE <e1>glucose</e1> protein excretion resistance increase included decrease besides <e2>necrosis</e2>
D012964_D007674 NONE <e1>sodium</e1> protein excretion resistance increase included <e2>injury</e2>
D012964_D007674 NONE <e1>sodium</e1> protein excretion resistance increase included upregulation (kim)-1 molecule <e2>injury</e2>
D012964_D009336 NONE <e1>sodium</e1> protein excretion resistance increase included decrease besides <e2>necrosis</e2>
24434397
D014148_D012640 NONE <e1>acid</e1> overdosage-induced generalized <e2>seizure</e2>
D014148_D012640 NONE <e1>tna</e1> overdose believed cause <e2>convulsions</e2>
D014148_D051437 NONE <e1>acid</e1> overdosage-induced generalized seizure <e2>failure</e2>
D014148_D006470 NONE <e1>acid</e1> administered control <e2>bleeding</e2>
D014148_D006470 NONE <e1>tna</e1> acid administered control <e2>bleeding</e2>
D014148_D004830 CID <e1>tna</e1> dose hours had episode <e2>convulsions</e2>
D014148_D062787 NONE <e1>tna</e1> <e2>overdose</e2>
8135424
D005442_D012640 CID <e1>flumazenil</e1> induces <e2>seizures</e2>
D005442_D012640 CID <e1>flumazenil</e1> administration unmask <e2>seizures</e2>
D005442_D012640 CID <e1>flumazenil</e1> unmask <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-diazepam</e1> intoxications induces <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-benzodiazepine</e1> intoxication unmask <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-diazepam</e1> intoxications model increase unmask <e2>seizures</e2>
D003975_D012640 CID <e1>cocaine-diazepam</e1> intoxications induces <e2>seizures</e2>
D003975_D012640 CID <e1>cocaine-diazepam</e1> intoxications model increase unmask <e2>seizures</e2>
D001569_D012640 NONE <e1>benzodiazepine</e1> flumazenil administration unmask <e2>seizures</e2>
D001569_D012640 NONE <e1>cocaine-benzodiazepine</e1> intoxication unmask <e2>seizures</e2>
24333387
D013311_D020258 NONE <e1>streptozotocin</e1> induced impairment events activation <e2>neurotoxicity</e2>
D013311_D020258 NONE <e1>stz</e1> treatment showed remains indicating <e2>neurotoxicity</e2>
D013311_D020258 NONE <e1>stz</e1> induced activation post <e2>neurotoxicity</e2>
D013311_D020258 NONE <e1>stz</e1> induced impairment factors activation <e2>neurotoxicity</e2>
D013311_D008569 CID <e1>streptozotocin</e1> induced <e2>impairment</e2>
D013311_D008569 CID <e1>streptozotocin</e1> toxicity post study induced rats <e2>impaired</e2>
D013311_D008569 CID <e1>stz</e1> streptozotocin toxicity post study induced rats <e2>impaired</e2>
D013311_D008569 CID <e1>stz</e1> administration days found <e2>deficit</e2>
D013311_D008569 CID <e1>stz</e1> induced <e2>impairment</e2>
D013311_D064420 NONE <e1>streptozotocin</e1> <e2>toxicity</e2>
D013311_D064420 NONE <e1>stz</e1> streptozotocin <e2>toxicity</e2>
D013311_D064420 NONE <e1>stz</e1> increased reduced activity preparation illustrating generation <e2>excitotoxicity</e2>
D013311_D007249 CID <e1>stz</e1> causes indicating activation <e2>neuroinflammation</e2>
D009573_D064420 NONE <e1>nitrite</e1> increased reduced activity preparation illustrating generation <e2>excitotoxicity</e2>
D002118_D064420 NONE <e1>ca(2</e1> nitrite increased reduced activity preparation illustrating generation <e2>excitotoxicity</e2>
D008559_D020258 NONE <e1>memantine</e1> treatment attenuated activation post <e2>neurotoxicity</e2>
D007052_D020258 NONE <e1>ibuprofen</e1> memantine treatment attenuated activation post <e2>neurotoxicity</e2>
24587916
D003907_D006973 CID <e1>dexamethasone-induced</e1> <e2>hypertension</e2>
D003907_D006973 CID <e1>dexamethasone-</e1> <e2>hypertension</e2>
D003907_D006973 CID <e1>dex-</e1> <e2>hypertension</e2>
D003907_D006973 CID <e1>dex</e1> administration effect stress <e2>hypertension</e2>
D003907_D006973 CID <e1>dex-induced</e1> <e2>hypertension</e2>
D003907_D006973 CID <e1>dex-induced</e1> <e2>hypertension</e2>
D006861_D015431 NONE <e1>h2o2</e1> reduced prevented <e2>loss</e2>
23952588
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> therapy leads development fluctuations <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> therapy present <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> therapy duration age had patients <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> therapy duration age had patients <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> dose had patients <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> dose had patients <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> therapy duration predictors <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> dose therapy duration predictors <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesia</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesia predictors <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa</e1> therapy <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa</e1> therapy disease <e2>pd</e2>
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesia patients <e2>pd</e2>
D007980_D010300 NONE <e1>levodopa</e1> therapy patients <e2>pd</e2>
24588023
D014148_D012640 CID <e1>acid</e1> seizures <e2>convulsive</e2>
D014148_D012640 CID <e1>acid</e1> <e2>seizures</e2>
D014148_D012640 CID <e1>acid</e1> cross-clamp aorta included predictors <e2>seizures</e2>
D014148_D012640 CID <e1>acid</e1> predictor <e2>seizures</e2>
D014148_D012640 CID <e1>acid</e1> factor weighed risk <e2>seizures</e2>
D014148_D006333 NONE <e1>acid</e1> cross-clamp aorta <e2>failure</e2>
D014148_D007035 NONE <e1>acid</e1> cross-clamp aorta arrest <e2>hypothermic</e2>
24040781
C107135_D011507 CID <e1>everolimus</e1> treated <e2>proteinuria</e2>
C107135_D011507 CID <e1>everolimus</e1> tacrolimus conversion developed <e2>proteinuria</e2>
C107135_D000686 CID <e1>everolimus</e1> treated proteinuria patient diagnosis amyloidosis <e2>al</e2>
C107135_D000686 CID <e1>everolimus</e1> treated proteinuria patient diagnosis <e2>amyloidosis</e2>
C107135_D000686 CID <e1>everolimus</e1> tacrolimus conversion developed gammapathy patient <e2>amyloidosis</e2>
D020123_D011507 NONE <e1>rapamycin</e1> inhibitors target treated patients complication <e2>proteinuria</e2>
D016559_D000686 NONE <e1>tacrolimus</e1> conversion developed gammapathy patient <e2>amyloidosis</e2>
D016559_D011507 NONE <e1>tacrolimus</e1> conversion developed <e2>proteinuria</e2>
6728873
D002110_D012640 CID <e1>caffeine</e1> doses scored characteristics induction <e2>seizure</e2>
-1_D064420 NONE <e1>alkylxanthines</e1> testing <e2>toxicity</e2>
3375885
D007213_D006947 CID <e1>indomethacin</e1> induced <e2>hyperkalemia</e2>
D007213_D006947 CID <e1>indomethacin</e1> caused hypoaldosteronism <e2>hyperkalemia</e2>
D007213_D006947 CID <e1>indomethacin</e1> therapy allowing correcting <e2>hyperkalemia</e2>
D009288_D006947 CID <e1>naproxen</e1> indomethacin induced <e2>hyperkalemia</e2>
D009288_D006947 CID <e1>naproxen</e1> indomethacin caused hypoaldosteronism <e2>hyperkalemia</e2>
D005438_D006947 NONE <e1>fludrocortisone</e1> reversed induced <e2>hyperkalemia</e2>
D005438_D006947 NONE <e1>fludrocortisone</e1> added correcting <e2>hyperkalemia</e2>
D008528_D001172 NONE <e1>acid</e1> nephropathy history patient <e2>arthritis</e2>
D008528_D007674 CID <e1>acid</e1> <e2>nephropathy</e2>
D008528_D006947 NONE <e1>acid</e1> nephropathy history patient caused hypoaldosteronism <e2>hyperkalemia</e2>
D008528_D006994 NONE <e1>acid</e1> nephropathy history patient caused <e2>hypoaldosteronism</e2>
D007213_D001172 NONE <e1>indomethacin</e1> caused patient <e2>arthritis</e2>
D007213_D007674 NONE <e1>indomethacin</e1> caused patient history <e2>nephropathy</e2>
D007213_D006994 CID <e1>indomethacin</e1> caused <e2>hypoaldosteronism</e2>
D009288_D001172 NONE <e1>naproxen</e1> indomethacin caused patient <e2>arthritis</e2>
D009288_D007674 NONE <e1>naproxen</e1> indomethacin caused patient history <e2>nephropathy</e2>
D009288_D006994 CID <e1>naproxen</e1> indomethacin caused <e2>hypoaldosteronism</e2>
D011453_D007674 NONE <e1>prostaglandin</e1> synthetase inhibitors acidosis predisposed <e2>disease</e2>
D011453_D006994 NONE <e1>prostaglandin</e1> synthetase inhibitors <e2>acidosis</e2>
9538487
D008094_D006944 CID <e1>lithium-induced</e1> insipidus precipitated <e2>coma</e2>
D008094_D006944 CID <e1>lithium</e1> treated depression history man admitted hyperosmolar <e2>coma</e2>
D008094_D018500 CID <e1>lithium-induced</e1> <e2>insipidus</e2>
D008094_D018500 CID <e1>lithium-induced</e1> likely indicated <e2>insipidus</e2>
D008094_D001714 NONE <e1>lithium</e1> treated <e2>depression</e2>
D005947_D011141 NONE <e1>glucose</e1> negative gave history <e2>polyuria</e2>
D005947_D011141 NONE <e1>glucose</e1> concentrations remained <e2>polyuric</e2>
D005947_D059606 NONE <e1>glucose</e1> negative gave history polyuria <e2>polydipsia</e2>
D005947_-1 NONE <e1>glucose</e1> concentrations remained recovery <e2>hyperglycaemia</e2>
D005947_D018500 NONE <e1>glucose</e1> concentrations remained indicated <e2>insipidus</e2>
D008094_-1 NONE <e1>lithium-induced</e1> likely indicated remained recovery <e2>hyperglycaemia</e2>
D008094_D011141 CID <e1>lithium-induced</e1> likely indicated remained <e2>polyuric</e2>
2239937
D002119_D006934 CID <e1>carbonate</e1> therapy patients etiology <e2>hypercalcemia</e2>
D002119_D006934 CID <e1>carbonate</e1> switching became <e2>hypercalcemic</e2>
D010710_D006934 NONE <e1>phosphate</e1> binder switching became <e2>hypercalcemic</e2>
D002118_D006934 NONE <e1>calcium</e1> reabsorption parameters compared order identify factors associated development <e2>hypercalcemia</e2>
D002118_D006934 NONE <e1>calcium</e1> values experiencing episodes <e2>hypercalcemic</e2>
D002118_D006934 NONE <e1>calcium</e1> values experiencing addition exhibited patients group <e2>hypercalcemic</e2>
D002118_D006934 NONE <e1>calcium</e1> concentration increase exhibited addition experiencing episodes <e2>hypercalcemic</e2>
D002118_D006934 NONE <e1>calcium</e1> concentration increase exhibited patients group <e2>hypercalcemic</e2>
D002118_D007674 NONE <e1>calcium</e1> reabsorption parameters compared etiology <e2>disease</e2>
2625524
D006220_D012640 NONE <e1>haloperidol</e1> failed prevent <e2>seizures</e2>
D006220_D012640 NONE <e1>haloperidol</e1> decreased incidence <e2>seizures</e2>
D006220_D012640 NONE <e1>haloperidol</e1> role suggest reducing incidence <e2>seizures</e2>
D006220_D012640 NONE <e1>haloperidol</e1> demonstrated ability reduce <e2>seizures</e2>
D000661_D012640 CID <e1>amphetamine-induced</e1> <e2>seizures</e2>
D000661_D012640 CID <e1>amphetamine</e1> exposure death haloperidol role suggest reducing incidence <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-induced</e1> <e2>seizures</e2>
D003042_D012640 CID <e1>cocaine-induced</e1> <e2>seizures</e2>
D004298_D012640 NONE <e1>dopamine</e1> blocker haloperidol role suggest reducing incidence <e2>seizures</e2>
11299446
C027429_D010302 CID <e1>veralipride</e1> use worsening <e2>parkinsonism</e2>
C027429_D010302 CID <e1>veralipride</e1> symptoms therapy worsening shown patient <e2>disease</e2>
3831029
C037293_D006333 NONE <e1>denopamine</e1> <e2>failure</e2>
C037293_D006333 NONE <e1>ta-064</e1> denopamine <e2>failure</e2>
C037293_D006333 NONE <e1>denopamine</e1> efficacy assessed improving <e2>failure</e2>
C037293_D006333 NONE <e1>denopamine</e1> trials warrant treatment <e2>failure</e2>
D010424_D006333 CID <e1>pentobarbital-induced</e1> <e2>failure</e2>
C037293_D001145 NONE <e1>denopamine</e1> doses induced <e2>arrhythmias</e2>
2974281
D011433_D006332 NONE <e1>propranolol</e1> effects <e2>hypertrophy</e2>
D011433_D006332 NONE <e1>propranolol</e1> blockers have potency prevent isoproterenol producing <e2>hypertrophy</e2>
D007545_D006332 CID <e1>isoproterenol-induced</e1> <e2>hypertrophy</e2>
D007545_D006332 CID <e1>isoproterenol-induced</e1> <e2>hypertrophy</e2>
D007545_D006332 CID <e1>isoproterenol</e1> producing <e2>hypertrophy</e2>
D009952_D006332 NONE <e1>ornithine</e1> activity beta-blockers <e2>hearts</e2>
D011433_D006984 NONE <e1>propranolol</e1> 24/76 stop changes pattern heart <e2>hypertrophied</e2>
24100257
C089750_D054549 CID <e1>zolmitriptan</e1> secondary <e2>syndrome</e2>
C089750_D054549 CID <e1>zolmitriptan</e1> secondary syndrome <e2>syndrome</e2>
C089750_D054549 CID <e1>zolmitriptan</e1> secondary vasospasm cases revealed associated <e2>ts</e2>
C089750_D008881 NONE <e1>zolmitriptan</e1> took had <e2>migraines</e2>
C089750_D008881 NONE <e1>zolmitriptan</e1> took revealed taking <e2>headache</e2>
C089750_D008881 NONE <e1>zolmitriptan</e1> taking revealed took had <e2>migraines</e2>
C089750_D008881 NONE <e1>zolmitriptan</e1> taking <e2>headache</e2>
C089750_D003329 CID <e1>zolmitriptan</e1> secondary <e2>vasospasm</e2>
15987266
D003513_D004827 NONE <e1>cycloheximide</e1> treated layer rats <e2>epileptic</e2>
D010862_D013226 CID <e1>pilocarpine</e1> induced <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilo</e1> pilocarpine induced <e2>epilepticus</e2>
D003513_D013226 NONE <e1>cycloheximide</e1> injected assessed intensity layer gyrus rats subject <e2>epilepticus</e2>
D003513_D013226 NONE <e1>chx</e1> cycloheximide injected assessed intensity layer gyrus rats subject <e2>epilepticus</e2>
19728177
D000082_D017114 CID <e1>acetaminophen</e1> female <e2>fhf</e2>
D000082_D017114 CID <e1>acetaminophen</e1> confirmed <e2>fhf</e2>
D000082_D017114 CID <e1>acetaminophen</e1> overdose patients <e2>fhf</e2>
D000082_D001929 CID <e1>acetaminophen</e1> <e2>edema</e2>
D000082_D001929 CID <e1>acetaminophen</e1> <e2>edema</e2>
D000082_D001929 CID <e1>acetaminophen</e1> overdose patients fhf <e2>edema</e2>
D000082_D064420 NONE <e1>acetaminophen</e1> <e2>toxicity</e2>
D000082_D062787 NONE <e1>acetaminophen</e1> <e2>overdose</e2>
D000082_D007035 NONE <e1>acetaminophen</e1> overdose patients used <e2>hypothermia</e2>
19531695
D005424_D003693 CID <e1>flecainide</e1> concentrations patient <e2>delirium</e2>
D005424_D003693 CID <e1>flecainide-induced</e1> <e2>delirium</e2>
D005424_D003693 CID <e1>flecainide</e1> cause <e2>delirium</e2>
D005424_D003693 CID <e1>flecainide</e1> reports <e2>delirium</e2>
D005424_D003693 CID <e1>flecainide-induced</e1> <e2>delirium</e2>
D005424_D003693 CID <e1>flecainide</e1> cause <e2>delirium</e2>
D005424_D003693 CID <e1>flecainide</e1> interaction indicates cause <e2>delirium</e2>
D005424_D003693 CID <e1>flecainide</e1> concentrations cause <e2>delirium</e2>
D017374_D003693 CID <e1>paroxetine</e1> interaction role <e2>delirium</e2>
D017374_D003693 CID <e1>paroxetine</e1> interaction associated <e2>delirium</e2>
D017374_D003693 CID <e1>paroxetine</e1> flecainide reports <e2>delirium</e2>
D017374_D003693 CID <e1>paroxetine</e1> flecainide interaction indicates cause <e2>delirium</e2>
D005424_D001281 NONE <e1>flecainide</e1> started prior <e2>fibrillation</e2>
D012964_D003693 NONE <e1>sodium</e1> channels interact agents flecainide cause <e2>delirium</e2>
D005424_D064420 NONE <e1>flecainide</e1> prescribed occur <e2>toxicity</e2>
D005424_D064420 NONE <e1>flecainide</e1> concentrations monitored occur <e2>toxicity</e2>
D017374_D064420 NONE <e1>paroxetine</e1> prescribed occur <e2>toxicity</e2>
6631522
C013102_D066126 NONE <e1>ha</e1> imaging alteration leading changes factor <e2>cardiotoxicity</e2>
D004317_D066126 CID <e1>doxorubicin</e1> <e2>cardiotoxicity</e2>
25951420
D010126_D010300 CID <e1>ozone</e1> associations <e2>disease</e2>
D010126_D010300 CID <e1>ozone</e1> associations matter <e2>disease</e2>
D010126_D010300 CID <e1>ozone</e1> <e2>disease</e2>
D052638_D010300 CID <e1>matter</e1> <e2>disease</e2>
D052638_D010300 CID <e1>matter</e1> ratio associations <e2>disease</e2>
11395263
D000431_D009203 NONE <e1>ethanol</e1> extract effect <e2>infarction</e2>
D007545_D009203 CID <e1>isoproterenol-induced</e1> <e2>infarction</e2>
D007545_D009203 CID <e1>isoproterenol-induced</e1> <e2>infarction</e2>
2907577
-1_D058186 NONE <e1>alkylxanthines</e1> effect <e2>failure</e2>
-1_D058186 NONE <e1>alkylxanthines</e1> effects examined rats developing <e2>failure</e2>
-1_D058186 NONE <e1>alkylxanthines</e1> noted lack indicates plays role <e2>arf</e2>
D005839_D058186 CID <e1>gentamicin-induced</e1> <e2>failure</e2>
D005839_D058186 CID <e1>gentamicin</e1> injections developing <e2>failure</e2>
D005839_D058186 CID <e1>gentamicin-induced</e1> <e2>arf</e2>
D000241_D007511 NONE <e1>adenosine</e1> antagonists shown benefit models <e2>ischaemic</e2>
D000241_D007674 NONE <e1>adenosine</e1> antagonists shown benefit models ischaemic <e2>nephrotoxic</e2>
D000241_D058186 NONE <e1>adenosine</e1> antagonists shown benefit models <e2>failure</e2>
D000241_D058186 NONE <e1>adenosine</e1> antagonists shown benefit models failure <e2>arf</e2>
D000241_D058186 NONE <e1>adenosine</e1> antagonists potencies effects examined rats developing <e2>failure</e2>
D000241_D058186 NONE <e1>adenosine</e1> plays role <e2>arf</e2>
C028322_D058186 NONE <e1>8-phenyltheophylline</e1> effects examined rats developing <e2>failure</e2>
D013806_D058186 NONE <e1>theophylline</e1> 8-phenyltheophylline effects examined rats developing <e2>failure</e2>
C034347_D058186 NONE <e1>enprofylline</e1> theophylline 8-phenyltheophylline effects examined rats developing <e2>failure</e2>
D014508_D009336 NONE <e1>urea</e1> biochemical indices <e2>necrosis</e2>
D003404_D009336 NONE <e1>creatinine</e1> urea biochemical indices <e2>necrosis</e2>
D010130_D009336 NONE <e1>acid</e1> clearances analysis functional biochemical indices <e2>necrosis</e2>
2983630
D002110_D016584 NONE <e1>caffeine</e1> effects <e2>disorders</e2>
D002110_D016584 NONE <e1>caffeine</e1> administration effects determined subjects patients meeting criteria agoraphobia <e2>attacks</e2>
D002110_D016584 NONE <e1>caffeine</e1> administration effects determined subjects patients meeting criteria agoraphobia attacks <e2>disorder</e2>
D002110_D016584 NONE <e1>caffeine</e1> effects similar those experienced <e2>attacks</e2>
D002110_D016584 NONE <e1>caffeine</e1> antagonist suggest have patients <e2>disorder</e2>
D002110_D000379 NONE <e1>caffeine</e1> administration effects determined subjects patients meeting criteria <e2>agoraphobia</e2>
D008734_D000379 NONE <e1>3-methoxy-4-hydroxyphenethyleneglycol</e1> levels pressure symptoms ratings effects determined subjects patients meeting criteria <e2>agoraphobia</e2>
D008734_D000379 NONE <e1>mhpg</e1> 3-methoxy-4-hydroxyphenethyleneglycol levels pressure symptoms ratings effects determined subjects patients meeting criteria <e2>agoraphobia</e2>
D008734_D016584 NONE <e1>3-methoxy-4-hydroxyphenethyleneglycol</e1> levels pressure symptoms ratings effects determined subjects patients meeting criteria agoraphobia <e2>attacks</e2>
D008734_D016584 NONE <e1>3-methoxy-4-hydroxyphenethyleneglycol</e1> levels pressure symptoms ratings effects determined subjects patients meeting criteria agoraphobia attacks <e2>disorder</e2>
D008734_D016584 NONE <e1>mhpg</e1> 3-methoxy-4-hydroxyphenethyleneglycol levels pressure symptoms ratings effects determined subjects patients meeting criteria agoraphobia <e2>attacks</e2>
D008734_D016584 NONE <e1>mhpg</e1> 3-methoxy-4-hydroxyphenethyleneglycol levels pressure symptoms ratings effects determined subjects patients meeting criteria agoraphobia attacks <e2>disorder</e2>
D006854_D000379 NONE <e1>cortisol</e1> 3-methoxy-4-hydroxyphenethyleneglycol levels pressure symptoms ratings effects determined subjects patients meeting criteria <e2>agoraphobia</e2>
D006854_D016584 NONE <e1>cortisol</e1> 3-methoxy-4-hydroxyphenethyleneglycol levels pressure symptoms ratings effects determined subjects patients meeting criteria agoraphobia <e2>attacks</e2>
D006854_D016584 NONE <e1>cortisol</e1> 3-methoxy-4-hydroxyphenethyleneglycol levels pressure symptoms ratings effects determined subjects patients meeting criteria agoraphobia attacks <e2>disorder</e2>
D002110_D001008 CID <e1>caffeine</e1> produced increases <e2>anxiety</e2>
D002110_D001008 CID <e1>caffeine-containing</e1> foods avoiding benefit patients <e2>disorders</e2>
D002110_D009325 CID <e1>caffeine</e1> produced increases fear <e2>nausea</e2>
D002110_-1 NONE <e1>caffeine</e1> produced increases fear nausea <e2>palpitations</e2>
D002110_D011595 NONE <e1>caffeine</e1> produced increases fear <e2>restlessness</e2>
D002110_D014202 CID <e1>caffeine</e1> produced <e2>tremors</e2>
D002110_D009421 NONE <e1>caffeine</e1> antagonist suggest have abnormalities <e2>systems</e2>
D000241_D016584 NONE <e1>adenosine</e1> antagonist suggest have patients <e2>disorder</e2>
D000241_D016584 NONE <e1>adenosine</e1> abnormalities have patients <e2>disorder</e2>
D000241_D009421 NONE <e1>adenosine</e1> antagonist suggest have abnormalities <e2>systems</e2>
D000241_D009421 NONE <e1>adenosine</e1> abnormalities <e2>systems</e2>
9128918
D004298_D006966 NONE <e1>dopamine</e1> neurons <e2>hyperprolactinemia</e2>
D004298_D006966 NONE <e1>dopamine</e1> receptor antagonist haloperidol treatment induced <e2>hyperprolactinemia</e2>
D004298_D006966 NONE <e1>dopamine</e1> concentrations increased months <e2>hyperprolactinemia</e2>
D004298_D006966 NONE <e1>da</e1> dopamine concentrations increased months <e2>hyperprolactinemia</e2>
D004298_D006966 NONE <e1>da</e1> concentrations increase produced months <e2>hyperprolactinemia</e2>
D004298_D006966 NONE <e1>da</e1> response lost followed <e2>hyperprolactinemia</e2>
D004298_D006966 NONE <e1>da</e1> levels change was decrease 6-months <e2>hyperprolactinemia</e2>
D004298_D006966 NONE <e1>da</e1> levels change was decrease increase 9-months <e2>hyperprolactinemia</e2>
D004298_D006966 NONE <e1>da</e1> concentrations increase decrease 6-months <e2>hyperprolactinemia</e2>
D004298_D006966 NONE <e1>da</e1> concentrations increase 9-months <e2>hyperprolactinemia</e2>
D006220_D006966 CID <e1>haloperidol</e1> treatment induced <e2>hyperprolactinemia</e2>
D006220_D006966 CID <e1>haloperidol-induced</e1> <e2>hyperprolactinemia</e2>
D009638_D006966 NONE <e1>norepinephrine</e1> da levels change was decrease 6-months <e2>hyperprolactinemia</e2>
D009638_D006966 NONE <e1>norepinephrine</e1> da levels change was decrease increase 9-months <e2>hyperprolactinemia</e2>
D009638_D006966 NONE <e1>ne</e1> norepinephrine da levels change was decrease 6-months <e2>hyperprolactinemia</e2>
D009638_D006966 NONE <e1>ne</e1> norepinephrine da levels change was decrease increase 9-months <e2>hyperprolactinemia</e2>
D012701_D006966 NONE <e1>serotonin</e1> da levels change was decrease 6-months <e2>hyperprolactinemia</e2>
D012701_D006966 NONE <e1>serotonin</e1> da levels change was decrease increase 9-months <e2>hyperprolactinemia</e2>
D012701_D006966 NONE <e1>5-ht</e1> serotonin da levels change was decrease 6-months <e2>hyperprolactinemia</e2>
D012701_D006966 NONE <e1>5-ht</e1> serotonin da levels change was decrease increase 9-months <e2>hyperprolactinemia</e2>
D006897_D006966 NONE <e1>acid</e1> decrease 6-months <e2>hyperprolactinemia</e2>
D006897_D006966 NONE <e1>acid</e1> decrease increase 9-months <e2>hyperprolactinemia</e2>
D006897_D006966 NONE <e1>5-hiaa</e1> acid decrease 6-months <e2>hyperprolactinemia</e2>
D006897_D006966 NONE <e1>5-hiaa</e1> acid decrease increase 9-months <e2>hyperprolactinemia</e2>
11936424
C055603_D007674 NONE <e1>temocapril</e1> modulates <e2>injury</e2>
C055603_D009401 NONE <e1>temocapril</e1> modulates injury <e2>nephrosis</e2>
C055603_D009401 NONE <e1>temocapril</e1> effective retarding protected rats <e2>neprotic</e2>
D000809_D007674 NONE <e1>angiotensin</e1> inhibitor temocapril modulates <e2>injury</e2>
D000809_D009401 NONE <e1>angiotensin</e1> inhibitor temocapril modulates injury <e2>nephrosis</e2>
D011692_D007674 NONE <e1>aminonucleoside</e1> nephrosis <e2>injury</e2>
D011692_D009401 CID <e1>aminonucleoside</e1> <e2>nephrosis</e2>
D011692_D009401 CID <e1>pan</e1> injection induced <e2>nephrosis</e2>
D011692_D009401 CID <e1>pan</e1> rats <e2>neprotic</e2>
C055603_D011507 NONE <e1>temocapril</e1> administration <e2>proteinuria</e2>
C055603_D011507 NONE <e1>temocapril</e1> attenuate <e2>proteinuria</e2>
C055603_D006984 NONE <e1>temocapril</e1> administration inhibited <e2>hypertrophy</e2>
C055603_D005921 NONE <e1>temocapril</e1> administration inhibited prevented <e2>glomerulosclerosis</e2>
C055603_D009404 NONE <e1>temocapril</e1> administration inhibited prevented rats <e2>nephrotic</e2>
D000809_D011507 NONE <e1>angiotensin</e1> enzyme inhibitor temocapril administration <e2>proteinuria</e2>
D000809_D006984 NONE <e1>angiotensin</e1> enzyme inhibitor temocapril administration inhibited <e2>hypertrophy</e2>
D000809_D005921 NONE <e1>angiotensin</e1> enzyme inhibitor temocapril administration inhibited prevented <e2>glomerulosclerosis</e2>
D000809_D009404 NONE <e1>angiotensin</e1> enzyme inhibitor temocapril administration inhibited prevented rats <e2>nephrotic</e2>
D011692_D011507 CID <e1>aminonucleoside</e1> induced rats prevented inhibited administration <e2>proteinuria</e2>
D011692_D011507 CID <e1>pan</e1> aminonucleoside induced rats prevented inhibited administration <e2>proteinuria</e2>
D011692_D006984 NONE <e1>aminonucleoside</e1> induced rats prevented inhibited <e2>hypertrophy</e2>
D011692_D006984 NONE <e1>pan</e1> aminonucleoside induced rats prevented inhibited <e2>hypertrophy</e2>
D011692_D005921 NONE <e1>aminonucleoside</e1> induced rats prevented <e2>glomerulosclerosis</e2>
D011692_D005921 NONE <e1>pan</e1> aminonucleoside induced rats prevented <e2>glomerulosclerosis</e2>
D011692_D005921 NONE <e1>pan</e1> group weeks % index <e2>glomerulosclerosis</e2>
D011692_D009404 NONE <e1>aminonucleoside</e1> induced rats <e2>nephrotic</e2>
D011692_D009404 NONE <e1>pan</e1> aminonucleoside induced rats <e2>nephrotic</e2>
24923469
7492040
D008012_D009203 NONE <e1>lidocaine</e1> safety patients <e2>infarction</e2>
D008012_D009203 NONE <e1>lidocaine</e1> safety setting <e2>infarction</e2>
D008012_D009203 NONE <e1>lidocaine</e1> safety setting infarction <e2>mi</e2>
D008012_D009203 NONE <e1>lidocaine</e1> received patients <e2>mi</e2>
D008012_D009203 NONE <e1>lidocaine</e1> received setting <e2>mi</e2>
D008012_D009203 NONE <e1>lidocaine</e1> administration seizures bradydysrhythmias exhibited died results patients received setting <e2>mi</e2>
D008012_D009203 NONE <e1>lidocaine</e1> enhance conclusion associated use patients <e2>mi</e2>
D008012_D009203 NONE <e1>lidocaine</e1> use patients <e2>mi</e2>
D003042_D009203 CID <e1>cocaine-associated</e1> <e2>infarction</e2>
D003042_D009203 CID <e1>cocaine-induced</e1> <e2>infarction</e2>
D003042_D009203 CID <e1>cocaine-induced</e1> infarction <e2>mi</e2>
D003042_D009203 CID <e1>cocaine-associated</e1> <e2>mi</e2>
D003042_D009203 CID <e1>cocaine-associated</e1> <e2>mi</e2>
D003042_D009203 CID <e1>cocaine</e1> toxicity enhance conclusion associated use patients <e2>mi</e2>
D003042_D009203 CID <e1>cocaine-associated</e1> <e2>mi</e2>
D008012_D001919 NONE <e1>lidocaine</e1> received patients results died exhibited <e2>bradydysrhythmias</e2>
D008012_D001919 NONE <e1>lidocaine</e1> administration seizures <e2>bradydysrhythmias</e2>
D008012_D017180 NONE <e1>lidocaine</e1> received patients results died exhibited bradydysrhythmias <e2>tachycardia</e2>
D008012_D017180 NONE <e1>lidocaine</e1> administration seizures bradydysrhythmias <e2>tachycardia</e2>
D008012_D014693 NONE <e1>lidocaine</e1> received patients results died exhibited bradydysrhythmias <e2>fibrillation</e2>
D008012_D014693 NONE <e1>lidocaine</e1> administration seizures bradydysrhythmias <e2>fibrillation</e2>
D008012_D012640 NONE <e1>lidocaine</e1> received patients results died exhibited bradydysrhythmias <e2>seizures</e2>
D008012_D012640 NONE <e1>lidocaine</e1> administration <e2>seizures</e2>
D003042_D001919 NONE <e1>cocaine-associated</e1> mi setting received patients results died exhibited <e2>bradydysrhythmias</e2>
D003042_D017180 NONE <e1>cocaine-associated</e1> mi setting received patients results died exhibited bradydysrhythmias <e2>tachycardia</e2>
D003042_D014693 NONE <e1>cocaine-associated</e1> mi setting received patients results died exhibited bradydysrhythmias <e2>fibrillation</e2>
D003042_D012640 NONE <e1>cocaine-associated</e1> mi setting received patients results died exhibited bradydysrhythmias <e2>seizures</e2>
D008012_D064420 NONE <e1>lidocaine</e1> enhance <e2>toxicity</e2>
D008012_D064420 NONE <e1>lidocaine</e1> use associated conclusion enhance <e2>toxicity</e2>
D008012_D002318 NONE <e1>lidocaine</e1> enhance conclusion associated cardiovascular <e2>toxicity</e2>
D008012_D002318 NONE <e1>lidocaine</e1> use associated cardiovascular <e2>toxicity</e2>
D008012_D002493 NONE <e1>lidocaine</e1> enhance conclusion associated cardiovascular <e2>toxicity</e2>
D008012_D002493 NONE <e1>lidocaine</e1> use associated cardiovascular <e2>toxicity</e2>
D003042_D064420 NONE <e1>cocaine</e1> <e2>toxicity</e2>
D003042_D064420 NONE <e1>cocaine-associated</e1> mi patients use associated conclusion enhance <e2>toxicity</e2>
D003042_D002318 NONE <e1>cocaine</e1> toxicity enhance conclusion associated cardiovascular <e2>toxicity</e2>
D003042_D002318 NONE <e1>cocaine-associated</e1> mi patients use associated cardiovascular <e2>toxicity</e2>
D003042_D002493 NONE <e1>cocaine</e1> toxicity enhance conclusion associated cardiovascular <e2>toxicity</e2>
D003042_D002493 NONE <e1>cocaine-associated</e1> mi patients use associated cardiovascular <e2>toxicity</e2>
17035713
C004656_D007674 NONE <e1>chloroacetaldehyde</e1> role <e2>nephropathy</e2>
C004656_D007674 NONE <e1>chloroacetaldehyde</e1> metabolite responsible <e2>damage</e2>
C004656_D007674 NONE <e1>caa</e1> chloroacetaldehyde metabolite responsible <e2>damage</e2>
-1_D007674 NONE <e1>sulfhydryl</e1> reagent chloroacetaldehyde role <e2>nephropathy</e2>
D013438_D007674 NONE <e1>thiol</e1> groups role <e2>nephropathy</e2>
D007069_D007674 CID <e1>ifosfamide</e1> <e2>nephropathy</e2>
D007069_D007674 CID <e1>ifosfamide</e1> metabolite responsible <e2>damage</e2>
D007069_D007674 CID <e1>ifo</e1> ifosfamide metabolite responsible <e2>damage</e2>
D007069_D007674 CID <e1>ifo</e1> therapy <e2>damage</e2>
D007069_D007674 CID <e1>ifo</e1> <e2>nephropathy</e2>
C004656_D009369 NONE <e1>chloroacetaldehyde</e1> metabolite responsible damage therapy <e2>anti-tumor</e2>
C004656_D009369 NONE <e1>caa</e1> chloroacetaldehyde metabolite responsible damage therapy <e2>anti-tumor</e2>
D007069_D009369 NONE <e1>ifosfamide</e1> metabolite responsible damage therapy <e2>anti-tumor</e2>
D007069_D009369 NONE <e1>ifo</e1> ifosfamide metabolite responsible damage therapy <e2>anti-tumor</e2>
D007069_D009369 NONE <e1>ifo</e1> therapy <e2>anti-tumor</e2>
C004656_D064420 NONE <e1>caa</e1> <e2>toxicity</e2>
C004656_D064420 NONE <e1>caa</e1> reacts mediating <e2>toxicity</e2>
D014343_D064420 NONE <e1>blue</e1> assay trypan determined <e2>toxicity</e2>
C004656_D009336 NONE <e1>caa</e1> reduced induced loss increase markers <e2>necrosis</e2>
C004656_D009336 NONE <e1>caa</e1> reaction slowed acidification attenuate effects markers <e2>necrosis</e2>
C004656_D009336 NONE <e1>caa</e1> effects markers <e2>necrosis</e2>
D013438_D009336 NONE <e1>thiols</e1> loss increase markers <e2>necrosis</e2>
D013438_D009336 NONE <e1>thiol</e1> donors reaction slowed acidification attenuate effects markers <e2>necrosis</e2>
D013438_D009336 NONE <e1>thiol</e1> depletion markers <e2>necrosis</e2>
D003545_D009336 NONE <e1>cysteine</e1> protease inhibition markers <e2>necrosis</e2>
D013438_D064420 NONE <e1>thiols</e1> protein reacts mediating <e2>toxicity</e2>
9831002
D008774_D009459 CID <e1>methylphenidate</e1> <e2>syndrome</e2>
D008774_D009459 CID <e1>methylphenidate</e1> caused female presented <e2>syndrome</e2>
D008774_D009459 CID <e1>methylphenidate</e1> caused patient <e2>syndrome</e2>
24072398
D008694_D020258 NONE <e1>methamphetamine</e1> dose <e2>neurotoxic</e2>
D008694_D003866 CID <e1>methamphetamine</e1> dose induces behaviour <e2>depressive-like</e2>
D008694_D003866 CID <e1>methamphetamine</e1> triggers leads states <e2>symptoms</e2>
D008694_D003866 CID <e1>meth</e1> methamphetamine triggers leads states <e2>symptoms</e2>
D008694_D003866 CID <e1>meth</e1> abuse disruption triggers leads states <e2>symptoms</e2>
D008694_D003866 CID <e1>meth</e1> dosage causes phenotype <e2>depressive</e2>
D008694_D003866 CID <e1>meth</e1> dose periods assessed behaviour <e2>depressive-like</e2>
D008694_D003866 CID <e1>meth</e1> induced profile <e2>depressive-like</e2>
D008694_D003866 CID <e1>meth</e1> dose induces behaviour <e2>depressive-like</e2>
D004298_D003866 NONE <e1>dopamine</e1> levels reduction indicated depletion accompanied profile <e2>depressive-like</e2>
D015102_D003866 NONE <e1>dopac</e1> dopamine levels reduction indicated depletion accompanied profile <e2>depressive-like</e2>
D006719_D003866 NONE <e1>hva</e1> dopamine levels reduction indicated depletion accompanied profile <e2>depressive-like</e2>
D014443_D003866 NONE <e1>tyrosine</e1> hydroxylase dopamine levels reduction indicated depletion accompanied profile <e2>depressive-like</e2>
D012701_D003866 NONE <e1>serotonin</e1> hydroxylase dopamine levels reduction indicated depletion accompanied profile <e2>depressive-like</e2>
18801087
D000638_D055370 CID <e1>amiodarone-related</e1> <e2>mass</e2>
D000638_D055370 CID <e1>amiodarone</e1> treatment developed <e2>mass</e2>
D000638_D055370 CID <e1>amiodarone-related</e1> lesion indicating suspected <e2>mass</e2>
D000638_D055370 CID <e1>amiodarone-related</e1> <e2>lesion</e2>
D000638_D055370 CID <e1>amiodarone</e1> treatment complication suggests highlights possibility difficult diagnosis <e2>lesion</e2>
D000638_D015433 CID <e1>amiodarone-related</e1> mass <e2>glomerulonephritis</e2>
D000638_D015433 CID <e1>amiodarone-related</e1> lesion diagnosis difficult possibility highlights suggests complication <e2>glomerulonephritis</e2>
D000638_D015433 CID <e1>amiodarone</e1> treatment complication <e2>glomerulonephritis</e2>
D000638_D006349 NONE <e1>amiodarone-related</e1> mass patient <e2>disease</e2>
D000638_D006349 NONE <e1>amiodarone</e1> treatment developed patient case <e2>disease</e2>
D000638_D001145 NONE <e1>amiodarone</e1> drug <e2>anti-arrhythmic</e2>
D000638_D013610 NONE <e1>amiodarone</e1> drug <e2>tachycardia</e2>
D000638_D011507 NONE <e1>amiodarone</e1> treatment developed mass <e2>proteinuria</e2>
D000638_D008175 NONE <e1>amiodarone-related</e1> lesion indicating suspected <e2>cancer</e2>
D000638_D009369 NONE <e1>amiodarone-related</e1> lesion <e2>neoplasm</e2>
D000638_D009369 NONE <e1>amiodarone</e1> treatment complication suggests highlights possibility difficult diagnosis lesion <e2>neoplasm</e2>
20927253
D019386_D010146 CID <e1>alendronate</e1> administration <e2>pain</e2>
D019386_D010146 CID <e1>alendronate</e1> administration admitted <e2>pain</e2>
D004164_D010024 NONE <e1>bisphosphonates</e1> caused <e2>osteoporosis</e2>
D004164_D010024 NONE <e1>bisphosphonate-related</e1> pain considered report patients <e2>osteoporosis</e2>
D004164_D010024 NONE <e1>bisphosphonate-related</e1> pain considered ascribing <e2>osteoporosis</e2>
D019386_D010024 NONE <e1>alendronate</e1> effective treatment <e2>osteoporosis</e2>
-1_D010024 NONE <e1>biphosphonate</e1> alendronate effective treatment <e2>osteoporosis</e2>
D004164_D010146 NONE <e1>bisphosphonate-related</e1> pain considered report <e2>pain</e2>
D004164_D010146 NONE <e1>bisphosphonate-related</e1> <e2>pain</e2>
24902786
D013739_D008569 NONE <e1>testosterone</e1> ameliorates <e2>impairment</e2>
D013739_D008569 NONE <e1>testosterone</e1> <e2>impairment</e2>
D013739_D008569 NONE <e1>testosterone</e1> replacement attenuated impaired <e2>memory</e2>
D013739_D008569 NONE <e1>testosterone</e1> replacement attenuated improving <e2>impairment</e2>
D013739_D008569 NONE <e1>testosterone</e1> administration ameliorates <e2>impairment</e2>
D013311_D008569 CID <e1>streptozotocin-induced</e1> <e2>impairment</e2>
D013311_D008569 CID <e1>streptozotocin</e1> <e2>impairment</e2>
D013311_D008569 CID <e1>(stz)-induced</e1> <e2>impairment</e2>
D013311_D008569 CID <e1>stz-</e1> impairment improving attenuated impaired <e2>memory</e2>
D013311_D008569 CID <e1>stz-</e1> <e2>impairment</e2>
D013311_D008569 CID <e1>stz-</e1> <e2>impairment</e2>
D005485_D008569 CID <e1>flutamide</e1> administration impaired <e2>memory</e2>
D005485_D008569 CID <e1>flutamide</e1> administration impaired attenuated improving <e2>impairment</e2>
C067431_D008569 CID <e1>letrozole</e1> administration impaired <e2>memory</e2>
C067431_D008569 CID <e1>letrozole</e1> administration impaired attenuated improving <e2>impairment</e2>
D013629_D008569 CID <e1>tamoxifen</e1> letrozole administration impaired <e2>memory</e2>
D013629_D008569 CID <e1>tamoxifen</e1> letrozole administration impaired attenuated improving <e2>impairment</e2>
8160791
D005839_D007674 CID <e1>gentamicin-mediated</e1> <e2>nephropathy</e2>
D005839_D007674 CID <e1>gentamicin</e1> scavengers effects mechanisms examine <e2>nephropathy</e2>
D005839_D007674 CID <e1>(gm)-mediated</e1> examine <e2>nephropathy</e2>
D005839_D007674 CID <e1>gm</e1> administration induced reduction flow <e2>damage</e2>
D005839_D007674 CID <e1>gm-mediated</e1> <e2>nephropathy</e2>
D005839_D007674 CID <e1>gm-mediated</e1> <e2>nephropathy</e2>
D005839_D007674 CID <e1>gm-induced</e1> vasoconstriction play differ have <e2>nephropathy</e2>
D006152_D007674 NONE <e1>monophosphate</e1> excretion reduction observed <e2>nephropathy</e2>
D006152_D007674 NONE <e1>cgmp</e1> excretion reduction observed <e2>nephropathy</e2>
C038983_D007674 NONE <e1>dmtu</e1> reduced <e2>damage</e2>
C038983_D007674 NONE <e1>dmtu</e1> sod suggest have <e2>nephropathy</e2>
C038983_D007674 NONE <e1>dmtu</e1> sod differ have <e2>nephropathy</e2>
D013481_D007674 NONE <e1>superoxide</e1> anions play differ have <e2>nephropathy</e2>
8701013
D015738_D003693 CID <e1>famotidine-associated</e1> <e2>delirium</e2>
D015738_D003693 CID <e1>famotidine</e1> associated shown propensity cause <e2>delirium</e2>
D015738_D003693 CID <e1>famotidine-associated</e1> <e2>delirium</e2>
D015738_D003693 CID <e1>famotidine</e1> removal cleared patients cases <e2>delirium</e2>
D015738_D014456 NONE <e1>famotidine</e1> antagonist used settings prevention <e2>ulcers</e2>
24684312
D018698_D006930 NONE <e1>glutamate</e1> variability <e2>hyperalgesia</e2>
D018698_D006930 NONE <e1>glutamate</e1> variability hyperalgesia <e2>allodynia</e2>
D018698_D006930 NONE <e1>glutamate</e1> injections attractive <e2>hyperalgesia</e2>
D018698_D006930 NONE <e1>glutamate</e1> injections attractive hyperalgesia aspects isolated <e2>allodynia</e2>
D018698_D006930 NONE <e1>glutamate</e1> injection g observed <e2>hyperalgesia</e2>
D018698_D006930 NONE <e1>glutamate</e1> , conclusion responses <e2>hyperalgesic</e2>
D018698_D006930 NONE <e1>glutamate</e1> , conclusion responses hyperalgesic <e2>allodynic</e2>
D002211_D006930 CID <e1>capsaicin</e1> glutamate variability <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin</e1> glutamate variability hyperalgesia <e2>allodynia</e2>
D002211_D006930 CID <e1>capsaicin</e1> glutamate injections attractive <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin</e1> glutamate injections attractive hyperalgesia aspects isolated <e2>allodynia</e2>
D002211_D006930 CID <e1>capsaicin</e1> detected <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin</e1> injection reproducible <e2>hyperalgesia</e2>
D002211_D006930 CID <e1>capsaicin</e1> injection reproducible hyperalgesia <e2>allodynia</e2>
D002211_D006930 CID <e1>capsaicin</e1> yield glutamate , conclusion responses <e2>hyperalgesic</e2>
D002211_D006930 CID <e1>capsaicin</e1> yield glutamate , conclusion responses hyperalgesic <e2>allodynic</e2>
D018698_D010146 NONE <e1>glutamate</e1> injections attractive use models <e2>pain</e2>
D018698_D013001 NONE <e1>glutamate</e1> injections attractive hyperalgesia aspects <e2>disorders</e2>
D002211_D010146 NONE <e1>capsaicin</e1> glutamate injections attractive use models <e2>pain</e2>
D002211_D013001 NONE <e1>capsaicin</e1> glutamate injections attractive hyperalgesia aspects <e2>disorders</e2>
3925479
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> caused enhancement <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol-induced</e1> <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> induced <e2>catalepsy</e2>
D006220_D002375 CID <e1>haloperidol</e1> neuroleptics produced <e2>catalepsy</e2>
D014150_D002375 NONE <e1>neuroleptic-induced</e1> catalepsy expression intact need promotes <e2>catalepsy</e2>
D014150_D002375 NONE <e1>neuroleptic-induced</e1> <e2>catalepsy</e2>
D014150_D002375 NONE <e1>neuroleptics</e1> produced <e2>catalepsy</e2>
D010862_D002375 CID <e1>pilocarpine</e1> cholinomimetic doses induce <e2>catalepsy</e2>
D010862_D002375 CID <e1>pilocarpine</e1> doses caused enhancement <e2>catalepsy</e2>
D001285_D002375 NONE <e1>atropine</e1> blocker disrupted <e2>catalepsy</e2>
D000109_D002375 NONE <e1>acetylcholine-synthesis</e1> inhibitor injection prevented <e2>catalepsy</e2>
D006426_D002375 NONE <e1>hemicholinium</e1> inhibitor injection prevented <e2>catalepsy</e2>
25084821
C069541_D009503 CID <e1>quetiapine-induced</e1> <e2>neutropenia</e2>
C069541_D009503 CID <e1>quetiapine</e1> derivative has risk causing dyscrasias <e2>neutropenia</e2>
C069541_D009503 CID <e1>quetiapine</e1> treatment developed <e2>neutropenia</e2>
C069541_D009503 CID <e1>quetiapine</e1> effect <e2>neutropenia</e2>
C069541_D001714 NONE <e1>quetiapine-induced</e1> neutropenia patient <e2>bipolar</e2>
C069541_D006528 NONE <e1>quetiapine-induced</e1> neutropenia patient <e2>carcinoma</e2>
C069541_D006528 NONE <e1>quetiapine</e1> treatment developed patient <e2>carcinoma</e2>
C069541_D006402 NONE <e1>quetiapine</e1> derivative has risk causing <e2>dyscrasias</e2>
D003024_D006402 NONE <e1>clozapine</e1> similar derivative has risk causing <e2>dyscrasias</e2>
D003024_D009503 NONE <e1>clozapine</e1> similar derivative has risk causing dyscrasias <e2>neutropenia</e2>
C069541_D007970 CID <e1>quetiapine</e1> treated developed <e2>leucopenia</e2>
C069541_D008107 NONE <e1>quetiapine</e1> reaction marker one <e2>dysfunction</e2>
C069541_D005334 CID <e1>quetiapine</e1> reaction marker <e2>fever</e2>
18341442
C026098_C562694 NONE <e1>levetiracetam</e1> adjunct treatment cats <e2>epilepsy</e2>
C026098_C562694 NONE <e1>levetiracetam</e1> administered adjunct treatment cats <e2>epilepsy</e2>
C026098_C562694 NONE <e1>levetiracetam</e1> tolerated useful adjunct treatment cats <e2>epilepsy</e2>
D010634_C562694 NONE <e1>phenobarbital</e1> treatment cats <e2>epilepsy</e2>
D010634_C562694 NONE <e1>phenobarbital</e1> treatment cats <e2>epilepsy</e2>
D010634_C562694 NONE <e1>phenobarbital</e1> controlled <e2>epilepsy</e2>
D010634_C562694 NONE <e1>phenobarbital</e1> treated had controlled <e2>epilepsy</e2>
D010634_C562694 NONE <e1>phenobarbital</e1> treatment cats <e2>epilepsy</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment initiation frequencies <e2>seizure</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment frequency <e2>seizure</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment <e2>seizures/mo</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment frequency higher frequency <e2>seizure</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment frequency higher <e2>seizures/mo</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment frequency higher reduction frequency <e2>seizure</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment initiation higher frequency <e2>seizure</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment initiation higher frequency treatment <e2>seizures/mo</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment initiation higher frequency <e2>seizure</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment initiation higher <e2>seizures/mo</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment initiation higher reduction frequency <e2>seizure</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment responded classified higher frequency <e2>seizure</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment responded classified higher frequency treatment <e2>seizures/mo</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment responded classified higher frequency <e2>seizure</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment responded classified higher <e2>seizures/mo</e2>
C026098_D012640 NONE <e1>levetiracetam</e1> treatment responded classified higher reduction frequency <e2>seizure</e2>
24341598
D012965_D007674 NONE <e1>chloride</e1> effects comparison prevention <e2>nephropathy</e2>
D004110_D007674 NONE <e1>diltiazem</e1> comparison prevention <e2>nephropathy</e2>
D003287_D007674 NONE <e1>contrast-induced</e1> <e2>nephropathy</e2>
D003287_D007674 NONE <e1>contrast-induced</e1> <e2>nephropathy</e2>
D003287_D058186 CID <e1>contrast</e1> material injected developed <e2>failure</e2>
D003287_D058186 CID <e1>contrast</e1> material injected developed failure <e2>arf</e2>
17028363
D000880_D058186 NONE <e1>anthraquinones</e1> containing pills intake associated <e2>failure</e2>
D000880_D058186 NONE <e1>anthraquinone</e1> derivatives contained use <e2>failure</e2>
D000880_D058186 NONE <e1>anthraquinone-containing</e1> agent <e2>injury</e2>
D004365_D007674 NONE <e1>herbs</e1> caused <e2>nephropathy</e2>
D034341_D007674 NONE <e1>acids</e1> use involving reported <e2>nephropathy</e2>
D004365_D058186 CID <e1>herbal</e1> pill use <e2>failure</e2>
D004008_D058186 CID <e1>diclofenac</e1> aggravated <e2>injury</e2>
D000880_D007674 NONE <e1>anthraquinone-containing</e1> agent use relationship remains considered <e2>nephropathy</e2>
D000880_D051437 NONE <e1>anthraquinone-containing</e1> agent use relationship remains considered patients present <e2>failure</e2>
24911645
C573355_D012640 NONE <e1>fc</e1> pretreated <e2>seizures</e2>
C573355_D012640 NONE <e1>gfc</e1> effects evaluate doses mg/kg parameters <e2>seizure</e2>
C573355_D012640 NONE <e1>gfc</e1> effects evaluate aimed study levels activity hippocampus <e2>seizures</e2>
C573355_D012640 NONE <e1>gfc</e1> produced <e2>seizure</e2>
C573355_D012640 NONE <e1>gfc</e1> exert demonstrated <e2>seizure</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> <e2>seizures</e2>
D010862_D012640 CID <e1>pilocarpine-induced</e1> epilepticus installation frequency reduce exert demonstrated <e2>seizure</e2>
D000596_D012640 NONE <e1>acid</e1> effects activity determine evaluate doses mg/kg parameters <e2>seizure</e2>
D000596_D012640 NONE <e1>acid</e1> effects activity determine evaluate aimed study levels activity hippocampus <e2>seizures</e2>
D005680_D012640 NONE <e1>acid</e1> acid effects activity determine evaluate doses mg/kg parameters <e2>seizure</e2>
D005680_D012640 NONE <e1>acid</e1> acid effects activity determine evaluate aimed study levels activity hippocampus <e2>seizures</e2>
D005680_D012640 NONE <e1>gaba</e1> acid acid effects activity determine evaluate doses mg/kg parameters <e2>seizure</e2>
D005680_D012640 NONE <e1>gaba</e1> acid acid effects activity determine evaluate aimed study levels activity hippocampus <e2>seizures</e2>
D018698_D012640 NONE <e1>glutamine</e1> acid acid effects activity determine evaluate doses mg/kg parameters <e2>seizure</e2>
D018698_D012640 NONE <e1>glutamine</e1> acid acid effects activity determine evaluate aimed study levels activity hippocampus <e2>seizures</e2>
D001224_D012640 NONE <e1>aspartate</e1> acid acid effects activity determine evaluate doses mg/kg parameters <e2>seizure</e2>
D001224_D012640 NONE <e1>aspartate</e1> acid acid effects activity determine evaluate aimed study levels activity hippocampus <e2>seizures</e2>
D005978_D012640 NONE <e1>glutathione</e1> aspartate acid acid effects activity determine evaluate doses mg/kg parameters <e2>seizure</e2>
D005978_D012640 NONE <e1>glutathione</e1> aspartate acid acid effects activity determine evaluate aimed study levels activity hippocampus <e2>seizures</e2>
C573355_D013226 NONE <e1>gfc</e1> exert reduce frequency installation <e2>epilepticus</e2>
D010862_D013226 CID <e1>pilocarpine-induced</e1> <e2>epilepticus</e2>
1905439
D016595_D003693 CID <e1>misoprostol</e1> administration associated woman <e2>delirium</e2>
D016595_D003693 CID <e1>misoprostol</e1> improved <e2>delirium</e2>
D016595_D003693 CID <e1>misoprostol</e1> therapy resulted <e2>delirium</e2>
D016595_D006261 NONE <e1>misoprostol</e1> associated reactions symptoms <e2>headache</e2>
12059909
D003520_D064420 NONE <e1>cyclophosphamide</e1> <e2>toxicity</e2>
D003520_D064420 NONE <e1>cy</e1> <e2>toxicity</e2>
D003520_D064420 NONE <e1>cy</e1> <e2>toxicity</e2>
D003520_D006470 CID <e1>cy</e1> toxicity caused cystitis <e2>haemorrhagic</e2>
D003520_D003556 CID <e1>cy</e1> toxicity caused <e2>cystitis</e2>
D003520_D003556 CID <e1>cy</e1> injection days appeared forms <e2>cystitis</e2>
26002693
C031763_D015464 NONE <e1>1,3-butadiene</e1> <e2>cml</e2>
C031763_D015464 NONE <e1>1,3-butadiene</e1> studies unassigned suggest associated <e2>leukemia</e2>
C031763_D015464 NONE <e1>1,3-butadiene</e1> studies unassigned suggest associated leukemia <e2>cml</e2>
3289726
D005047_D009422 NONE <e1>etoposide</e1> therapy <e2>dysfunction</e2>
D005047_D005910 NONE <e1>etoposide</e1> therapy <e2>glioma</e2>
D005047_D005910 NONE <e1>etoposide</e1> therapy <e2>glioma</e2>
D005047_D009369 NONE <e1>etoposide</e1> used treatment <e2>tumors</e2>
D005047_D009369 NONE <e1>213</e1> vp-16 etoposide used treatment <e2>tumors</e2>
D005047_D019337 NONE <e1>etoposide</e1> used treatment tumors <e2>malignancies</e2>
D005047_D019337 NONE <e1>213</e1> vp-16 etoposide used treatment tumors <e2>malignancies</e2>
D005047_D064420 NONE <e1>etoposide</e1> therapy <e2>toxicity</e2>
1615846
D015248_D006951 NONE <e1>gemfibrozil-lovastatin</e1> therapy <e2>hyperlipoproteinemias</e2>
D008148_D006951 NONE <e1>gemfibrozil-lovastatin</e1> therapy <e2>hyperlipoproteinemias</e2>
D015248_D006949 NONE <e1>gemfibrozil-lovastatin</e1> treatment safety assess patients <e2>hyperlipidemia</e2>
D015248_D002340 NONE <e1>gemfibrozil-lovastatin</e1> treatment safety assess had <e2>disease</e2>
D008148_D006949 NONE <e1>gemfibrozil-lovastatin</e1> treatment safety assess patients <e2>hyperlipidemia</e2>
D008148_D002340 NONE <e1>gemfibrozil-lovastatin</e1> treatment safety assess had <e2>disease</e2>
D003401_D009220 NONE <e1>creatine</e1> phosphokinase % occurred <e2>myositis</e2>
D003401_D012206 NONE <e1>creatine</e1> phosphokinase % occurred had <e2>rhabdomyolysis</e2>
D003401_D009212 NONE <e1>creatine</e1> phosphokinase % occurred had rhabdomyolysis <e2>myoglobinuria</e2>
17384765
D004113_D003072 CID <e1>succimer</e1> learning attention produces lasting <e2>impairment</e2>
D004113_D003072 NONE <e1>succimer</e1> treatment <e2>dysfunction</e2>
D007854_D003072 NONE <e1>lead-exposed</e1> rats regulation attention produces lasting <e2>impairment</e2>
D007854_D003072 NONE <e1>lead</e1> exposure absence learning attention produces lasting <e2>impairment</e2>
D007854_D003072 NONE <e1>pb</e1> exposed rats treatment <e2>dysfunction</e2>
D007854_D003072 NONE <e1>pb</e1> regimen produced that magnitude comparable <e2>dysfunction</e2>
D007854_D003072 NONE <e1>pb</e1> exposure alleviate <e2>deficits</e2>
D007854_D007855 NONE <e1>pb</e1> exposure model agent treatment <e2>poisoning</e2>
D004113_D007855 NONE <e1>succimer</e1> treatment exposure model agent treatment <e2>poisoning</e2>
D007854_D007859 CID <e1>pb</e1> exposure produced impairments learning attention control <e2>regulation</e2>
D007854_D007859 CID <e1>pb-exposed</e1> children seen dysfunction areas paralleling produced impairments learning attention control <e2>regulation</e2>
D007854_D019958 CID <e1>pb</e1> exposure produced impairments learning attention control <e2>regulation</e2>
D007854_D019958 CID <e1>pb-exposed</e1> children seen dysfunction areas paralleling produced impairments learning attention control <e2>regulation</e2>
D004113_D019964 NONE <e1>succimer</e1> treatment <e2>dysfunction</e2>
D007854_D019964 NONE <e1>pb</e1> exposed rats treatment <e2>dysfunction</e2>
D007854_D019964 NONE <e1>pb</e1> regimen produced that magnitude comparable <e2>dysfunction</e2>
15625689
D007980_D010300 NONE <e1>levodopa-induced</e1> dyskinesia characterize dynamics patients <e2>pd</e2>
D007980_D010300 NONE <e1>levodopa</e1> role suggest confirm predictor alterations <e2>pd</e2>
D007980_D004409 CID <e1>levodopa-induced</e1> <e2>dyskinesia</e2>
D007980_D004409 CID <e1>levodopa</e1> dose basis explained study patients <e2>dyskinetic</e2>
D007980_D003680 NONE <e1>levodopa</e1> role suggest confirm predictor <e2>dysphagia</e2>
448423
D000614_D013345 NONE <e1>acid</e1> therapy associated <e2>hemorrhage</e2>
D000614_D007674 NONE <e1>acid</e1> therapy <e2>thrombosis</e2>
D015119_D013345 CID <e1>acid</e1> used prevent rebleeding patients <e2>hemorrhage</e2>
D015119_D013345 CID <e1>acid</e1> used prevent rebleeding patients hemorrhage <e2>sah</e2>
D015119_D013345 CID <e1>eaca</e1> acid used prevent rebleeding patients <e2>hemorrhage</e2>
D015119_D013345 CID <e1>eaca</e1> acid used prevent rebleeding patients hemorrhage <e2>sah</e2>
D015119_D013345 CID <e1>eaca</e1> treated syndromes patients thrombi deterioration patients <e2>sah</e2>
D015119_D013345 CID <e1>eaca</e1> therapy patient <e2>sah</e2>
D015119_D013345 CID <e1>eaca</e1> therapy patient documentation <e2>sah</e2>
D015119_D013927 CID <e1>eaca</e1> therapy complications <e2>thrombotic</e2>
D015119_D013927 CID <e1>eaca</e1> treated syndromes patients <e2>thrombi</e2>
D015119_D013927 CID <e1>eaca</e1> implicated observed <e2>thrombi</e2>
D015119_D013927 CID <e1>eaca</e1> implicated pathogenesis <e2>thrombi</e2>
D015119_D020767 CID <e1>eaca</e1> treated syndromes patients thrombi deterioration <e2>thrombosis</e2>
D015119_D013923 NONE <e1>eaca</e1> treated syndromes patients thrombi deterioration <e2>phenomena</e2>
D015119_D004211 NONE <e1>eaca</e1> implicated pathogenesis thrombi patients <e2>coagulation</e2>
D015119_D004211 NONE <e1>eaca</e1> implicated pathogenesis thrombi patients coagulation <e2>coagulopathies</e2>
D015119_D007238 NONE <e1>eaca</e1> implicated describes <e2>infarction</e2>
D015119_D007674 CID <e1>eaca</e1> implicated describes infarction thrombosis <e2>artery</e2>
8755612
D004967_D009369 NONE <e1>estrogen-induced</e1> tumor separation growth <e2>tumor</e2>
D004967_D009369 NONE <e1>estrogen-induced</e1> <e2>tumor</e2>
D004967_D006470 NONE <e1>estrogen-induced</e1> tumor separation growth phenotypes <e2>hemorrhagic</e2>
D004967_D006470 NONE <e1>estrogen</e1> administration induces growth tumors <e2>hemorrhagic</e2>
D004967_D010911 NONE <e1>estrogen</e1> administration induces growth <e2>tumors</e2>
D004054_D006470 NONE <e1>diethylstilbestrol</e1> treatment weeks caused become <e2>hemorrhagic</e2>
D004054_D006470 NONE <e1>des</e1> treatment weeks caused become <e2>hemorrhagic</e2>
D004054_D006470 NONE <e1>des-induced</e1> growth exhibited exhibited phenotype <e2>hemorrhagic</e2>
12452552
D018967_D007676 NONE <e1>risperidone</e1> administration developed patient <e2>failure</e2>
D018967_D007676 NONE <e1>risperidone</e1> administration developed patient failure <e2>crf</e2>
D018967_D009459 CID <e1>risperidone</e1> administration developed <e2>syndrome</e2>
D018967_D009459 CID <e1>risperidone</e1> administration developed syndrome <e2>nms</e2>
D008728_D007676 NONE <e1>levomepromazine</e1> risperidone administration developed patient <e2>failure</e2>
D008728_D007676 NONE <e1>levomepromazine</e1> risperidone administration developed patient failure <e2>crf</e2>
D008728_D009459 CID <e1>levomepromazine</e1> risperidone administration developed <e2>syndrome</e2>
D008728_D009459 CID <e1>levomepromazine</e1> risperidone administration developed syndrome <e2>nms</e2>
24126708
D007980_D010300 NONE <e1>levodopa</e1> effects patients <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa</e1> therapy <e2>disease</e2>
D007980_D004409 CID <e1>levodopa</e1> therapy lead outcomes fluctuations <e2>dyskinesia</e2>
D007980_D006212 CID <e1>levodopa</e1> therapy lead outcomes fluctuations dyskinesia <e2>hallucinations</e2>
11708428
D011241_D001008 CID <e1>prednisone</e1> induces <e2>anxiety</e2>
D011241_D001008 CID <e1>prednisone</e1> pdn produces <e2>anxiety</e2>
D011241_D001008 CID <e1>pdn</e1> produces <e2>anxiety</e2>
D011241_D001008 CID <e1>pdn</e1> treated rats groups documented <e2>anxiety</e2>
D011241_D001008 CID <e1>pdn</e1> exposure induced <e2>anxiety</e2>
1858969
D004049_D004660 CID <e1>diethylcarbamazine</e1> treatment cases <e2>encephalitis</e2>
D004049_D004660 CID <e1>diethylcarbamazine</e1> treatment cases <e2>encephalitis</e2>
D004049_D004660 CID <e1>dec</e1> diethylcarbamazine treatment cases <e2>encephalitis</e2>
D004049_D008118 NONE <e1>diethylcarbamazine</e1> treatment <e2>loiasis</e2>
D004049_D005368 NONE <e1>diethylcarbamazine</e1> treatment cases observed patients <e2>filariasis</e2>
D004049_D005368 NONE <e1>dec</e1> diethylcarbamazine treatment cases observed patients <e2>filariasis</e2>
6615679
D013999_D001919 CID <e1>timolol</e1> associated <e2>bradycardia</e2>
D013999_D001919 CID <e1>maleate</e1> drops nitrate treated man developed <e2>bradycardia</e2>
D013999_D007022 CID <e1>timolol</e1> associated bradycardia <e2>hypotension</e2>
D013999_D007022 CID <e1>maleate</e1> drops nitrate treated man developed became <e2>hypotensive</e2>
D010862_D001919 CID <e1>pilocarpine</e1> timolol associated <e2>bradycardia</e2>
D010862_D001919 CID <e1>nitrate</e1> treated man developed <e2>bradycardia</e2>
D010862_D007022 CID <e1>pilocarpine</e1> timolol associated bradycardia <e2>hypotension</e2>
D010862_D007022 CID <e1>nitrate</e1> treated man developed became <e2>hypotensive</e2>
D006221_D001919 NONE <e1>halothane</e1> anaesthesia hypotensive became developed <e2>bradycardia</e2>
D006221_D001919 NONE <e1>halothane</e1> anaesthesia enhanced <e2>bradycardia</e2>
D006221_D007022 NONE <e1>halothane</e1> anaesthesia <e2>hypotensive</e2>
D006221_D007022 NONE <e1>halothane</e1> anaesthesia enhanced bradycardia <e2>hypotension</e2>
24088636
C098010_D009901 CID <e1>linezolid-induced</e1> optic <e2>neuropathy</e2>
C098010_D014786 NONE <e1>linezolid</e1> therapy associated <e2>vision</e2>
C098010_D014786 NONE <e1>linezolid</e1> drugs treatment tuberculosis presented loss <e2>vision</e2>
C098010_D054908 NONE <e1>linezolid</e1> drugs treatment <e2>tuberculosis</e2>
C098010_D054908 NONE <e1>linezolid</e1> drugs treatment tuberculosis <e2>xdr-tb</e2>
D004977_D054908 NONE <e1>ethambutol</e1> linezolid drugs treatment <e2>tuberculosis</e2>
D004977_D054908 NONE <e1>ethambutol</e1> linezolid drugs treatment tuberculosis <e2>xdr-tb</e2>
D004977_D014786 NONE <e1>ethambutol</e1> linezolid drugs treatment tuberculosis presented loss <e2>vision</e2>
D004977_D009901 NONE <e1>ethambutol-induced</e1> <e2>neuropathy</e2>
D004977_D009901 NONE <e1>ethambutol</e1> withdrawn suspected <e2>neuropathy</e2>
D004977_D015354 NONE <e1>ethambutol</e1> withdrawal occurred deterioration <e2>vision</e2>
24727461
C005975_D028361 NONE <e1>hydroxytyrosol</e1> ameliorates stress <e2>dysfunction</e2>
C005975_D066126 NONE <e1>hydroxytyrosol</e1> ameliorates stress <e2>cardiotoxicity</e2>
C005975_D066126 NONE <e1>hydroxytyrosol</e1> ameliorated <e2>toxicity</e2>
C005975_D001943 NONE <e1>hydroxytyrosol</e1> ameliorates stress cardiotoxicity rats <e2>cancer</e2>
C005975_D001943 NONE <e1>hydroxytyrosol</e1> rats <e2>cancer</e2>
C005975_D001943 NONE <e1>hydroxytyrosol</e1> control groups divided rats bearing <e2>tumors</e2>
C005975_D001943 NONE <e1>hydroxytyrosol</e1> doxorubicin groups divided rats bearing <e2>tumors</e2>
D004317_D028361 NONE <e1>doxorubicin-induced</e1> cardiotoxicity stress <e2>dysfunction</e2>
D004317_D028361 NONE <e1>doxorubicin</e1> causes cardiotoxicity characterized increases stress <e2>dysfunction</e2>
D004317_D066126 NONE <e1>doxorubicin-induced</e1> <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin</e1> causes <e2>cardiotoxicity</e2>
D004317_D066126 NONE <e1>doxorubicin-associated</e1> <e2>toxicity</e2>
D004317_D001943 NONE <e1>doxorubicin-induced</e1> cardiotoxicity rats <e2>cancer</e2>
D004317_D001943 NONE <e1>doxorubicin-associated</e1> toxicity ameliorated hydroxytyrosol rats <e2>cancer</e2>
D004317_D001943 NONE <e1>doxorubicin</e1> groups divided rats bearing <e2>tumors</e2>
D004317_D001943 NONE <e1>doxorubicin</e1> groups divided rats bearing <e2>tumors</e2>
D004317_D009369 NONE <e1>doxorubicin</e1> drugs effect potentiate shown involved processes <e2>cancer</e2>
D004317_D002318 NONE <e1>doxorubicin</e1> drugs effect potentiate shown involved processes cancer <e2>disease</e2>
C005975_D006331 NONE <e1>hydroxytyrosol</e1> improved <e2>disturbances</e2>
C005975_D006331 NONE <e1>hydroxytyrosol</e1> <e2>damage</e2>
D004317_D006331 CID <e1>doxorubicin</e1> enhanced <e2>disturbances</e2>
D004317_D006331 CID <e1>doxorubicin</e1> provoked <e2>damage</e2>
1424076
D014750_D007177 CID <e1>vincristine</e1> syndrome secretion <e2>hormone</e2>
D014750_D007177 CID <e1>vincristine</e1> infusion attributed <e2>hormone</e2>
D014750_D009101 NONE <e1>vincristine</e1> infusion treated woman <e2>myeloma</e2>
D004317_D009101 NONE <e1>doxorubicin</e1> vincristine infusion treated woman <e2>myeloma</e2>
D003907_D009101 NONE <e1>dexamethasone</e1> days infusion treated woman <e2>myeloma</e2>
24554916
D010758_D002779 CID <e1>phosphorus</e1> poisoning presentation <e2>cholestatic</e2>
D010758_D002779 CID <e1>phosphorus</e1> poisoning case patient presented features <e2>cholestasis</e2>
D010758_D002779 CID <e1>phosphorus</e1> poisoning case patient highlighting fact feature <e2>cholestasis</e2>
D010758_D002779 CID <e1>phosphorus</e1> hepatotoxicity feature fact highlighting patient presented features <e2>cholestasis</e2>
D010758_D002779 CID <e1>phosphorus</e1> hepatotoxicity feature <e2>cholestasis</e2>
D010758_D011041 NONE <e1>phosphorus</e1> <e2>poisoning</e2>
D010758_D011041 NONE <e1>phosphorus</e1> <e2>poisoning</e2>
D010758_D011041 NONE <e1>phosphorus</e1> <e2>poisoning</e2>
D010758_D011041 NONE <e1>phosphorus</e1> hepatotoxicity feature fact highlighting patient case <e2>poisoning</e2>
D010758_D056486 NONE <e1>phosphorus</e1> known cause <e2>hepatotoxicity</e2>
D010758_D056486 NONE <e1>phosphorus</e1> poisoning case patient highlighting fact feature <e2>hepatotoxicity</e2>
D010758_D056486 NONE <e1>phosphorus</e1> <e2>hepatotoxicity</e2>
D010758_D006505 CID <e1>phosphorus</e1> poisoning manifests <e2>hepatitis</e2>
D010758_D017114 CID <e1>phosphorus</e1> poisoning manifests hepatitis leading <e2>failure</e2>
24571687
D020927_D019462 CID <e1>dexmedetomidine</e1> <e2>syncope</e2>
D020927_D001919 CID <e1>dexmedetomidine</e1> syncope <e2>bradycardia</e2>
D020927_D001919 CID <e1>dexmedetomidine</e1> administration girl report syncope <e2>bradycardia</e2>
D020927_D013575 NONE <e1>dexmedetomidine</e1> administration girl report <e2>syncope</e2>
8312983
D005473_D003693 CID <e1>fluoxetine</e1> treatment <e2>delirium</e2>
D005473_D003693 CID <e1>fluoxetine</e1> connected <e2>delirium</e2>
D005473_D003693 CID <e1>fluoxetine</e1> fluoxetine connected <e2>delirium</e2>
D015283_D006970 NONE <e1>citalopram</e1> concentration associated <e2>somnolence</e2>
D015283_D020820 NONE <e1>citalopram</e1> concentration associated somnolence <e2>difficulties</e2>
D005473_D006948 CID <e1>fluoxetine</e1> connected delirium <e2>hyperkinetic</e2>
D005473_D006948 CID <e1>fluoxetine</e1> fluoxetine connected delirium <e2>hyperkinetic</e2>
C036139_D006948 NONE <e1>desmethylfluoxetine</e1> fluoxetine fluoxetine connected delirium <e2>hyperkinetic</e2>
C036139_D003693 NONE <e1>desmethylfluoxetine</e1> fluoxetine fluoxetine connected <e2>delirium</e2>
12372954
D009530_D009395 CID <e1>nicergoline</e1> <e2>nephritis</e2>
D009530_D009395 CID <e1>sermion</e1> nicergoline <e2>nephritis</e2>
D009530_D009395 CID <e1>nicergoline</e1> case <e2>nephritis</e2>
D009530_D009395 CID <e1>nicergoline</e1> case nephritis <e2>ain</e2>
D009530_D009395 CID <e1>sermion</e1> nicergoline case <e2>nephritis</e2>
D009530_D009395 CID <e1>sermion</e1> nicergoline case nephritis <e2>ain</e2>
D009530_D009395 CID <e1>nicergoline-associated</e1> <e2>ain</e2>
D009530_D012170 NONE <e1>nicergoline</e1> taking <e2>occlusion</e2>
C036067_D012170 NONE <e1>lysine</e1> nicergoline taking <e2>occlusion</e2>
1564030
D005473_D001714 CID <e1>fluoxetine</e1> treatment associated <e2>mania</e2>
D005473_D001714 CID <e1>fluoxetine</e1> reported induce <e2>mania</e2>
D005473_D001714 CID <e1>fluoxetine</e1> pharmacotherapy developed <e2>mania</e2>
D005473_D001714 CID <e1>fluoxetine</e1> pharmacotherapy development <e2>mania</e2>
D005473_D001714 CID <e1>fluoxetine</e1> pharmacotherapy development mania <e2>hypomania</e2>
D005473_D001714 CID <e1>fluoxetine</e1> pharmacotherapy development factors combination history disorder <e2>disorder</e2>
D005473_D001714 CID <e1>fluoxetine</e1> pharmacotherapy development factors combination diagnosis <e2>disorder</e2>
D005473_D001714 CID <e1>fluoxetine</e1> <e2>mania</e2>
D005473_D003866 NONE <e1>fluoxetine</e1> gaining acceptance treatment <e2>depression</e2>
D005473_D003866 NONE <e1>fluoxetine</e1> pharmacotherapy developed cases adolescents <e2>depressed</e2>
D005473_D003866 NONE <e1>fluoxetine</e1> pharmacotherapy development factors combination <e2>depression</e2>
D012701_D003866 NONE <e1>serotonin</e1> inhibitor fluoxetine gaining acceptance treatment <e2>depression</e2>
D005473_D001289 NONE <e1>fluoxetine</e1> pharmacotherapy development factors combination <e2>disorder</e2>
D005473_D011618 NONE <e1>fluoxetine</e1> pharmacotherapy development factors combination depression features <e2>psychotic</e2>
D005473_D019964 NONE <e1>fluoxetine</e1> pharmacotherapy development factors combination history <e2>disorder</e2>
19553912
D020123_D000740 CID <e1>sirolimus</e1> role <e2>anemia</e2>
D020123_D000740 CID <e1>sirolimus</e1> implicated playing role <e2>anemia</e2>
D020123_D000740 CID <e1>rapamycin</e1> inhibitor target sirolimus implicated playing role <e2>anemia</e2>
D020123_D000740 CID <e1>sirolimus</e1> associated <e2>anemia</e2>
17496739
C085143_D012640 NONE <e1>piperacillin/tazobactam-induced</e1> <e2>seizure</e2>
D010878_D020258 NONE <e1>piperacillin</e1> <e2>neurotoxicity</e2>
D010878_D020258 NONE <e1>piperacillin</e1> associated <e2>neurotoxicity</e2>
C085143_D007676 NONE <e1>piperacillin/tazobactam</e1> doses episodes behavior tremor speech developed <e2>disease</e2>
C085143_D014202 CID <e1>piperacillin/tazobactam</e1> doses episodes behavior <e2>tremor</e2>
C085143_D003221 CID <e1>piperacillin/tazobactam</e1> doses episodes behavior <e2>confusion</e2>
C085143_D004830 CID <e1>piperacillin/tazobactam</e1> doses of <e2>seizure</e2>
C085143_D004830 CID <e1>piperacillin/tazobactam</e1> doses of seizure <e2>gtcs</e2>
C085143_D004830 CID <e1>piperacillin/tazobactam</e1> dose recurred episode <e2>gtcs</e2>
C085143_D001987 NONE <e1>piperacillin/tazobactam</e1> doses episodes behavior tremor speech developed disease woman report given <e2>bronchiectasis</e2>
C085143_D060085 NONE <e1>piperacillin/tazobactam</e1> doses episodes behavior tremor speech developed disease woman report given bronchiectasis <e2>infection</e2>
D000641_D007964 NONE <e1>ammonia</e1> electrolyte <e2>leukocytosis</e2>
D010878_D001927 NONE <e1>piperacillin-induced</e1> <e2>encephalopathy</e2>
D010878_D001927 NONE <e1>piperacillin</e1> removing inefficient terminate <e2>encephalopathy</e2>
D010878_D001927 NONE <e1>piperacillin-induced</e1> <e2>encephalopathy</e2>
D010878_D006463 NONE <e1>piperacillin-induced</e1> encephalopathy considered patients <e2>uremic</e2>
12119460
D005472_D013274 NONE <e1>5-fluorouracil</e1> folinic acid combination treatment <e2>cancer</e2>
D005472_D013274 NONE <e1>5-fluorouracil</e1> infusion part regimens <e2>cancer</e2>
D005472_D013274 NONE <e1>5-fluorouracil</e1> infusion part regimens cancer <e2>agc</e2>
D005472_D013274 NONE <e1>5-fu</e1> 5-fluorouracil infusion part regimens <e2>cancer</e2>
D005472_D013274 NONE <e1>5-fu</e1> 5-fluorouracil infusion part regimens cancer <e2>agc</e2>
D005472_D013274 NONE <e1>5-fu</e1> mg/m(2 receive recruited patients <e2>agc</e2>
D005472_D013274 NONE <e1>5-fu/fa/mmc</e1> regimen <e2>agc</e2>
D002955_D013274 NONE <e1>acid</e1> combination treatment <e2>cancer</e2>
D002955_D013274 NONE <e1>acid</e1> 5-fluorouracil infusion part regimens <e2>cancer</e2>
D002955_D013274 NONE <e1>acid</e1> 5-fluorouracil infusion part regimens cancer <e2>agc</e2>
D002955_D013274 NONE <e1>fa</e1> acid 5-fluorouracil infusion part regimens <e2>cancer</e2>
D002955_D013274 NONE <e1>fa</e1> acid 5-fluorouracil infusion part regimens cancer <e2>agc</e2>
D002955_D013274 NONE <e1>fa</e1> preceded mg/m(2 receive recruited patients <e2>agc</e2>
D002955_D013274 NONE <e1>5-fu/fa/mmc</e1> regimen <e2>agc</e2>
D016685_D013274 NONE <e1>c</e1> combination treatment <e2>cancer</e2>
D016685_D013274 NONE <e1>5-fu/fa/mmc</e1> regimen <e2>agc</e2>
D005472_D064420 NONE <e1>5-fluorouracil</e1> infusion shown effective <e2>toxicity</e2>
D005472_D064420 NONE <e1>5-fu</e1> 5-fluorouracil infusion shown effective <e2>toxicity</e2>
D005472_D064420 NONE <e1>5-fu</e1> study found rate <e2>toxicity</e2>
D002955_D064420 NONE <e1>acid</e1> 5-fluorouracil infusion shown effective <e2>toxicity</e2>
D002955_D064420 NONE <e1>fa</e1> acid 5-fluorouracil infusion shown effective <e2>toxicity</e2>
D002955_D064420 NONE <e1>fa</e1> c 5-fu study found rate <e2>toxicity</e2>
D016685_D064420 NONE <e1>c</e1> 5-fu study found rate <e2>toxicity</e2>
D016685_D064420 NONE <e1>mmc</e1> c 5-fu study found rate <e2>toxicity</e2>
D002945_D006463 NONE <e1>cisplatin-containing</e1> regimens alternative serve has considered occur <e2>hus</e2>
12912689
D016190_D012175 NONE <e1>carboplatin</e1> chemotherapy <e2>retinoblastoma</e2>
D016190_D012175 NONE <e1>carboplatin</e1> injections used adjunct chemotherapy <e2>retinoblastoma</e2>
D016190_D012175 NONE <e1>carboplatin</e1> received patients <e2>retinoblastoma</e2>
D016190_D012175 NONE <e1>carboplatin</e1> injections <e2>retinoblastoma</e2>
D016190_D064420 NONE <e1>carboplatin</e1> injections used adjunct <e2>toxicity-free</e2>
D016190_D064420 NONE <e1>carboplatin</e1> free <e2>toxicity</e2>
D016190_D015835 CID <e1>carboplatin</e1> chemotherapy treated patients <e2>motility</e2>
D016190_D015835 CID <e1>carboplatin</e1> received patients <e2>motility</e2>
D016190_D005355 CID <e1>carboplatin</e1> chemotherapy associated <e2>fibrosis</e2>
9158667
D014212_D013927 CID <e1>acid</e1> therapy complications <e2>thrombotic</e2>
D014212_D015473 NONE <e1>acid</e1> therapy complications <e2>leukemia</e2>
D014212_D015473 NONE <e1>acid</e1> treated <e2>leukemia</e2>
D014212_D015473 NONE <e1>acid</e1> treated leukemia <e2>apl</e2>
D014212_D015473 NONE <e1>atra</e1> acid treated <e2>leukemia</e2>
D014212_D015473 NONE <e1>atra</e1> acid treated leukemia <e2>apl</e2>
D014212_D015473 NONE <e1>atra</e1> treated patient <e2>apl</e2>
D014212_D015473 NONE <e1>atra</e1> therapy patients <e2>apl</e2>
D014212_D015473 NONE <e1>atra</e1> protocol included presented signs <e2>apl</e2>
D014212_D015473 NONE <e1>atra</e1> choice patients <e2>apl</e2>
D014212_D058186 CID <e1>acid</e1> treated leukemia patient occlusion case <e2>failure</e2>
D014212_D058186 CID <e1>atra</e1> acid treated leukemia patient occlusion case <e2>failure</e2>
D014212_D058186 CID <e1>atra</e1> treated patient <e2>failure</e2>
D014212_-1 NONE <e1>acid</e1> treated leukemia patient occlusion <e2>vessels</e2>
D014212_-1 NONE <e1>atra</e1> acid treated leukemia patient occlusion <e2>vessels</e2>
D014148_D058186 NONE <e1>acid</e1> acid treated leukemia patient occlusion case <e2>failure</e2>
D014148_-1 NONE <e1>acid</e1> acid treated leukemia patient occlusion <e2>vessels</e2>
D014148_D015473 NONE <e1>acid</e1> acid treated <e2>leukemia</e2>
D014148_D015473 NONE <e1>acid</e1> acid treated leukemia <e2>apl</e2>
D014212_D013923 NONE <e1>atra</e1> therapy associated complications <e2>thromboembolic</e2>
D006493_D013927 NONE <e1>heparin</e1> using avoided events <e2>thrombotic</e2>
15265979
D000638_D056486 CID <e1>amiodarone</e1> reported cause <e2>hepatotoxicity</e2>
D000638_D056486 CID <e1>amiodarone</e1> effects <e2>hepatotoxic</e2>
D000638_D056486 CID <e1>amiodarone</e1> effects information provide indicate protects <e2>hepatotoxicity</e2>
D000638_D056486 CID <e1>amiodarone-induced</e1> hepatotoxicity protects indicate provide information effects <e2>hepatotoxic</e2>
D000638_D056486 CID <e1>amiodarone-induced</e1> <e2>hepatotoxicity</e2>
D000638_D006529 CID <e1>amiodarone</e1> induced <e2>hepatomegaly</e2>
D000638_D006529 CID <e1>amiodarone</e1> effects dependent indicated absence induction <e2>hepatomegaly</e2>
D014280_D006529 NONE <e1>triglycerides</e1> decrease induced <e2>hepatomegaly</e2>
D005947_D006529 NONE <e1>glucose</e1> triglycerides decrease induced <e2>hepatomegaly</e2>
D000638_D015431 NONE <e1>amiodarone</e1> treatment resulted rate extent <e2>loss</e2>
D000638_D006528 NONE <e1>amiodarone</e1> inability activate human pparalpha expressed cells <e2>hepatoma</e2>
D000638_D006528 NONE <e1>amiodarone</e1> effects indirect indicates activate human pparalpha expressed cells <e2>hepatoma</e2>
1117341
D015119_D006943 CID <e1>amino</e1> compounds effect <e2>hyperglycemic</e2>
D015119_D006943 CID <e1>amino</e1> derivatives amounts feeding resulted <e2>hyperglycemia</e2>
C037652_D006943 NONE <e1>caproate</e1> related effect <e2>hyperglycemic</e2>
C037652_D006943 NONE <e1>caproate</e1> derivatives amounts feeding resulted <e2>hyperglycemia</e2>
D015119_D006030 NONE <e1>amino</e1> derivatives amounts feeding resulted hyperglycemia <e2>glucosuria</e2>
C037652_D006030 NONE <e1>caproate</e1> derivatives amounts feeding resulted hyperglycemia <e2>glucosuria</e2>
D005947_D006943 NONE <e1>glucose</e1> curve <e2>hyperglycemia</e2>
D005947_D006030 NONE <e1>glucose</e1> curve hyperglycemia <e2>glucosuria</e2>
19108278
D011433_D001145 NONE <e1>propranolol</e1> isomers properties <e2>arrhythmias</e2>
D011433_D001145 NONE <e1>propranolol</e1> isomers capable preventing <e2>arrhythmias</e2>
D011433_D001145 NONE <e1>(-)-propranolol</e1> dose mg/kg capable preventing <e2>arrhythmias</e2>
D011433_D001145 NONE <e1>(+)-propranolol</e1> that mg/kg capable preventing <e2>arrhythmias</e2>
D004837_D001145 CID <e1>adrenaline-induced</e1> cardiac <e2>arrhythmias</e2>
D004837_D001145 CID <e1>adrenaline.7</e1> dose increasing surmountable blockade <e2>arrhythmias</e2>
D006221_D001145 CID <e1>halothane</e1> anaesthetized cats <e2>arrhythmias</e2>
D011433_D017180 NONE <e1>propranolol</e1> isomers capable reversing <e2>tachycardia</e2>
D010042_D017180 CID <e1>ouabain</e1> caused <e2>tachycardia</e2>
1451544
D017275_D006973 NONE <e1>isradipine</e1> treatment <e2>hypertension</e2>
D017275_D006261 CID <e1>isradipine</e1> studies reported frequent dizziness <e2>headache</e2>
D017275_D004244 CID <e1>isradipine</e1> studies reported frequent <e2>dizziness</e2>
D017275_-1 NONE <e1>isradipine</e1> studies reported frequent dizziness <e2>palpitation</e2>
D017275_D005483 CID <e1>isradipine</e1> studies reported frequent dizziness palpitation <e2>flushing</e2>
1395192
D001971_D009203 CID <e1>bromocriptine</e1> <e2>infarction</e2>
D001971_D009203 CID <e1>bromocriptine</e1> implicated reports <e2>infarction</e2>
3475563
D001507_D002180 CID <e1>dipropionate</e1> hoarseness <e2>candidiasis</e2>
D001507_D002180 CID <e1>beclomethasone</e1> placed patients developed hoarseness <e2>thrush</e2>
D001507_D006685 CID <e1>dipropionate</e1> <e2>hoarseness</e2>
D001507_D006685 CID <e1>beclomethasone</e1> placed patients developed <e2>hoarseness</e2>
D001507_D006685 CID <e1>beclomethasone</e1> restarted rate patients develop <e2>hoarseness</e2>
D001507_D006685 CID <e1>beclomethasone</e1> use increase risk developing <e2>hoarseness</e2>
D001507_D001249 NONE <e1>beclomethasone</e1> placed patients <e2>asthmatic</e2>
D011241_D006685 NONE <e1>prednisone</e1> use increase risk developing <e2>hoarseness</e2>
D011241_D002177 NONE <e1>prednisone</e1> use increase risk developing hoarseness <e2>candidiasis</e2>
D001507_D002177 NONE <e1>beclomethasone</e1> use increase risk developing hoarseness <e2>candidiasis</e2>
11799346
D015662_D001714 CID <e1>cotrimoxazole</e1> involved episodes <e2>manic</e2>
D008795_D001714 CID <e1>metronidazole</e1> cotrimoxazole involved episodes <e2>manic</e2>
D004917_D001714 CID <e1>erythromycin</e1> metronidazole cotrimoxazole involved episodes <e2>manic</e2>
D017291_D001714 CID <e1>clarithromycin</e1> showed associated development <e2>mania</e2>
D002939_D001714 CID <e1>ciprofloxacin</e1> clarithromycin showed associated development <e2>mania</e2>
10764869
D016559_D009901 CID <e1>tacrolimus</e1> patient <e2>neuropathy</e2>
D016559_D009901 CID <e1>fk506</e1> tacrolimus patient <e2>neuropathy</e2>
D016559_D009901 CID <e1>tacrolimus</e1> <e2>neuropathy</e2>
D016559_D009901 CID <e1>506</e1> fk tacrolimus <e2>neuropathy</e2>
D016559_D009901 CID <e1>tacrolimus</e1> associated <e2>toxicity</e2>
D016559_D015354 NONE <e1>tacrolimus</e1> discontinuation occurred deterioration <e2>vision</e2>
24595967
D018817_D008569 CID <e1>ecstasy</e1> users consolidation <e2>memory</e2>
D018817_D008569 CID <e1>ecstasy</e1> users demonstrated consolidation <e2>memory</e2>
D018817_D008569 CID <e1>ecstasy-associated</e1> dysfunction underlie <e2>impairments</e2>
D018817_D008569 CID <e1>ecstasy</e1> users <e2>impairments</e2>
D018817_D012893 CID <e1>ecstasy</e1> users marked <e2>impairments</e2>
48835
D011433_D007003 NONE <e1>propranolol</e1> effects <e2>hypoglycaemia</e2>
17572393
D008550_D054220 NONE <e1>melatonin</e1> effects model <e2>dysplasia</e2>
D008550_D054220 NONE <e1>melatonin</e1> effects <e2>dysplasia</e2>
D002330_D054220 CID <e1>bcnu-induced</e1> <e2>dysplasia</e2>
D002330_D054220 CID <e1>carmustine-[1,3-bis</e1> (2-chloroethyl)-1-nitrosoure exposure induced cerebellum alterations evaluate designed investigate effects <e2>dysplasia</e2>
D002330_D054220 CID <e1>(2-chloroethyl)-1-nitrosoure</e1> exposure induced cerebellum alterations evaluate designed investigate effects <e2>dysplasia</e2>
D002330_D054220 CID <e1>bcnu</e1> designed investigate effects <e2>dysplasia</e2>
D002330_D054220 CID <e1>bcnu-induced</e1> <e2>dysplasia</e2>
D002330_D054220 CID <e1>bcnu-exposed</e1> group <e2>dysplasia</e2>
12677626
C476513_D020258 NONE <e1>levobupivacaine</e1> administration <e2>toxicity</e2>
C476513_D004830 CID <e1>levobupivacaine</e1> injection describe cases <e2>seizures</e2>
C476513_D004830 CID <e1>levobupivacaine</e1> % administration developed <e2>seizures</e2>
D004837_D004830 NONE <e1>epinephrine</e1> % administration developed <e2>seizures</e2>
D004837_D004830 NONE <e1>epinephrine</e1> administration signs aspiration developed <e2>seizures</e2>
D013874_D012640 NONE <e1>thiopental</e1> treated <e2>seizures</e2>
D013390_D012640 NONE <e1>succinylcholine</e1> addition treated <e2>seizures</e2>
C476513_D066126 NONE <e1>levobupivacaine</e1> have profile <e2>toxicity</e2>
C476513_D066126 NONE <e1>levobupivacaine</e1> amounts reach have profile <e2>toxicity</e2>
C476513_D012640 NONE <e1>levobupivacaine</e1> have reach conclusions result <e2>convulsions</e2>
C476513_D012640 NONE <e1>levobupivacaine</e1> amounts reach conclusions result <e2>convulsions</e2>
D002045_D066126 NONE <e1>bupivacaine</e1> profile <e2>toxicity</e2>
D002045_D012640 NONE <e1>bupivacaine</e1> profile have reach conclusions result <e2>convulsions</e2>
7727612
D008140_D009207 CID <e1>lorazepam</e1> therapy associated <e2>myoclonus</e2>
D008140_D009207 CID <e1>lorazepam</e1> administration <e2>myoclonus</e2>
17543491
19293073
D001241_D003327 NONE <e1>aspirin</e1> discuss adults risk <e2>disease</e2>
D001241_D009203 NONE <e1>aspirin</e1> taking prevention <e2>infarctions</e2>
D001241_D009203 NONE <e1>aspirin</e1> reduces risk <e2>infarction</e2>
D001241_D020521 CID <e1>aspirin</e1> taking prevention infarctions <e2>strokes</e2>
D001241_D020521 CID <e1>aspirin</e1> reviews selected randomized decrease events <e2>strokes</e2>
D001241_D020521 CID <e1>aspirin</e1> reviews selected randomized decrease events strokes death events <e2>stroke</e2>
D001241_D020521 CID <e1>aspirin</e1> reviews selected randomized increase <e2>strokes</e2>
D001241_D020521 CID <e1>aspirin</e1> decrease events <e2>strokes</e2>
D001241_D020521 CID <e1>aspirin</e1> decrease events strokes death events <e2>stroke</e2>
D001241_D020521 CID <e1>aspirin</e1> decrease randomized increase <e2>strokes</e2>
D001241_D020521 CID <e1>aspirin</e1> increase randomized decrease events <e2>strokes</e2>
D001241_D020521 CID <e1>aspirin</e1> increase randomized decrease events strokes death events <e2>stroke</e2>
D001241_D020521 CID <e1>aspirin</e1> increase <e2>strokes</e2>
D001241_D020521 CID <e1>aspirin</e1> use <e2>strokes</e2>
D001241_D020521 CID <e1>aspirin</e1> reduces risk infarction men <e2>strokes</e2>
D001241_D002318 NONE <e1>aspirin</e1> reviews prevention <e2>disease</e2>
D001241_D002318 NONE <e1>aspirin</e1> reviews <e2>cvd</e2>
D001241_D002318 NONE <e1>aspirin</e1> reviews selected randomized decrease events strokes death mortality <e2>cvd</e2>
D001241_D002318 NONE <e1>aspirin</e1> decrease randomized selected reviews prevention <e2>disease</e2>
D001241_D002318 NONE <e1>aspirin</e1> decrease randomized selected reviews <e2>cvd</e2>
D001241_D002318 NONE <e1>aspirin</e1> decrease events strokes death mortality <e2>cvd</e2>
D001241_D002318 NONE <e1>aspirin</e1> increase randomized selected reviews prevention <e2>disease</e2>
D001241_D002318 NONE <e1>aspirin</e1> increase randomized selected reviews <e2>cvd</e2>
D001241_D002318 NONE <e1>aspirin</e1> increase randomized decrease events strokes death mortality <e2>cvd</e2>
D001241_D002318 NONE <e1>aspirin</e1> use reduces number events <e2>cvd</e2>
D001241_D002318 NONE <e1>aspirin</e1> use reduces number events patients <e2>cvd</e2>
D001241_D002318 NONE <e1>aspirin</e1> seem affect mortality <e2>cvd</e2>
D001241_D002318 NONE <e1>aspirin</e1> evidence prevention <e2>cvd</e2>
D001241_D006471 CID <e1>aspirin</e1> reviews selected randomized increase strokes <e2>bleeding</e2>
D001241_D006471 CID <e1>aspirin</e1> decrease randomized increase strokes <e2>bleeding</e2>
D001241_D006471 CID <e1>aspirin</e1> increase strokes <e2>bleeding</e2>
D001241_D006471 CID <e1>aspirin</e1> use increases risk events events <e2>bleeding</e2>
D001241_D020300 CID <e1>aspirin</e1> reviews selected randomized increase <e2>strokes</e2>
D001241_D020300 CID <e1>aspirin</e1> decrease randomized increase <e2>strokes</e2>
D001241_D020300 CID <e1>aspirin</e1> increase <e2>strokes</e2>
D001241_D020300 CID <e1>aspirin</e1> use <e2>strokes</e2>
D001241_D006470 NONE <e1>aspirin</e1> use increases risk events <e2>bleeding</e2>
D001241_D006470 NONE <e1>aspirin</e1> use increases risk events <e2>bleeding</e2>
3125850
D013390_D005207 CID <e1>suxamethonium-induced</e1> <e2>fasciculations</e2>
D013390_D005207 CID <e1>suxamethonium</e1> caused <e2>fasciculations</e2>
D013390_D005207 CID <e1>suxamethonium</e1> caused <e2>fasciculations</e2>
D013390_D005207 CID <e1>suxamethonium-induced</e1> <e2>fasciculations</e2>
D015760_D005207 NONE <e1>alfentanil</e1> inhibition increase <e2>fasciculations</e2>
D015760_D005207 NONE <e1>alfentanil</e1> group greater incidence <e2>fasciculations</e2>
D015760_D005207 NONE <e1>alfentanil</e1> group higher pressure <e2>fasciculations</e2>
D015760_D005207 NONE <e1>alfentanil</e1> kg-1 inhibits incidence <e2>fasciculations</e2>
D014867_D005207 NONE <e1>h2o</e1> cm higher pressure <e2>fasciculations</e2>
D014867_D005207 NONE <e1>h2o</e1> cm higher pressure <e2>fasciculations</e2>
19655282
D003042_D002637 CID <e1>cocaine-associated</e1> <e2>pain</e2>
D003042_D002637 CID <e1>cocaine-associated</e1> <e2>pain</e2>
D003042_D002637 CID <e1>cocaine-associated</e1> <e2>pain</e2>
D003042_D002637 CID <e1>cocaine-associated</e1> <e2>pain</e2>
D003042_D002637 CID <e1>cocaine-associated</e1> <e2>pain</e2>
D003042_D002637 CID <e1>cocaine-associated</e1> ischemia result discharged patients <e2>pain</e2>
D003042_D002637 CID <e1>cocaine</e1> associated <e2>pain</e2>
D003042_D054058 NONE <e1>cocaine-associated</e1> pain presenting patients admitted receive rule <e2>syndrome</e2>
D003042_D003329 NONE <e1>cocaine-associated</e1> pain efficacious account <e2>vasospasm</e2>
D003042_D007511 NONE <e1>cocaine-associated</e1> pain efficacious account some <e2>ischemia</e2>
D003042_D007511 NONE <e1>cocaine-associated</e1> ischemia result discharged patients pain ecg <e2>non-ischemic</e2>
D003042_D007511 NONE <e1>cocaine</e1> associated pain ecg <e2>non-ischemic</e2>
D003042_D017202 CID <e1>cocaine-associated</e1> <e2>ischemia</e2>
D003042_D017202 CID <e1>cocaine</e1> associated pain patients discharged result <e2>ischemia</e2>
24284476
D047310_D000647 NONE <e1>apigenin</e1> prevent <e2>amnesia</e2>
D012601_D000647 CID <e1>scopolamine</e1> induced <e2>amnesia</e2>
10985896
D004317_D010051 NONE <e1>doxorubicin</e1> trial <e2>cancers</e2>
D004317_D010051 NONE <e1>doxorubicin</e1> demonstrated agent <e2>cancer</e2>
D004317_D010051 NONE <e1>doxil</e1> doxorubicin demonstrated agent <e2>cancer</e2>
D004317_D010051 NONE <e1>doxorubicin</e1> treated methods <e2>cancers</e2>
D004317_D005185 NONE <e1>doxorubicin</e1> trial <e2>cancers</e2>
D004317_D005185 NONE <e1>doxorubicin</e1> treated methods <e2>cancers</e2>
D004317_D010534 NONE <e1>doxorubicin</e1> trial cancers carcinoma <e2>peritoneum</e2>
D004317_D010534 NONE <e1>doxorubicin</e1> treated methods cancers <e2>carcinoma</e2>
D010984_D010051 NONE <e1>platinum/paclitaxel-refractory</e1> ovarian <e2>cancers</e2>
D010984_D010051 NONE <e1>platinum-resistant</e1> <e2>cancer</e2>
D010984_D010051 NONE <e1>platinum/paclitaxel-refractory</e1> disease <e2>cancers</e2>
D010984_D010051 NONE <e1>platinum-</e1> <e2>cancer</e2>
D010984_D005185 NONE <e1>platinum/paclitaxel-refractory</e1> ovarian <e2>cancers</e2>
D010984_D005185 NONE <e1>platinum/paclitaxel-refractory</e1> disease <e2>cancers</e2>
D010984_D010534 NONE <e1>platinum/paclitaxel-refractory</e1> ovarian cancers carcinoma <e2>peritoneum</e2>
D010984_D010534 NONE <e1>platinum/paclitaxel-refractory</e1> disease cancers <e2>carcinoma</e2>
D017239_D010051 NONE <e1>platinum/paclitaxel-refractory</e1> ovarian <e2>cancers</e2>
D017239_D010051 NONE <e1>platinum/paclitaxel-refractory</e1> disease <e2>cancers</e2>
D017239_D010051 NONE <e1>paclitaxel-refractory</e1> <e2>cancer</e2>
D017239_D005185 NONE <e1>platinum/paclitaxel-refractory</e1> ovarian <e2>cancers</e2>
D017239_D005185 NONE <e1>platinum/paclitaxel-refractory</e1> disease <e2>cancers</e2>
D017239_D010534 NONE <e1>platinum/paclitaxel-refractory</e1> ovarian cancers carcinoma <e2>peritoneum</e2>
D017239_D010534 NONE <e1>platinum/paclitaxel-refractory</e1> disease cancers <e2>carcinoma</e2>
D004317_D064420 NONE <e1>doxorubicin</e1> demonstrated agent <e2>toxicity</e2>
D004317_D064420 NONE <e1>doxil</e1> doxorubicin demonstrated agent <e2>toxicity</e2>
D004317_D064420 NONE <e1>doxorubicin</e1> regimen results <e2>toxicity</e2>
D004317_D060831 CID <e1>doxorubicin</e1> demonstrated <e2>erythrodysesthesia</e2>
D004317_D060831 CID <e1>doxorubicin</e1> demonstrated erythrodysesthesia <e2>syndrome</e2>
D004317_D060831 CID <e1>doxil</e1> doxorubicin demonstrated <e2>erythrodysesthesia</e2>
D004317_D060831 CID <e1>doxil</e1> doxorubicin demonstrated erythrodysesthesia <e2>syndrome</e2>
D004317_D060831 CID <e1>doxorubicin</e1> regimen results toxicity <e2>syndrome</e2>
D004317_D013280 CID <e1>doxorubicin</e1> demonstrated erythrodysesthesia <e2>stomatitis</e2>
D004317_D013280 CID <e1>doxil</e1> doxorubicin demonstrated erythrodysesthesia <e2>stomatitis</e2>
D004317_D013280 CID <e1>doxorubicin</e1> regimen results toxicity syndrome <e2>stomatitis</e2>
D010984_D064420 NONE <e1>platinum-resistant</e1> cancer agent <e2>toxicity</e2>
D010984_D060831 NONE <e1>platinum-resistant</e1> cancer agent demonstrated <e2>erythrodysesthesia</e2>
D010984_D060831 NONE <e1>platinum-resistant</e1> cancer agent demonstrated erythrodysesthesia <e2>syndrome</e2>
D010984_D013280 NONE <e1>platinum-resistant</e1> cancer agent demonstrated erythrodysesthesia <e2>stomatitis</e2>
10939760
D013411_D058186 CID <e1>sulfadiazine</e1> <e2>nephrotoxicity</e2>
D013411_D058186 CID <e1>sulfadiazine</e1> acute <e2>nephrotoxicity</e2>
D013411_D014123 NONE <e1>sulfadiazine</e1> acute nephrotoxicity reviving use <e2>toxoplasmosis</e2>
D013411_D009846 NONE <e1>sulfadiazine</e1> treatment developed <e2>oliguria</e2>
D013411_D015746 NONE <e1>sulfadiazine</e1> treatment developed oliguria <e2>pain</e2>
D013411_D051437 NONE <e1>sulfadiazine</e1> treatment developed oliguria <e2>failure</e2>
D013411_D007669 CID <e1>sulfadiazine</e1> treatment developed showed <e2>calculi</e2>
14748761
C030852_D009369 NONE <e1>vnr</e1> comparing agents treatment <e2>malignancies</e2>
C030852_D009369 NONE <e1>vnr</e1> comparing treatment <e2>cancer</e2>
C030852_D066126 CID <e1>vnr</e1> events risk similar vindesine drugs <e2>cardiotoxic</e2>
D014751_D066126 NONE <e1>vindesine</e1> drugs <e2>cardiotoxic</e2>
D014751_D066126 NONE <e1>vds</e1> vindesine drugs <e2>cardiotoxic</e2>
D005472_D066126 NONE <e1>fluorouracil</e1> vindesine drugs <e2>cardiotoxic</e2>
D018943_D066126 NONE <e1>anthracyclines</e1> fluorouracil vindesine drugs <e2>cardiotoxic</e2>
C056507_D066126 NONE <e1>gemcitabine</e1> fluorouracil vindesine drugs <e2>cardiotoxic</e2>
C056507_D066126 NONE <e1>gem</e1> gemcitabine fluorouracil vindesine drugs <e2>cardiotoxic</e2>
3423103
D003000_D007022 CID <e1>clonidine-induced</e1> <e2>hypotension</e2>
D003000_D007022 CID <e1>clonidine-induced</e1> <e2>hypotension</e2>
D003000_D007022 CID <e1>clonidine-induced</e1> <e2>hypotension</e2>
D003000_D001919 CID <e1>clonidine-induced</e1> hypotension <e2>bradycardia</e2>
D003000_D001919 CID <e1>clonidine-induced</e1> <e2>bradycardia</e2>
D003000_D001919 CID <e1>clonidine</e1> responses <e2>bradycardiac</e2>
D003000_D001919 CID <e1>clonidine-induced</e1> hypotension <e2>bradycardia</e2>
D012701_D001919 NONE <e1>5-ht</e1> nerves destruction reduced magnitude responses <e2>bradycardiac</e2>
D015116_D001919 NONE <e1>5,7-dihydroxytryptamine</e1> injection produced nerves destruction reduced magnitude responses <e2>bradycardiac</e2>
15094729
D020888_D014786 CID <e1>vigabatrin</e1> <e2>defects</e2>
D020888_D014786 CID <e1>vigabatrin-associated</e1> changes have known patients group <e2>defects</e2>
D020888_D014786 CID <e1>vigabatrin</e1> therapy presumed <e2>defects</e2>
D020888_D014786 CID <e1>vigabatrin-associated</e1> <e2>defects</e2>
D020888_D012640 NONE <e1>vigabatrin-associated</e1> changes have known patients group defects history determine control <e2>seizure</e2>
D020888_D064420 NONE <e1>vigabatrin-associated</e1> defects pathogenesis reaction <e2>toxicity</e2>
1280707
D002045_D001145 CID <e1>bupivacaine</e1> ad50 concentration caused become <e2>arrhythmic</e2>
D002045_D001145 CID <e1>bupivacaine</e1> concentration caused become <e2>arrhythmic</e2>
D002045_D001145 CID <e1>bupivacaine</e1> <e2>arrhythmia</e2>
D011374_D001145 CID <e1>progesterone</e1> hcl exposure effect determined determining ad50 concentration caused become <e2>arrhythmic</e2>
D006851_D001145 NONE <e1>hcl</e1> exposure effect determined determining ad50 concentration caused become <e2>arrhythmic</e2>
7477981
D007980_D004409 NONE <e1>levodopa-induced</e1> <e2>dyskinesias</e2>
D007980_D004409 NONE <e1>levodopa-responsive</e1> patients severity disability <e2>dyskinesias</e2>
D007980_D004409 NONE <e1>levodopa-</e1> reduce <e2>dyskinesias</e2>
D005473_D004409 CID <e1>fluoxetine</e1> improved <e2>dyskinesias</e2>
D005473_D004409 CID <e1>fluoxetine</e1> administration severity disability <e2>dyskinesias</e2>
D005473_D004409 CID <e1>fluoxetine</e1> treatment was improvement <e2>dyskinesias</e2>
D005473_D004409 CID <e1>fluoxetine</e1> transmission reduce <e2>dyskinesias</e2>
D007980_D009069 NONE <e1>levodopa-responsive</e1> patients severity <e2>disability</e2>
D007980_D009069 NONE <e1>levodopa-</e1> reduce <e2>disability</e2>
D007980_D010300 NONE <e1>levodopa-responsive</e1> patients <e2>disease</e2>
D007980_D010300 NONE <e1>levodopa-</e1> reduce disability <e2>parkinsonian</e2>
D004298_D009069 NONE <e1>dopamine</e1> agonist challenge severity <e2>disability</e2>
D004298_D009069 NONE <e1>dopamine</e1> agonist-induced levodopa- reduce <e2>disability</e2>
D004298_D004409 NONE <e1>dopamine</e1> agonist challenge severity disability <e2>dyskinesias</e2>
D004298_D004409 NONE <e1>dopamine</e1> agonist-induced levodopa- reduce <e2>dyskinesias</e2>
D004298_D010300 NONE <e1>dopamine</e1> agonist challenge severity patients <e2>disease</e2>
D004298_D010300 NONE <e1>dopamine</e1> agonist-induced levodopa- reduce disability <e2>parkinsonian</e2>
D001058_D009069 NONE <e1>apomorphine</e1> agonist challenge severity <e2>disability</e2>
D001058_D009069 NONE <e1>apomorphine-induced</e1> dyskinesias modification <e2>disability</e2>
D001058_D004409 CID <e1>apomorphine</e1> agonist challenge severity disability <e2>dyskinesias</e2>
D001058_D004409 CID <e1>apomorphine-induced</e1> <e2>dyskinesias</e2>
D001058_D010300 NONE <e1>apomorphine</e1> agonist challenge severity patients <e2>disease</e2>
D001058_D010300 NONE <e1>apomorphine-induced</e1> dyskinesias modification disability <e2>parkinsonian</e2>
D005473_D009069 NONE <e1>fluoxetine</e1> administration severity <e2>disability</e2>
D005473_D009069 NONE <e1>fluoxetine</e1> treatment was improvement dyskinesias modification <e2>disability</e2>
D005473_D009069 NONE <e1>fluoxetine</e1> transmission reduce <e2>disability</e2>
D005473_D010300 NONE <e1>fluoxetine</e1> administration severity patients <e2>disease</e2>
D005473_D010300 NONE <e1>fluoxetine</e1> treatment was improvement dyskinesias modification disability <e2>parkinsonian</e2>
D005473_D010300 NONE <e1>fluoxetine</e1> transmission reduce disability <e2>parkinsonian</e2>
18165598
D002045_D010146 NONE <e1>bupivacaine</e1> effects expression <e2>pain</e2>
D002045_D010146 NONE <e1>bupivacaine</e1> effects expression model <e2>pain</e2>
D002045_D010146 NONE <e1>bupivacaine/rofecoxib</e1> group reported <e2>pain</e2>
D002045_D010146 NONE <e1>bupivacaine/rofecoxib</e1> group reported results reported <e2>pain</e2>
D002045_D010146 NONE <e1>bupivacaine/placebo</e1> group reported results reported <e2>pain</e2>
D002045_D010146 NONE <e1>bupivacaine/placebo</e1> group reported <e2>pain</e2>
D002045_D010146 NONE <e1>bupivacaine</e1> stimulates expression associated production <e2>pain</e2>
D008012_D010146 NONE <e1>lidocaine</e1> bupivacaine effects expression <e2>pain</e2>
D008012_D010146 NONE <e1>lidocaine</e1> bupivacaine effects expression model <e2>pain</e2>
D015232_D010146 NONE <e1>e2</e1> release effects expression <e2>pain</e2>
D015232_D010146 NONE <e1>e2</e1> release effects expression model <e2>pain</e2>
D015232_D010146 NONE <e1>pge2</e1> levels higher reported results reported <e2>pain</e2>
D015232_D010146 NONE <e1>pge2</e1> levels higher reported <e2>pain</e2>
D015232_D010146 NONE <e1>pge2</e1> production <e2>pain</e2>
D002045_D010149 CID <e1>bupivacaine</e1> effects expression increases <e2>pain</e2>
D015232_D010149 NONE <e1>e2</e1> bupivacaine effects expression increases <e2>pain</e2>
D015232_D010149 NONE <e1>pge2</e1> e2 bupivacaine effects expression increases <e2>pain</e2>
C116926_D010146 NONE <e1>bupivacaine/rofecoxib</e1> group reported <e2>pain</e2>
C116926_D010146 NONE <e1>bupivacaine/rofecoxib</e1> group reported results reported <e2>pain</e2>
D002045_D017695 NONE <e1>bupivacaine</e1> stimulates expression <e2>injury</e2>
D015232_D017695 NONE <e1>pge2</e1> production associated expression <e2>injury</e2>
